bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
eprosartan is a CHEMICAL, renin is a GENE-Y, angiotensin is a CHEMICAL, Angiotensin II type 1 receptor is a GENE-Y, eprosartan is a CHEMICAL, angiotensin II type 1 receptor is a GENE-Y, AT1 is a GENE-Y, Eprosartan is a CHEMICAL, AT1 receptors is a GENE-Y, AT1 receptors is a GENE-Y, noradrenaline is a CHEMICAL, eprosartan is a CHEMICAL, angiotensin - converting enzyme is a GENE-Y, Eprosartan is a CHEMICAL, Eprosartan is a CHEMICAL	21749_task0	Sentence: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus.	[ "Introduction", ":", "The", "pharmacological", "profile", "of", "eprosartan", "--", "implications", "for", "cerebrovascular", "and", "cardiovascular", "risk", "reduction", ".", "\n", "Moderate", "elevations", "in", "blood", "pressure", "translate", "to", "significant", "increases", "in", "cardiovascular", "and", "cerebro", "vascular", "risk", ".", "Beneficially", ",", "this", "relationship", "allows", "small", "decreases", "in", "blood", "pressure", "to", "be", "associated", "with", "risk", "reduction", ".", "Both", "the", "renin", "-", "angiotensin", "system", "and", "the", "sympathetic", "nervous", "system", "are", "involved", "in", "hypertension", ",", "hence", "targeting", "these", "systems", "is", "likely", "to", "be", "of", "benefit", "in", "the", "treatment", "of", "hypertension", ".", "Angiotensin", "II", "type", "1", "receptor", "blockers", "(", "ARBs", ")", "are", "used", "for", "controlling", "blood", "pressure", "and", "treating", "heart", "failure", "in", "a", "broad", "range", "of", "patients", ",", "including", "those", "with", "diabetes", "and", "the", "elderly", ".", "Not", "only", "have", "ARBs", "shown", "good", "efficacy", "and", "tolerability", ",", "they", "also", "appear", "to", "have", "a", "protective", "effect", "that", "goes", "beyond", "that", "expected", "from", "the", "reduction", "of", "blood", "pressure", ".", "The", "ARB", "eprosartan", "is", "a", "nonbiphenyl", "nontetrazole", "angiotensin", "II", "type", "1", "receptor", "(", "AT1", ")", "antagonist", ",", "which", "acts", "to", "decrease", "total", "peripheral", "resistance", ".", "Eprosartan", "acts", "at", "vascular", "AT1", "receptors", "(", "postsynaptically", ")", "and", "at", "presynaptic", "AT1", "receptors", ",", "where", "it", "inhibits", "noradrenaline", "release", ".", "In", "clinical", "studies", ",", "eprosartan", "has", "been", "shown", "to", "significantly", "reduce", "cardiovascular", "and", "cerebrovascular", "events", ",", "whilst", "avoiding", "the", "persistent", "cough", "that", "commonly", "occurs", "with", "the", "use", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", ".", "Eprosartan", "can", "also", "be", "differentiated", "from", "other", "ARBs", "due", "to", "its", "noradrenergic", "effects", ",", "which", "other", "ARBs", "used", "at", "therapeutic", "doses", "do", "not", "possess", ".", "Eprosartan", ",", "therefore", ",", "represents", "a", "useful", "therapeutic", "option", "in", "the", "management", "of", "patients", "with", "hypertension", ",", "including", "those", "with", "a", "history", "of", "stroke", "or", "with", "co", "-", "morbid", "type", "2", "diabetes", "mellitus", "." ]	[ "GENE-Y", "CHEMICAL" ]
eprosartan is a CHEMICAL, renin is a GENE-Y, angiotensin is a CHEMICAL, Angiotensin II type 1 receptor is a GENE-Y, eprosartan is a CHEMICAL, angiotensin II type 1 receptor is a GENE-Y, AT1 is a GENE-Y, Eprosartan is a CHEMICAL, AT1 receptors is a GENE-Y, AT1 receptors is a GENE-Y, noradrenaline is a CHEMICAL, eprosartan is a CHEMICAL, angiotensin - converting enzyme is a GENE-Y, Eprosartan is a CHEMICAL, Eprosartan is a CHEMICAL	21749_task1	Sentence: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus. Instructions: please typing these entity words according to sentence: eprosartan, renin, angiotensin, Angiotensin II type 1 receptor, eprosartan, angiotensin II type 1 receptor, AT1, Eprosartan, AT1 receptors, AT1 receptors, noradrenaline, eprosartan, angiotensin - converting enzyme, Eprosartan, Eprosartan Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus.	[ "Introduction", ":", "The", "pharmacological", "profile", "of", "eprosartan", "--", "implications", "for", "cerebrovascular", "and", "cardiovascular", "risk", "reduction", ".", "\n", "Moderate", "elevations", "in", "blood", "pressure", "translate", "to", "significant", "increases", "in", "cardiovascular", "and", "cerebro", "vascular", "risk", ".", "Beneficially", ",", "this", "relationship", "allows", "small", "decreases", "in", "blood", "pressure", "to", "be", "associated", "with", "risk", "reduction", ".", "Both", "the", "renin", "-", "angiotensin", "system", "and", "the", "sympathetic", "nervous", "system", "are", "involved", "in", "hypertension", ",", "hence", "targeting", "these", "systems", "is", "likely", "to", "be", "of", "benefit", "in", "the", "treatment", "of", "hypertension", ".", "Angiotensin", "II", "type", "1", "receptor", "blockers", "(", "ARBs", ")", "are", "used", "for", "controlling", "blood", "pressure", "and", "treating", "heart", "failure", "in", "a", "broad", "range", "of", "patients", ",", "including", "those", "with", "diabetes", "and", "the", "elderly", ".", "Not", "only", "have", "ARBs", "shown", "good", "efficacy", "and", "tolerability", ",", "they", "also", "appear", "to", "have", "a", "protective", "effect", "that", "goes", "beyond", "that", "expected", "from", "the", "reduction", "of", "blood", "pressure", ".", "The", "ARB", "eprosartan", "is", "a", "nonbiphenyl", "nontetrazole", "angiotensin", "II", "type", "1", "receptor", "(", "AT1", ")", "antagonist", ",", "which", "acts", "to", "decrease", "total", "peripheral", "resistance", ".", "Eprosartan", "acts", "at", "vascular", "AT1", "receptors", "(", "postsynaptically", ")", "and", "at", "presynaptic", "AT1", "receptors", ",", "where", "it", "inhibits", "noradrenaline", "release", ".", "In", "clinical", "studies", ",", "eprosartan", "has", "been", "shown", "to", "significantly", "reduce", "cardiovascular", "and", "cerebrovascular", "events", ",", "whilst", "avoiding", "the", "persistent", "cough", "that", "commonly", "occurs", "with", "the", "use", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", ".", "Eprosartan", "can", "also", "be", "differentiated", "from", "other", "ARBs", "due", "to", "its", "noradrenergic", "effects", ",", "which", "other", "ARBs", "used", "at", "therapeutic", "doses", "do", "not", "possess", ".", "Eprosartan", ",", "therefore", ",", "represents", "a", "useful", "therapeutic", "option", "in", "the", "management", "of", "patients", "with", "hypertension", ",", "including", "those", "with", "a", "history", "of", "stroke", "or", "with", "co", "-", "morbid", "type", "2", "diabetes", "mellitus", "." ]	[ "GENE-Y", "CHEMICAL" ]
eprosartan, renin, angiotensin, Angiotensin II type 1 receptor, eprosartan, angiotensin II type 1 receptor, AT1, Eprosartan, AT1 receptors, AT1 receptors, noradrenaline, eprosartan, angiotensin - converting enzyme, Eprosartan, Eprosartan	21749_task2	Sentence: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus.	[ "Introduction", ":", "The", "pharmacological", "profile", "of", "eprosartan", "--", "implications", "for", "cerebrovascular", "and", "cardiovascular", "risk", "reduction", ".", "\n", "Moderate", "elevations", "in", "blood", "pressure", "translate", "to", "significant", "increases", "in", "cardiovascular", "and", "cerebro", "vascular", "risk", ".", "Beneficially", ",", "this", "relationship", "allows", "small", "decreases", "in", "blood", "pressure", "to", "be", "associated", "with", "risk", "reduction", ".", "Both", "the", "renin", "-", "angiotensin", "system", "and", "the", "sympathetic", "nervous", "system", "are", "involved", "in", "hypertension", ",", "hence", "targeting", "these", "systems", "is", "likely", "to", "be", "of", "benefit", "in", "the", "treatment", "of", "hypertension", ".", "Angiotensin", "II", "type", "1", "receptor", "blockers", "(", "ARBs", ")", "are", "used", "for", "controlling", "blood", "pressure", "and", "treating", "heart", "failure", "in", "a", "broad", "range", "of", "patients", ",", "including", "those", "with", "diabetes", "and", "the", "elderly", ".", "Not", "only", "have", "ARBs", "shown", "good", "efficacy", "and", "tolerability", ",", "they", "also", "appear", "to", "have", "a", "protective", "effect", "that", "goes", "beyond", "that", "expected", "from", "the", "reduction", "of", "blood", "pressure", ".", "The", "ARB", "eprosartan", "is", "a", "nonbiphenyl", "nontetrazole", "angiotensin", "II", "type", "1", "receptor", "(", "AT1", ")", "antagonist", ",", "which", "acts", "to", "decrease", "total", "peripheral", "resistance", ".", "Eprosartan", "acts", "at", "vascular", "AT1", "receptors", "(", "postsynaptically", ")", "and", "at", "presynaptic", "AT1", "receptors", ",", "where", "it", "inhibits", "noradrenaline", "release", ".", "In", "clinical", "studies", ",", "eprosartan", "has", "been", "shown", "to", "significantly", "reduce", "cardiovascular", "and", "cerebrovascular", "events", ",", "whilst", "avoiding", "the", "persistent", "cough", "that", "commonly", "occurs", "with", "the", "use", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", ".", "Eprosartan", "can", "also", "be", "differentiated", "from", "other", "ARBs", "due", "to", "its", "noradrenergic", "effects", ",", "which", "other", "ARBs", "used", "at", "therapeutic", "doses", "do", "not", "possess", ".", "Eprosartan", ",", "therefore", ",", "represents", "a", "useful", "therapeutic", "option", "in", "the", "management", "of", "patients", "with", "hypertension", ",", "including", "those", "with", "a", "history", "of", "stroke", "or", "with", "co", "-", "morbid", "type", "2", "diabetes", "mellitus", "." ]	[ "GENE-Y", "CHEMICAL" ]
Competitive memory training ( COMET ) is a Intervention_Other, low self - esteem is a Outcome_Mental, depressive disorders is a Participant_Condition, Low self - esteem is a Outcome_Mental, of is a Intervention_Other, Competitive Memory Training ( COMET ) is a Intervention_Other, Sixty - one is a Participant_Sample-size, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] is a Intervention_Other, ongoing regular therapy ( TAU only is a Intervention_Control, effects of COMET is a Outcome_Mental, stable is a Outcome_Mental, significant improvement is a Outcome_Other, large effect sizes on indices of self - esteem , depression , and depressive rumination . is a Outcome_Mental, therapeutic effects is a Outcome_Mental	54510_task0	Sentence: Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Control, Participant_Condition, Intervention_Other, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders .	[ "Competitive", "memory", "training", "(", "COMET", ")", "for", "treating", "low", "self", "-", "esteem", "in", "patients", "with", "depressive", "disorders", ":", "a", "randomized", "clinical", "trial", ".", "BACKGROUND", "Self", "-", "esteem", "is", "a", "major", "concern", "in", "mood", "disorders", ".", "Low", "self", "-", "esteem", "is", "a", "symptom", "of", "depressive", "disorders", "and", "is", "considered", "by", "some", "to", "be", "a", "predictor", "for", "relapse", ",", "whereas", "high", "self", "-", "esteem", "seems", "to", "buffer", "against", "depression", ".", "Recently", ",", "Competitive", "Memory", "Training", "(", "COMET", ")", "has", "shown", "to", "be", "effective", "for", "the", "enhancement", "of", "self", "-", "esteem", "in", "several", "psychopathological", "conditions", ".", "The", "current", "study", "assesses", "whether", "COMET", "is", "also", "an", "effective", "intervention", "for", "patients", "with", "depressive", "disorders", ".", "METHODS", "Sixty", "-", "one", "patients", "with", "depressive", "disorders", "who", "were", "already", "in", "therapy", "in", "an", "outpatient", "mental", "health", "institution", "were", "randomly", "assigned", "to", "either", "eight", "group", "sessions", "of", "COMET", "in", "addition", "to", "their", "regular", "therapy", "(", "COMET", "+", "therapy", "as", "usual", "[", "TAU", "]", ":", "the", "experimental", "group", ")", "or", "to", "8", "weeks", "of", "ongoing", "regular", "therapy", "(", "TAU", "only", ":", "the", "control", "group", ")", ".", "These", "latter", "(", "control", ")", "patients", "received", "COMET", "after", "their", "TAU", "only", "period", ".", "All", "patients", "in", "both", "groups", "that", "completed", "COMET", "were", "contacted", "3", "and", "6", "months", "later", "to", "assess", "whether", "the", "effects", "of", "COMET", "had", "remained", "stable", ".", "RESULTS", "Compared", "to", "the", "patients", "who", "received", "TAU", "only", ",", "patients", "in", "the", "COMET", "+", "TAU", "condition", "showed", "significant", "improvement", "with", "large", "effect", "sizes", "on", "indices", "of", "self", "-", "esteem", ",", "depression", ",", "and", "depressive", "rumination", ".", "The", "therapeutic", "effects", "of", "COMET", "+", "TAU", "remained", "stable", "after", "3", "and", "6", "months", "on", "all", "outcome", "measures", "or", "improved", "even", "further", ".", "CONCLUSION", "COMET", "for", "low", "self", "-", "esteem", "seems", "to", "be", "an", "efficacious", "trans", "-", "diagnostic", "intervention", "that", "can", "relatively", "easily", "be", "added", "to", "the", "regular", "treatment", "of", "patients", "with", "depressive", "disorders", "." ]	[ "Outcome_Mental", "Intervention_Other", "Intervention_Control", "Outcome_Other", "Participant_Condition", "Participant_Sample-size" ]
Competitive memory training ( COMET ) is a Intervention_Other, low self - esteem is a Outcome_Mental, depressive disorders is a Participant_Condition, Low self - esteem is a Outcome_Mental, of is a Intervention_Other, Competitive Memory Training ( COMET ) is a Intervention_Other, Sixty - one is a Participant_Sample-size, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] is a Intervention_Other, ongoing regular therapy ( TAU only is a Intervention_Control, effects of COMET is a Outcome_Mental, stable is a Outcome_Mental, significant improvement is a Outcome_Other, large effect sizes on indices of self - esteem , depression , and depressive rumination . is a Outcome_Mental, therapeutic effects is a Outcome_Mental	54510_task1	Sentence: Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders . Instructions: please typing these entity words according to sentence: Competitive memory training ( COMET ), low self - esteem, depressive disorders, Low self - esteem, of, Competitive Memory Training ( COMET ), Sixty - one, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ], ongoing regular therapy ( TAU only, effects of COMET, stable, significant improvement, large effect sizes on indices of self - esteem , depression , and depressive rumination ., therapeutic effects Options: Intervention_Control, Participant_Condition, Intervention_Other, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders .	[ "Competitive", "memory", "training", "(", "COMET", ")", "for", "treating", "low", "self", "-", "esteem", "in", "patients", "with", "depressive", "disorders", ":", "a", "randomized", "clinical", "trial", ".", "BACKGROUND", "Self", "-", "esteem", "is", "a", "major", "concern", "in", "mood", "disorders", ".", "Low", "self", "-", "esteem", "is", "a", "symptom", "of", "depressive", "disorders", "and", "is", "considered", "by", "some", "to", "be", "a", "predictor", "for", "relapse", ",", "whereas", "high", "self", "-", "esteem", "seems", "to", "buffer", "against", "depression", ".", "Recently", ",", "Competitive", "Memory", "Training", "(", "COMET", ")", "has", "shown", "to", "be", "effective", "for", "the", "enhancement", "of", "self", "-", "esteem", "in", "several", "psychopathological", "conditions", ".", "The", "current", "study", "assesses", "whether", "COMET", "is", "also", "an", "effective", "intervention", "for", "patients", "with", "depressive", "disorders", ".", "METHODS", "Sixty", "-", "one", "patients", "with", "depressive", "disorders", "who", "were", "already", "in", "therapy", "in", "an", "outpatient", "mental", "health", "institution", "were", "randomly", "assigned", "to", "either", "eight", "group", "sessions", "of", "COMET", "in", "addition", "to", "their", "regular", "therapy", "(", "COMET", "+", "therapy", "as", "usual", "[", "TAU", "]", ":", "the", "experimental", "group", ")", "or", "to", "8", "weeks", "of", "ongoing", "regular", "therapy", "(", "TAU", "only", ":", "the", "control", "group", ")", ".", "These", "latter", "(", "control", ")", "patients", "received", "COMET", "after", "their", "TAU", "only", "period", ".", "All", "patients", "in", "both", "groups", "that", "completed", "COMET", "were", "contacted", "3", "and", "6", "months", "later", "to", "assess", "whether", "the", "effects", "of", "COMET", "had", "remained", "stable", ".", "RESULTS", "Compared", "to", "the", "patients", "who", "received", "TAU", "only", ",", "patients", "in", "the", "COMET", "+", "TAU", "condition", "showed", "significant", "improvement", "with", "large", "effect", "sizes", "on", "indices", "of", "self", "-", "esteem", ",", "depression", ",", "and", "depressive", "rumination", ".", "The", "therapeutic", "effects", "of", "COMET", "+", "TAU", "remained", "stable", "after", "3", "and", "6", "months", "on", "all", "outcome", "measures", "or", "improved", "even", "further", ".", "CONCLUSION", "COMET", "for", "low", "self", "-", "esteem", "seems", "to", "be", "an", "efficacious", "trans", "-", "diagnostic", "intervention", "that", "can", "relatively", "easily", "be", "added", "to", "the", "regular", "treatment", "of", "patients", "with", "depressive", "disorders", "." ]	[ "Outcome_Mental", "Intervention_Other", "Intervention_Control", "Outcome_Other", "Participant_Condition", "Participant_Sample-size" ]
Competitive memory training ( COMET ), low self - esteem, depressive disorders, Low self - esteem, of, Competitive Memory Training ( COMET ), Sixty - one, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ], ongoing regular therapy ( TAU only, effects of COMET, stable, significant improvement, large effect sizes on indices of self - esteem , depression , and depressive rumination ., therapeutic effects	54510_task2	Sentence: Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders .	[ "Competitive", "memory", "training", "(", "COMET", ")", "for", "treating", "low", "self", "-", "esteem", "in", "patients", "with", "depressive", "disorders", ":", "a", "randomized", "clinical", "trial", ".", "BACKGROUND", "Self", "-", "esteem", "is", "a", "major", "concern", "in", "mood", "disorders", ".", "Low", "self", "-", "esteem", "is", "a", "symptom", "of", "depressive", "disorders", "and", "is", "considered", "by", "some", "to", "be", "a", "predictor", "for", "relapse", ",", "whereas", "high", "self", "-", "esteem", "seems", "to", "buffer", "against", "depression", ".", "Recently", ",", "Competitive", "Memory", "Training", "(", "COMET", ")", "has", "shown", "to", "be", "effective", "for", "the", "enhancement", "of", "self", "-", "esteem", "in", "several", "psychopathological", "conditions", ".", "The", "current", "study", "assesses", "whether", "COMET", "is", "also", "an", "effective", "intervention", "for", "patients", "with", "depressive", "disorders", ".", "METHODS", "Sixty", "-", "one", "patients", "with", "depressive", "disorders", "who", "were", "already", "in", "therapy", "in", "an", "outpatient", "mental", "health", "institution", "were", "randomly", "assigned", "to", "either", "eight", "group", "sessions", "of", "COMET", "in", "addition", "to", "their", "regular", "therapy", "(", "COMET", "+", "therapy", "as", "usual", "[", "TAU", "]", ":", "the", "experimental", "group", ")", "or", "to", "8", "weeks", "of", "ongoing", "regular", "therapy", "(", "TAU", "only", ":", "the", "control", "group", ")", ".", "These", "latter", "(", "control", ")", "patients", "received", "COMET", "after", "their", "TAU", "only", "period", ".", "All", "patients", "in", "both", "groups", "that", "completed", "COMET", "were", "contacted", "3", "and", "6", "months", "later", "to", "assess", "whether", "the", "effects", "of", "COMET", "had", "remained", "stable", ".", "RESULTS", "Compared", "to", "the", "patients", "who", "received", "TAU", "only", ",", "patients", "in", "the", "COMET", "+", "TAU", "condition", "showed", "significant", "improvement", "with", "large", "effect", "sizes", "on", "indices", "of", "self", "-", "esteem", ",", "depression", ",", "and", "depressive", "rumination", ".", "The", "therapeutic", "effects", "of", "COMET", "+", "TAU", "remained", "stable", "after", "3", "and", "6", "months", "on", "all", "outcome", "measures", "or", "improved", "even", "further", ".", "CONCLUSION", "COMET", "for", "low", "self", "-", "esteem", "seems", "to", "be", "an", "efficacious", "trans", "-", "diagnostic", "intervention", "that", "can", "relatively", "easily", "be", "added", "to", "the", "regular", "treatment", "of", "patients", "with", "depressive", "disorders", "." ]	[ "Outcome_Mental", "Intervention_Other", "Intervention_Control", "Outcome_Other", "Participant_Condition", "Participant_Sample-size" ]
lactate dehydrogenase - X is a GENE-Y	2751392_task0	Sentence: Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]	Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats.	[ "Developmental", "changes", "in", "lactate", "dehydrogenase", "-", "X", "activity", "in", "young", "jaundiced", "male", "rats", "." ]	[ "CHEMICAL", "GENE-Y" ]
lactate dehydrogenase - X is a GENE-Y	2751392_task1	Sentence: Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats. Instructions: please typing these entity words according to sentence: lactate dehydrogenase - X Options: GENE-Y	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]	Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats.	[ "Developmental", "changes", "in", "lactate", "dehydrogenase", "-", "X", "activity", "in", "young", "jaundiced", "male", "rats", "." ]	[ "CHEMICAL", "GENE-Y" ]
lactate dehydrogenase - X	2751392_task2	Sentence: Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]	Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats.	[ "Developmental", "changes", "in", "lactate", "dehydrogenase", "-", "X", "activity", "in", "young", "jaundiced", "male", "rats", "." ]	[ "CHEMICAL", "GENE-Y" ]
MnSOD is a protein, catalase is a protein, quinclorac is a compound, bensulfuron - methyl is a compound	DS.d76_task0	Sentence: MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12.	[ "MnSOD", "and", "two", "additional", "catalase", "isozymes", "were", "induced", "by", "quinclorac", "or", "bensulfuron", "-", "methyl", "in", "S.", "maltophilia", "WZ2", ",", "but", "not", "in", "E.", "coli", "K12", "." ]	[ "compound", "protein" ]
MnSOD is a protein, catalase is a protein, quinclorac is a compound, bensulfuron - methyl is a compound	DS.d76_task1	Sentence: MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12. Instructions: please typing these entity words according to sentence: MnSOD, catalase, quinclorac, bensulfuron - methyl Options: compound, protein	[ "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12.	[ "MnSOD", "and", "two", "additional", "catalase", "isozymes", "were", "induced", "by", "quinclorac", "or", "bensulfuron", "-", "methyl", "in", "S.", "maltophilia", "WZ2", ",", "but", "not", "in", "E.", "coli", "K12", "." ]	[ "compound", "protein" ]
MnSOD, catalase, quinclorac, bensulfuron - methyl	DS.d76_task2	Sentence: MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12. Instructions: please extract entity words from the input sentence	[ "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12.	[ "MnSOD", "and", "two", "additional", "catalase", "isozymes", "were", "induced", "by", "quinclorac", "or", "bensulfuron", "-", "methyl", "in", "S.", "maltophilia", "WZ2", ",", "but", "not", "in", "E.", "coli", "K12", "." ]	[ "compound", "protein" ]
depression among low - income patients with cancer . is a Participant_Condition, Alleviating Depression Among Patients With is a Intervention_Educational, Cancer ( ADAPt - C ) collaborative care management is a Intervention_Other, major depression is a Outcome_Mental, intervention is a Intervention_Educational, enhanced usual care is a Intervention_Educational, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education is a Intervention_Educational, structured psychotherapy is a Intervention_Psychological, maintenance / relapse prevention support is a Intervention_Educational, antidepressant medications is a Intervention_Pharmacological, depressive symptoms is a Outcome_Mental, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale is a Outcome_Other, PHQ-9 score is a Outcome_Other, greater rates of depression treatment is a Outcome_Mental, better quality - of - life outcomes is a Outcome_Other, emotional is a Outcome_Mental, physical well - being is a Outcome_Mental, ADAPt - C collaborative care is a Intervention_Educational	37259_task0	Sentence: Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics .	[ "Randomized", "controlled", "trial", "of", "collaborative", "care", "management", "of", "depression", "among", "low", "-", "income", "patients", "with", "cancer", ".", "PURPOSE", "To", "determine", "the", "effectiveness", "of", "the", "Alleviating", "Depression", "Among", "Patients", "With", "Cancer", "(", "ADAPt", "-", "C", ")", "collaborative", "care", "management", "for", "major", "depression", "or", "dysthymia", ".", "PATIENTS", "AND", "METHODS", "Study", "patients", "included", "472", "low", "-", "income", ",", "predominantly", "female", "Hispanic", "patients", "with", "cancer", "age", ">", "or=", "18", "years", "with", "major", "depression", "(", "49", "%", ")", ",", "dysthymia", "(", "5", "%", ")", ",", "or", "both", "(", "46", "%", ")", ".", "Patients", "were", "randomly", "assigned", "to", "intervention", "(", "n", "=", "242", ")", "or", "enhanced", "usual", "care", "(", "EUC", ";", "n", "=", "230", ")", ".", "Intervention", "patients", "had", "access", "for", "up", "to", "12", "months", "to", "a", "depression", "clinical", "specialist", "(", "supervised", "by", "a", "psychiatrist", ")", "who", "offered", "education", ",", "structured", "psychotherapy", ",", "and", "maintenance", "/", "relapse", "prevention", "support", ".", "The", "psychiatrist", "prescribed", "antidepressant", "medications", "for", "patients", "preferring", "or", "assessed", "to", "require", "medication", ".", "RESULTS", "At", "12", "months", ",", "63", "%", "of", "intervention", "patients", "had", "a", "50", "%", "or", "greater", "reduction", "in", "depressive", "symptoms", "from", "baseline", "as", "assessed", "by", "the", "Patient", "Health", "Questionnaire-9", "(", "PHQ-9", ")", "depression", "scale", "compared", "with", "50", "%", "of", "EUC", "patients", "(", "odds", "ratio", "[", "OR", "]", "=", "1.98", ";", "95", "%", "CI", ",", "1.16", "to", "3.38", ";", "P", "=", ".01", ")", ".", "Improvement", "was", "also", "found", "for", "5-point", "decrease", "in", "PHQ-9", "score", "among", "72.2", "%", "of", "intervention", "patients", "compared", "with", "59.7", "%", "of", "EUC", "patients", "(", "OR", "=", "1.99", ";", "95", "%", "CI", ",", "1.14", "to", "3.50", ";", "P", "=", ".02", ")", ".", "Intervention", "patients", "also", "experienced", "greater", "rates", "of", "depression", "treatment", "(", "72.3", "%", "v", "10.4", "%", "of", "EUC", "patients", ";", "P", "<", ".0001", ")", "and", "significantly", "better", "quality", "-", "of", "-", "life", "outcomes", ",", "including", "social", "/", "family", "(", "adjusted", "mean", "difference", "between", "groups", ",", "2.7", ";", "95", "%", "CI", ",", "1.22", "to", "4.17", ";", "P", "<", ".001", ")", ",", "emotional", "(", "adjusted", "mean", "difference", ",", "1.29", ";", "95", "%", "CI", ",", "0.26", "to", "2.22", ";", "P", "=", ".01", ")", ",", "functional", "(", "adjusted", "mean", "difference", ",", "1.34", ";", "95", "%", "CI", ",", "0.08", "to", "2.59", ";", "P", "=", ".04", ")", ",", "and", "physical", "well", "-", "being", "(", "adjusted", "mean", "difference", ",", "2.79", ";", "95", "%", "CI", ",", "0.49", "to", "5.1", ";", "P", "=", ".02", ")", ".", "CONCLUSION", "ADAPt", "-", "C", "collaborative", "care", "is", "feasible", "and", "results", "in", "significant", "reduction", "in", "depressive", "symptoms", ",", "improvement", "in", "quality", "of", "life", ",", "and", "lower", "pain", "levels", "compared", "with", "EUC", "for", "patients", "with", "depressive", "disorders", "in", "a", "low", "-", "income", ",", "predominantly", "Hispanic", "population", "in", "public", "sector", "oncology", "clinics", "." ]	[ "Intervention_Educational", "Outcome_Other", "Participant_Condition", "Intervention_Other", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Psychological" ]
depression among low - income patients with cancer . is a Participant_Condition, Alleviating Depression Among Patients With is a Intervention_Educational, Cancer ( ADAPt - C ) collaborative care management is a Intervention_Other, major depression is a Outcome_Mental, intervention is a Intervention_Educational, enhanced usual care is a Intervention_Educational, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education is a Intervention_Educational, structured psychotherapy is a Intervention_Psychological, maintenance / relapse prevention support is a Intervention_Educational, antidepressant medications is a Intervention_Pharmacological, depressive symptoms is a Outcome_Mental, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale is a Outcome_Other, PHQ-9 score is a Outcome_Other, greater rates of depression treatment is a Outcome_Mental, better quality - of - life outcomes is a Outcome_Other, emotional is a Outcome_Mental, physical well - being is a Outcome_Mental, ADAPt - C collaborative care is a Intervention_Educational	37259_task1	Sentence: Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics . Instructions: please typing these entity words according to sentence: depression among low - income patients with cancer ., Alleviating Depression Among Patients With, Cancer ( ADAPt - C ) collaborative care management, major depression, intervention, enhanced usual care, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education, structured psychotherapy, maintenance / relapse prevention support, antidepressant medications, depressive symptoms, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale, PHQ-9 score, greater rates of depression treatment, better quality - of - life outcomes, emotional, physical well - being, ADAPt - C collaborative care Options: Intervention_Psychological, Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics .	[ "Randomized", "controlled", "trial", "of", "collaborative", "care", "management", "of", "depression", "among", "low", "-", "income", "patients", "with", "cancer", ".", "PURPOSE", "To", "determine", "the", "effectiveness", "of", "the", "Alleviating", "Depression", "Among", "Patients", "With", "Cancer", "(", "ADAPt", "-", "C", ")", "collaborative", "care", "management", "for", "major", "depression", "or", "dysthymia", ".", "PATIENTS", "AND", "METHODS", "Study", "patients", "included", "472", "low", "-", "income", ",", "predominantly", "female", "Hispanic", "patients", "with", "cancer", "age", ">", "or=", "18", "years", "with", "major", "depression", "(", "49", "%", ")", ",", "dysthymia", "(", "5", "%", ")", ",", "or", "both", "(", "46", "%", ")", ".", "Patients", "were", "randomly", "assigned", "to", "intervention", "(", "n", "=", "242", ")", "or", "enhanced", "usual", "care", "(", "EUC", ";", "n", "=", "230", ")", ".", "Intervention", "patients", "had", "access", "for", "up", "to", "12", "months", "to", "a", "depression", "clinical", "specialist", "(", "supervised", "by", "a", "psychiatrist", ")", "who", "offered", "education", ",", "structured", "psychotherapy", ",", "and", "maintenance", "/", "relapse", "prevention", "support", ".", "The", "psychiatrist", "prescribed", "antidepressant", "medications", "for", "patients", "preferring", "or", "assessed", "to", "require", "medication", ".", "RESULTS", "At", "12", "months", ",", "63", "%", "of", "intervention", "patients", "had", "a", "50", "%", "or", "greater", "reduction", "in", "depressive", "symptoms", "from", "baseline", "as", "assessed", "by", "the", "Patient", "Health", "Questionnaire-9", "(", "PHQ-9", ")", "depression", "scale", "compared", "with", "50", "%", "of", "EUC", "patients", "(", "odds", "ratio", "[", "OR", "]", "=", "1.98", ";", "95", "%", "CI", ",", "1.16", "to", "3.38", ";", "P", "=", ".01", ")", ".", "Improvement", "was", "also", "found", "for", "5-point", "decrease", "in", "PHQ-9", "score", "among", "72.2", "%", "of", "intervention", "patients", "compared", "with", "59.7", "%", "of", "EUC", "patients", "(", "OR", "=", "1.99", ";", "95", "%", "CI", ",", "1.14", "to", "3.50", ";", "P", "=", ".02", ")", ".", "Intervention", "patients", "also", "experienced", "greater", "rates", "of", "depression", "treatment", "(", "72.3", "%", "v", "10.4", "%", "of", "EUC", "patients", ";", "P", "<", ".0001", ")", "and", "significantly", "better", "quality", "-", "of", "-", "life", "outcomes", ",", "including", "social", "/", "family", "(", "adjusted", "mean", "difference", "between", "groups", ",", "2.7", ";", "95", "%", "CI", ",", "1.22", "to", "4.17", ";", "P", "<", ".001", ")", ",", "emotional", "(", "adjusted", "mean", "difference", ",", "1.29", ";", "95", "%", "CI", ",", "0.26", "to", "2.22", ";", "P", "=", ".01", ")", ",", "functional", "(", "adjusted", "mean", "difference", ",", "1.34", ";", "95", "%", "CI", ",", "0.08", "to", "2.59", ";", "P", "=", ".04", ")", ",", "and", "physical", "well", "-", "being", "(", "adjusted", "mean", "difference", ",", "2.79", ";", "95", "%", "CI", ",", "0.49", "to", "5.1", ";", "P", "=", ".02", ")", ".", "CONCLUSION", "ADAPt", "-", "C", "collaborative", "care", "is", "feasible", "and", "results", "in", "significant", "reduction", "in", "depressive", "symptoms", ",", "improvement", "in", "quality", "of", "life", ",", "and", "lower", "pain", "levels", "compared", "with", "EUC", "for", "patients", "with", "depressive", "disorders", "in", "a", "low", "-", "income", ",", "predominantly", "Hispanic", "population", "in", "public", "sector", "oncology", "clinics", "." ]	[ "Intervention_Educational", "Outcome_Other", "Participant_Condition", "Intervention_Other", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Psychological" ]
depression among low - income patients with cancer ., Alleviating Depression Among Patients With, Cancer ( ADAPt - C ) collaborative care management, major depression, intervention, enhanced usual care, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education, structured psychotherapy, maintenance / relapse prevention support, antidepressant medications, depressive symptoms, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale, PHQ-9 score, greater rates of depression treatment, better quality - of - life outcomes, emotional, physical well - being, ADAPt - C collaborative care	37259_task2	Sentence: Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics .	[ "Randomized", "controlled", "trial", "of", "collaborative", "care", "management", "of", "depression", "among", "low", "-", "income", "patients", "with", "cancer", ".", "PURPOSE", "To", "determine", "the", "effectiveness", "of", "the", "Alleviating", "Depression", "Among", "Patients", "With", "Cancer", "(", "ADAPt", "-", "C", ")", "collaborative", "care", "management", "for", "major", "depression", "or", "dysthymia", ".", "PATIENTS", "AND", "METHODS", "Study", "patients", "included", "472", "low", "-", "income", ",", "predominantly", "female", "Hispanic", "patients", "with", "cancer", "age", ">", "or=", "18", "years", "with", "major", "depression", "(", "49", "%", ")", ",", "dysthymia", "(", "5", "%", ")", ",", "or", "both", "(", "46", "%", ")", ".", "Patients", "were", "randomly", "assigned", "to", "intervention", "(", "n", "=", "242", ")", "or", "enhanced", "usual", "care", "(", "EUC", ";", "n", "=", "230", ")", ".", "Intervention", "patients", "had", "access", "for", "up", "to", "12", "months", "to", "a", "depression", "clinical", "specialist", "(", "supervised", "by", "a", "psychiatrist", ")", "who", "offered", "education", ",", "structured", "psychotherapy", ",", "and", "maintenance", "/", "relapse", "prevention", "support", ".", "The", "psychiatrist", "prescribed", "antidepressant", "medications", "for", "patients", "preferring", "or", "assessed", "to", "require", "medication", ".", "RESULTS", "At", "12", "months", ",", "63", "%", "of", "intervention", "patients", "had", "a", "50", "%", "or", "greater", "reduction", "in", "depressive", "symptoms", "from", "baseline", "as", "assessed", "by", "the", "Patient", "Health", "Questionnaire-9", "(", "PHQ-9", ")", "depression", "scale", "compared", "with", "50", "%", "of", "EUC", "patients", "(", "odds", "ratio", "[", "OR", "]", "=", "1.98", ";", "95", "%", "CI", ",", "1.16", "to", "3.38", ";", "P", "=", ".01", ")", ".", "Improvement", "was", "also", "found", "for", "5-point", "decrease", "in", "PHQ-9", "score", "among", "72.2", "%", "of", "intervention", "patients", "compared", "with", "59.7", "%", "of", "EUC", "patients", "(", "OR", "=", "1.99", ";", "95", "%", "CI", ",", "1.14", "to", "3.50", ";", "P", "=", ".02", ")", ".", "Intervention", "patients", "also", "experienced", "greater", "rates", "of", "depression", "treatment", "(", "72.3", "%", "v", "10.4", "%", "of", "EUC", "patients", ";", "P", "<", ".0001", ")", "and", "significantly", "better", "quality", "-", "of", "-", "life", "outcomes", ",", "including", "social", "/", "family", "(", "adjusted", "mean", "difference", "between", "groups", ",", "2.7", ";", "95", "%", "CI", ",", "1.22", "to", "4.17", ";", "P", "<", ".001", ")", ",", "emotional", "(", "adjusted", "mean", "difference", ",", "1.29", ";", "95", "%", "CI", ",", "0.26", "to", "2.22", ";", "P", "=", ".01", ")", ",", "functional", "(", "adjusted", "mean", "difference", ",", "1.34", ";", "95", "%", "CI", ",", "0.08", "to", "2.59", ";", "P", "=", ".04", ")", ",", "and", "physical", "well", "-", "being", "(", "adjusted", "mean", "difference", ",", "2.79", ";", "95", "%", "CI", ",", "0.49", "to", "5.1", ";", "P", "=", ".02", ")", ".", "CONCLUSION", "ADAPt", "-", "C", "collaborative", "care", "is", "feasible", "and", "results", "in", "significant", "reduction", "in", "depressive", "symptoms", ",", "improvement", "in", "quality", "of", "life", ",", "and", "lower", "pain", "levels", "compared", "with", "EUC", "for", "patients", "with", "depressive", "disorders", "in", "a", "low", "-", "income", ",", "predominantly", "Hispanic", "population", "in", "public", "sector", "oncology", "clinics", "." ]	[ "Intervention_Educational", "Outcome_Other", "Participant_Condition", "Intervention_Other", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Psychological" ]
Bacillus intermedius is a Microorganism, streptomycin - resistant is a Phenotype, Bacillus intermedius S3 - 19 is a Microorganism, B. intermedius is a Microorganism, Bacillus is a Microorganism	70_task0	Sentence: Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties.	[ "Isolation", "and", "properties", "of", "extracellular", "alkaline", "phosphatase", "from", "Bacillus", "intermedius", ".", "Alkaline", "phosphatase", "(", "APase", ")", "was", "isolated", "from", "the", "culture", "liquid", "of", "the", "streptomycin", "-", "resistant", "strain", "of", "Bacillus", "intermedius", "S3", "-", "19", "and", "purified", "as", "a", "homogeneous", "preparation", "by", "ion", "-", "exchange", "chromatography", "and", "FPLC", ".", "Electrophoresis", "and", "gel", "-", "filtration", "revealed", "that", "the", "active", "enzyme", "is", "a", "monomer", "with", "molecular", "weight", "of", "46", "-", "47", "kD.", "The", "enzyme", "possessed", "phosphomonoesterase", "and", "phosphodiesterase", "activities", "with", "maximal", "levels", "at", "pH", "9.5", "and", "55", "degreesC", "and", "was", "stable", "until", "60", "degreesC", "at", "pH", "8.0", "-", "10.0", ".", "The", "isolated", "APase", "exhibits", "a", "broad", "specificity", "towards", "a", "wide", "variety", "of", "substrates", ".", "The", "effect", "of", "divalent", "metal", "ions", "and", "other", "reagents", "on", "its", "catalytic", "activities", "was", "studied", ".", "It", "was", "concluded", "that", "alkaline", "phosphatase", "of", "B.", "intermedius", "is", "similar", "to", "the", "secreted", "alkaline", "phosphatases", "from", "other", "Bacillus", "species", "in", "its", "physicochemical", "and", "catalytic", "properties", ".", " " ]	[ "Microorganism", "Phenotype" ]
Bacillus intermedius is a Microorganism, streptomycin - resistant is a Phenotype, Bacillus intermedius S3 - 19 is a Microorganism, B. intermedius is a Microorganism, Bacillus is a Microorganism	70_task1	Sentence: Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties. Instructions: please typing these entity words according to sentence: Bacillus intermedius, streptomycin - resistant, Bacillus intermedius S3 - 19, B. intermedius, Bacillus Options: Microorganism, Phenotype	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties.	[ "Isolation", "and", "properties", "of", "extracellular", "alkaline", "phosphatase", "from", "Bacillus", "intermedius", ".", "Alkaline", "phosphatase", "(", "APase", ")", "was", "isolated", "from", "the", "culture", "liquid", "of", "the", "streptomycin", "-", "resistant", "strain", "of", "Bacillus", "intermedius", "S3", "-", "19", "and", "purified", "as", "a", "homogeneous", "preparation", "by", "ion", "-", "exchange", "chromatography", "and", "FPLC", ".", "Electrophoresis", "and", "gel", "-", "filtration", "revealed", "that", "the", "active", "enzyme", "is", "a", "monomer", "with", "molecular", "weight", "of", "46", "-", "47", "kD.", "The", "enzyme", "possessed", "phosphomonoesterase", "and", "phosphodiesterase", "activities", "with", "maximal", "levels", "at", "pH", "9.5", "and", "55", "degreesC", "and", "was", "stable", "until", "60", "degreesC", "at", "pH", "8.0", "-", "10.0", ".", "The", "isolated", "APase", "exhibits", "a", "broad", "specificity", "towards", "a", "wide", "variety", "of", "substrates", ".", "The", "effect", "of", "divalent", "metal", "ions", "and", "other", "reagents", "on", "its", "catalytic", "activities", "was", "studied", ".", "It", "was", "concluded", "that", "alkaline", "phosphatase", "of", "B.", "intermedius", "is", "similar", "to", "the", "secreted", "alkaline", "phosphatases", "from", "other", "Bacillus", "species", "in", "its", "physicochemical", "and", "catalytic", "properties", ".", " " ]	[ "Microorganism", "Phenotype" ]
Bacillus intermedius, streptomycin - resistant, Bacillus intermedius S3 - 19, B. intermedius, Bacillus	70_task2	Sentence: Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties.	[ "Isolation", "and", "properties", "of", "extracellular", "alkaline", "phosphatase", "from", "Bacillus", "intermedius", ".", "Alkaline", "phosphatase", "(", "APase", ")", "was", "isolated", "from", "the", "culture", "liquid", "of", "the", "streptomycin", "-", "resistant", "strain", "of", "Bacillus", "intermedius", "S3", "-", "19", "and", "purified", "as", "a", "homogeneous", "preparation", "by", "ion", "-", "exchange", "chromatography", "and", "FPLC", ".", "Electrophoresis", "and", "gel", "-", "filtration", "revealed", "that", "the", "active", "enzyme", "is", "a", "monomer", "with", "molecular", "weight", "of", "46", "-", "47", "kD.", "The", "enzyme", "possessed", "phosphomonoesterase", "and", "phosphodiesterase", "activities", "with", "maximal", "levels", "at", "pH", "9.5", "and", "55", "degreesC", "and", "was", "stable", "until", "60", "degreesC", "at", "pH", "8.0", "-", "10.0", ".", "The", "isolated", "APase", "exhibits", "a", "broad", "specificity", "towards", "a", "wide", "variety", "of", "substrates", ".", "The", "effect", "of", "divalent", "metal", "ions", "and", "other", "reagents", "on", "its", "catalytic", "activities", "was", "studied", ".", "It", "was", "concluded", "that", "alkaline", "phosphatase", "of", "B.", "intermedius", "is", "similar", "to", "the", "secreted", "alkaline", "phosphatases", "from", "other", "Bacillus", "species", "in", "its", "physicochemical", "and", "catalytic", "properties", ".", " " ]	[ "Microorganism", "Phenotype" ]
Respiratoren is an umlsterm, Ventilation is an umlsterm, Druckanstiegszeit is an umlsterm, Atemarbeit is an umlsterm, Patienten is an umlsterm, Atemwegsobstruktion is an umlsterm, COPD is an umlsterm, Patienten is an umlsterm, Lungenerkrankung is an umlsterm, Atemarbeit is an umlsterm, Druckunterstuetzung is an umlsterm, Druckanstiegszeit is an umlsterm, Druckanstiegszeit is an umlsterm, Patientengruppen is an umlsterm, Atemarbeit is an umlsterm, Druckanstiegszeiten is an umlsterm, Druckunterstuetzung is an umlsterm, intrinsischen PEEP is an umlsterm, Patienten is an umlsterm, COPD is an umlsterm, Patientenatemarbeit is an umlsterm, Patienten is an umlsterm, Druckanstiegszeit is an umlsterm	DerAnaesthesist.60451051.ger.abstr_task0	Sentence: Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein .	[ "Bei", "einigen", "Respiratoren", "kann", "unter", "Pressure", "Support", "Ventilation", "(", "PSV", ")", "der", "Inspirationsfluss", "(", "V.", "i", ")", "durch", "Veraenderung", "der", "Druckanstiegszeit", "variiert", "werden", ".", "Ueber", "den", "Einfluss", "des", "Inspirationsflussprofils", "unter", "PSV", "auf", "die", "Atemarbeit", "ist", "besonders", "bei", "Patienten", "mit", "chronischer", "Atemwegsobstruktion", "(", "COPD", ")", "kaum", "etwas", "bekannt", ".", "Wir", "untersuchten", "an", "6", "COPD", "-", "Patienten", "und", "6", "Patienten", "ohne", "Lungenerkrankung", "(", "Kontrollgruppe", ")", "die", "Effekte", "einer", "Variation", "von", "V.", "i", "unter", "PSV", "auf", "atemmechanische", "Variablen", "und", "die", "mechanische", "Atemarbeit", ".", "Unter", "individuell", "eingestellter", "Druckunterstuetzung", "wurde", "die", "Druckanstiegszeit", "in", "5", "Stufen", "veraendert", ".", "Die", "Verlaengerung", "der", "Druckanstiegszeit", "verminderte", "den", "initialen", "V.", "i", "in", "beiden", "Patientengruppen", ".", "Gleichzeitig", "stieg", "die", "Atemarbeit", "in", "der", "COPD", "-", "Gruppe", "bei", "verringertem", "V.", "i", "signifikant", "an", ".", "Eine", "Ursache", "hierfuer", "war", ",", "dass", "bei", "den", "COPD", "-", "Patienten", "bei", "langsamen", "Druckanstiegszeiten", "die", "eingestellte", "Druckunterstuetzung", "nicht", "mehr", "erreicht", "wurde", ".", "Der", "langsamere", "V.", "i", "fuehrte", "zu", "einer", "Verlaengerung", "der", "Inspiration", "auf", "Kosten", "der", "Exspirationszeit", ".", "Dies", "verursachte", "bei", "COPD", "-", "Patienten", "eine", "unerwuenschte", "Erhoehung", "des", "intrinsischen", "PEEP", ".", "Die", "Auswirkungen", "eines", "niedrigeren", "V.", "i", "unter", "PSV", "in", "der", "Kontrollgruppe", "waren", "klinisch", "nur", "wenig", "relevant", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "besonders", "bei", "Patienten", "mit", "COPD", "unter", "PSV", "hohe", "initiale", "Inspirationsfluesse", "zu", "bevorzugen", "sind", ",", "da", "ein", "niedriger", "Fluss", "die", "Patientenatemarbeit", "erhoeht", "und", "eine", "dynamische", "Lungenueberblaehung", "verstaerkt", ".", "Allerdings", "konnte", "bei", "einem", "Patienten", "ein", "vorzeitiger", "Inspirationsabbruch", "aufgrund", "eines", "hohen", "Initialflusses", "durch", "Anpassung", "des", "Flussprofils", "korrigiert", "werden", ".", "In", "Einzelfaellen", "kann", "daher", "eine", "Verlaengerung", "der", "Druckanstiegszeit", "bis", "auf", "maximal", "1", "s", "sinnvoll", "sein", "." ]	[ "umlsterm" ]
Respiratoren is an umlsterm, Ventilation is an umlsterm, Druckanstiegszeit is an umlsterm, Atemarbeit is an umlsterm, Patienten is an umlsterm, Atemwegsobstruktion is an umlsterm, COPD is an umlsterm, Patienten is an umlsterm, Lungenerkrankung is an umlsterm, Atemarbeit is an umlsterm, Druckunterstuetzung is an umlsterm, Druckanstiegszeit is an umlsterm, Druckanstiegszeit is an umlsterm, Patientengruppen is an umlsterm, Atemarbeit is an umlsterm, Druckanstiegszeiten is an umlsterm, Druckunterstuetzung is an umlsterm, intrinsischen PEEP is an umlsterm, Patienten is an umlsterm, COPD is an umlsterm, Patientenatemarbeit is an umlsterm, Patienten is an umlsterm, Druckanstiegszeit is an umlsterm	DerAnaesthesist.60451051.ger.abstr_task1	Sentence: Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein . Instructions: please typing these entity words according to sentence: Respiratoren, Ventilation, Druckanstiegszeit, Atemarbeit, Patienten, Atemwegsobstruktion, COPD, Patienten, Lungenerkrankung, Atemarbeit, Druckunterstuetzung, Druckanstiegszeit, Druckanstiegszeit, Patientengruppen, Atemarbeit, Druckanstiegszeiten, Druckunterstuetzung, intrinsischen PEEP, Patienten, COPD, Patientenatemarbeit, Patienten, Druckanstiegszeit Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein .	[ "Bei", "einigen", "Respiratoren", "kann", "unter", "Pressure", "Support", "Ventilation", "(", "PSV", ")", "der", "Inspirationsfluss", "(", "V.", "i", ")", "durch", "Veraenderung", "der", "Druckanstiegszeit", "variiert", "werden", ".", "Ueber", "den", "Einfluss", "des", "Inspirationsflussprofils", "unter", "PSV", "auf", "die", "Atemarbeit", "ist", "besonders", "bei", "Patienten", "mit", "chronischer", "Atemwegsobstruktion", "(", "COPD", ")", "kaum", "etwas", "bekannt", ".", "Wir", "untersuchten", "an", "6", "COPD", "-", "Patienten", "und", "6", "Patienten", "ohne", "Lungenerkrankung", "(", "Kontrollgruppe", ")", "die", "Effekte", "einer", "Variation", "von", "V.", "i", "unter", "PSV", "auf", "atemmechanische", "Variablen", "und", "die", "mechanische", "Atemarbeit", ".", "Unter", "individuell", "eingestellter", "Druckunterstuetzung", "wurde", "die", "Druckanstiegszeit", "in", "5", "Stufen", "veraendert", ".", "Die", "Verlaengerung", "der", "Druckanstiegszeit", "verminderte", "den", "initialen", "V.", "i", "in", "beiden", "Patientengruppen", ".", "Gleichzeitig", "stieg", "die", "Atemarbeit", "in", "der", "COPD", "-", "Gruppe", "bei", "verringertem", "V.", "i", "signifikant", "an", ".", "Eine", "Ursache", "hierfuer", "war", ",", "dass", "bei", "den", "COPD", "-", "Patienten", "bei", "langsamen", "Druckanstiegszeiten", "die", "eingestellte", "Druckunterstuetzung", "nicht", "mehr", "erreicht", "wurde", ".", "Der", "langsamere", "V.", "i", "fuehrte", "zu", "einer", "Verlaengerung", "der", "Inspiration", "auf", "Kosten", "der", "Exspirationszeit", ".", "Dies", "verursachte", "bei", "COPD", "-", "Patienten", "eine", "unerwuenschte", "Erhoehung", "des", "intrinsischen", "PEEP", ".", "Die", "Auswirkungen", "eines", "niedrigeren", "V.", "i", "unter", "PSV", "in", "der", "Kontrollgruppe", "waren", "klinisch", "nur", "wenig", "relevant", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "besonders", "bei", "Patienten", "mit", "COPD", "unter", "PSV", "hohe", "initiale", "Inspirationsfluesse", "zu", "bevorzugen", "sind", ",", "da", "ein", "niedriger", "Fluss", "die", "Patientenatemarbeit", "erhoeht", "und", "eine", "dynamische", "Lungenueberblaehung", "verstaerkt", ".", "Allerdings", "konnte", "bei", "einem", "Patienten", "ein", "vorzeitiger", "Inspirationsabbruch", "aufgrund", "eines", "hohen", "Initialflusses", "durch", "Anpassung", "des", "Flussprofils", "korrigiert", "werden", ".", "In", "Einzelfaellen", "kann", "daher", "eine", "Verlaengerung", "der", "Druckanstiegszeit", "bis", "auf", "maximal", "1", "s", "sinnvoll", "sein", "." ]	[ "umlsterm" ]
Respiratoren, Ventilation, Druckanstiegszeit, Atemarbeit, Patienten, Atemwegsobstruktion, COPD, Patienten, Lungenerkrankung, Atemarbeit, Druckunterstuetzung, Druckanstiegszeit, Druckanstiegszeit, Patientengruppen, Atemarbeit, Druckanstiegszeiten, Druckunterstuetzung, intrinsischen PEEP, Patienten, COPD, Patientenatemarbeit, Patienten, Druckanstiegszeit	DerAnaesthesist.60451051.ger.abstr_task2	Sentence: Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein .	[ "Bei", "einigen", "Respiratoren", "kann", "unter", "Pressure", "Support", "Ventilation", "(", "PSV", ")", "der", "Inspirationsfluss", "(", "V.", "i", ")", "durch", "Veraenderung", "der", "Druckanstiegszeit", "variiert", "werden", ".", "Ueber", "den", "Einfluss", "des", "Inspirationsflussprofils", "unter", "PSV", "auf", "die", "Atemarbeit", "ist", "besonders", "bei", "Patienten", "mit", "chronischer", "Atemwegsobstruktion", "(", "COPD", ")", "kaum", "etwas", "bekannt", ".", "Wir", "untersuchten", "an", "6", "COPD", "-", "Patienten", "und", "6", "Patienten", "ohne", "Lungenerkrankung", "(", "Kontrollgruppe", ")", "die", "Effekte", "einer", "Variation", "von", "V.", "i", "unter", "PSV", "auf", "atemmechanische", "Variablen", "und", "die", "mechanische", "Atemarbeit", ".", "Unter", "individuell", "eingestellter", "Druckunterstuetzung", "wurde", "die", "Druckanstiegszeit", "in", "5", "Stufen", "veraendert", ".", "Die", "Verlaengerung", "der", "Druckanstiegszeit", "verminderte", "den", "initialen", "V.", "i", "in", "beiden", "Patientengruppen", ".", "Gleichzeitig", "stieg", "die", "Atemarbeit", "in", "der", "COPD", "-", "Gruppe", "bei", "verringertem", "V.", "i", "signifikant", "an", ".", "Eine", "Ursache", "hierfuer", "war", ",", "dass", "bei", "den", "COPD", "-", "Patienten", "bei", "langsamen", "Druckanstiegszeiten", "die", "eingestellte", "Druckunterstuetzung", "nicht", "mehr", "erreicht", "wurde", ".", "Der", "langsamere", "V.", "i", "fuehrte", "zu", "einer", "Verlaengerung", "der", "Inspiration", "auf", "Kosten", "der", "Exspirationszeit", ".", "Dies", "verursachte", "bei", "COPD", "-", "Patienten", "eine", "unerwuenschte", "Erhoehung", "des", "intrinsischen", "PEEP", ".", "Die", "Auswirkungen", "eines", "niedrigeren", "V.", "i", "unter", "PSV", "in", "der", "Kontrollgruppe", "waren", "klinisch", "nur", "wenig", "relevant", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "besonders", "bei", "Patienten", "mit", "COPD", "unter", "PSV", "hohe", "initiale", "Inspirationsfluesse", "zu", "bevorzugen", "sind", ",", "da", "ein", "niedriger", "Fluss", "die", "Patientenatemarbeit", "erhoeht", "und", "eine", "dynamische", "Lungenueberblaehung", "verstaerkt", ".", "Allerdings", "konnte", "bei", "einem", "Patienten", "ein", "vorzeitiger", "Inspirationsabbruch", "aufgrund", "eines", "hohen", "Initialflusses", "durch", "Anpassung", "des", "Flussprofils", "korrigiert", "werden", ".", "In", "Einzelfaellen", "kann", "daher", "eine", "Verlaengerung", "der", "Druckanstiegszeit", "bis", "auf", "maximal", "1", "s", "sinnvoll", "sein", "." ]	[ "umlsterm" ]
Transcriptional and posttranscriptional regulation is a (AND other_name other_name), erythroid gene expression is an other_name, anthracycline - induced differentiation is an other_name, human erythroleukemic cells is a cell_type	24063_task0	Sentence: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name, (AND other_name other_name)	[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]	Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.	[ "Transcriptional", "and", "posttranscriptional", "regulation", "of", "erythroid", "gene", "expression", "in", "anthracycline", "-", "induced", "differentiation", "of", "human", "erythroleukemic", "cells", "." ]	[ "(AND other_name other_name)", "protein_molecule", "(BUT_NOT cell_line cell_line)", "other_name", "cell_line", "cell_type", "protein_family_or_group", "(AND RNA_molecule RNA_molecule)", "", "DNA_family_or_group", "DNA_domain_or_region", "RNA_family_or_group", "other_organic_compound", "other_artificial_source" ]
Transcriptional and posttranscriptional regulation is a (AND other_name other_name), erythroid gene expression is an other_name, anthracycline - induced differentiation is an other_name, human erythroleukemic cells is a cell_type	24063_task1	Sentence: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Instructions: please typing these entity words according to sentence: Transcriptional and posttranscriptional regulation, erythroid gene expression, anthracycline - induced differentiation, human erythroleukemic cells Options: cell_type, other_name, (AND other_name other_name)	[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]	Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.	[ "Transcriptional", "and", "posttranscriptional", "regulation", "of", "erythroid", "gene", "expression", "in", "anthracycline", "-", "induced", "differentiation", "of", "human", "erythroleukemic", "cells", "." ]	[ "(AND other_name other_name)", "protein_molecule", "(BUT_NOT cell_line cell_line)", "other_name", "cell_line", "cell_type", "protein_family_or_group", "(AND RNA_molecule RNA_molecule)", "", "DNA_family_or_group", "DNA_domain_or_region", "RNA_family_or_group", "other_organic_compound", "other_artificial_source" ]
Transcriptional and posttranscriptional regulation, erythroid gene expression, anthracycline - induced differentiation, human erythroleukemic cells	24063_task2	Sentence: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Instructions: please extract entity words from the input sentence	[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]	Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.	[ "Transcriptional", "and", "posttranscriptional", "regulation", "of", "erythroid", "gene", "expression", "in", "anthracycline", "-", "induced", "differentiation", "of", "human", "erythroleukemic", "cells", "." ]	[ "(AND other_name other_name)", "protein_molecule", "(BUT_NOT cell_line cell_line)", "other_name", "cell_line", "cell_type", "protein_family_or_group", "(AND RNA_molecule RNA_molecule)", "", "DNA_family_or_group", "DNA_domain_or_region", "RNA_family_or_group", "other_organic_compound", "other_artificial_source" ]
tumor necrosis factor alpha is a Protein, TNF - alpha is a Protein, p24 antigen is a Protein	858_task0	Sentence: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients.	[ "Potent", "inhibition", "of", "HIV", "type", "1", "replication", "by", "an", "antiinflammatory", "alkaloid", ",", "cepharanthine", ",", "in", "chronically", "infected", "monocytic", "cells", ".", "\n", "Cepharanthine", "is", "a", "biscoclaurine", "alkaloid", "isolated", "from", "Stephania", "cepharantha", "Hayata", "and", "has", "been", "shown", "to", "have", "antiinflammatory", ",", "antiallergic", ",", "and", "immunomodulatory", "activities", "in", "vivo", ".", "As", "several", "inflammatory", "cytokines", "and", "oxidative", "stresses", "are", "involved", "in", "the", "pathogenesis", "of", "HIV-1", "infection", ",", "we", "investigated", "the", "inhibitory", "effects", "of", "cepharanthine", "on", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha)-", "and", "phorbol", "12-myristate", "13-acetate", "(", "PMA)-induced", "HIV-1", "replication", "in", "chronically", "infected", "cell", "lines", ".", "Two", "chronically", "HIV-1-infected", "cell", "lines", ",", "U1", "(", "monocytic", ")", "and", "ACH-2", "(", "T", "lymphocytic", ")", ",", "were", "stimulated", "with", "TNF", "-", "alpha", "or", "PMA", "and", "cultured", "in", "the", "presence", "of", "various", "concentrations", "of", "the", "compound", ".", "HIV-1", "replication", "was", "determined", "by", "p24", "antigen", "level", ".", "The", "inhibitory", "effects", "of", "cepharanthine", "on", "HIV-1", "long", "terminal", "repeat", "(", "LTR)-driven", "gene", "expression", "and", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", "activation", "were", "also", "examined", ".", "Cepharanthine", "dose", "dependently", "inhibited", "HIV-1", "replication", "in", "TNF", "-", "alpha-", "and", "PMA", "-", "stimulated", "U1", "cells", "but", "not", "in", "ACH-2", "cells", ".", "Its", "50", "%", "effective", "and", "cytotoxic", "concentrations", "were", "0.016", "and", "2.2", "microg", "/", "ml", "in", "PMA", "-", "stimulated", "U1", "cells", ",", "respectively", ".", "Cepharanthine", "was", "found", "to", "suppress", "HIV-1", "LTR", "-", "driven", "gene", "expression", "through", "the", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "These", "results", "indicate", "that", "cepharanthine", "is", "a", "highly", "potent", "inhibitor", "of", "HIV-1", "replication", "in", "a", "chronically", "infected", "monocytic", "cell", "line", ".", "Since", "biscoclaurine", "alkaloids", ",", "containing", "cepharanthine", "as", "a", "major", "component", ",", "are", "widely", "used", "for", "the", "treatment", "of", "patients", "with", "various", "inflammatory", "diseases", "in", "Japan", ",", "cepharanthine", "should", "be", "further", "pursued", "for", "its", "chemotherapeutic", "potential", "in", "HIV-1-infected", "patients", "." ]	[ "Protein" ]
tumor necrosis factor alpha is a Protein, TNF - alpha is a Protein, p24 antigen is a Protein	858_task1	Sentence: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients. Instructions: please typing these entity words according to sentence: tumor necrosis factor alpha, TNF - alpha, p24 antigen Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients.	[ "Potent", "inhibition", "of", "HIV", "type", "1", "replication", "by", "an", "antiinflammatory", "alkaloid", ",", "cepharanthine", ",", "in", "chronically", "infected", "monocytic", "cells", ".", "\n", "Cepharanthine", "is", "a", "biscoclaurine", "alkaloid", "isolated", "from", "Stephania", "cepharantha", "Hayata", "and", "has", "been", "shown", "to", "have", "antiinflammatory", ",", "antiallergic", ",", "and", "immunomodulatory", "activities", "in", "vivo", ".", "As", "several", "inflammatory", "cytokines", "and", "oxidative", "stresses", "are", "involved", "in", "the", "pathogenesis", "of", "HIV-1", "infection", ",", "we", "investigated", "the", "inhibitory", "effects", "of", "cepharanthine", "on", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha)-", "and", "phorbol", "12-myristate", "13-acetate", "(", "PMA)-induced", "HIV-1", "replication", "in", "chronically", "infected", "cell", "lines", ".", "Two", "chronically", "HIV-1-infected", "cell", "lines", ",", "U1", "(", "monocytic", ")", "and", "ACH-2", "(", "T", "lymphocytic", ")", ",", "were", "stimulated", "with", "TNF", "-", "alpha", "or", "PMA", "and", "cultured", "in", "the", "presence", "of", "various", "concentrations", "of", "the", "compound", ".", "HIV-1", "replication", "was", "determined", "by", "p24", "antigen", "level", ".", "The", "inhibitory", "effects", "of", "cepharanthine", "on", "HIV-1", "long", "terminal", "repeat", "(", "LTR)-driven", "gene", "expression", "and", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", "activation", "were", "also", "examined", ".", "Cepharanthine", "dose", "dependently", "inhibited", "HIV-1", "replication", "in", "TNF", "-", "alpha-", "and", "PMA", "-", "stimulated", "U1", "cells", "but", "not", "in", "ACH-2", "cells", ".", "Its", "50", "%", "effective", "and", "cytotoxic", "concentrations", "were", "0.016", "and", "2.2", "microg", "/", "ml", "in", "PMA", "-", "stimulated", "U1", "cells", ",", "respectively", ".", "Cepharanthine", "was", "found", "to", "suppress", "HIV-1", "LTR", "-", "driven", "gene", "expression", "through", "the", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "These", "results", "indicate", "that", "cepharanthine", "is", "a", "highly", "potent", "inhibitor", "of", "HIV-1", "replication", "in", "a", "chronically", "infected", "monocytic", "cell", "line", ".", "Since", "biscoclaurine", "alkaloids", ",", "containing", "cepharanthine", "as", "a", "major", "component", ",", "are", "widely", "used", "for", "the", "treatment", "of", "patients", "with", "various", "inflammatory", "diseases", "in", "Japan", ",", "cepharanthine", "should", "be", "further", "pursued", "for", "its", "chemotherapeutic", "potential", "in", "HIV-1-infected", "patients", "." ]	[ "Protein" ]
tumor necrosis factor alpha, TNF - alpha, p24 antigen	858_task2	Sentence: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients.	[ "Potent", "inhibition", "of", "HIV", "type", "1", "replication", "by", "an", "antiinflammatory", "alkaloid", ",", "cepharanthine", ",", "in", "chronically", "infected", "monocytic", "cells", ".", "\n", "Cepharanthine", "is", "a", "biscoclaurine", "alkaloid", "isolated", "from", "Stephania", "cepharantha", "Hayata", "and", "has", "been", "shown", "to", "have", "antiinflammatory", ",", "antiallergic", ",", "and", "immunomodulatory", "activities", "in", "vivo", ".", "As", "several", "inflammatory", "cytokines", "and", "oxidative", "stresses", "are", "involved", "in", "the", "pathogenesis", "of", "HIV-1", "infection", ",", "we", "investigated", "the", "inhibitory", "effects", "of", "cepharanthine", "on", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha)-", "and", "phorbol", "12-myristate", "13-acetate", "(", "PMA)-induced", "HIV-1", "replication", "in", "chronically", "infected", "cell", "lines", ".", "Two", "chronically", "HIV-1-infected", "cell", "lines", ",", "U1", "(", "monocytic", ")", "and", "ACH-2", "(", "T", "lymphocytic", ")", ",", "were", "stimulated", "with", "TNF", "-", "alpha", "or", "PMA", "and", "cultured", "in", "the", "presence", "of", "various", "concentrations", "of", "the", "compound", ".", "HIV-1", "replication", "was", "determined", "by", "p24", "antigen", "level", ".", "The", "inhibitory", "effects", "of", "cepharanthine", "on", "HIV-1", "long", "terminal", "repeat", "(", "LTR)-driven", "gene", "expression", "and", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", "activation", "were", "also", "examined", ".", "Cepharanthine", "dose", "dependently", "inhibited", "HIV-1", "replication", "in", "TNF", "-", "alpha-", "and", "PMA", "-", "stimulated", "U1", "cells", "but", "not", "in", "ACH-2", "cells", ".", "Its", "50", "%", "effective", "and", "cytotoxic", "concentrations", "were", "0.016", "and", "2.2", "microg", "/", "ml", "in", "PMA", "-", "stimulated", "U1", "cells", ",", "respectively", ".", "Cepharanthine", "was", "found", "to", "suppress", "HIV-1", "LTR", "-", "driven", "gene", "expression", "through", "the", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "These", "results", "indicate", "that", "cepharanthine", "is", "a", "highly", "potent", "inhibitor", "of", "HIV-1", "replication", "in", "a", "chronically", "infected", "monocytic", "cell", "line", ".", "Since", "biscoclaurine", "alkaloids", ",", "containing", "cepharanthine", "as", "a", "major", "component", ",", "are", "widely", "used", "for", "the", "treatment", "of", "patients", "with", "various", "inflammatory", "diseases", "in", "Japan", ",", "cepharanthine", "should", "be", "further", "pursued", "for", "its", "chemotherapeutic", "potential", "in", "HIV-1-infected", "patients", "." ]	[ "Protein" ]
DNA methyltransferases is a GENE-N, methyl cytosine - binding proteins is a GENE-N	23246732_task0	Sentence: Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]	Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus.	[ "Influence", "of", "developmental", "lead", "exposure", "on", "expression", "of", "DNA", "methyltransferases", "and", "methyl", "cytosine", "-", "binding", "proteins", "in", "hippocampus", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
DNA methyltransferases is a GENE-N, methyl cytosine - binding proteins is a GENE-N	23246732_task1	Sentence: Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Instructions: please typing these entity words according to sentence: DNA methyltransferases, methyl cytosine - binding proteins Options: GENE-N	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]	Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus.	[ "Influence", "of", "developmental", "lead", "exposure", "on", "expression", "of", "DNA", "methyltransferases", "and", "methyl", "cytosine", "-", "binding", "proteins", "in", "hippocampus", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
DNA methyltransferases, methyl cytosine - binding proteins	23246732_task2	Sentence: Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]	Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus.	[ "Influence", "of", "developmental", "lead", "exposure", "on", "expression", "of", "DNA", "methyltransferases", "and", "methyl", "cytosine", "-", "binding", "proteins", "in", "hippocampus", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
melanoma is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, lesión pulmonar is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor maligno muy indiferenciado is a MORFOLOGIA_NEOPLASIA, MELANOMA is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, metastásico is a MORFOLOGIA_NEOPLASIA, metástasis de melanoma is a MORFOLOGIA_NEOPLASIA	289_task0	Sentence: Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta.	[ "Anamnesis", "\n", "Varón", "de", "61", "años", "con", "antecedentes", "personales", "de", "tabaquismo", ",", "diabetes", "mellitus", "tipo", "2", ",", "enfermedad", "renal", "crónica", "secundaria", "a", "nefropatía", "diabética", "y", "melanoma", "cutáneo", "intervenido", "(", "estadío", "Ib", ")", "en", "1993", ",", "sin", "evidencia", "de", "recidiva", "en", "seguimiento", "posterior", ".", "Consultó", "en", "el", "servicio", "de", "Urgencias", "por", "cuadro", "catarral", "y", "astenia", "de", "1", "mes", "de", "evolución", "sin", "otra", "sintomatología", "añadida", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "presentaba", "un", "buen", "estado", "general", "y", "las", "constantes", "vitales", "se", "encontraban", "en", "rango", "de", "normalidad", ".", "En", "la", "exploración", "física", "destacaba", "una", "cicatriz", "quirúrgica", "de", "melanoma", "extirpado", "en", "región", "dorsal", ",", "así", "como", "disminución", "del", "murmullo", "vesicular", "en", "base", "izquierda", "a", "la", "auscultación", "pulmonar", ".", "No", "se", "objetivaron", "lesiones", "dérmicas", "sospechosas", "de", "malignidad", "ni", "otros", "hallazgos", "de", "interés", "en", "la", "exploración", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "radiografía", "de", "tórax", "se", "produjo", "hallazgo", "casual", "de", "una", "masa", "retrocardíaca", "de", "bordes", "bien", "definidos", ".", "El", "TAC", "torácico", "confirmó", "la", "presencia", "de", "una", "lesión", "pulmonar", "de", "7", "cm", "a", "nivel", "del", "lóbulo", "inferior", "izquierdo", "y", "un", "conglomerado", "adenopático", "subcarinal", "de", "3.5x2.5", "cm", ".", "\n", "El", "hemograma", "mostró", "una", "anemia", "leve", ",", "con", "hemoglobina", "de", "11.5", ",", "y", "una", "leucocitosis", "de", "17100", "con", "desviación", "izquierda", ".", "La", "coagulación", "no", "presentaba", "alteraciones", ",", "y", "en", "la", "bioquímica", "destacaba", "una", "creatinina", "de", "1.49", "y", "una", "PCR", "de", "50.9", ",", "sin", "otros", "hallazgos", "reseñables", ".", "Se", "solicitaron", "marcadores", "tumorales", ",", "encontrándose", "todos", "ellos", "en", "rango", "de", "normalidad", ".", "\n", "Se", "procedió", "a", "realización", "de", "broncoscopia", "con", "toma", "de", "biopsia", "de", "la", "masa", "pulmonar", ",", "sin", "poder", "alcanzar", "una", "tipificación", "histológica", "debido", "a", "la", "gran", "indiferenciación", "y", "extensa", "necrosis", "tumoral", "de", "la", "lesión", ".", "Se", "llevó", "a", "cabo", "biopsia", "guiada", "por", "TAC", ",", "que", "aportó", "un", "diagnóstico", "de", "tumor", "maligno", "muy", "indiferenciado", ",", "sin", "poder", "precisar", "el", "origen", "primario", ".", "\n\n", "Diagnóstico", "\n", "Ante", "la", "escasa", "información", "aportada", "por", "las", "sucesivas", "biopsias", "de", "la", "masa", ",", "se", "realizó", "una", "biopsia", "ganglionar", "mediante", "EBUS", "del", "conglomerado", "adenopático", "descrito", "en", "el", "TAC", ".", "En", "esta", "ocasión", ",", "la", "anatomía", "patológica", "arrojó", "un", "resultado", "compatible", "con", "INFILTRACIÓN", "POR", "MELANOMA", ",", "con", "fuerte", "expresión", "positiva", "para", "MELAN", "-", "A", "y", "HMB-45", "y", "reordenamiento", "del", "gen", "BRAF", "V600E.", "\n", "El", "estudio", "de", "extensión", "mediante", "PET", "-", "TAC", "mostró", "captación", "a", "nivel", "de", "la", "masa", "pulmonar", "y", "el", "conglomerado", "adenopático", "subcarinal", ",", "además", "de", "objetivar", "zonas", "hipercaptantes", "susceptibles", "de", "origen", "metastásico", "a", "nivel", "de", "glándula", "suprarrenal", "izquierda", "e", "íleon", ".", "\n\n", "Tratamiento", "\n", "Se", "inició", "tratamiento", "con", "inhibidores", "de", "BRAF", "y", "MEK", "(", "Dabrafenib", "y", "Trametinib", ")", ".", "\n\n", "Evolución", "\n", "Un", "mes", "después", "del", "diagnóstico", "el", "paciente", "ingresó", "por", "cuadro", "de", "dolor", "y", "distensión", "abdominal", ";", "se", "diagnosticó", "de", "obstrucción", "intestinal", "y", "fue", "intervenido", "de", "urgencia", ".", "La", "anatomía", "patológica", "de", "la", "pieza", "quirúrgica", "resultó", "compatible", "con", "metástasis", "de", "melanoma", ",", "con", "mutación", "del", "gen", "BRAF", "y", "con", "pérdida", "de", "marcadores", "melanocíticos", ".", "\n", "En", "la", "actualidad", "el", "paciente", "continúa", "con", "tratamiento", "tras", "un", "intervalo", "libre", "de", "progresión", "de", "9", "meses", ",", "habiéndose", "objetivado", "una", "respuesta", "parcial", "mayor", "morfológica", "como", "máxima", "respuesta", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
melanoma is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, lesión pulmonar is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor maligno muy indiferenciado is a MORFOLOGIA_NEOPLASIA, MELANOMA is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, metastásico is a MORFOLOGIA_NEOPLASIA, metástasis de melanoma is a MORFOLOGIA_NEOPLASIA	289_task1	Sentence: Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta. Instructions: please typing these entity words according to sentence: melanoma, melanoma, malignidad, lesión pulmonar, masa pulmonar, tumoral, tumor maligno muy indiferenciado, MELANOMA, masa pulmonar, metastásico, metástasis de melanoma Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta.	[ "Anamnesis", "\n", "Varón", "de", "61", "años", "con", "antecedentes", "personales", "de", "tabaquismo", ",", "diabetes", "mellitus", "tipo", "2", ",", "enfermedad", "renal", "crónica", "secundaria", "a", "nefropatía", "diabética", "y", "melanoma", "cutáneo", "intervenido", "(", "estadío", "Ib", ")", "en", "1993", ",", "sin", "evidencia", "de", "recidiva", "en", "seguimiento", "posterior", ".", "Consultó", "en", "el", "servicio", "de", "Urgencias", "por", "cuadro", "catarral", "y", "astenia", "de", "1", "mes", "de", "evolución", "sin", "otra", "sintomatología", "añadida", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "presentaba", "un", "buen", "estado", "general", "y", "las", "constantes", "vitales", "se", "encontraban", "en", "rango", "de", "normalidad", ".", "En", "la", "exploración", "física", "destacaba", "una", "cicatriz", "quirúrgica", "de", "melanoma", "extirpado", "en", "región", "dorsal", ",", "así", "como", "disminución", "del", "murmullo", "vesicular", "en", "base", "izquierda", "a", "la", "auscultación", "pulmonar", ".", "No", "se", "objetivaron", "lesiones", "dérmicas", "sospechosas", "de", "malignidad", "ni", "otros", "hallazgos", "de", "interés", "en", "la", "exploración", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "radiografía", "de", "tórax", "se", "produjo", "hallazgo", "casual", "de", "una", "masa", "retrocardíaca", "de", "bordes", "bien", "definidos", ".", "El", "TAC", "torácico", "confirmó", "la", "presencia", "de", "una", "lesión", "pulmonar", "de", "7", "cm", "a", "nivel", "del", "lóbulo", "inferior", "izquierdo", "y", "un", "conglomerado", "adenopático", "subcarinal", "de", "3.5x2.5", "cm", ".", "\n", "El", "hemograma", "mostró", "una", "anemia", "leve", ",", "con", "hemoglobina", "de", "11.5", ",", "y", "una", "leucocitosis", "de", "17100", "con", "desviación", "izquierda", ".", "La", "coagulación", "no", "presentaba", "alteraciones", ",", "y", "en", "la", "bioquímica", "destacaba", "una", "creatinina", "de", "1.49", "y", "una", "PCR", "de", "50.9", ",", "sin", "otros", "hallazgos", "reseñables", ".", "Se", "solicitaron", "marcadores", "tumorales", ",", "encontrándose", "todos", "ellos", "en", "rango", "de", "normalidad", ".", "\n", "Se", "procedió", "a", "realización", "de", "broncoscopia", "con", "toma", "de", "biopsia", "de", "la", "masa", "pulmonar", ",", "sin", "poder", "alcanzar", "una", "tipificación", "histológica", "debido", "a", "la", "gran", "indiferenciación", "y", "extensa", "necrosis", "tumoral", "de", "la", "lesión", ".", "Se", "llevó", "a", "cabo", "biopsia", "guiada", "por", "TAC", ",", "que", "aportó", "un", "diagnóstico", "de", "tumor", "maligno", "muy", "indiferenciado", ",", "sin", "poder", "precisar", "el", "origen", "primario", ".", "\n\n", "Diagnóstico", "\n", "Ante", "la", "escasa", "información", "aportada", "por", "las", "sucesivas", "biopsias", "de", "la", "masa", ",", "se", "realizó", "una", "biopsia", "ganglionar", "mediante", "EBUS", "del", "conglomerado", "adenopático", "descrito", "en", "el", "TAC", ".", "En", "esta", "ocasión", ",", "la", "anatomía", "patológica", "arrojó", "un", "resultado", "compatible", "con", "INFILTRACIÓN", "POR", "MELANOMA", ",", "con", "fuerte", "expresión", "positiva", "para", "MELAN", "-", "A", "y", "HMB-45", "y", "reordenamiento", "del", "gen", "BRAF", "V600E.", "\n", "El", "estudio", "de", "extensión", "mediante", "PET", "-", "TAC", "mostró", "captación", "a", "nivel", "de", "la", "masa", "pulmonar", "y", "el", "conglomerado", "adenopático", "subcarinal", ",", "además", "de", "objetivar", "zonas", "hipercaptantes", "susceptibles", "de", "origen", "metastásico", "a", "nivel", "de", "glándula", "suprarrenal", "izquierda", "e", "íleon", ".", "\n\n", "Tratamiento", "\n", "Se", "inició", "tratamiento", "con", "inhibidores", "de", "BRAF", "y", "MEK", "(", "Dabrafenib", "y", "Trametinib", ")", ".", "\n\n", "Evolución", "\n", "Un", "mes", "después", "del", "diagnóstico", "el", "paciente", "ingresó", "por", "cuadro", "de", "dolor", "y", "distensión", "abdominal", ";", "se", "diagnosticó", "de", "obstrucción", "intestinal", "y", "fue", "intervenido", "de", "urgencia", ".", "La", "anatomía", "patológica", "de", "la", "pieza", "quirúrgica", "resultó", "compatible", "con", "metástasis", "de", "melanoma", ",", "con", "mutación", "del", "gen", "BRAF", "y", "con", "pérdida", "de", "marcadores", "melanocíticos", ".", "\n", "En", "la", "actualidad", "el", "paciente", "continúa", "con", "tratamiento", "tras", "un", "intervalo", "libre", "de", "progresión", "de", "9", "meses", ",", "habiéndose", "objetivado", "una", "respuesta", "parcial", "mayor", "morfológica", "como", "máxima", "respuesta", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
melanoma, melanoma, malignidad, lesión pulmonar, masa pulmonar, tumoral, tumor maligno muy indiferenciado, MELANOMA, masa pulmonar, metastásico, metástasis de melanoma	289_task2	Sentence: Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta.	[ "Anamnesis", "\n", "Varón", "de", "61", "años", "con", "antecedentes", "personales", "de", "tabaquismo", ",", "diabetes", "mellitus", "tipo", "2", ",", "enfermedad", "renal", "crónica", "secundaria", "a", "nefropatía", "diabética", "y", "melanoma", "cutáneo", "intervenido", "(", "estadío", "Ib", ")", "en", "1993", ",", "sin", "evidencia", "de", "recidiva", "en", "seguimiento", "posterior", ".", "Consultó", "en", "el", "servicio", "de", "Urgencias", "por", "cuadro", "catarral", "y", "astenia", "de", "1", "mes", "de", "evolución", "sin", "otra", "sintomatología", "añadida", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "presentaba", "un", "buen", "estado", "general", "y", "las", "constantes", "vitales", "se", "encontraban", "en", "rango", "de", "normalidad", ".", "En", "la", "exploración", "física", "destacaba", "una", "cicatriz", "quirúrgica", "de", "melanoma", "extirpado", "en", "región", "dorsal", ",", "así", "como", "disminución", "del", "murmullo", "vesicular", "en", "base", "izquierda", "a", "la", "auscultación", "pulmonar", ".", "No", "se", "objetivaron", "lesiones", "dérmicas", "sospechosas", "de", "malignidad", "ni", "otros", "hallazgos", "de", "interés", "en", "la", "exploración", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "radiografía", "de", "tórax", "se", "produjo", "hallazgo", "casual", "de", "una", "masa", "retrocardíaca", "de", "bordes", "bien", "definidos", ".", "El", "TAC", "torácico", "confirmó", "la", "presencia", "de", "una", "lesión", "pulmonar", "de", "7", "cm", "a", "nivel", "del", "lóbulo", "inferior", "izquierdo", "y", "un", "conglomerado", "adenopático", "subcarinal", "de", "3.5x2.5", "cm", ".", "\n", "El", "hemograma", "mostró", "una", "anemia", "leve", ",", "con", "hemoglobina", "de", "11.5", ",", "y", "una", "leucocitosis", "de", "17100", "con", "desviación", "izquierda", ".", "La", "coagulación", "no", "presentaba", "alteraciones", ",", "y", "en", "la", "bioquímica", "destacaba", "una", "creatinina", "de", "1.49", "y", "una", "PCR", "de", "50.9", ",", "sin", "otros", "hallazgos", "reseñables", ".", "Se", "solicitaron", "marcadores", "tumorales", ",", "encontrándose", "todos", "ellos", "en", "rango", "de", "normalidad", ".", "\n", "Se", "procedió", "a", "realización", "de", "broncoscopia", "con", "toma", "de", "biopsia", "de", "la", "masa", "pulmonar", ",", "sin", "poder", "alcanzar", "una", "tipificación", "histológica", "debido", "a", "la", "gran", "indiferenciación", "y", "extensa", "necrosis", "tumoral", "de", "la", "lesión", ".", "Se", "llevó", "a", "cabo", "biopsia", "guiada", "por", "TAC", ",", "que", "aportó", "un", "diagnóstico", "de", "tumor", "maligno", "muy", "indiferenciado", ",", "sin", "poder", "precisar", "el", "origen", "primario", ".", "\n\n", "Diagnóstico", "\n", "Ante", "la", "escasa", "información", "aportada", "por", "las", "sucesivas", "biopsias", "de", "la", "masa", ",", "se", "realizó", "una", "biopsia", "ganglionar", "mediante", "EBUS", "del", "conglomerado", "adenopático", "descrito", "en", "el", "TAC", ".", "En", "esta", "ocasión", ",", "la", "anatomía", "patológica", "arrojó", "un", "resultado", "compatible", "con", "INFILTRACIÓN", "POR", "MELANOMA", ",", "con", "fuerte", "expresión", "positiva", "para", "MELAN", "-", "A", "y", "HMB-45", "y", "reordenamiento", "del", "gen", "BRAF", "V600E.", "\n", "El", "estudio", "de", "extensión", "mediante", "PET", "-", "TAC", "mostró", "captación", "a", "nivel", "de", "la", "masa", "pulmonar", "y", "el", "conglomerado", "adenopático", "subcarinal", ",", "además", "de", "objetivar", "zonas", "hipercaptantes", "susceptibles", "de", "origen", "metastásico", "a", "nivel", "de", "glándula", "suprarrenal", "izquierda", "e", "íleon", ".", "\n\n", "Tratamiento", "\n", "Se", "inició", "tratamiento", "con", "inhibidores", "de", "BRAF", "y", "MEK", "(", "Dabrafenib", "y", "Trametinib", ")", ".", "\n\n", "Evolución", "\n", "Un", "mes", "después", "del", "diagnóstico", "el", "paciente", "ingresó", "por", "cuadro", "de", "dolor", "y", "distensión", "abdominal", ";", "se", "diagnosticó", "de", "obstrucción", "intestinal", "y", "fue", "intervenido", "de", "urgencia", ".", "La", "anatomía", "patológica", "de", "la", "pieza", "quirúrgica", "resultó", "compatible", "con", "metástasis", "de", "melanoma", ",", "con", "mutación", "del", "gen", "BRAF", "y", "con", "pérdida", "de", "marcadores", "melanocíticos", ".", "\n", "En", "la", "actualidad", "el", "paciente", "continúa", "con", "tratamiento", "tras", "un", "intervalo", "libre", "de", "progresión", "de", "9", "meses", ",", "habiéndose", "objetivado", "una", "respuesta", "parcial", "mayor", "morfológica", "como", "máxima", "respuesta", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
total occlusive ionic silver - containing dressing combination is a Intervention_Physical, risk of surgical site infection : is a Outcome_Adverse-effects, total occlusive ionic silver - containing dressing ( TOISD ) combination is a Intervention_Physical, no dressing is a Intervention_Control	53467_task0	Sentence: Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Adverse-effects, Intervention_Control	[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI .	[ "Efficacy", "of", "a", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "combination", "in", "decreasing", "risk", "of", "surgical", "site", "infection", ":", "an", "RCT", ".", "OBJECTIVE", "To", "perform", "a", "comparative", "assessment", "of", "the", "efficacy", "of", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "(", "TOISD", ")", "combination", "vs", "no", "dressing", "after", "colorectal", "surgery", ".", "METHOD", "The", "surgical", "sites", "from", "both", "groups", "were", "swabbed", "and", "sent", "for", "culture", "and", "sensitivity", "upon", "wound", "closure", "(", "superficial", "incisional", "skin", "surface", ")", "in", "the", "operating", "theatre", ",", "as", "a", "baseline", "for", "bacterial", "colonisation", ".", "The", "patients", "'", "surgical", "wounds", "in", "the", "study", "group", "were", "dressed", "with", "TOISD", "combination", "and", "the", "patient", "'", "s", "surgical", "wounds", "in", "the", "control", "group", "received", "the", "conventional", "method", "of", "no", "dressing", ".", "A", "second", "swab", "was", "taken", "from", "the", "superficial", "incisional", "skin", "surface", "for", "culture", "and", "sensitivity", "investigation", "between", "the", "fifth", "to", "seventh", "postoperative", "day", "for", "comparison", "of", "the", "bacterial", "colonisation", "in", "the", "two", "groups", ".", "RESULTS", "One", "-", "hundred", "and", "sixty", "-", "six", "patients", "were", "recruited", ".", "Six", "patients", "dropped", "out", "before", "the", "fifth", "postoperative", "day", ",", "leaving", "79", "patients", "in", "the", "control", "group", "and", "81", "patients", "in", "the", "study", "group", ".", "Microbial", "swab", "cultures", "revealed", "significant", "differences", "between", "the", "two", "groups", "(", "p", "<", "0.001", ",", "mean=1.43±0.63", ")", "in", "bacterial", "colonisation", ".", "The", "odds", "ratio", "(", "OR", ")", "of", "patients", "with", "wounds", "in", "the", "control", "group", "was", "4.1", "(", "95", "%", "CI", "is", "1.884", ",", "8.964", ")", "more", "likely", "to", "be", "contaminated", "with", "bacteria", "compared", "with", "wounds", "covered", "with", "occlusive", "ionic", "silver", "-", "containing", "dressing", ".", "CONCLUSION", "TOISD", "was", "found", "to", "be", "effective", "in", "reducing", "bacterial", "colonisation", "on", "the", "surgical", "site", "compared", "with", "no", "dressing", ".", "However", ",", "it", "properties", "were", "unable", "to", "be", "put", "into", "use", "if", "there", "were", "the", "surgical", "sites", "were", "not", "infested", "with", "bacterial", ".", "Although", "TOISD", "might", "not", "be", "necessarily", "on", "surgical", "incisional", "site", "not", "infested", "with", "bacteria", "for", "the", "initial", "post", "-", "operation", "days", ",", "it", "is", "helpful", "in", "preventing", "further", "transcription", "and", "division", "for", "opportunistic", "bacteria", ",", "thus", "might", "reduce", "the", "risk", "of", "superficial", "incisional", "SSI", ".", "The", "use", "of", "TOSID", "though", "statistically", "insignificant", "compared", "to", "no", "dressing", ",", "could", "also", "be", "possible", "in", "reducing", "the", "risk", "and", "exaceration", "of", "deep", "incisional", "SSI", "." ]	[ "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
total occlusive ionic silver - containing dressing combination is a Intervention_Physical, risk of surgical site infection : is a Outcome_Adverse-effects, total occlusive ionic silver - containing dressing ( TOISD ) combination is a Intervention_Physical, no dressing is a Intervention_Control	53467_task1	Sentence: Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI . Instructions: please typing these entity words according to sentence: total occlusive ionic silver - containing dressing combination, risk of surgical site infection :, total occlusive ionic silver - containing dressing ( TOISD ) combination, no dressing Options: Intervention_Physical, Outcome_Adverse-effects, Intervention_Control	[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI .	[ "Efficacy", "of", "a", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "combination", "in", "decreasing", "risk", "of", "surgical", "site", "infection", ":", "an", "RCT", ".", "OBJECTIVE", "To", "perform", "a", "comparative", "assessment", "of", "the", "efficacy", "of", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "(", "TOISD", ")", "combination", "vs", "no", "dressing", "after", "colorectal", "surgery", ".", "METHOD", "The", "surgical", "sites", "from", "both", "groups", "were", "swabbed", "and", "sent", "for", "culture", "and", "sensitivity", "upon", "wound", "closure", "(", "superficial", "incisional", "skin", "surface", ")", "in", "the", "operating", "theatre", ",", "as", "a", "baseline", "for", "bacterial", "colonisation", ".", "The", "patients", "'", "surgical", "wounds", "in", "the", "study", "group", "were", "dressed", "with", "TOISD", "combination", "and", "the", "patient", "'", "s", "surgical", "wounds", "in", "the", "control", "group", "received", "the", "conventional", "method", "of", "no", "dressing", ".", "A", "second", "swab", "was", "taken", "from", "the", "superficial", "incisional", "skin", "surface", "for", "culture", "and", "sensitivity", "investigation", "between", "the", "fifth", "to", "seventh", "postoperative", "day", "for", "comparison", "of", "the", "bacterial", "colonisation", "in", "the", "two", "groups", ".", "RESULTS", "One", "-", "hundred", "and", "sixty", "-", "six", "patients", "were", "recruited", ".", "Six", "patients", "dropped", "out", "before", "the", "fifth", "postoperative", "day", ",", "leaving", "79", "patients", "in", "the", "control", "group", "and", "81", "patients", "in", "the", "study", "group", ".", "Microbial", "swab", "cultures", "revealed", "significant", "differences", "between", "the", "two", "groups", "(", "p", "<", "0.001", ",", "mean=1.43±0.63", ")", "in", "bacterial", "colonisation", ".", "The", "odds", "ratio", "(", "OR", ")", "of", "patients", "with", "wounds", "in", "the", "control", "group", "was", "4.1", "(", "95", "%", "CI", "is", "1.884", ",", "8.964", ")", "more", "likely", "to", "be", "contaminated", "with", "bacteria", "compared", "with", "wounds", "covered", "with", "occlusive", "ionic", "silver", "-", "containing", "dressing", ".", "CONCLUSION", "TOISD", "was", "found", "to", "be", "effective", "in", "reducing", "bacterial", "colonisation", "on", "the", "surgical", "site", "compared", "with", "no", "dressing", ".", "However", ",", "it", "properties", "were", "unable", "to", "be", "put", "into", "use", "if", "there", "were", "the", "surgical", "sites", "were", "not", "infested", "with", "bacterial", ".", "Although", "TOISD", "might", "not", "be", "necessarily", "on", "surgical", "incisional", "site", "not", "infested", "with", "bacteria", "for", "the", "initial", "post", "-", "operation", "days", ",", "it", "is", "helpful", "in", "preventing", "further", "transcription", "and", "division", "for", "opportunistic", "bacteria", ",", "thus", "might", "reduce", "the", "risk", "of", "superficial", "incisional", "SSI", ".", "The", "use", "of", "TOSID", "though", "statistically", "insignificant", "compared", "to", "no", "dressing", ",", "could", "also", "be", "possible", "in", "reducing", "the", "risk", "and", "exaceration", "of", "deep", "incisional", "SSI", "." ]	[ "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
total occlusive ionic silver - containing dressing combination, risk of surgical site infection :, total occlusive ionic silver - containing dressing ( TOISD ) combination, no dressing	53467_task2	Sentence: Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI .	[ "Efficacy", "of", "a", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "combination", "in", "decreasing", "risk", "of", "surgical", "site", "infection", ":", "an", "RCT", ".", "OBJECTIVE", "To", "perform", "a", "comparative", "assessment", "of", "the", "efficacy", "of", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "(", "TOISD", ")", "combination", "vs", "no", "dressing", "after", "colorectal", "surgery", ".", "METHOD", "The", "surgical", "sites", "from", "both", "groups", "were", "swabbed", "and", "sent", "for", "culture", "and", "sensitivity", "upon", "wound", "closure", "(", "superficial", "incisional", "skin", "surface", ")", "in", "the", "operating", "theatre", ",", "as", "a", "baseline", "for", "bacterial", "colonisation", ".", "The", "patients", "'", "surgical", "wounds", "in", "the", "study", "group", "were", "dressed", "with", "TOISD", "combination", "and", "the", "patient", "'", "s", "surgical", "wounds", "in", "the", "control", "group", "received", "the", "conventional", "method", "of", "no", "dressing", ".", "A", "second", "swab", "was", "taken", "from", "the", "superficial", "incisional", "skin", "surface", "for", "culture", "and", "sensitivity", "investigation", "between", "the", "fifth", "to", "seventh", "postoperative", "day", "for", "comparison", "of", "the", "bacterial", "colonisation", "in", "the", "two", "groups", ".", "RESULTS", "One", "-", "hundred", "and", "sixty", "-", "six", "patients", "were", "recruited", ".", "Six", "patients", "dropped", "out", "before", "the", "fifth", "postoperative", "day", ",", "leaving", "79", "patients", "in", "the", "control", "group", "and", "81", "patients", "in", "the", "study", "group", ".", "Microbial", "swab", "cultures", "revealed", "significant", "differences", "between", "the", "two", "groups", "(", "p", "<", "0.001", ",", "mean=1.43±0.63", ")", "in", "bacterial", "colonisation", ".", "The", "odds", "ratio", "(", "OR", ")", "of", "patients", "with", "wounds", "in", "the", "control", "group", "was", "4.1", "(", "95", "%", "CI", "is", "1.884", ",", "8.964", ")", "more", "likely", "to", "be", "contaminated", "with", "bacteria", "compared", "with", "wounds", "covered", "with", "occlusive", "ionic", "silver", "-", "containing", "dressing", ".", "CONCLUSION", "TOISD", "was", "found", "to", "be", "effective", "in", "reducing", "bacterial", "colonisation", "on", "the", "surgical", "site", "compared", "with", "no", "dressing", ".", "However", ",", "it", "properties", "were", "unable", "to", "be", "put", "into", "use", "if", "there", "were", "the", "surgical", "sites", "were", "not", "infested", "with", "bacterial", ".", "Although", "TOISD", "might", "not", "be", "necessarily", "on", "surgical", "incisional", "site", "not", "infested", "with", "bacteria", "for", "the", "initial", "post", "-", "operation", "days", ",", "it", "is", "helpful", "in", "preventing", "further", "transcription", "and", "division", "for", "opportunistic", "bacteria", ",", "thus", "might", "reduce", "the", "risk", "of", "superficial", "incisional", "SSI", ".", "The", "use", "of", "TOSID", "though", "statistically", "insignificant", "compared", "to", "no", "dressing", ",", "could", "also", "be", "possible", "in", "reducing", "the", "risk", "and", "exaceration", "of", "deep", "incisional", "SSI", "." ]	[ "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
GI toxicity is a ADVERSE, GI toxicity is a ADVERSE, hypertension is a ADVERSE, renal impairment is a ADVERSE	example-261_task0	Sentence: Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality.	[ "Utility", "of", "published", "guidelines", "on", "the", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "in", "the", "elderly", ".", " ", "Canadian", "Consensus", "guidelines", "regarding", "appropriate", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAID", ")", "were", "recently", "published", ".", "This", "study", "was", "done", "to", "evaluate", "the", "application", "of", "these", "guidelines", "on", "NSAID", "practice", "patterns", "in", "frail", "elderly", "patients", "referred", "to", "a", "specialist", "Geriatric", "Assessment", "Clinic", ".", "A", "retrospective", "chart", "review", "was", "undertaken", "of", "referrals", "who", "were", "currently", "prescribed", "NSAIDs", ".", "Data", "were", "captured", "on", "age", ",", "sex", ",", "weight", ",", "diagnoses", ",", "medications", "and", "dosages", ",", "indication", "for", "NSAID", "treatment", ",", "lying", "BP", "(", "as", "assessed", "in", "the", "clinic", ")", "and", "recent", "serum", "creatinine", "result", ".", "Creatinine", "clearance", "was", "subsequently", "calculated", "use", "the", "Cockcroft", "-", "Gault", "equation", ".", "Complete", "data", "were", "available", "on", "107", "patients", "(", "68", "%", "women", ",", "average", "age", "80.6", "years", ")", ".", "Thirty", "percent", "were", "on", "a", "traditional", "NSAID", ",", "the", "remainder", "were", "on", "a", "Coxib", ".", "Concomitant", "aspirin", "was", "prescribed", "in", "37", "%", ".", "Cytoprotection", "was", "being", "used", "in", "38", "%", "and", "did", "not", "increase", "appreciably", "in", "patients", "with", "additional", "risk", "factors", "for", "GI", "toxicity", ",", "i.e", ".", ",", "concomitant", "aspirin", "usage", "(", "35", "%", ")", ",", "and", "history", "of", "GI", "toxicity", "(", "48", "%", ")", ".", "Sixty", "-", "seven", "were", "taking", "anti", "-", "hypertensive", "medications", ",", "although", "more", "than", "two", "thirds", "of", "these", "patients", "were", "uncontrolled", ".", "Newly", "diagnosed", "hypertension", "was", "present", "in", "19.6", "%", ".", "Calculated", "creatinine", "clearance", "revealed", "moderate", "to", "severe", "renal", "impairment", "in", "79", "%", "of", "subjects", ",", "although", "serum", "creatinine", "was", "only", "elevated", "in", "18", "%", ".", "In", "total", ",", "70", "%", "of", "subjects", "were", "found", "to", "have", "relative", "or", "absolute", "risk", "factors", "for", "NSAID", "therapy", ".", "Given", "the", "high", "prevalence", "of", "potential", "contraindications", "to", "anti", "-", "inflammatory", "drug", "usage", "in", "this", "study", ",", "we", "advocate", "the", "dissemination", "and", "application", "of", "these", "guidelines", "in", "geriatric", "patients", "in", "an", "attempt", "to", "reduce", "potential", "morbidity", "and", "mortality", "." ]	[ "ADVERSE" ]
GI toxicity is a ADVERSE, GI toxicity is a ADVERSE, hypertension is a ADVERSE, renal impairment is a ADVERSE	example-261_task1	Sentence: Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality. Instructions: please typing these entity words according to sentence: GI toxicity, GI toxicity, hypertension, renal impairment Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality.	[ "Utility", "of", "published", "guidelines", "on", "the", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "in", "the", "elderly", ".", " ", "Canadian", "Consensus", "guidelines", "regarding", "appropriate", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAID", ")", "were", "recently", "published", ".", "This", "study", "was", "done", "to", "evaluate", "the", "application", "of", "these", "guidelines", "on", "NSAID", "practice", "patterns", "in", "frail", "elderly", "patients", "referred", "to", "a", "specialist", "Geriatric", "Assessment", "Clinic", ".", "A", "retrospective", "chart", "review", "was", "undertaken", "of", "referrals", "who", "were", "currently", "prescribed", "NSAIDs", ".", "Data", "were", "captured", "on", "age", ",", "sex", ",", "weight", ",", "diagnoses", ",", "medications", "and", "dosages", ",", "indication", "for", "NSAID", "treatment", ",", "lying", "BP", "(", "as", "assessed", "in", "the", "clinic", ")", "and", "recent", "serum", "creatinine", "result", ".", "Creatinine", "clearance", "was", "subsequently", "calculated", "use", "the", "Cockcroft", "-", "Gault", "equation", ".", "Complete", "data", "were", "available", "on", "107", "patients", "(", "68", "%", "women", ",", "average", "age", "80.6", "years", ")", ".", "Thirty", "percent", "were", "on", "a", "traditional", "NSAID", ",", "the", "remainder", "were", "on", "a", "Coxib", ".", "Concomitant", "aspirin", "was", "prescribed", "in", "37", "%", ".", "Cytoprotection", "was", "being", "used", "in", "38", "%", "and", "did", "not", "increase", "appreciably", "in", "patients", "with", "additional", "risk", "factors", "for", "GI", "toxicity", ",", "i.e", ".", ",", "concomitant", "aspirin", "usage", "(", "35", "%", ")", ",", "and", "history", "of", "GI", "toxicity", "(", "48", "%", ")", ".", "Sixty", "-", "seven", "were", "taking", "anti", "-", "hypertensive", "medications", ",", "although", "more", "than", "two", "thirds", "of", "these", "patients", "were", "uncontrolled", ".", "Newly", "diagnosed", "hypertension", "was", "present", "in", "19.6", "%", ".", "Calculated", "creatinine", "clearance", "revealed", "moderate", "to", "severe", "renal", "impairment", "in", "79", "%", "of", "subjects", ",", "although", "serum", "creatinine", "was", "only", "elevated", "in", "18", "%", ".", "In", "total", ",", "70", "%", "of", "subjects", "were", "found", "to", "have", "relative", "or", "absolute", "risk", "factors", "for", "NSAID", "therapy", ".", "Given", "the", "high", "prevalence", "of", "potential", "contraindications", "to", "anti", "-", "inflammatory", "drug", "usage", "in", "this", "study", ",", "we", "advocate", "the", "dissemination", "and", "application", "of", "these", "guidelines", "in", "geriatric", "patients", "in", "an", "attempt", "to", "reduce", "potential", "morbidity", "and", "mortality", "." ]	[ "ADVERSE" ]
GI toxicity, GI toxicity, hypertension, renal impairment	example-261_task2	Sentence: Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality.	[ "Utility", "of", "published", "guidelines", "on", "the", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "in", "the", "elderly", ".", " ", "Canadian", "Consensus", "guidelines", "regarding", "appropriate", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAID", ")", "were", "recently", "published", ".", "This", "study", "was", "done", "to", "evaluate", "the", "application", "of", "these", "guidelines", "on", "NSAID", "practice", "patterns", "in", "frail", "elderly", "patients", "referred", "to", "a", "specialist", "Geriatric", "Assessment", "Clinic", ".", "A", "retrospective", "chart", "review", "was", "undertaken", "of", "referrals", "who", "were", "currently", "prescribed", "NSAIDs", ".", "Data", "were", "captured", "on", "age", ",", "sex", ",", "weight", ",", "diagnoses", ",", "medications", "and", "dosages", ",", "indication", "for", "NSAID", "treatment", ",", "lying", "BP", "(", "as", "assessed", "in", "the", "clinic", ")", "and", "recent", "serum", "creatinine", "result", ".", "Creatinine", "clearance", "was", "subsequently", "calculated", "use", "the", "Cockcroft", "-", "Gault", "equation", ".", "Complete", "data", "were", "available", "on", "107", "patients", "(", "68", "%", "women", ",", "average", "age", "80.6", "years", ")", ".", "Thirty", "percent", "were", "on", "a", "traditional", "NSAID", ",", "the", "remainder", "were", "on", "a", "Coxib", ".", "Concomitant", "aspirin", "was", "prescribed", "in", "37", "%", ".", "Cytoprotection", "was", "being", "used", "in", "38", "%", "and", "did", "not", "increase", "appreciably", "in", "patients", "with", "additional", "risk", "factors", "for", "GI", "toxicity", ",", "i.e", ".", ",", "concomitant", "aspirin", "usage", "(", "35", "%", ")", ",", "and", "history", "of", "GI", "toxicity", "(", "48", "%", ")", ".", "Sixty", "-", "seven", "were", "taking", "anti", "-", "hypertensive", "medications", ",", "although", "more", "than", "two", "thirds", "of", "these", "patients", "were", "uncontrolled", ".", "Newly", "diagnosed", "hypertension", "was", "present", "in", "19.6", "%", ".", "Calculated", "creatinine", "clearance", "revealed", "moderate", "to", "severe", "renal", "impairment", "in", "79", "%", "of", "subjects", ",", "although", "serum", "creatinine", "was", "only", "elevated", "in", "18", "%", ".", "In", "total", ",", "70", "%", "of", "subjects", "were", "found", "to", "have", "relative", "or", "absolute", "risk", "factors", "for", "NSAID", "therapy", ".", "Given", "the", "high", "prevalence", "of", "potential", "contraindications", "to", "anti", "-", "inflammatory", "drug", "usage", "in", "this", "study", ",", "we", "advocate", "the", "dissemination", "and", "application", "of", "these", "guidelines", "in", "geriatric", "patients", "in", "an", "attempt", "to", "reduce", "potential", "morbidity", "and", "mortality", "." ]	[ "ADVERSE" ]
methotrexate is an intervention, progression of muscle weakness is an outcome, serum creatine kinase activity is an outcome	1434_task0	Sentence: We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome	[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]	We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity .	[ "We", "conclude", "that", "oral", "methotrexate", "did", "not", "slow", "down", "progression", "of", "muscle", "weakness", "but", "decreased", "serum", "creatine", "kinase", "activity", "." ]	[ "outcome", "intervention" ]
methotrexate is an intervention, progression of muscle weakness is an outcome, serum creatine kinase activity is an outcome	1434_task1	Sentence: We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity . Instructions: please typing these entity words according to sentence: methotrexate, progression of muscle weakness, serum creatine kinase activity Options: intervention, outcome	[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]	We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity .	[ "We", "conclude", "that", "oral", "methotrexate", "did", "not", "slow", "down", "progression", "of", "muscle", "weakness", "but", "decreased", "serum", "creatine", "kinase", "activity", "." ]	[ "outcome", "intervention" ]
methotrexate, progression of muscle weakness, serum creatine kinase activity	1434_task2	Sentence: We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]	We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity .	[ "We", "conclude", "that", "oral", "methotrexate", "did", "not", "slow", "down", "progression", "of", "muscle", "weakness", "but", "decreased", "serum", "creatine", "kinase", "activity", "." ]	[ "outcome", "intervention" ]
microsomal triglyceride transfer protein is a gene, manganese superoxide dismutase is a gene	73_task0	Sentence: Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene	[ "O", "O", "O", "B-gene", "I-gene", "I-gene", "I-gene", "O", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O" ]	Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.	[ "Polymorphisms", "of", " ", "microsomal", "triglyceride", "transfer", "protein", " ", "gene", "and", " ", "manganese", "superoxide", "dismutase", " ", "gene", "in", "non", "-", "alcoholic", "steatohepatitis", "." ]	[ "gene", "variant" ]
microsomal triglyceride transfer protein is a gene, manganese superoxide dismutase is a gene	73_task1	Sentence: Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. Instructions: please typing these entity words according to sentence: microsomal triglyceride transfer protein, manganese superoxide dismutase Options: gene	[ "O", "O", "O", "B-gene", "I-gene", "I-gene", "I-gene", "O", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O" ]	Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.	[ "Polymorphisms", "of", " ", "microsomal", "triglyceride", "transfer", "protein", " ", "gene", "and", " ", "manganese", "superoxide", "dismutase", " ", "gene", "in", "non", "-", "alcoholic", "steatohepatitis", "." ]	[ "gene", "variant" ]
microsomal triglyceride transfer protein, manganese superoxide dismutase	73_task2	Sentence: Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-gene", "I-gene", "I-gene", "I-gene", "O", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O" ]	Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.	[ "Polymorphisms", "of", " ", "microsomal", "triglyceride", "transfer", "protein", " ", "gene", "and", " ", "manganese", "superoxide", "dismutase", " ", "gene", "in", "non", "-", "alcoholic", "steatohepatitis", "." ]	[ "gene", "variant" ]
BRLF1 is a Protein, BZLF1 is a Protein, BZLF1 is a Protein, BRLF1 is a Protein	8799177_task0	Sentence: Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific.	[ "Epstein", "-", "Barr", "viral", "latency", "is", "disrupted", "by", "the", "immediate", "-", "early", "BRLF1", "protein", "through", "a", "cell", "-", "specific", "mechanism", ".", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ",", "the", "causative", "agent", "of", "infectious", "mononucleosis", ",", "is", "a", "human", "herpesvirus", "associated", "with", "epithelial", "cell", "malignancies", "(", "nasopharyngeal", "carcinoma", ")", "as", "well", "as", "B", "-", "cell", "malignancies", ".", "Understanding", "how", "viral", "latency", "is", "disrupted", "is", "a", "central", "issue", "in", "herpesvirus", "biology", ".", "Epithelial", "cells", "are", "the", "major", "site", "of", "lytic", "EBV", "replication", "within", "the", "human", "host", ",", "and", "viral", "reactivation", "occurs", "in", "EBV", "-", "associated", "nasopharyngeal", "carcinomas", ".", "It", "is", "known", "that", "expression", "of", "a", "single", "viral", "immediate", "-", "early", "protein", ",", "BZLF1", ",", "is", "sufficient", "to", "initiate", "the", "switch", "from", "latent", "to", "lytic", "infection", "in", "B", "cells", ".", "Cellular", "regulation", "of", "BZLF1", "transcription", "is", "therefore", "thought", "to", "play", "a", "key", "role", "in", "regulating", "the", "stringency", "of", "viral", "latency", ".", "Here", "we", "show", "that", ",", "unexpectedly", ",", "expression", "of", "another", "viral", "immediate", "-", "early", "protein", ",", "BRLF1", ",", "can", "disrupt", "viral", "latency", "in", "an", "epithelial", "cell", "-", "specific", "fashion", ".", "Therefore", ",", "the", "mechanisms", "leading", "to", "disruption", "of", "EBV", "latency", "appear", "to", "be", "cell", "-", "type", "specific", "." ]	[ "Protein" ]
BRLF1 is a Protein, BZLF1 is a Protein, BZLF1 is a Protein, BRLF1 is a Protein	8799177_task1	Sentence: Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific. Instructions: please typing these entity words according to sentence: BRLF1, BZLF1, BZLF1, BRLF1 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific.	[ "Epstein", "-", "Barr", "viral", "latency", "is", "disrupted", "by", "the", "immediate", "-", "early", "BRLF1", "protein", "through", "a", "cell", "-", "specific", "mechanism", ".", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ",", "the", "causative", "agent", "of", "infectious", "mononucleosis", ",", "is", "a", "human", "herpesvirus", "associated", "with", "epithelial", "cell", "malignancies", "(", "nasopharyngeal", "carcinoma", ")", "as", "well", "as", "B", "-", "cell", "malignancies", ".", "Understanding", "how", "viral", "latency", "is", "disrupted", "is", "a", "central", "issue", "in", "herpesvirus", "biology", ".", "Epithelial", "cells", "are", "the", "major", "site", "of", "lytic", "EBV", "replication", "within", "the", "human", "host", ",", "and", "viral", "reactivation", "occurs", "in", "EBV", "-", "associated", "nasopharyngeal", "carcinomas", ".", "It", "is", "known", "that", "expression", "of", "a", "single", "viral", "immediate", "-", "early", "protein", ",", "BZLF1", ",", "is", "sufficient", "to", "initiate", "the", "switch", "from", "latent", "to", "lytic", "infection", "in", "B", "cells", ".", "Cellular", "regulation", "of", "BZLF1", "transcription", "is", "therefore", "thought", "to", "play", "a", "key", "role", "in", "regulating", "the", "stringency", "of", "viral", "latency", ".", "Here", "we", "show", "that", ",", "unexpectedly", ",", "expression", "of", "another", "viral", "immediate", "-", "early", "protein", ",", "BRLF1", ",", "can", "disrupt", "viral", "latency", "in", "an", "epithelial", "cell", "-", "specific", "fashion", ".", "Therefore", ",", "the", "mechanisms", "leading", "to", "disruption", "of", "EBV", "latency", "appear", "to", "be", "cell", "-", "type", "specific", "." ]	[ "Protein" ]
BRLF1, BZLF1, BZLF1, BRLF1	8799177_task2	Sentence: Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific.	[ "Epstein", "-", "Barr", "viral", "latency", "is", "disrupted", "by", "the", "immediate", "-", "early", "BRLF1", "protein", "through", "a", "cell", "-", "specific", "mechanism", ".", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ",", "the", "causative", "agent", "of", "infectious", "mononucleosis", ",", "is", "a", "human", "herpesvirus", "associated", "with", "epithelial", "cell", "malignancies", "(", "nasopharyngeal", "carcinoma", ")", "as", "well", "as", "B", "-", "cell", "malignancies", ".", "Understanding", "how", "viral", "latency", "is", "disrupted", "is", "a", "central", "issue", "in", "herpesvirus", "biology", ".", "Epithelial", "cells", "are", "the", "major", "site", "of", "lytic", "EBV", "replication", "within", "the", "human", "host", ",", "and", "viral", "reactivation", "occurs", "in", "EBV", "-", "associated", "nasopharyngeal", "carcinomas", ".", "It", "is", "known", "that", "expression", "of", "a", "single", "viral", "immediate", "-", "early", "protein", ",", "BZLF1", ",", "is", "sufficient", "to", "initiate", "the", "switch", "from", "latent", "to", "lytic", "infection", "in", "B", "cells", ".", "Cellular", "regulation", "of", "BZLF1", "transcription", "is", "therefore", "thought", "to", "play", "a", "key", "role", "in", "regulating", "the", "stringency", "of", "viral", "latency", ".", "Here", "we", "show", "that", ",", "unexpectedly", ",", "expression", "of", "another", "viral", "immediate", "-", "early", "protein", ",", "BRLF1", ",", "can", "disrupt", "viral", "latency", "in", "an", "epithelial", "cell", "-", "specific", "fashion", ".", "Therefore", ",", "the", "mechanisms", "leading", "to", "disruption", "of", "EBV", "latency", "appear", "to", "be", "cell", "-", "type", "specific", "." ]	[ "Protein" ]
Abstract is an umlsterm, birth is an umlsterm, anomalies is an umlsterm, family is an umlsterm, history is an umlsterm, disorder is an umlsterm, Physical examination is an umlsterm, toe is an umlsterm, toe is an umlsterm, toe is an umlsterm, syndactylia is an umlsterm, fingers is an umlsterm, congenital is an umlsterm	DerHautarzt.50460053.eng.abstr_task0	Sentence: Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported .	[ "Abstract", ".", "A", "1-year", "-", "old", "girl", "shows", "changes", "of", "the", "toenails", "since", "birth", ".", "There", "are", "no", "associated", "anomalies", "typical", "for", "genodermatoses", ",", "nor", "is", "there", "a", "family", "history", "of", "this", "disorder", ".", "Physical", "examination", "shows", "missing", "or", "incomplete", "toenails", ".", "In", "addition", "a", "shortening", "of", "the", "second", "toe", "on", "both", "sides", "and", "the", "third", "toe", "on", "the", "left", "side", "is", "found", ".", "The", "second", "and", "third", "toe", "on", "the", "left", "side", "shows", "incomplete", "syndactylia", ".", "The", "fingers", "and", "fingernails", "are", "all", "normal", ".", "Isolated", "congenital", "onychodysplasia", "of", "the", "toenails", "has", "not", "been", "previously", "reported", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, birth is an umlsterm, anomalies is an umlsterm, family is an umlsterm, history is an umlsterm, disorder is an umlsterm, Physical examination is an umlsterm, toe is an umlsterm, toe is an umlsterm, toe is an umlsterm, syndactylia is an umlsterm, fingers is an umlsterm, congenital is an umlsterm	DerHautarzt.50460053.eng.abstr_task1	Sentence: Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported . Instructions: please typing these entity words according to sentence: Abstract, birth, anomalies, family, history, disorder, Physical examination, toe, toe, toe, syndactylia, fingers, congenital Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported .	[ "Abstract", ".", "A", "1-year", "-", "old", "girl", "shows", "changes", "of", "the", "toenails", "since", "birth", ".", "There", "are", "no", "associated", "anomalies", "typical", "for", "genodermatoses", ",", "nor", "is", "there", "a", "family", "history", "of", "this", "disorder", ".", "Physical", "examination", "shows", "missing", "or", "incomplete", "toenails", ".", "In", "addition", "a", "shortening", "of", "the", "second", "toe", "on", "both", "sides", "and", "the", "third", "toe", "on", "the", "left", "side", "is", "found", ".", "The", "second", "and", "third", "toe", "on", "the", "left", "side", "shows", "incomplete", "syndactylia", ".", "The", "fingers", "and", "fingernails", "are", "all", "normal", ".", "Isolated", "congenital", "onychodysplasia", "of", "the", "toenails", "has", "not", "been", "previously", "reported", "." ]	[ "umlsterm" ]
Abstract, birth, anomalies, family, history, disorder, Physical examination, toe, toe, toe, syndactylia, fingers, congenital	DerHautarzt.50460053.eng.abstr_task2	Sentence: Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported .	[ "Abstract", ".", "A", "1-year", "-", "old", "girl", "shows", "changes", "of", "the", "toenails", "since", "birth", ".", "There", "are", "no", "associated", "anomalies", "typical", "for", "genodermatoses", ",", "nor", "is", "there", "a", "family", "history", "of", "this", "disorder", ".", "Physical", "examination", "shows", "missing", "or", "incomplete", "toenails", ".", "In", "addition", "a", "shortening", "of", "the", "second", "toe", "on", "both", "sides", "and", "the", "third", "toe", "on", "the", "left", "side", "is", "found", ".", "The", "second", "and", "third", "toe", "on", "the", "left", "side", "shows", "incomplete", "syndactylia", ".", "The", "fingers", "and", "fingernails", "are", "all", "normal", ".", "Isolated", "congenital", "onychodysplasia", "of", "the", "toenails", "has", "not", "been", "previously", "reported", "." ]	[ "umlsterm" ]
Children is an umlsterm, risk is an umlsterm, adults is an umlsterm, infection is an umlsterm, prophylaxis is an umlsterm, bacterial infections is an umlsterm, paper is an umlsterm, preventive measures is an umlsterm, children is an umlsterm, education is an umlsterm, patient is an umlsterm, parents is an umlsterm, Vaccinations is an umlsterm, Streptococcus pneumoniae is an umlsterm, Hemophilus influenzae is an umlsterm, Neisseria meningitidis is an umlsterm, antibiotic prophylaxis is an umlsterm, children is an umlsterm, vaccine is an umlsterm, development is an umlsterm, antibiotic resistance is an umlsterm	DerChirurg.70680591.eng.abstr_task0	Sentence: Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed .	[ "Children", "are", "exposed", "to", "a", "greater", "risk", "than", "adults", "for", "severe", "late", "postsplenectomy", "infection", ".", "Therefore", ",", "prophylaxis", "against", "bacterial", "infections", "need", "to", "be", "more", "extensive", ".", "This", "paper", "presents", "a", "protocol", "for", "preventive", "measures", "in", "children", ".", "Repeated", "education", "of", "the", "patient", "and", "his", "/", "her", "parents", "about", "the", "consequences", "of", "splenic", "loss", "is", "mandatory", ".", "Vaccinations", "against", "Streptococcus", "pneumoniae", "and", "Hemophilus", "influenzae", "are", "highly", "recommended", "and", "also", "against", "Neisseria", "meningitidis", "in", "certain", "situations", ".", "The", "importance", "of", "long", "-", "term", "antibiotic", "prophylaxis", "in", "children", "is", "emphasized", ".", "Recent", "advances", "in", "vaccine", "development", "and", "the", "increasing", "problems", "with", "antibiotic", "resistance", "are", "discussed", "." ]	[ "umlsterm" ]
Children is an umlsterm, risk is an umlsterm, adults is an umlsterm, infection is an umlsterm, prophylaxis is an umlsterm, bacterial infections is an umlsterm, paper is an umlsterm, preventive measures is an umlsterm, children is an umlsterm, education is an umlsterm, patient is an umlsterm, parents is an umlsterm, Vaccinations is an umlsterm, Streptococcus pneumoniae is an umlsterm, Hemophilus influenzae is an umlsterm, Neisseria meningitidis is an umlsterm, antibiotic prophylaxis is an umlsterm, children is an umlsterm, vaccine is an umlsterm, development is an umlsterm, antibiotic resistance is an umlsterm	DerChirurg.70680591.eng.abstr_task1	Sentence: Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed . Instructions: please typing these entity words according to sentence: Children, risk, adults, infection, prophylaxis, bacterial infections, paper, preventive measures, children, education, patient, parents, Vaccinations, Streptococcus pneumoniae, Hemophilus influenzae, Neisseria meningitidis, antibiotic prophylaxis, children, vaccine, development, antibiotic resistance Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed .	[ "Children", "are", "exposed", "to", "a", "greater", "risk", "than", "adults", "for", "severe", "late", "postsplenectomy", "infection", ".", "Therefore", ",", "prophylaxis", "against", "bacterial", "infections", "need", "to", "be", "more", "extensive", ".", "This", "paper", "presents", "a", "protocol", "for", "preventive", "measures", "in", "children", ".", "Repeated", "education", "of", "the", "patient", "and", "his", "/", "her", "parents", "about", "the", "consequences", "of", "splenic", "loss", "is", "mandatory", ".", "Vaccinations", "against", "Streptococcus", "pneumoniae", "and", "Hemophilus", "influenzae", "are", "highly", "recommended", "and", "also", "against", "Neisseria", "meningitidis", "in", "certain", "situations", ".", "The", "importance", "of", "long", "-", "term", "antibiotic", "prophylaxis", "in", "children", "is", "emphasized", ".", "Recent", "advances", "in", "vaccine", "development", "and", "the", "increasing", "problems", "with", "antibiotic", "resistance", "are", "discussed", "." ]	[ "umlsterm" ]
Children, risk, adults, infection, prophylaxis, bacterial infections, paper, preventive measures, children, education, patient, parents, Vaccinations, Streptococcus pneumoniae, Hemophilus influenzae, Neisseria meningitidis, antibiotic prophylaxis, children, vaccine, development, antibiotic resistance	DerChirurg.70680591.eng.abstr_task2	Sentence: Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed .	[ "Children", "are", "exposed", "to", "a", "greater", "risk", "than", "adults", "for", "severe", "late", "postsplenectomy", "infection", ".", "Therefore", ",", "prophylaxis", "against", "bacterial", "infections", "need", "to", "be", "more", "extensive", ".", "This", "paper", "presents", "a", "protocol", "for", "preventive", "measures", "in", "children", ".", "Repeated", "education", "of", "the", "patient", "and", "his", "/", "her", "parents", "about", "the", "consequences", "of", "splenic", "loss", "is", "mandatory", ".", "Vaccinations", "against", "Streptococcus", "pneumoniae", "and", "Hemophilus", "influenzae", "are", "highly", "recommended", "and", "also", "against", "Neisseria", "meningitidis", "in", "certain", "situations", ".", "The", "importance", "of", "long", "-", "term", "antibiotic", "prophylaxis", "in", "children", "is", "emphasized", ".", "Recent", "advances", "in", "vaccine", "development", "and", "the", "increasing", "problems", "with", "antibiotic", "resistance", "are", "discussed", "." ]	[ "umlsterm" ]
SP-1 is a Protein, site is a Entity, interleukin-1 beta is a Protein, promoter is a Entity, interleukin-1beta is a Protein, IL-1beta is a Protein, IL-1beta is a Protein, promoter is a Entity, promoter segment is a Entity, 43-mer oligonucleotide is a Entity, cis - acting element is a Entity, transcription factor consensus sequence oligonucleotides is a Entity, SP-1 is a Protein, regulatory element is a Entity, SP-1 is a Protein, consensus sequence is a Entity, TCCCCTCCCCT motif is a Entity, low - mobility complexes is a Entity, IL-1beta is a Protein, tumor necrosis factor - alpha is a Protein, SP-1 is a Protein, site is a Entity, SP-1 is a Protein, site is a Entity, IL-1beta is a Protein, promoter is a Entity	188_task0	Sentence: A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes.	[ "A", "novel", "SP-1", "site", "in", "the", "human", "interleukin-1", "beta", "promoter", "confers", "preferential", "transcriptional", "activity", "in", "keratinocytes", ".", "\n", "To", "investigate", "the", "mechanisms", "of", "transcriptional", "activation", "of", "interleukin-1beta", "(", "IL-1beta", ")", "in", "non", "-", "monocytic", "cells", ",", "we", "constructed", "a", "series", "of", "reporter", "plasmids", "with", "the", "bacterial", "chloramphenicol", "acetyltransferase", "gene", "linked", "to", "various", "parts", "of", "the", "human", "IL-1beta", "promoter", "and", "performed", "transient", "transfection", "experiments", ".", "We", "identified", "a", "promoter", "segment", "that", "activates", "transcription", "most", "efficiently", "in", "keratinocytes", ".", "Electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "with", "a", "43-mer", "oligonucleotide", "derived", "from", "the", "functionally", "identified", "cis", "-", "acting", "element", "revealed", "specific", "complexes", ".", "By", "competition", "analysis", "with", "transcription", "factor", "consensus", "sequence", "oligonucleotides", "and", "by", "immunosupershift", ",", "transcription", "factor", "SP-1", "or", "a", "closely", "related", "protein", "was", "shown", "to", "bind", "to", "this", "regulatory", "element", ".", "The", "closest", "match", "to", "the", "known", "SP-1", "consensus", "sequence", "within", "the", "respective", "region", "is", "a", "TCCCCTCCCCT", "motif", ".", "Mutation", "of", "this", "motif", "almost", "completely", ",", "and", "specifically", ",", "abolished", "the", "binding", "of", "two", "low", "-", "mobility", "complexes", "and", "led", "to", "a", "95", "%", "decrease", "of", "constitutive", "transcriptional", "activation", "of", "a", "reporter", "construct", "IL-1beta", "(", "-170/+108", ")", ".", "Likewise", ",", "activation", "of", "this", "reporter", "construct", "by", "tumor", "necrosis", "factor", "-", "alpha", "depended", "on", "the", "SP-1", "site", ".", "These", "observations", "suggest", "that", "a", "so", "-", "far", "-", "unrecognized", "SP-1", "site", "in", "the", "human", "IL-1beta", "promoter", "may", "participate", "in", "the", "transcriptional", "regulation", "of", "this", "gene", "in", "keratinocytes", ".", "\n" ]	[ "Entity", "Protein" ]
SP-1 is a Protein, site is a Entity, interleukin-1 beta is a Protein, promoter is a Entity, interleukin-1beta is a Protein, IL-1beta is a Protein, IL-1beta is a Protein, promoter is a Entity, promoter segment is a Entity, 43-mer oligonucleotide is a Entity, cis - acting element is a Entity, transcription factor consensus sequence oligonucleotides is a Entity, SP-1 is a Protein, regulatory element is a Entity, SP-1 is a Protein, consensus sequence is a Entity, TCCCCTCCCCT motif is a Entity, low - mobility complexes is a Entity, IL-1beta is a Protein, tumor necrosis factor - alpha is a Protein, SP-1 is a Protein, site is a Entity, SP-1 is a Protein, site is a Entity, IL-1beta is a Protein, promoter is a Entity	188_task1	Sentence: A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes. Instructions: please typing these entity words according to sentence: SP-1, site, interleukin-1 beta, promoter, interleukin-1beta, IL-1beta, IL-1beta, promoter, promoter segment, 43-mer oligonucleotide, cis - acting element, transcription factor consensus sequence oligonucleotides, SP-1, regulatory element, SP-1, consensus sequence, TCCCCTCCCCT motif, low - mobility complexes, IL-1beta, tumor necrosis factor - alpha, SP-1, site, SP-1, site, IL-1beta, promoter Options: Entity, Protein	[ "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes.	[ "A", "novel", "SP-1", "site", "in", "the", "human", "interleukin-1", "beta", "promoter", "confers", "preferential", "transcriptional", "activity", "in", "keratinocytes", ".", "\n", "To", "investigate", "the", "mechanisms", "of", "transcriptional", "activation", "of", "interleukin-1beta", "(", "IL-1beta", ")", "in", "non", "-", "monocytic", "cells", ",", "we", "constructed", "a", "series", "of", "reporter", "plasmids", "with", "the", "bacterial", "chloramphenicol", "acetyltransferase", "gene", "linked", "to", "various", "parts", "of", "the", "human", "IL-1beta", "promoter", "and", "performed", "transient", "transfection", "experiments", ".", "We", "identified", "a", "promoter", "segment", "that", "activates", "transcription", "most", "efficiently", "in", "keratinocytes", ".", "Electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "with", "a", "43-mer", "oligonucleotide", "derived", "from", "the", "functionally", "identified", "cis", "-", "acting", "element", "revealed", "specific", "complexes", ".", "By", "competition", "analysis", "with", "transcription", "factor", "consensus", "sequence", "oligonucleotides", "and", "by", "immunosupershift", ",", "transcription", "factor", "SP-1", "or", "a", "closely", "related", "protein", "was", "shown", "to", "bind", "to", "this", "regulatory", "element", ".", "The", "closest", "match", "to", "the", "known", "SP-1", "consensus", "sequence", "within", "the", "respective", "region", "is", "a", "TCCCCTCCCCT", "motif", ".", "Mutation", "of", "this", "motif", "almost", "completely", ",", "and", "specifically", ",", "abolished", "the", "binding", "of", "two", "low", "-", "mobility", "complexes", "and", "led", "to", "a", "95", "%", "decrease", "of", "constitutive", "transcriptional", "activation", "of", "a", "reporter", "construct", "IL-1beta", "(", "-170/+108", ")", ".", "Likewise", ",", "activation", "of", "this", "reporter", "construct", "by", "tumor", "necrosis", "factor", "-", "alpha", "depended", "on", "the", "SP-1", "site", ".", "These", "observations", "suggest", "that", "a", "so", "-", "far", "-", "unrecognized", "SP-1", "site", "in", "the", "human", "IL-1beta", "promoter", "may", "participate", "in", "the", "transcriptional", "regulation", "of", "this", "gene", "in", "keratinocytes", ".", "\n" ]	[ "Entity", "Protein" ]
SP-1, site, interleukin-1 beta, promoter, interleukin-1beta, IL-1beta, IL-1beta, promoter, promoter segment, 43-mer oligonucleotide, cis - acting element, transcription factor consensus sequence oligonucleotides, SP-1, regulatory element, SP-1, consensus sequence, TCCCCTCCCCT motif, low - mobility complexes, IL-1beta, tumor necrosis factor - alpha, SP-1, site, SP-1, site, IL-1beta, promoter	188_task2	Sentence: A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes.	[ "A", "novel", "SP-1", "site", "in", "the", "human", "interleukin-1", "beta", "promoter", "confers", "preferential", "transcriptional", "activity", "in", "keratinocytes", ".", "\n", "To", "investigate", "the", "mechanisms", "of", "transcriptional", "activation", "of", "interleukin-1beta", "(", "IL-1beta", ")", "in", "non", "-", "monocytic", "cells", ",", "we", "constructed", "a", "series", "of", "reporter", "plasmids", "with", "the", "bacterial", "chloramphenicol", "acetyltransferase", "gene", "linked", "to", "various", "parts", "of", "the", "human", "IL-1beta", "promoter", "and", "performed", "transient", "transfection", "experiments", ".", "We", "identified", "a", "promoter", "segment", "that", "activates", "transcription", "most", "efficiently", "in", "keratinocytes", ".", "Electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "with", "a", "43-mer", "oligonucleotide", "derived", "from", "the", "functionally", "identified", "cis", "-", "acting", "element", "revealed", "specific", "complexes", ".", "By", "competition", "analysis", "with", "transcription", "factor", "consensus", "sequence", "oligonucleotides", "and", "by", "immunosupershift", ",", "transcription", "factor", "SP-1", "or", "a", "closely", "related", "protein", "was", "shown", "to", "bind", "to", "this", "regulatory", "element", ".", "The", "closest", "match", "to", "the", "known", "SP-1", "consensus", "sequence", "within", "the", "respective", "region", "is", "a", "TCCCCTCCCCT", "motif", ".", "Mutation", "of", "this", "motif", "almost", "completely", ",", "and", "specifically", ",", "abolished", "the", "binding", "of", "two", "low", "-", "mobility", "complexes", "and", "led", "to", "a", "95", "%", "decrease", "of", "constitutive", "transcriptional", "activation", "of", "a", "reporter", "construct", "IL-1beta", "(", "-170/+108", ")", ".", "Likewise", ",", "activation", "of", "this", "reporter", "construct", "by", "tumor", "necrosis", "factor", "-", "alpha", "depended", "on", "the", "SP-1", "site", ".", "These", "observations", "suggest", "that", "a", "so", "-", "far", "-", "unrecognized", "SP-1", "site", "in", "the", "human", "IL-1beta", "promoter", "may", "participate", "in", "the", "transcriptional", "regulation", "of", "this", "gene", "in", "keratinocytes", ".", "\n" ]	[ "Entity", "Protein" ]
profilin is a Individual_protein, actin is a Individual_protein	648_task0	Sentence: Structural studies on the ribbon-to-helix transition in profilin: actin crystals. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O" ]	Structural studies on the ribbon-to-helix transition in profilin: actin crystals.	[ "Structural", "studies", "on", "the", "ribbon", "-", "to", "-", "helix", "transition", "in", "profilin", ":", "actin", "crystals", "." ]	[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein	648_task1	Sentence: Structural studies on the ribbon-to-helix transition in profilin: actin crystals. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O" ]	Structural studies on the ribbon-to-helix transition in profilin: actin crystals.	[ "Structural", "studies", "on", "the", "ribbon", "-", "to", "-", "helix", "transition", "in", "profilin", ":", "actin", "crystals", "." ]	[ "Individual_protein" ]
profilin, actin	648_task2	Sentence: Structural studies on the ribbon-to-helix transition in profilin: actin crystals. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O" ]	Structural studies on the ribbon-to-helix transition in profilin: actin crystals.	[ "Structural", "studies", "on", "the", "ribbon", "-", "to", "-", "helix", "transition", "in", "profilin", ":", "actin", "crystals", "." ]	[ "Individual_protein" ]
LAD - stent is an umlsterm, cardiopulmonary resuscitation is an umlsterm, CPR is an umlsterm, stent is an umlsterm, implantation is an umlsterm, knowledge is an umlsterm	ZfuerKardiologie.90880296.eng.abstr_task0	Sentence: We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case .	[ "We", "report", "a", "case", "of", "LAD", "-", "stent", "deformation", "by", "extracorporeal", "cardiopulmonary", "resuscitation", "(", "CPR", ")", "shortly", "after", "stent", "implantation", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "." ]	[ "umlsterm" ]
LAD - stent is an umlsterm, cardiopulmonary resuscitation is an umlsterm, CPR is an umlsterm, stent is an umlsterm, implantation is an umlsterm, knowledge is an umlsterm	ZfuerKardiologie.90880296.eng.abstr_task1	Sentence: We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case . Instructions: please typing these entity words according to sentence: LAD - stent, cardiopulmonary resuscitation, CPR, stent, implantation, knowledge Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case .	[ "We", "report", "a", "case", "of", "LAD", "-", "stent", "deformation", "by", "extracorporeal", "cardiopulmonary", "resuscitation", "(", "CPR", ")", "shortly", "after", "stent", "implantation", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "." ]	[ "umlsterm" ]
LAD - stent, cardiopulmonary resuscitation, CPR, stent, implantation, knowledge	ZfuerKardiologie.90880296.eng.abstr_task2	Sentence: We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case .	[ "We", "report", "a", "case", "of", "LAD", "-", "stent", "deformation", "by", "extracorporeal", "cardiopulmonary", "resuscitation", "(", "CPR", ")", "shortly", "after", "stent", "implantation", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "." ]	[ "umlsterm" ]
Behandlung is an umlsterm, Verwendung is an umlsterm, Techniken is an umlsterm, Leichenstudie is an umlsterm, Methodik is an umlsterm, Rohrprothese is an umlsterm, Stent is an umlsterm, Leichenextremitaeten is an umlsterm, Extremitaeten is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Patienten is an umlsterm, Leichenstudie is an umlsterm, Methode is an umlsterm, Patienten is an umlsterm	Gefaesschirurgie.90040194.ger.abstr_task0	Sentence: Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen .	[ "Fragestellung", ":", "Die", "Implantation", "eines", "femoropoplitealen", "Bypasses", "stellt", "heute", "den", "Goldstandard", "zur", "Behandlung", "der", "AVK", "bei", "Verschlussprozessen", "im", "femoropoplitealen", "Bereich", "dar", ".", "Durch", "Verwendung", "interventioneller", "Techniken", "konnte", "ein", "endovasculaer", "implantierbares", "Bypassystem", "entwickelt", "werden", ".", "Im", "Rahmen", "einer", "Leichenstudie", "wurde", "die", "technische", "Funktionsfaehigkeit", "des", "neuen", "Systems", "erprobt", "und", "danach", "die", "Evaluation", "in", "der", "humanen", "Anwendung", "begonnen", ".", "Methodik", ":", "Der", "Endopass", "besteht", "aus", "einer", "53", "cm", "langen", ",", "duennwandigen", "Rohrprothese", "aus", "Polycarbourethan", ".", "Das", "distale", "Ende", "ist", "auf", "eine", "Laenge", "von", "4", "cm", "mit", "einem", "selbstexpandierenden", "Stent", "armiert", ".", "Die", "Implantation", "erfolgt", "ueber", "eine", "Leisteninzision", ".", "Nach", "antegrader", "Ringsonden", "-", "TEA", "wird", "der", "Endopass", "ueber", "einem", "Fuehrungsdraht", "in", "der", "A.", "femoralis", "superficialis", "plaziert", ".", "Die", "proximale", "Anastomose", "erfolgt", "chirurgisch", ".", "Ergebnisse", ":", "Die", "technische", "Durchfuehrbarkeit", "und", "Funktionsfaehigkeit", "wurde", "an", "12", "Leichenextremitaeten", "erprobt", ".", "Bei", "8", "Extremitaeten", "mit", "Verschluessen", "der", "A.", "femoralis", "superficialis", "konnte", "das", "Verfahren", "in", "7", "Faellen", "technisch", "durchgefuehrt", "werden", ".", "Entscheidende", "Probleme", "sind", "die", "komplette", "Ringsonden", "-", "TEA", ",", "die", "Plazierung", "des", "Fuehrungsdrahts", "nach", "TEA", "und", "die", "Entfaltung", "des", "Endopasses", "aus", "dem", "Introducer", ".", "Nach", "Aenderung", "des", "Equipments", "und", "Freigabe", "der", "Anwendung", "durch", "die", "Ethikkommission", "wurde", "der", "Endopass", "von", "6/97", "bis", "3/98", "bisher", "bei", "5", "Patienten", "angewandt", ".", "Bei", "3", "Patienten", "ist", "der", "Endopass", "offen", "und", "zeigt", "eine", "gute", "Funktion", ".", "Ein", "Patient", "erlitt", "einen", "nicht", "korrigierbaren", "Fruehverschluss", "bei", "schlechter", "Ausstrombahn", "und", "bei", "einem", "Patienten", "musste", "das", "Verfahren", "bei", "Ringsondenperforation", "gewechselt", "werden", ".", "Schlussfolgerungen", ":", "Die", "Erfahrungen", "der", "Leichenstudie", "und", "der", "ersten", "humanen", "Anwendungen", "bestaetigen", "die", "praktische", "Durchfuehrbarkeit", "der", "Methode", ".", "Es", "sind", "jedoch", "weitere", "Entwicklungsarbeit", "und", "methodische", "Verbesserungen", "notwendig", ",", "die", "nur", "durch", "weitere", "Erfahrungen", "am", "Patienten", "gewonnen", "werden", "koennen", "." ]	[ "umlsterm" ]
Behandlung is an umlsterm, Verwendung is an umlsterm, Techniken is an umlsterm, Leichenstudie is an umlsterm, Methodik is an umlsterm, Rohrprothese is an umlsterm, Stent is an umlsterm, Leichenextremitaeten is an umlsterm, Extremitaeten is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Patienten is an umlsterm, Leichenstudie is an umlsterm, Methode is an umlsterm, Patienten is an umlsterm	Gefaesschirurgie.90040194.ger.abstr_task1	Sentence: Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen . Instructions: please typing these entity words according to sentence: Behandlung, Verwendung, Techniken, Leichenstudie, Methodik, Rohrprothese, Stent, Leichenextremitaeten, Extremitaeten, Ethikkommission, Patienten, Patienten, Patient, Patienten, Leichenstudie, Methode, Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen .	[ "Fragestellung", ":", "Die", "Implantation", "eines", "femoropoplitealen", "Bypasses", "stellt", "heute", "den", "Goldstandard", "zur", "Behandlung", "der", "AVK", "bei", "Verschlussprozessen", "im", "femoropoplitealen", "Bereich", "dar", ".", "Durch", "Verwendung", "interventioneller", "Techniken", "konnte", "ein", "endovasculaer", "implantierbares", "Bypassystem", "entwickelt", "werden", ".", "Im", "Rahmen", "einer", "Leichenstudie", "wurde", "die", "technische", "Funktionsfaehigkeit", "des", "neuen", "Systems", "erprobt", "und", "danach", "die", "Evaluation", "in", "der", "humanen", "Anwendung", "begonnen", ".", "Methodik", ":", "Der", "Endopass", "besteht", "aus", "einer", "53", "cm", "langen", ",", "duennwandigen", "Rohrprothese", "aus", "Polycarbourethan", ".", "Das", "distale", "Ende", "ist", "auf", "eine", "Laenge", "von", "4", "cm", "mit", "einem", "selbstexpandierenden", "Stent", "armiert", ".", "Die", "Implantation", "erfolgt", "ueber", "eine", "Leisteninzision", ".", "Nach", "antegrader", "Ringsonden", "-", "TEA", "wird", "der", "Endopass", "ueber", "einem", "Fuehrungsdraht", "in", "der", "A.", "femoralis", "superficialis", "plaziert", ".", "Die", "proximale", "Anastomose", "erfolgt", "chirurgisch", ".", "Ergebnisse", ":", "Die", "technische", "Durchfuehrbarkeit", "und", "Funktionsfaehigkeit", "wurde", "an", "12", "Leichenextremitaeten", "erprobt", ".", "Bei", "8", "Extremitaeten", "mit", "Verschluessen", "der", "A.", "femoralis", "superficialis", "konnte", "das", "Verfahren", "in", "7", "Faellen", "technisch", "durchgefuehrt", "werden", ".", "Entscheidende", "Probleme", "sind", "die", "komplette", "Ringsonden", "-", "TEA", ",", "die", "Plazierung", "des", "Fuehrungsdrahts", "nach", "TEA", "und", "die", "Entfaltung", "des", "Endopasses", "aus", "dem", "Introducer", ".", "Nach", "Aenderung", "des", "Equipments", "und", "Freigabe", "der", "Anwendung", "durch", "die", "Ethikkommission", "wurde", "der", "Endopass", "von", "6/97", "bis", "3/98", "bisher", "bei", "5", "Patienten", "angewandt", ".", "Bei", "3", "Patienten", "ist", "der", "Endopass", "offen", "und", "zeigt", "eine", "gute", "Funktion", ".", "Ein", "Patient", "erlitt", "einen", "nicht", "korrigierbaren", "Fruehverschluss", "bei", "schlechter", "Ausstrombahn", "und", "bei", "einem", "Patienten", "musste", "das", "Verfahren", "bei", "Ringsondenperforation", "gewechselt", "werden", ".", "Schlussfolgerungen", ":", "Die", "Erfahrungen", "der", "Leichenstudie", "und", "der", "ersten", "humanen", "Anwendungen", "bestaetigen", "die", "praktische", "Durchfuehrbarkeit", "der", "Methode", ".", "Es", "sind", "jedoch", "weitere", "Entwicklungsarbeit", "und", "methodische", "Verbesserungen", "notwendig", ",", "die", "nur", "durch", "weitere", "Erfahrungen", "am", "Patienten", "gewonnen", "werden", "koennen", "." ]	[ "umlsterm" ]
Behandlung, Verwendung, Techniken, Leichenstudie, Methodik, Rohrprothese, Stent, Leichenextremitaeten, Extremitaeten, Ethikkommission, Patienten, Patienten, Patient, Patienten, Leichenstudie, Methode, Patienten	Gefaesschirurgie.90040194.ger.abstr_task2	Sentence: Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen .	[ "Fragestellung", ":", "Die", "Implantation", "eines", "femoropoplitealen", "Bypasses", "stellt", "heute", "den", "Goldstandard", "zur", "Behandlung", "der", "AVK", "bei", "Verschlussprozessen", "im", "femoropoplitealen", "Bereich", "dar", ".", "Durch", "Verwendung", "interventioneller", "Techniken", "konnte", "ein", "endovasculaer", "implantierbares", "Bypassystem", "entwickelt", "werden", ".", "Im", "Rahmen", "einer", "Leichenstudie", "wurde", "die", "technische", "Funktionsfaehigkeit", "des", "neuen", "Systems", "erprobt", "und", "danach", "die", "Evaluation", "in", "der", "humanen", "Anwendung", "begonnen", ".", "Methodik", ":", "Der", "Endopass", "besteht", "aus", "einer", "53", "cm", "langen", ",", "duennwandigen", "Rohrprothese", "aus", "Polycarbourethan", ".", "Das", "distale", "Ende", "ist", "auf", "eine", "Laenge", "von", "4", "cm", "mit", "einem", "selbstexpandierenden", "Stent", "armiert", ".", "Die", "Implantation", "erfolgt", "ueber", "eine", "Leisteninzision", ".", "Nach", "antegrader", "Ringsonden", "-", "TEA", "wird", "der", "Endopass", "ueber", "einem", "Fuehrungsdraht", "in", "der", "A.", "femoralis", "superficialis", "plaziert", ".", "Die", "proximale", "Anastomose", "erfolgt", "chirurgisch", ".", "Ergebnisse", ":", "Die", "technische", "Durchfuehrbarkeit", "und", "Funktionsfaehigkeit", "wurde", "an", "12", "Leichenextremitaeten", "erprobt", ".", "Bei", "8", "Extremitaeten", "mit", "Verschluessen", "der", "A.", "femoralis", "superficialis", "konnte", "das", "Verfahren", "in", "7", "Faellen", "technisch", "durchgefuehrt", "werden", ".", "Entscheidende", "Probleme", "sind", "die", "komplette", "Ringsonden", "-", "TEA", ",", "die", "Plazierung", "des", "Fuehrungsdrahts", "nach", "TEA", "und", "die", "Entfaltung", "des", "Endopasses", "aus", "dem", "Introducer", ".", "Nach", "Aenderung", "des", "Equipments", "und", "Freigabe", "der", "Anwendung", "durch", "die", "Ethikkommission", "wurde", "der", "Endopass", "von", "6/97", "bis", "3/98", "bisher", "bei", "5", "Patienten", "angewandt", ".", "Bei", "3", "Patienten", "ist", "der", "Endopass", "offen", "und", "zeigt", "eine", "gute", "Funktion", ".", "Ein", "Patient", "erlitt", "einen", "nicht", "korrigierbaren", "Fruehverschluss", "bei", "schlechter", "Ausstrombahn", "und", "bei", "einem", "Patienten", "musste", "das", "Verfahren", "bei", "Ringsondenperforation", "gewechselt", "werden", ".", "Schlussfolgerungen", ":", "Die", "Erfahrungen", "der", "Leichenstudie", "und", "der", "ersten", "humanen", "Anwendungen", "bestaetigen", "die", "praktische", "Durchfuehrbarkeit", "der", "Methode", ".", "Es", "sind", "jedoch", "weitere", "Entwicklungsarbeit", "und", "methodische", "Verbesserungen", "notwendig", ",", "die", "nur", "durch", "weitere", "Erfahrungen", "am", "Patienten", "gewonnen", "werden", "koennen", "." ]	[ "umlsterm" ]
surgery is an umlsterm, LASIK is an umlsterm, intraocular pressure is an umlsterm, intraocular pressure is an umlsterm, pressure is an umlsterm	DerOpthalmologe.80950137.eng.abstr_task0	Sentence: Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure .	[ "Microkeratome", "systems", "are", "being", "increasingly", "applied", "in", "lamellar", "corneal", "surgery", "(", "e", ".", "g", ".", ",", "LASIK", ")", ".", "The", "results", "of", "the", "few", "studies", "on", "intraocular", "pressure", "changes", "during", "the", "microkeratome", "cut", "vary", "widely", ".", "In", "this", "study", ",", "we", "examined", "the", "intraocular", "pressure", "pattern", "(", "IOP", ")", "in", "relation", "to", "the", "initial", "pressure", "." ]	[ "umlsterm" ]
surgery is an umlsterm, LASIK is an umlsterm, intraocular pressure is an umlsterm, intraocular pressure is an umlsterm, pressure is an umlsterm	DerOpthalmologe.80950137.eng.abstr_task1	Sentence: Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure . Instructions: please typing these entity words according to sentence: surgery, LASIK, intraocular pressure, intraocular pressure, pressure Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure .	[ "Microkeratome", "systems", "are", "being", "increasingly", "applied", "in", "lamellar", "corneal", "surgery", "(", "e", ".", "g", ".", ",", "LASIK", ")", ".", "The", "results", "of", "the", "few", "studies", "on", "intraocular", "pressure", "changes", "during", "the", "microkeratome", "cut", "vary", "widely", ".", "In", "this", "study", ",", "we", "examined", "the", "intraocular", "pressure", "pattern", "(", "IOP", ")", "in", "relation", "to", "the", "initial", "pressure", "." ]	[ "umlsterm" ]
surgery, LASIK, intraocular pressure, intraocular pressure, pressure	DerOpthalmologe.80950137.eng.abstr_task2	Sentence: Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure .	[ "Microkeratome", "systems", "are", "being", "increasingly", "applied", "in", "lamellar", "corneal", "surgery", "(", "e", ".", "g", ".", ",", "LASIK", ")", ".", "The", "results", "of", "the", "few", "studies", "on", "intraocular", "pressure", "changes", "during", "the", "microkeratome", "cut", "vary", "widely", ".", "In", "this", "study", ",", "we", "examined", "the", "intraocular", "pressure", "pattern", "(", "IOP", ")", "in", "relation", "to", "the", "initial", "pressure", "." ]	[ "umlsterm" ]
Aloe and Placebo is a Intervention_Control, Powder is a Intervention_Pharmacological, Breast Cancer is a Participant_Condition, aloe extract is a Intervention_Pharmacological, moist cream is a Intervention_Pharmacological, dry powder skin care regimen . is a Intervention_Pharmacological, 248 is a Participant_Sample-size, breast cancer is a Participant_Condition, powder , aloe cream is a Intervention_Pharmacological, placebo cream . is a Intervention_Control	69884_task0	Sentence: Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Pharmacological, Intervention_Control, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy .	[ "Three", "-", "Arm", "Randomized", "Phase", "III", "Trial", ":", "Quality", "Aloe", "and", "Placebo", "Cream", "Versus", "Powder", "as", "Skin", "Treatment", "During", "Breast", "Cancer", "Radiation", "Therapy", ".", "BACKGROUND", "The", "efficacy", "of", "aloe", "extract", "in", "reducing", "radiation", "-", "induced", "skin", "injury", "is", "controversial", ".", "The", "purpose", "of", "the", "present", "3-arm", "randomized", "trial", "was", "to", "test", "the", "efficacy", "of", "quality", "-", "tested", "aloe", "extract", "in", "reducing", "the", "severity", "of", "radiation", "-", "induced", "skin", "injury", "and", ",", "secondarily", ",", "to", "examine", "the", "effect", "of", "a", "moist", "cream", "versus", "a", "dry", "powder", "skin", "care", "regimen", ".", "MATERIALS", "AND", "METHODS", "A", "total", "of", "248", "patients", "with", "breast", "cancer", "were", "randomized", "to", "powder", ",", "aloe", "cream", ",", "or", "placebo", "cream", ".", "Acute", "skin", "toxicity", "was", "scored", "weekly", "and", "after", "treatment", "at", "weeks", "1", ",", "2", ",", "and", "4", "using", "a", "modified", "10-point", "Catterall", "scale", ".", "The", "patients", "scored", "their", "symptom", "severity", "using", "a", "6-point", "Likert", "scale", "and", "kept", "an", "acute", "phase", "diary", ".", "RESULTS", "The", "aloe", "formulation", "did", "not", "reduce", "acute", "skin", "toxicity", "or", "symptom", "severity", ".", "Patients", "with", "a", "greater", "body", "mass", "index", "were", "more", "likely", "to", "develop", "acute", "skin", "toxicity", ".", "A", "similar", "pattern", "of", "increased", "skin", "reaction", "toxicity", "occurred", "with", "both", "study", "creams", "compared", "with", "the", "dry", "powder", "regimen", ".", "CONCLUSION", "No", "evidence", "was", "found", "to", "support", "prophylactic", "application", "of", "quality", "aloe", "extract", "or", "cream", "to", "improve", "the", "symptoms", "or", "reduce", "the", "skin", "reaction", "severity", ".", "Our", "results", "support", "a", "dry", "skin", "care", "regimen", "of", "powder", "during", "radiation", "therapy", "." ]	[ "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition", "Participant_Sample-size" ]
Aloe and Placebo is a Intervention_Control, Powder is a Intervention_Pharmacological, Breast Cancer is a Participant_Condition, aloe extract is a Intervention_Pharmacological, moist cream is a Intervention_Pharmacological, dry powder skin care regimen . is a Intervention_Pharmacological, 248 is a Participant_Sample-size, breast cancer is a Participant_Condition, powder , aloe cream is a Intervention_Pharmacological, placebo cream . is a Intervention_Control	69884_task1	Sentence: Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy . Instructions: please typing these entity words according to sentence: Aloe and Placebo, Powder, Breast Cancer, aloe extract, moist cream, dry powder skin care regimen ., 248, breast cancer, powder , aloe cream, placebo cream . Options: Participant_Condition, Intervention_Pharmacological, Intervention_Control, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy .	[ "Three", "-", "Arm", "Randomized", "Phase", "III", "Trial", ":", "Quality", "Aloe", "and", "Placebo", "Cream", "Versus", "Powder", "as", "Skin", "Treatment", "During", "Breast", "Cancer", "Radiation", "Therapy", ".", "BACKGROUND", "The", "efficacy", "of", "aloe", "extract", "in", "reducing", "radiation", "-", "induced", "skin", "injury", "is", "controversial", ".", "The", "purpose", "of", "the", "present", "3-arm", "randomized", "trial", "was", "to", "test", "the", "efficacy", "of", "quality", "-", "tested", "aloe", "extract", "in", "reducing", "the", "severity", "of", "radiation", "-", "induced", "skin", "injury", "and", ",", "secondarily", ",", "to", "examine", "the", "effect", "of", "a", "moist", "cream", "versus", "a", "dry", "powder", "skin", "care", "regimen", ".", "MATERIALS", "AND", "METHODS", "A", "total", "of", "248", "patients", "with", "breast", "cancer", "were", "randomized", "to", "powder", ",", "aloe", "cream", ",", "or", "placebo", "cream", ".", "Acute", "skin", "toxicity", "was", "scored", "weekly", "and", "after", "treatment", "at", "weeks", "1", ",", "2", ",", "and", "4", "using", "a", "modified", "10-point", "Catterall", "scale", ".", "The", "patients", "scored", "their", "symptom", "severity", "using", "a", "6-point", "Likert", "scale", "and", "kept", "an", "acute", "phase", "diary", ".", "RESULTS", "The", "aloe", "formulation", "did", "not", "reduce", "acute", "skin", "toxicity", "or", "symptom", "severity", ".", "Patients", "with", "a", "greater", "body", "mass", "index", "were", "more", "likely", "to", "develop", "acute", "skin", "toxicity", ".", "A", "similar", "pattern", "of", "increased", "skin", "reaction", "toxicity", "occurred", "with", "both", "study", "creams", "compared", "with", "the", "dry", "powder", "regimen", ".", "CONCLUSION", "No", "evidence", "was", "found", "to", "support", "prophylactic", "application", "of", "quality", "aloe", "extract", "or", "cream", "to", "improve", "the", "symptoms", "or", "reduce", "the", "skin", "reaction", "severity", ".", "Our", "results", "support", "a", "dry", "skin", "care", "regimen", "of", "powder", "during", "radiation", "therapy", "." ]	[ "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition", "Participant_Sample-size" ]
Aloe and Placebo, Powder, Breast Cancer, aloe extract, moist cream, dry powder skin care regimen ., 248, breast cancer, powder , aloe cream, placebo cream .	69884_task2	Sentence: Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy .	[ "Three", "-", "Arm", "Randomized", "Phase", "III", "Trial", ":", "Quality", "Aloe", "and", "Placebo", "Cream", "Versus", "Powder", "as", "Skin", "Treatment", "During", "Breast", "Cancer", "Radiation", "Therapy", ".", "BACKGROUND", "The", "efficacy", "of", "aloe", "extract", "in", "reducing", "radiation", "-", "induced", "skin", "injury", "is", "controversial", ".", "The", "purpose", "of", "the", "present", "3-arm", "randomized", "trial", "was", "to", "test", "the", "efficacy", "of", "quality", "-", "tested", "aloe", "extract", "in", "reducing", "the", "severity", "of", "radiation", "-", "induced", "skin", "injury", "and", ",", "secondarily", ",", "to", "examine", "the", "effect", "of", "a", "moist", "cream", "versus", "a", "dry", "powder", "skin", "care", "regimen", ".", "MATERIALS", "AND", "METHODS", "A", "total", "of", "248", "patients", "with", "breast", "cancer", "were", "randomized", "to", "powder", ",", "aloe", "cream", ",", "or", "placebo", "cream", ".", "Acute", "skin", "toxicity", "was", "scored", "weekly", "and", "after", "treatment", "at", "weeks", "1", ",", "2", ",", "and", "4", "using", "a", "modified", "10-point", "Catterall", "scale", ".", "The", "patients", "scored", "their", "symptom", "severity", "using", "a", "6-point", "Likert", "scale", "and", "kept", "an", "acute", "phase", "diary", ".", "RESULTS", "The", "aloe", "formulation", "did", "not", "reduce", "acute", "skin", "toxicity", "or", "symptom", "severity", ".", "Patients", "with", "a", "greater", "body", "mass", "index", "were", "more", "likely", "to", "develop", "acute", "skin", "toxicity", ".", "A", "similar", "pattern", "of", "increased", "skin", "reaction", "toxicity", "occurred", "with", "both", "study", "creams", "compared", "with", "the", "dry", "powder", "regimen", ".", "CONCLUSION", "No", "evidence", "was", "found", "to", "support", "prophylactic", "application", "of", "quality", "aloe", "extract", "or", "cream", "to", "improve", "the", "symptoms", "or", "reduce", "the", "skin", "reaction", "severity", ".", "Our", "results", "support", "a", "dry", "skin", "care", "regimen", "of", "powder", "during", "radiation", "therapy", "." ]	[ "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition", "Participant_Sample-size" ]
angiography is an umlsterm, vascular resistance is an umlsterm, surgery is an umlsterm, Peripheral resistance is an umlsterm, method is an umlsterm, pressure is an umlsterm, measurement is an umlsterm, patients is an umlsterm, blood is an umlsterm, blood is an umlsterm, angiographies is an umlsterm, recommendations is an umlsterm, Standards is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, Society is an umlsterm, Cardiovascular Surgery is an umlsterm, association is an umlsterm, angiography is an umlsterm, cor - relation is an umlsterm, regression analyses is an umlsterm, overall is an umlsterm, regression analysis is an umlsterm, popliteal artery is an umlsterm, angiography is an umlsterm, peripheral resistance is an umlsterm	Gefaesschirurgie.70020208.eng.abstr_task0	Sentence: The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance .	[ "The", "correlation", "between", "angiography", "and", "vascular", "resistance", "measured", "during", "surgery", "is", "still", "controversial", ".", "Peripheral", "resistance", "in", "40", "infra", "-", "inguinal", "reconstructions", "was", "measured", "using", "a", "new", "method", "which", "integrates", "pressure", "and", "flow", "measurement", "into", "a", "temporary", "bypass", "system", ".", "Data", "are", "therefore", "collected", "under", "maximal", "physiological", "conditions", "using", "the", "patients", "'", "own", "blood", "and", "pulsatile", "blood", "flow", ".", "The", "angiographies", "were", "scored", "according", "to", "the", "recommendations", "of", "the", "Ad", "Hoc", "Committee", "on", "Reporting", "Standards", ",", "Society", "for", "Vascular", "Surgery", ",", "International", "Society", "for", "Cardiovascular", "Surgery", "(", "SVS", "/", "ISCVS", ")", ".", "To", "estimate", "the", "association", "between", "angiography", "and", "resistance", "both", "simple", "cor", "-", "relation", "and", "multiple", "regression", "analyses", "were", "computed", ".", "The", "overall", "correlation", "coefficient", "was", "rs", "=", "0.34", "(", "P", "0.05", ")", ".", "Multiple", "regression", "analysis", "only", "revealed", "a", "prospective", "model", "for", "the", "popliteal", "artery", ".", "The", "results", "indicated", "that", "there", "is", "a", "poor", "correlation", "between", "angiography", "and", "peripheral", "resistance", "." ]	[ "umlsterm" ]
angiography is an umlsterm, vascular resistance is an umlsterm, surgery is an umlsterm, Peripheral resistance is an umlsterm, method is an umlsterm, pressure is an umlsterm, measurement is an umlsterm, patients is an umlsterm, blood is an umlsterm, blood is an umlsterm, angiographies is an umlsterm, recommendations is an umlsterm, Standards is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, Society is an umlsterm, Cardiovascular Surgery is an umlsterm, association is an umlsterm, angiography is an umlsterm, cor - relation is an umlsterm, regression analyses is an umlsterm, overall is an umlsterm, regression analysis is an umlsterm, popliteal artery is an umlsterm, angiography is an umlsterm, peripheral resistance is an umlsterm	Gefaesschirurgie.70020208.eng.abstr_task1	Sentence: The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance . Instructions: please typing these entity words according to sentence: angiography, vascular resistance, surgery, Peripheral resistance, method, pressure, measurement, patients, blood, blood, angiographies, recommendations, Standards, Society, Vascular Surgery, Society, Cardiovascular Surgery, association, angiography, cor - relation, regression analyses, overall, regression analysis, popliteal artery, angiography, peripheral resistance Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance .	[ "The", "correlation", "between", "angiography", "and", "vascular", "resistance", "measured", "during", "surgery", "is", "still", "controversial", ".", "Peripheral", "resistance", "in", "40", "infra", "-", "inguinal", "reconstructions", "was", "measured", "using", "a", "new", "method", "which", "integrates", "pressure", "and", "flow", "measurement", "into", "a", "temporary", "bypass", "system", ".", "Data", "are", "therefore", "collected", "under", "maximal", "physiological", "conditions", "using", "the", "patients", "'", "own", "blood", "and", "pulsatile", "blood", "flow", ".", "The", "angiographies", "were", "scored", "according", "to", "the", "recommendations", "of", "the", "Ad", "Hoc", "Committee", "on", "Reporting", "Standards", ",", "Society", "for", "Vascular", "Surgery", ",", "International", "Society", "for", "Cardiovascular", "Surgery", "(", "SVS", "/", "ISCVS", ")", ".", "To", "estimate", "the", "association", "between", "angiography", "and", "resistance", "both", "simple", "cor", "-", "relation", "and", "multiple", "regression", "analyses", "were", "computed", ".", "The", "overall", "correlation", "coefficient", "was", "rs", "=", "0.34", "(", "P", "0.05", ")", ".", "Multiple", "regression", "analysis", "only", "revealed", "a", "prospective", "model", "for", "the", "popliteal", "artery", ".", "The", "results", "indicated", "that", "there", "is", "a", "poor", "correlation", "between", "angiography", "and", "peripheral", "resistance", "." ]	[ "umlsterm" ]
angiography, vascular resistance, surgery, Peripheral resistance, method, pressure, measurement, patients, blood, blood, angiographies, recommendations, Standards, Society, Vascular Surgery, Society, Cardiovascular Surgery, association, angiography, cor - relation, regression analyses, overall, regression analysis, popliteal artery, angiography, peripheral resistance	Gefaesschirurgie.70020208.eng.abstr_task2	Sentence: The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]	The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance .	[ "The", "correlation", "between", "angiography", "and", "vascular", "resistance", "measured", "during", "surgery", "is", "still", "controversial", ".", "Peripheral", "resistance", "in", "40", "infra", "-", "inguinal", "reconstructions", "was", "measured", "using", "a", "new", "method", "which", "integrates", "pressure", "and", "flow", "measurement", "into", "a", "temporary", "bypass", "system", ".", "Data", "are", "therefore", "collected", "under", "maximal", "physiological", "conditions", "using", "the", "patients", "'", "own", "blood", "and", "pulsatile", "blood", "flow", ".", "The", "angiographies", "were", "scored", "according", "to", "the", "recommendations", "of", "the", "Ad", "Hoc", "Committee", "on", "Reporting", "Standards", ",", "Society", "for", "Vascular", "Surgery", ",", "International", "Society", "for", "Cardiovascular", "Surgery", "(", "SVS", "/", "ISCVS", ")", ".", "To", "estimate", "the", "association", "between", "angiography", "and", "resistance", "both", "simple", "cor", "-", "relation", "and", "multiple", "regression", "analyses", "were", "computed", ".", "The", "overall", "correlation", "coefficient", "was", "rs", "=", "0.34", "(", "P", "0.05", ")", ".", "Multiple", "regression", "analysis", "only", "revealed", "a", "prospective", "model", "for", "the", "popliteal", "artery", ".", "The", "results", "indicated", "that", "there", "is", "a", "poor", "correlation", "between", "angiography", "and", "peripheral", "resistance", "." ]	[ "umlsterm" ]
argininosuccinate synthetase is a Gene, argininosuccinate synthetase is a Gene, A118 T is a SNP, A192V is a SNP, R272C is a SNP, G280R is a SNP, R304W is a SNP, R363L is a SNP, R304W is a SNP	220_task0	Sentence: Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene, SNP	[ "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations.	[ "Mutations", "in", "argininosuccinate", "synthetase", "mRNA", "of", "Japanese", "patients", ",", "causing", "classical", "citrullinemia", ".", "Citrullinemia", "is", "an", "autosomal", "recessive", "disease", "caused", "by", "a", "genetic", "deficiency", "of", "argininosuccinate", "synthetase", ".", "In", "order", "to", "characterize", "mutations", "in", "Japanese", "patients", "with", "classical", "citrullinemia", ",", "RNA", "isolated", "from", "10", "unrelated", "patients", "was", "reverse", "-", "transcribed", ",", "and", "cDNA", "amplified", "by", "PCR", "was", "cloned", "and", "sequenced", ".", "The", "10", "mutations", "identified", "included", "6", "missense", "mutations", "(", "A118", "T", ",", "A192V", ",", "R272C", ",", "G280R", ",", "R304W", ",", "and", "R363L", ")", ",", "2", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "7", "or", "exon", "13", ",", "1", "mutation", "with", "a", "deletion", "of", "the", "first", "7", "bp", "in", "exon", "16", "(", "which", "might", "be", "caused", "by", "abnormal", "splicing", ")", ",", "and", "1", "mutation", "with", "an", "insertion", "of", "37", "bp", "within", "exons", "15", "and", "16", "in", "cDNA", ".", "The", "insertion", "mutation", "and", "the", "five", "missense", "mutations", "(", "R304W", "being", "excluded", ")", "are", "new", "mutations", "described", "in", "the", "present", "paper", ".", "These", "are", "in", "addition", "to", "14", "mutations", "(", "9", "missense", "mutations", ",", "4", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "in", "mRNA", ",", "and", "1", "splicing", "mutation", ")", "that", "we", "identified", "previously", "in", "mainly", "American", "patients", "with", "neonatal", "citrullinemia", ".", "Two", "of", "these", "20", "mutations", ",", "a", "deletion", "of", "exon", "13", "sequence", "and", "a", "7-bp", "deletion", "in", "exon", "16", ",", "were", "common", "to", "Japanese", "and", "American", "populations", "from", "different", "ethnic", "backgrounds", ";", "however", ",", "other", "mutations", "were", "unique", "to", "each", "population", ".", "Furthermore", ",", "the", "presence", "of", "a", "frequent", "mutation", "--", "the", "exon", "7", "deletion", "mutation", "in", "mRNA", ",", "which", "accounts", "for", "10", "of", "23", "affected", "alleles", "--", "was", "demonstrated", "in", "Japanese", "citrullinemia", ".", "This", "differs", "from", "the", "situation", "in", "the", "United", "States", ",", "where", "there", "was", "far", "greater", "heterogeneity", "of", "mutations", ".", "\n" ]	[ "Gene", "SNP" ]
argininosuccinate synthetase is a Gene, argininosuccinate synthetase is a Gene, A118 T is a SNP, A192V is a SNP, R272C is a SNP, G280R is a SNP, R304W is a SNP, R363L is a SNP, R304W is a SNP	220_task1	Sentence: Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations. Instructions: please typing these entity words according to sentence: argininosuccinate synthetase, argininosuccinate synthetase, A118 T, A192V, R272C, G280R, R304W, R363L, R304W Options: Gene, SNP	[ "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations.	[ "Mutations", "in", "argininosuccinate", "synthetase", "mRNA", "of", "Japanese", "patients", ",", "causing", "classical", "citrullinemia", ".", "Citrullinemia", "is", "an", "autosomal", "recessive", "disease", "caused", "by", "a", "genetic", "deficiency", "of", "argininosuccinate", "synthetase", ".", "In", "order", "to", "characterize", "mutations", "in", "Japanese", "patients", "with", "classical", "citrullinemia", ",", "RNA", "isolated", "from", "10", "unrelated", "patients", "was", "reverse", "-", "transcribed", ",", "and", "cDNA", "amplified", "by", "PCR", "was", "cloned", "and", "sequenced", ".", "The", "10", "mutations", "identified", "included", "6", "missense", "mutations", "(", "A118", "T", ",", "A192V", ",", "R272C", ",", "G280R", ",", "R304W", ",", "and", "R363L", ")", ",", "2", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "7", "or", "exon", "13", ",", "1", "mutation", "with", "a", "deletion", "of", "the", "first", "7", "bp", "in", "exon", "16", "(", "which", "might", "be", "caused", "by", "abnormal", "splicing", ")", ",", "and", "1", "mutation", "with", "an", "insertion", "of", "37", "bp", "within", "exons", "15", "and", "16", "in", "cDNA", ".", "The", "insertion", "mutation", "and", "the", "five", "missense", "mutations", "(", "R304W", "being", "excluded", ")", "are", "new", "mutations", "described", "in", "the", "present", "paper", ".", "These", "are", "in", "addition", "to", "14", "mutations", "(", "9", "missense", "mutations", ",", "4", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "in", "mRNA", ",", "and", "1", "splicing", "mutation", ")", "that", "we", "identified", "previously", "in", "mainly", "American", "patients", "with", "neonatal", "citrullinemia", ".", "Two", "of", "these", "20", "mutations", ",", "a", "deletion", "of", "exon", "13", "sequence", "and", "a", "7-bp", "deletion", "in", "exon", "16", ",", "were", "common", "to", "Japanese", "and", "American", "populations", "from", "different", "ethnic", "backgrounds", ";", "however", ",", "other", "mutations", "were", "unique", "to", "each", "population", ".", "Furthermore", ",", "the", "presence", "of", "a", "frequent", "mutation", "--", "the", "exon", "7", "deletion", "mutation", "in", "mRNA", ",", "which", "accounts", "for", "10", "of", "23", "affected", "alleles", "--", "was", "demonstrated", "in", "Japanese", "citrullinemia", ".", "This", "differs", "from", "the", "situation", "in", "the", "United", "States", ",", "where", "there", "was", "far", "greater", "heterogeneity", "of", "mutations", ".", "\n" ]	[ "Gene", "SNP" ]
argininosuccinate synthetase, argininosuccinate synthetase, A118 T, A192V, R272C, G280R, R304W, R363L, R304W	220_task2	Sentence: Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations.	[ "Mutations", "in", "argininosuccinate", "synthetase", "mRNA", "of", "Japanese", "patients", ",", "causing", "classical", "citrullinemia", ".", "Citrullinemia", "is", "an", "autosomal", "recessive", "disease", "caused", "by", "a", "genetic", "deficiency", "of", "argininosuccinate", "synthetase", ".", "In", "order", "to", "characterize", "mutations", "in", "Japanese", "patients", "with", "classical", "citrullinemia", ",", "RNA", "isolated", "from", "10", "unrelated", "patients", "was", "reverse", "-", "transcribed", ",", "and", "cDNA", "amplified", "by", "PCR", "was", "cloned", "and", "sequenced", ".", "The", "10", "mutations", "identified", "included", "6", "missense", "mutations", "(", "A118", "T", ",", "A192V", ",", "R272C", ",", "G280R", ",", "R304W", ",", "and", "R363L", ")", ",", "2", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "7", "or", "exon", "13", ",", "1", "mutation", "with", "a", "deletion", "of", "the", "first", "7", "bp", "in", "exon", "16", "(", "which", "might", "be", "caused", "by", "abnormal", "splicing", ")", ",", "and", "1", "mutation", "with", "an", "insertion", "of", "37", "bp", "within", "exons", "15", "and", "16", "in", "cDNA", ".", "The", "insertion", "mutation", "and", "the", "five", "missense", "mutations", "(", "R304W", "being", "excluded", ")", "are", "new", "mutations", "described", "in", "the", "present", "paper", ".", "These", "are", "in", "addition", "to", "14", "mutations", "(", "9", "missense", "mutations", ",", "4", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "in", "mRNA", ",", "and", "1", "splicing", "mutation", ")", "that", "we", "identified", "previously", "in", "mainly", "American", "patients", "with", "neonatal", "citrullinemia", ".", "Two", "of", "these", "20", "mutations", ",", "a", "deletion", "of", "exon", "13", "sequence", "and", "a", "7-bp", "deletion", "in", "exon", "16", ",", "were", "common", "to", "Japanese", "and", "American", "populations", "from", "different", "ethnic", "backgrounds", ";", "however", ",", "other", "mutations", "were", "unique", "to", "each", "population", ".", "Furthermore", ",", "the", "presence", "of", "a", "frequent", "mutation", "--", "the", "exon", "7", "deletion", "mutation", "in", "mRNA", ",", "which", "accounts", "for", "10", "of", "23", "affected", "alleles", "--", "was", "demonstrated", "in", "Japanese", "citrullinemia", ".", "This", "differs", "from", "the", "situation", "in", "the", "United", "States", ",", "where", "there", "was", "far", "greater", "heterogeneity", "of", "mutations", ".", "\n" ]	[ "Gene", "SNP" ]
SMC6 is a GENE-Y, ATPase domain is a GENE-N	23518413_task0	Sentence: SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N	[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities.	[ "SMC6", "is", "an", "essential", "gene", "in", "mice", ",", "but", "a", "hypomorphic", "mutant", "in", "the", "ATPase", "domain", "has", "a", "mild", "phenotype", "with", "a", "range", "of", "subtle", "abnormalities", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
SMC6 is a GENE-Y, ATPase domain is a GENE-N	23518413_task1	Sentence: SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities. Instructions: please typing these entity words according to sentence: SMC6, ATPase domain Options: GENE-Y, GENE-N	[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities.	[ "SMC6", "is", "an", "essential", "gene", "in", "mice", ",", "but", "a", "hypomorphic", "mutant", "in", "the", "ATPase", "domain", "has", "a", "mild", "phenotype", "with", "a", "range", "of", "subtle", "abnormalities", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
SMC6, ATPase domain	23518413_task2	Sentence: SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities.	[ "SMC6", "is", "an", "essential", "gene", "in", "mice", ",", "but", "a", "hypomorphic", "mutant", "in", "the", "ATPase", "domain", "has", "a", "mild", "phenotype", "with", "a", "range", "of", "subtle", "abnormalities", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
History is a Observation, significant is a Qualifier, skin disease is a Condition, skin manifestations is a Condition, allergic illness or other dermatologic condition is a Scope, except is a Negation, chronic moderate or severe is a Scope, atopic dermatitis is a Condition, skin diseases is a Condition, except is a Negation, chronic atopic dermatitis is a Condition, could disturb the study assessment and evaluation of the skin is a Qualifier, active is a Temporal, systemic medication is a Drug, chronic atopic dermatitis is a Condition, within one month is a Temporal, active is a Temporal, topical medication is a Drug, chronic atopic dermatitis is a Condition, within two weeks is a Temporal, sunny holiday , UV - light therapy or solarium use is a Scope, within one month before beginning of study treatments is a Temporal, planning is a Observation, during the study or within 7 days after the study is a Scope, Allergy is a Condition, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment is a Scope, History is a Observation, skin - related cancer is a Condition, acquired immunodeficiency is a Condition, ongoing is a Temporal, therapy that cause immunosuppression is a Procedure, clinically significant is a Qualifier, laboratory test is a Procedure, Suspected is a Observation, current is a Temporal, drug or alcohol abuse is a Scope, Clinically significant is a Qualifier, illness is a Condition, during the 4 weeks prior to the first dose administration is a Temporal	NCT01320579_exc_task0	Sentence: History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Observation, Procedure, Negation, Scope, Drug	[ "B-Observation", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Procedure", "I-Procedure", "O", "O", "B-Observation", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study	[ "History", "of", "other", "significant", "skin", "disease", ",", "or", "skin", "manifestations", "of", "allergic", "illness", "or", "other", "dermatologic", "condition", ",", "except", "chronic", "moderate", "or", "severe", "atopic", "dermatitis", ",", "that", "would", "interfere", "with", "the", "trial", "assessments", "or", "compromise", "the", "patient", "'s", "safety", "according", "to", "the", "opinion", "of", "the", "Investigator", "\n", "Present", "symptoms", "of", "other", "skin", "diseases", ",", "except", "chronic", "atopic", "dermatitis", ",", "that", "could", "disturb", "the", "study", "assessment", "and", "evaluation", "of", "the", "skin", "\n", "Current", "use", "of", "any", "active", "systemic", "medication", "for", "chronic", "atopic", "dermatitis", "within", "one", "month", "\n", "Current", "use", "of", "active", "topical", "medication", "in", "the", "planned", "investigational", "area", "for", "chronic", "atopic", "dermatitis", "within", "two", "weeks", "\n", "History", "of", "a", "sunny", "holiday", ",", "UV", "-", "light", "therapy", "or", "solarium", "use", "within", "one", "month", "before", "beginning", "of", "study", "treatments", ",", "or", "planning", "such", "during", "the", "study", "or", "within", "7", "days", "after", "the", "study", "\n", "Allergy", "to", "cis", "-", "UCA", ",", "or", "any", "constituents", "of", "the", "placebo", "emulsion", "cream", "or", "any", "constituents", "of", "Protopic", "®", "ointment", "\n", "History", "of", "any", "skin", "-", "related", "cancer", "\n", "Congenital", "or", "acquired", "immunodeficiency", "or", "ongoing", "therapy", "that", "cause", "immunosuppression", "\n", "Earlier", "participation", "in", "a", "clinical", "study", "performed", "with", "cis", "-", "UCA", "\n", "Any", "clinically", "significant", "laboratory", "test", "result", "\n", "Suspected", "current", "drug", "or", "alcohol", "abuse", "\n", "Clinically", "significant", "illness", "during", "the", "4", "weeks", "prior", "to", "the", "first", "dose", "administration", "\n", "Any", "other", "condition", "that", "in", "the", "opinion", "of", "the", "Investigator", "would", "interfere", "with", "the", "evaluation", "of", "the", "study", "results", "or", "constitute", "a", "health", "hazard", "for", "the", "patient", "\n", "Unwillingness", "or", "doubtful", "capacity", "to", "comply", "with", "the", "protocol", "\n", "Doubtful", "availability", "to", "complete", "the", "study", " \n \n" ]	[ "Scope", "Qualifier", "Temporal", "Procedure", "Reference_point", "Condition", "Drug", "Observation", "Negation" ]
History is a Observation, significant is a Qualifier, skin disease is a Condition, skin manifestations is a Condition, allergic illness or other dermatologic condition is a Scope, except is a Negation, chronic moderate or severe is a Scope, atopic dermatitis is a Condition, skin diseases is a Condition, except is a Negation, chronic atopic dermatitis is a Condition, could disturb the study assessment and evaluation of the skin is a Qualifier, active is a Temporal, systemic medication is a Drug, chronic atopic dermatitis is a Condition, within one month is a Temporal, active is a Temporal, topical medication is a Drug, chronic atopic dermatitis is a Condition, within two weeks is a Temporal, sunny holiday , UV - light therapy or solarium use is a Scope, within one month before beginning of study treatments is a Temporal, planning is a Observation, during the study or within 7 days after the study is a Scope, Allergy is a Condition, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment is a Scope, History is a Observation, skin - related cancer is a Condition, acquired immunodeficiency is a Condition, ongoing is a Temporal, therapy that cause immunosuppression is a Procedure, clinically significant is a Qualifier, laboratory test is a Procedure, Suspected is a Observation, current is a Temporal, drug or alcohol abuse is a Scope, Clinically significant is a Qualifier, illness is a Condition, during the 4 weeks prior to the first dose administration is a Temporal	NCT01320579_exc_task1	Sentence: History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study Instructions: please typing these entity words according to sentence: History, significant, skin disease, skin manifestations, allergic illness or other dermatologic condition, except, chronic moderate or severe, atopic dermatitis, skin diseases, except, chronic atopic dermatitis, could disturb the study assessment and evaluation of the skin, active, systemic medication, chronic atopic dermatitis, within one month, active, topical medication, chronic atopic dermatitis, within two weeks, sunny holiday , UV - light therapy or solarium use, within one month before beginning of study treatments, planning, during the study or within 7 days after the study, Allergy, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment, History, skin - related cancer, acquired immunodeficiency, ongoing, therapy that cause immunosuppression, clinically significant, laboratory test, Suspected, current, drug or alcohol abuse, Clinically significant, illness, during the 4 weeks prior to the first dose administration Options: Temporal, Condition, Qualifier, Observation, Procedure, Negation, Scope, Drug	[ "B-Observation", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Procedure", "I-Procedure", "O", "O", "B-Observation", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study	[ "History", "of", "other", "significant", "skin", "disease", ",", "or", "skin", "manifestations", "of", "allergic", "illness", "or", "other", "dermatologic", "condition", ",", "except", "chronic", "moderate", "or", "severe", "atopic", "dermatitis", ",", "that", "would", "interfere", "with", "the", "trial", "assessments", "or", "compromise", "the", "patient", "'s", "safety", "according", "to", "the", "opinion", "of", "the", "Investigator", "\n", "Present", "symptoms", "of", "other", "skin", "diseases", ",", "except", "chronic", "atopic", "dermatitis", ",", "that", "could", "disturb", "the", "study", "assessment", "and", "evaluation", "of", "the", "skin", "\n", "Current", "use", "of", "any", "active", "systemic", "medication", "for", "chronic", "atopic", "dermatitis", "within", "one", "month", "\n", "Current", "use", "of", "active", "topical", "medication", "in", "the", "planned", "investigational", "area", "for", "chronic", "atopic", "dermatitis", "within", "two", "weeks", "\n", "History", "of", "a", "sunny", "holiday", ",", "UV", "-", "light", "therapy", "or", "solarium", "use", "within", "one", "month", "before", "beginning", "of", "study", "treatments", ",", "or", "planning", "such", "during", "the", "study", "or", "within", "7", "days", "after", "the", "study", "\n", "Allergy", "to", "cis", "-", "UCA", ",", "or", "any", "constituents", "of", "the", "placebo", "emulsion", "cream", "or", "any", "constituents", "of", "Protopic", "®", "ointment", "\n", "History", "of", "any", "skin", "-", "related", "cancer", "\n", "Congenital", "or", "acquired", "immunodeficiency", "or", "ongoing", "therapy", "that", "cause", "immunosuppression", "\n", "Earlier", "participation", "in", "a", "clinical", "study", "performed", "with", "cis", "-", "UCA", "\n", "Any", "clinically", "significant", "laboratory", "test", "result", "\n", "Suspected", "current", "drug", "or", "alcohol", "abuse", "\n", "Clinically", "significant", "illness", "during", "the", "4", "weeks", "prior", "to", "the", "first", "dose", "administration", "\n", "Any", "other", "condition", "that", "in", "the", "opinion", "of", "the", "Investigator", "would", "interfere", "with", "the", "evaluation", "of", "the", "study", "results", "or", "constitute", "a", "health", "hazard", "for", "the", "patient", "\n", "Unwillingness", "or", "doubtful", "capacity", "to", "comply", "with", "the", "protocol", "\n", "Doubtful", "availability", "to", "complete", "the", "study", " \n \n" ]	[ "Scope", "Qualifier", "Temporal", "Procedure", "Reference_point", "Condition", "Drug", "Observation", "Negation" ]
History, significant, skin disease, skin manifestations, allergic illness or other dermatologic condition, except, chronic moderate or severe, atopic dermatitis, skin diseases, except, chronic atopic dermatitis, could disturb the study assessment and evaluation of the skin, active, systemic medication, chronic atopic dermatitis, within one month, active, topical medication, chronic atopic dermatitis, within two weeks, sunny holiday , UV - light therapy or solarium use, within one month before beginning of study treatments, planning, during the study or within 7 days after the study, Allergy, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment, History, skin - related cancer, acquired immunodeficiency, ongoing, therapy that cause immunosuppression, clinically significant, laboratory test, Suspected, current, drug or alcohol abuse, Clinically significant, illness, during the 4 weeks prior to the first dose administration	NCT01320579_exc_task2	Sentence: History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study Instructions: please extract entity words from the input sentence	[ "B-Observation", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Procedure", "I-Procedure", "O", "O", "B-Observation", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study	[ "History", "of", "other", "significant", "skin", "disease", ",", "or", "skin", "manifestations", "of", "allergic", "illness", "or", "other", "dermatologic", "condition", ",", "except", "chronic", "moderate", "or", "severe", "atopic", "dermatitis", ",", "that", "would", "interfere", "with", "the", "trial", "assessments", "or", "compromise", "the", "patient", "'s", "safety", "according", "to", "the", "opinion", "of", "the", "Investigator", "\n", "Present", "symptoms", "of", "other", "skin", "diseases", ",", "except", "chronic", "atopic", "dermatitis", ",", "that", "could", "disturb", "the", "study", "assessment", "and", "evaluation", "of", "the", "skin", "\n", "Current", "use", "of", "any", "active", "systemic", "medication", "for", "chronic", "atopic", "dermatitis", "within", "one", "month", "\n", "Current", "use", "of", "active", "topical", "medication", "in", "the", "planned", "investigational", "area", "for", "chronic", "atopic", "dermatitis", "within", "two", "weeks", "\n", "History", "of", "a", "sunny", "holiday", ",", "UV", "-", "light", "therapy", "or", "solarium", "use", "within", "one", "month", "before", "beginning", "of", "study", "treatments", ",", "or", "planning", "such", "during", "the", "study", "or", "within", "7", "days", "after", "the", "study", "\n", "Allergy", "to", "cis", "-", "UCA", ",", "or", "any", "constituents", "of", "the", "placebo", "emulsion", "cream", "or", "any", "constituents", "of", "Protopic", "®", "ointment", "\n", "History", "of", "any", "skin", "-", "related", "cancer", "\n", "Congenital", "or", "acquired", "immunodeficiency", "or", "ongoing", "therapy", "that", "cause", "immunosuppression", "\n", "Earlier", "participation", "in", "a", "clinical", "study", "performed", "with", "cis", "-", "UCA", "\n", "Any", "clinically", "significant", "laboratory", "test", "result", "\n", "Suspected", "current", "drug", "or", "alcohol", "abuse", "\n", "Clinically", "significant", "illness", "during", "the", "4", "weeks", "prior", "to", "the", "first", "dose", "administration", "\n", "Any", "other", "condition", "that", "in", "the", "opinion", "of", "the", "Investigator", "would", "interfere", "with", "the", "evaluation", "of", "the", "study", "results", "or", "constitute", "a", "health", "hazard", "for", "the", "patient", "\n", "Unwillingness", "or", "doubtful", "capacity", "to", "comply", "with", "the", "protocol", "\n", "Doubtful", "availability", "to", "complete", "the", "study", " \n \n" ]	[ "Scope", "Qualifier", "Temporal", "Procedure", "Reference_point", "Condition", "Drug", "Observation", "Negation" ]
Doppelblindstudie is an umlsterm, Patienten is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Analgetika is an umlsterm, Adrenalin is an umlsterm, Patienten is an umlsterm, Intoxikation is an umlsterm, Injektionsende is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Zyanose is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Prilocain is an umlsterm	DerAnaesthesist.60450052.ger.abstr_task0	Sentence: In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist .	[ "In", "einer", "prospektiven", ",", "randomisierten", "Doppelblindstudie", "wurde", "bei", "3", "mal", "20", "Patienten", "eine", "kombinierte", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", "durchgefuehrt", ".", "Wir", "verglichen", "den", "Blockadeerfolg", ",", "die", "arteriellen", "Serumspiegel", "und", "die", "Nebenwirkungen", "beim", "Einsatz", "von", "700", "mg", "Mepivacain", "1", "%", "ohne", "Gruppe", "I", ")", "(", "und", "mit", "Adrenalin", "1:350000", "(", "Gruppe", "II", ")", "sowie", "700", "mg", "Prilocain", "1", "%", "(", "Gruppe", "III", ")", ".", "Der", "primaere", "Blockadeerfolg", "ohne", "supplementierende", "Analgetika", "war", "in", "allen", "drei", "Gruppen", "vergleichbar", "und", "lag", "zwischen", "90", "und", "95", "%", ".", "Die", "maximalen", "Serumspiegel", "betrugen", "in", "Gruppe", "I", "3,91", "+", "/-", "0,95", "µg", "/", "ml", "nach", "60", "min", "und", "in", "Gruppe", "II", "2,94", "+", "/-", "0,58", "µg", "/", "ml", "nach", "120", "min", ".", "Zu", "allen", "Zeitpunkten", "fuehrte", "Adrenalin", "zu", "einer", "signifikanten", "Reduktion", "der", "Mepivacain", "-", "Serumspiegel", "(", "p", "0,01", ")", ".", "In", "der", "Prilocaingruppe", "waren", "die", "maximalen", "Serumspiegel", "mit", "2,07", "+", "/-", "0,56", "µg", "/", "ml", "signifikant", "niedriger", "als", "in", "beiden", "Mepivacaingruppen", "(", "p", "0,001", ")", "und", "traten", "nach", "15", "min", "auch", "signifikant", "frueher", "auf", ".", "Bei", "keinem", "Patienten", "fanden", "sich", "Symptome", "oder", "klinische", "Zeichen", "einer", "Intoxikation", "durch", "zu", "hohe", "intravasale", "Lokalanaesthetikumspiegel", ".", "Als", "einzige", "Nebenwirkung", "kam", "es", "in", "der", "Prilocaingruppe", "zu", "einer", "Methaemoglobinbildung", "von", "im", "Median", "10,1", "%", "3", "bis", "4", "h", "nach", "Injektionsende", ",", "wobei", "drei", "Patienten", "Werte", "zwischen", "16", "und", "17", "%", "aufwiesen", ".", "Bei", "fuenf", "Patienten", "dieser", "Gruppe", "war", "auch", "nach", "6", "h", "noch", "eine", "ausgepraegte", "periphere", "Zyanose", "nachweisbar", ".", "Sowohl", "Mepivacain", "1", "%", "ohne", "und", "mit", "Adrenalin", "als", "auch", "Prilocain", "1", "%", "eignen", "sich", "in", "einer", "Dosierung", "von", "700", "mg", "fuer", "die", "Durchfuehrung", "der", "kombinierten", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", ",", "wobei", "Prilocain", "allerdings", "den", "Nachteil", "einer", "im", "Einzelfall", "klinisch", "relevanten", "Methaemoglobinbildung", "aufweist", "." ]	[ "umlsterm" ]
Doppelblindstudie is an umlsterm, Patienten is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Analgetika is an umlsterm, Adrenalin is an umlsterm, Patienten is an umlsterm, Intoxikation is an umlsterm, Injektionsende is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Zyanose is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Prilocain is an umlsterm	DerAnaesthesist.60450052.ger.abstr_task1	Sentence: In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist . Instructions: please typing these entity words according to sentence: Doppelblindstudie, Patienten, Mepivacain, Adrenalin, Prilocain, Analgetika, Adrenalin, Patienten, Intoxikation, Injektionsende, Patienten, Patienten, Zyanose, Mepivacain, Adrenalin, Prilocain, Prilocain Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist .	[ "In", "einer", "prospektiven", ",", "randomisierten", "Doppelblindstudie", "wurde", "bei", "3", "mal", "20", "Patienten", "eine", "kombinierte", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", "durchgefuehrt", ".", "Wir", "verglichen", "den", "Blockadeerfolg", ",", "die", "arteriellen", "Serumspiegel", "und", "die", "Nebenwirkungen", "beim", "Einsatz", "von", "700", "mg", "Mepivacain", "1", "%", "ohne", "Gruppe", "I", ")", "(", "und", "mit", "Adrenalin", "1:350000", "(", "Gruppe", "II", ")", "sowie", "700", "mg", "Prilocain", "1", "%", "(", "Gruppe", "III", ")", ".", "Der", "primaere", "Blockadeerfolg", "ohne", "supplementierende", "Analgetika", "war", "in", "allen", "drei", "Gruppen", "vergleichbar", "und", "lag", "zwischen", "90", "und", "95", "%", ".", "Die", "maximalen", "Serumspiegel", "betrugen", "in", "Gruppe", "I", "3,91", "+", "/-", "0,95", "µg", "/", "ml", "nach", "60", "min", "und", "in", "Gruppe", "II", "2,94", "+", "/-", "0,58", "µg", "/", "ml", "nach", "120", "min", ".", "Zu", "allen", "Zeitpunkten", "fuehrte", "Adrenalin", "zu", "einer", "signifikanten", "Reduktion", "der", "Mepivacain", "-", "Serumspiegel", "(", "p", "0,01", ")", ".", "In", "der", "Prilocaingruppe", "waren", "die", "maximalen", "Serumspiegel", "mit", "2,07", "+", "/-", "0,56", "µg", "/", "ml", "signifikant", "niedriger", "als", "in", "beiden", "Mepivacaingruppen", "(", "p", "0,001", ")", "und", "traten", "nach", "15", "min", "auch", "signifikant", "frueher", "auf", ".", "Bei", "keinem", "Patienten", "fanden", "sich", "Symptome", "oder", "klinische", "Zeichen", "einer", "Intoxikation", "durch", "zu", "hohe", "intravasale", "Lokalanaesthetikumspiegel", ".", "Als", "einzige", "Nebenwirkung", "kam", "es", "in", "der", "Prilocaingruppe", "zu", "einer", "Methaemoglobinbildung", "von", "im", "Median", "10,1", "%", "3", "bis", "4", "h", "nach", "Injektionsende", ",", "wobei", "drei", "Patienten", "Werte", "zwischen", "16", "und", "17", "%", "aufwiesen", ".", "Bei", "fuenf", "Patienten", "dieser", "Gruppe", "war", "auch", "nach", "6", "h", "noch", "eine", "ausgepraegte", "periphere", "Zyanose", "nachweisbar", ".", "Sowohl", "Mepivacain", "1", "%", "ohne", "und", "mit", "Adrenalin", "als", "auch", "Prilocain", "1", "%", "eignen", "sich", "in", "einer", "Dosierung", "von", "700", "mg", "fuer", "die", "Durchfuehrung", "der", "kombinierten", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", ",", "wobei", "Prilocain", "allerdings", "den", "Nachteil", "einer", "im", "Einzelfall", "klinisch", "relevanten", "Methaemoglobinbildung", "aufweist", "." ]	[ "umlsterm" ]
Doppelblindstudie, Patienten, Mepivacain, Adrenalin, Prilocain, Analgetika, Adrenalin, Patienten, Intoxikation, Injektionsende, Patienten, Patienten, Zyanose, Mepivacain, Adrenalin, Prilocain, Prilocain	DerAnaesthesist.60450052.ger.abstr_task2	Sentence: In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist .	[ "In", "einer", "prospektiven", ",", "randomisierten", "Doppelblindstudie", "wurde", "bei", "3", "mal", "20", "Patienten", "eine", "kombinierte", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", "durchgefuehrt", ".", "Wir", "verglichen", "den", "Blockadeerfolg", ",", "die", "arteriellen", "Serumspiegel", "und", "die", "Nebenwirkungen", "beim", "Einsatz", "von", "700", "mg", "Mepivacain", "1", "%", "ohne", "Gruppe", "I", ")", "(", "und", "mit", "Adrenalin", "1:350000", "(", "Gruppe", "II", ")", "sowie", "700", "mg", "Prilocain", "1", "%", "(", "Gruppe", "III", ")", ".", "Der", "primaere", "Blockadeerfolg", "ohne", "supplementierende", "Analgetika", "war", "in", "allen", "drei", "Gruppen", "vergleichbar", "und", "lag", "zwischen", "90", "und", "95", "%", ".", "Die", "maximalen", "Serumspiegel", "betrugen", "in", "Gruppe", "I", "3,91", "+", "/-", "0,95", "µg", "/", "ml", "nach", "60", "min", "und", "in", "Gruppe", "II", "2,94", "+", "/-", "0,58", "µg", "/", "ml", "nach", "120", "min", ".", "Zu", "allen", "Zeitpunkten", "fuehrte", "Adrenalin", "zu", "einer", "signifikanten", "Reduktion", "der", "Mepivacain", "-", "Serumspiegel", "(", "p", "0,01", ")", ".", "In", "der", "Prilocaingruppe", "waren", "die", "maximalen", "Serumspiegel", "mit", "2,07", "+", "/-", "0,56", "µg", "/", "ml", "signifikant", "niedriger", "als", "in", "beiden", "Mepivacaingruppen", "(", "p", "0,001", ")", "und", "traten", "nach", "15", "min", "auch", "signifikant", "frueher", "auf", ".", "Bei", "keinem", "Patienten", "fanden", "sich", "Symptome", "oder", "klinische", "Zeichen", "einer", "Intoxikation", "durch", "zu", "hohe", "intravasale", "Lokalanaesthetikumspiegel", ".", "Als", "einzige", "Nebenwirkung", "kam", "es", "in", "der", "Prilocaingruppe", "zu", "einer", "Methaemoglobinbildung", "von", "im", "Median", "10,1", "%", "3", "bis", "4", "h", "nach", "Injektionsende", ",", "wobei", "drei", "Patienten", "Werte", "zwischen", "16", "und", "17", "%", "aufwiesen", ".", "Bei", "fuenf", "Patienten", "dieser", "Gruppe", "war", "auch", "nach", "6", "h", "noch", "eine", "ausgepraegte", "periphere", "Zyanose", "nachweisbar", ".", "Sowohl", "Mepivacain", "1", "%", "ohne", "und", "mit", "Adrenalin", "als", "auch", "Prilocain", "1", "%", "eignen", "sich", "in", "einer", "Dosierung", "von", "700", "mg", "fuer", "die", "Durchfuehrung", "der", "kombinierten", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", ",", "wobei", "Prilocain", "allerdings", "den", "Nachteil", "einer", "im", "Einzelfall", "klinisch", "relevanten", "Methaemoglobinbildung", "aufweist", "." ]	[ "umlsterm" ]
ADP is a CHEMICAL, guanosine is a CHEMICAL, SCO5461 is a GENE-Y	23212047_task0	Sentence: ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]	ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor.	[ "ADP", "-", "ribosylation", "of", "guanosine", "by", "SCO5461", "protein", "secreted", "from", "Streptomyces", "coelicolor", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
ADP is a CHEMICAL, guanosine is a CHEMICAL, SCO5461 is a GENE-Y	23212047_task1	Sentence: ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor. Instructions: please typing these entity words according to sentence: ADP, guanosine, SCO5461 Options: GENE-Y, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]	ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor.	[ "ADP", "-", "ribosylation", "of", "guanosine", "by", "SCO5461", "protein", "secreted", "from", "Streptomyces", "coelicolor", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
ADP, guanosine, SCO5461	23212047_task2	Sentence: ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]	ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor.	[ "ADP", "-", "ribosylation", "of", "guanosine", "by", "SCO5461", "protein", "secreted", "from", "Streptomyces", "coelicolor", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein	10_task0	Sentence: Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC).	[ "Increase", "of", "IRF-4", "expression", "in", "hematopoietic", "cells", "after", "demethylating", "treatment", "\n", "We", "next", "analyzed", "whether", "promoter", "methylation", "could", "be", "responsible", "for", "down", "-", "regulation", "of", "IRF-4", "expression", ".", "A", "region", "including", "exon1", "in", "the", "IRF-4", "promoter", "exhibited", "a", "large", "number", "of", "CpG", "-", "rich", "sequences", "(", "Figure", "3A", ")", ".", "Several", "chemical", "substances", "such", "as", "5-aza-2-deoxycytidine", "(", "AzadC", ")", "or", "5-azacytidine", "(", "AzaC", ")", "inhibit", "de", "novo", "and", "maintenance", "methylation", ",", "and", "thus", "can", "be", "used", "to", "discern", "promoter", "methylation", "(", "32,33", ")", ".", "We", "used", "AzadC", "to", "generate", "unmethylated", "DNA", ".", "A", "72", "h", "AzadC", "-", "treatment", "resulted", "in", "a", "concentration", "-", "dependent", "activation", "of", "IRF-4", "transcription", "in", "Jurkat", "and", "CML", "-", "T1", "T", "-", "cells", "as", "well", "as", "in", "U-937", ",", "K-562", "and", "EM-2", "cell", "lines", "(", "Figure", "2A", ")", ".", "IRF-4", "transcription", "was", "induced", "in", "a", "time", "-", "dependent", "manner", "and", "was", "observed", "as", "early", "as", "24", "h", "after", "treatment", "with", "AzadC", "and", "increased", "over", "time", "until", "72", "h", "(", "Figure", "2B", ")", ".", "Time", "and", "strength", "of", "the", "appearance", "of", "IRF-4", "transcripts", "varied", "among", "cell", "lines", ",", "i.e", ".", "CML", "-", "T1", "responded", "strongest", "to", "AzadC", "-", "treatment", "(", "data", "not", "shown", ")", ".", "In", "line", "with", "this", ",", "AzadC", "-", "treatment", "of", "CML", "-", "T1", "and", "LAMA-84", "cells", "also", "translated", "in", "an", "induction", "of", "IRF-4", "protein", "expression", "(", "Figure", "2C", ")", ".", "Accordingly", ",", "treatment", "of", "the", "IRF-4-positive", "cell", "line", "BV-173", ",", "SD-1", "and", "RPMI-8226", "with", "AzadC", "had", "no", "effect", "on", "IRF-4", "expression", "(", "Figure", "2D", ")", ".", "There", "was", "no", "difference", "in", "the", "effects", "of", "AzaC", "versus", "AzadC", ",", "as", "both", "increased", "the", "IRF-4", "mRNA", "level", "in", "CML", "-", "T1", "cells", "as", "well", "(", "data", "not", "shown", ")", ".", "This", "implied", "that", "promoter", "methylation", "may", "control", "IRF-4", "expression", ",", "but", "an", "alternative", "explanation", "may", "be", "activation", "of", "positive", "transcriptional", "regulators", "of", "IRF-4", "by", "AzadC", "(", "or", "AzaC", ")", ".", "\n" ]	[ "Protein" ]
IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein	10_task1	Sentence: Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC). Instructions: please typing these entity words according to sentence: IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4 Options: Protein	[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC).	[ "Increase", "of", "IRF-4", "expression", "in", "hematopoietic", "cells", "after", "demethylating", "treatment", "\n", "We", "next", "analyzed", "whether", "promoter", "methylation", "could", "be", "responsible", "for", "down", "-", "regulation", "of", "IRF-4", "expression", ".", "A", "region", "including", "exon1", "in", "the", "IRF-4", "promoter", "exhibited", "a", "large", "number", "of", "CpG", "-", "rich", "sequences", "(", "Figure", "3A", ")", ".", "Several", "chemical", "substances", "such", "as", "5-aza-2-deoxycytidine", "(", "AzadC", ")", "or", "5-azacytidine", "(", "AzaC", ")", "inhibit", "de", "novo", "and", "maintenance", "methylation", ",", "and", "thus", "can", "be", "used", "to", "discern", "promoter", "methylation", "(", "32,33", ")", ".", "We", "used", "AzadC", "to", "generate", "unmethylated", "DNA", ".", "A", "72", "h", "AzadC", "-", "treatment", "resulted", "in", "a", "concentration", "-", "dependent", "activation", "of", "IRF-4", "transcription", "in", "Jurkat", "and", "CML", "-", "T1", "T", "-", "cells", "as", "well", "as", "in", "U-937", ",", "K-562", "and", "EM-2", "cell", "lines", "(", "Figure", "2A", ")", ".", "IRF-4", "transcription", "was", "induced", "in", "a", "time", "-", "dependent", "manner", "and", "was", "observed", "as", "early", "as", "24", "h", "after", "treatment", "with", "AzadC", "and", "increased", "over", "time", "until", "72", "h", "(", "Figure", "2B", ")", ".", "Time", "and", "strength", "of", "the", "appearance", "of", "IRF-4", "transcripts", "varied", "among", "cell", "lines", ",", "i.e", ".", "CML", "-", "T1", "responded", "strongest", "to", "AzadC", "-", "treatment", "(", "data", "not", "shown", ")", ".", "In", "line", "with", "this", ",", "AzadC", "-", "treatment", "of", "CML", "-", "T1", "and", "LAMA-84", "cells", "also", "translated", "in", "an", "induction", "of", "IRF-4", "protein", "expression", "(", "Figure", "2C", ")", ".", "Accordingly", ",", "treatment", "of", "the", "IRF-4-positive", "cell", "line", "BV-173", ",", "SD-1", "and", "RPMI-8226", "with", "AzadC", "had", "no", "effect", "on", "IRF-4", "expression", "(", "Figure", "2D", ")", ".", "There", "was", "no", "difference", "in", "the", "effects", "of", "AzaC", "versus", "AzadC", ",", "as", "both", "increased", "the", "IRF-4", "mRNA", "level", "in", "CML", "-", "T1", "cells", "as", "well", "(", "data", "not", "shown", ")", ".", "This", "implied", "that", "promoter", "methylation", "may", "control", "IRF-4", "expression", ",", "but", "an", "alternative", "explanation", "may", "be", "activation", "of", "positive", "transcriptional", "regulators", "of", "IRF-4", "by", "AzadC", "(", "or", "AzaC", ")", ".", "\n" ]	[ "Protein" ]
IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4	10_task2	Sentence: Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC). Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC).	[ "Increase", "of", "IRF-4", "expression", "in", "hematopoietic", "cells", "after", "demethylating", "treatment", "\n", "We", "next", "analyzed", "whether", "promoter", "methylation", "could", "be", "responsible", "for", "down", "-", "regulation", "of", "IRF-4", "expression", ".", "A", "region", "including", "exon1", "in", "the", "IRF-4", "promoter", "exhibited", "a", "large", "number", "of", "CpG", "-", "rich", "sequences", "(", "Figure", "3A", ")", ".", "Several", "chemical", "substances", "such", "as", "5-aza-2-deoxycytidine", "(", "AzadC", ")", "or", "5-azacytidine", "(", "AzaC", ")", "inhibit", "de", "novo", "and", "maintenance", "methylation", ",", "and", "thus", "can", "be", "used", "to", "discern", "promoter", "methylation", "(", "32,33", ")", ".", "We", "used", "AzadC", "to", "generate", "unmethylated", "DNA", ".", "A", "72", "h", "AzadC", "-", "treatment", "resulted", "in", "a", "concentration", "-", "dependent", "activation", "of", "IRF-4", "transcription", "in", "Jurkat", "and", "CML", "-", "T1", "T", "-", "cells", "as", "well", "as", "in", "U-937", ",", "K-562", "and", "EM-2", "cell", "lines", "(", "Figure", "2A", ")", ".", "IRF-4", "transcription", "was", "induced", "in", "a", "time", "-", "dependent", "manner", "and", "was", "observed", "as", "early", "as", "24", "h", "after", "treatment", "with", "AzadC", "and", "increased", "over", "time", "until", "72", "h", "(", "Figure", "2B", ")", ".", "Time", "and", "strength", "of", "the", "appearance", "of", "IRF-4", "transcripts", "varied", "among", "cell", "lines", ",", "i.e", ".", "CML", "-", "T1", "responded", "strongest", "to", "AzadC", "-", "treatment", "(", "data", "not", "shown", ")", ".", "In", "line", "with", "this", ",", "AzadC", "-", "treatment", "of", "CML", "-", "T1", "and", "LAMA-84", "cells", "also", "translated", "in", "an", "induction", "of", "IRF-4", "protein", "expression", "(", "Figure", "2C", ")", ".", "Accordingly", ",", "treatment", "of", "the", "IRF-4-positive", "cell", "line", "BV-173", ",", "SD-1", "and", "RPMI-8226", "with", "AzadC", "had", "no", "effect", "on", "IRF-4", "expression", "(", "Figure", "2D", ")", ".", "There", "was", "no", "difference", "in", "the", "effects", "of", "AzaC", "versus", "AzadC", ",", "as", "both", "increased", "the", "IRF-4", "mRNA", "level", "in", "CML", "-", "T1", "cells", "as", "well", "(", "data", "not", "shown", ")", ".", "This", "implied", "that", "promoter", "methylation", "may", "control", "IRF-4", "expression", ",", "but", "an", "alternative", "explanation", "may", "be", "activation", "of", "positive", "transcriptional", "regulators", "of", "IRF-4", "by", "AzadC", "(", "or", "AzaC", ")", ".", "\n" ]	[ "Protein" ]
Arp11 is a protein, Arp1 is a protein, actin is a protein-family	1.0alpha7.train.244_task0	Sentence: At present, we do not know whether Arp11 binds directly to Arp1 or actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "B-protein-family", "O" ]	At present, we do not know whether Arp11 binds directly to Arp1 or actin.	[ "At", "present", ",", "we", "do", "not", "know", "whether", "Arp11", "binds", "directly", "to", "Arp1", "or", "actin", "." ]	[ "protein", "protein-family" ]
Arp11 is a protein, Arp1 is a protein, actin is a protein-family	1.0alpha7.train.244_task1	Sentence: At present, we do not know whether Arp11 binds directly to Arp1 or actin. Instructions: please typing these entity words according to sentence: Arp11, Arp1, actin Options: protein-family, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "B-protein-family", "O" ]	At present, we do not know whether Arp11 binds directly to Arp1 or actin.	[ "At", "present", ",", "we", "do", "not", "know", "whether", "Arp11", "binds", "directly", "to", "Arp1", "or", "actin", "." ]	[ "protein", "protein-family" ]
Arp11, Arp1, actin	1.0alpha7.train.244_task2	Sentence: At present, we do not know whether Arp11 binds directly to Arp1 or actin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "B-protein-family", "O" ]	At present, we do not know whether Arp11 binds directly to Arp1 or actin.	[ "At", "present", ",", "we", "do", "not", "know", "whether", "Arp11", "binds", "directly", "to", "Arp1", "or", "actin", "." ]	[ "protein", "protein-family" ]
Arrhythmiemechanismus is an umlsterm, Arrhythmien is an umlsterm, Sinustachykardie is an umlsterm, ektope atriale Tachykardie is an umlsterm, Vorhofflimmern is an umlsterm, Vorhofflattern is an umlsterm, Tachykardien is an umlsterm, Arrhythmien is an umlsterm, Elektrophysiologie is an umlsterm	ZfuerKardiologie.0089x043.ger.abstr_task0	Sentence: Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns .	[ "Hinter", "dem", "Begriff", "\"", "supraventrikulaere", "Tachyarrhythmien", "\"", "verbergen", "sich", "elektrophysiologisch", "unterschiedliche", "Rhythmusstoerungen", ".", "Nach", "Identifizierung", "des", "Arrhythmiemechanismus", "'", "ist", "eine", "Lokalisation", "des", "Schwachpunktes", "der", "Rhythmusstoerung", "durch", "verschiedene", "Mappingtechniken", "erforderlich", ".", "Danach", "erfolgt", "in", "der", "Regel", "die", "Ablation", "als", "fokale", "Ablation", "bei", "automatischen", "Arrhythmien", "(", "Sinustachykardie", ",", "ektope", "atriale", "Tachykardie", ",", "fokales", "Vorhofflimmern", ")", "oder", "zur", "Unterbrechung", "von", "Leitbahnen", "(", "Praeexzitationssyndrom", ",", "AV", "-", "Knoten", "-", "Tachykardie", ")", ".", "Eine", "singulaere", "Ablationslinie", "ist", "fuer", "das", "isthmusabhaengige", "Vorhofflattern", "und", "fuer", "einige", "inzisionale", "Tachykardien", "erforderlich", ";", "dieses", "Vorgehen", "ist", "bereits", "weniger", "verbreitet", ".", "Multiple", "Ablationslinien", "sind", "fuer", "die", "Ablation", "eines", "Vorhofflimmerns", "erforderlich", ",", "was", "gegenwaertig", "nur", "in", "wenigen", "Zentren", "erfolgen", "kann", ".", "Verschiedene", "Arrhythmien", "sind", "bislang", "zu", "wenig", "verstanden", ",", "nicht", "induzierbar", ",", "nicht", "genau", "lokalisierbar", "und", "damit", "bislang", "nicht", "abladierbar", ".", "Neue", "dreidimensionale", "Mappingmethoden", ",", "koennten", "hier", "weiterhelfen", ".", "Die", "gegenwaertig", "groesste", "Herausforderung", "der", "interventionellen", "Elektrophysiologie", "ist", "die", "Ablation", "des", "Vorhofflimmerns", "." ]	[ "umlsterm" ]
Arrhythmiemechanismus is an umlsterm, Arrhythmien is an umlsterm, Sinustachykardie is an umlsterm, ektope atriale Tachykardie is an umlsterm, Vorhofflimmern is an umlsterm, Vorhofflattern is an umlsterm, Tachykardien is an umlsterm, Arrhythmien is an umlsterm, Elektrophysiologie is an umlsterm	ZfuerKardiologie.0089x043.ger.abstr_task1	Sentence: Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns . Instructions: please typing these entity words according to sentence: Arrhythmiemechanismus, Arrhythmien, Sinustachykardie, ektope atriale Tachykardie, Vorhofflimmern, Vorhofflattern, Tachykardien, Arrhythmien, Elektrophysiologie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns .	[ "Hinter", "dem", "Begriff", "\"", "supraventrikulaere", "Tachyarrhythmien", "\"", "verbergen", "sich", "elektrophysiologisch", "unterschiedliche", "Rhythmusstoerungen", ".", "Nach", "Identifizierung", "des", "Arrhythmiemechanismus", "'", "ist", "eine", "Lokalisation", "des", "Schwachpunktes", "der", "Rhythmusstoerung", "durch", "verschiedene", "Mappingtechniken", "erforderlich", ".", "Danach", "erfolgt", "in", "der", "Regel", "die", "Ablation", "als", "fokale", "Ablation", "bei", "automatischen", "Arrhythmien", "(", "Sinustachykardie", ",", "ektope", "atriale", "Tachykardie", ",", "fokales", "Vorhofflimmern", ")", "oder", "zur", "Unterbrechung", "von", "Leitbahnen", "(", "Praeexzitationssyndrom", ",", "AV", "-", "Knoten", "-", "Tachykardie", ")", ".", "Eine", "singulaere", "Ablationslinie", "ist", "fuer", "das", "isthmusabhaengige", "Vorhofflattern", "und", "fuer", "einige", "inzisionale", "Tachykardien", "erforderlich", ";", "dieses", "Vorgehen", "ist", "bereits", "weniger", "verbreitet", ".", "Multiple", "Ablationslinien", "sind", "fuer", "die", "Ablation", "eines", "Vorhofflimmerns", "erforderlich", ",", "was", "gegenwaertig", "nur", "in", "wenigen", "Zentren", "erfolgen", "kann", ".", "Verschiedene", "Arrhythmien", "sind", "bislang", "zu", "wenig", "verstanden", ",", "nicht", "induzierbar", ",", "nicht", "genau", "lokalisierbar", "und", "damit", "bislang", "nicht", "abladierbar", ".", "Neue", "dreidimensionale", "Mappingmethoden", ",", "koennten", "hier", "weiterhelfen", ".", "Die", "gegenwaertig", "groesste", "Herausforderung", "der", "interventionellen", "Elektrophysiologie", "ist", "die", "Ablation", "des", "Vorhofflimmerns", "." ]	[ "umlsterm" ]
Arrhythmiemechanismus, Arrhythmien, Sinustachykardie, ektope atriale Tachykardie, Vorhofflimmern, Vorhofflattern, Tachykardien, Arrhythmien, Elektrophysiologie	ZfuerKardiologie.0089x043.ger.abstr_task2	Sentence: Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns .	[ "Hinter", "dem", "Begriff", "\"", "supraventrikulaere", "Tachyarrhythmien", "\"", "verbergen", "sich", "elektrophysiologisch", "unterschiedliche", "Rhythmusstoerungen", ".", "Nach", "Identifizierung", "des", "Arrhythmiemechanismus", "'", "ist", "eine", "Lokalisation", "des", "Schwachpunktes", "der", "Rhythmusstoerung", "durch", "verschiedene", "Mappingtechniken", "erforderlich", ".", "Danach", "erfolgt", "in", "der", "Regel", "die", "Ablation", "als", "fokale", "Ablation", "bei", "automatischen", "Arrhythmien", "(", "Sinustachykardie", ",", "ektope", "atriale", "Tachykardie", ",", "fokales", "Vorhofflimmern", ")", "oder", "zur", "Unterbrechung", "von", "Leitbahnen", "(", "Praeexzitationssyndrom", ",", "AV", "-", "Knoten", "-", "Tachykardie", ")", ".", "Eine", "singulaere", "Ablationslinie", "ist", "fuer", "das", "isthmusabhaengige", "Vorhofflattern", "und", "fuer", "einige", "inzisionale", "Tachykardien", "erforderlich", ";", "dieses", "Vorgehen", "ist", "bereits", "weniger", "verbreitet", ".", "Multiple", "Ablationslinien", "sind", "fuer", "die", "Ablation", "eines", "Vorhofflimmerns", "erforderlich", ",", "was", "gegenwaertig", "nur", "in", "wenigen", "Zentren", "erfolgen", "kann", ".", "Verschiedene", "Arrhythmien", "sind", "bislang", "zu", "wenig", "verstanden", ",", "nicht", "induzierbar", ",", "nicht", "genau", "lokalisierbar", "und", "damit", "bislang", "nicht", "abladierbar", ".", "Neue", "dreidimensionale", "Mappingmethoden", ",", "koennten", "hier", "weiterhelfen", ".", "Die", "gegenwaertig", "groesste", "Herausforderung", "der", "interventionellen", "Elektrophysiologie", "ist", "die", "Ablation", "des", "Vorhofflimmerns", "." ]	[ "umlsterm" ]
Retinoblastoma is a Protein, Oct-1 is a Protein, interleukin-8 is a Protein, retinoblastoma is a Protein, IFN - gamma is a Protein, Rb is a Protein, IFN - gamma is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Oct-1 is a Protein, interleukin 8 is a Protein, promoter is a Entity, Oct-1 is a Protein, Rb is a Protein, interleukin 8 is a Protein	215_task0	Sentence: Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines.	[ "Retinoblastoma", "protein", "expression", "leads", "to", "reduced", "Oct-1", "DNA", "binding", "activity", "and", "enhances", "interleukin-8", "expression", ".", "\n", "Tumor", "cell", "lines", "with", "a", "defective", "retinoblastoma", "gene", "are", "unable", "to", "transcribe", "the", "HLA", "class", "II", "genes", "in", "response", "to", "IFN", "-", "gamma", "treatment", ",", "and", "reconstitution", "of", "functional", "Rb", "rescues", "IFN", "-", "gamma", "-", "induced", "class", "II", "gene", "expression", ".", "However", ",", "the", "molecular", "mechanism", "of", "Rb", "rescue", "of", "the", "class", "II", "genes", "is", "unknown", ".", "We", "have", "examined", "the", "effect", "of", "Rb", "expression", "on", "the", "activation", "of", "the", "promoter", "for", "HLA", "-", "DRA", ",", "the", "prototype", "class", "II", "gene", ".", "Oct-1", ",", "a", "POU", "domain", "transcription", "factor", ",", "was", "identified", "as", "a", "repressor", "of", "HLA", "-", "DRA", "promoter", "activity", "in", "the", "Rb", "-", "defective", "cells", ".", "Rb", "expression", "led", "to", "phosphorylation", "of", "Oct-1", ",", "thus", "relieving", "its", "repressive", "effect", ".", "Oct-1", "has", "also", "been", "shown", "to", "repress", "interleukin", "8", "promoter", "activity", ".", "Consistent", "with", "reduced", "levels", "of", "Oct-1", "DNA", "binding", "activity", "in", "the", "Rb", "-", "transformed", "cell", "lines", ",", "interleukin", "8", "expression", "is", "higher", "in", "these", "cell", "lines", "." ]	[ "Protein", "Entity" ]

eprosartan is a CHEMICAL, renin is a GENE-Y, angiotensin is a CHEMICAL, Angiotensin II type 1 receptor is a GENE-Y, eprosartan is a CHEMICAL, angiotensin II type 1 receptor is a GENE-Y, AT1 is a GENE-Y, Eprosartan is a CHEMICAL, AT1 receptors is a GENE-Y, AT1 receptors is a GENE-Y, noradrenaline is a CHEMICAL, eprosartan is a CHEMICAL, angiotensin - converting enzyme is a GENE-Y, Eprosartan is a CHEMICAL, Eprosartan is a CHEMICAL

21749_task0

Sentence: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus.

[ "Introduction", ":", "The", "pharmacological", "profile", "of", "eprosartan", "--", "implications", "for", "cerebrovascular", "and", "cardiovascular", "risk", "reduction", ".", "\n", "Moderate", "elevations", "in", "blood", "pressure", "translate", "to", "significant", "increases", "in", "cardiovascular", "and", "cerebro", "vascular", "risk", ".", "Beneficially", ",", "this", "relationship", "allows", "small", "decreases", "in", "blood", "pressure", "to", "be", "associated", "with", "risk", "reduction", ".", "Both", "the", "renin", "-", "angiotensin", "system", "and", "the", "sympathetic", "nervous", "system", "are", "involved", "in", "hypertension", ",", "hence", "targeting", "these", "systems", "is", "likely", "to", "be", "of", "benefit", "in", "the", "treatment", "of", "hypertension", ".", "Angiotensin", "II", "type", "1", "receptor", "blockers", "(", "ARBs", ")", "are", "used", "for", "controlling", "blood", "pressure", "and", "treating", "heart", "failure", "in", "a", "broad", "range", "of", "patients", ",", "including", "those", "with", "diabetes", "and", "the", "elderly", ".", "Not", "only", "have", "ARBs", "shown", "good", "efficacy", "and", "tolerability", ",", "they", "also", "appear", "to", "have", "a", "protective", "effect", "that", "goes", "beyond", "that", "expected", "from", "the", "reduction", "of", "blood", "pressure", ".", "The", "ARB", "eprosartan", "is", "a", "nonbiphenyl", "nontetrazole", "angiotensin", "II", "type", "1", "receptor", "(", "AT1", ")", "antagonist", ",", "which", "acts", "to", "decrease", "total", "peripheral", "resistance", ".", "Eprosartan", "acts", "at", "vascular", "AT1", "receptors", "(", "postsynaptically", ")", "and", "at", "presynaptic", "AT1", "receptors", ",", "where", "it", "inhibits", "noradrenaline", "release", ".", "In", "clinical", "studies", ",", "eprosartan", "has", "been", "shown", "to", "significantly", "reduce", "cardiovascular", "and", "cerebrovascular", "events", ",", "whilst", "avoiding", "the", "persistent", "cough", "that", "commonly", "occurs", "with", "the", "use", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", ".", "Eprosartan", "can", "also", "be", "differentiated", "from", "other", "ARBs", "due", "to", "its", "noradrenergic", "effects", ",", "which", "other", "ARBs", "used", "at", "therapeutic", "doses", "do", "not", "possess", ".", "Eprosartan", ",", "therefore", ",", "represents", "a", "useful", "therapeutic", "option", "in", "the", "management", "of", "patients", "with", "hypertension", ",", "including", "those", "with", "a", "history", "of", "stroke", "or", "with", "co", "-", "morbid", "type", "2", "diabetes", "mellitus", "." ]

[ "GENE-Y", "CHEMICAL" ]

eprosartan is a CHEMICAL, renin is a GENE-Y, angiotensin is a CHEMICAL, Angiotensin II type 1 receptor is a GENE-Y, eprosartan is a CHEMICAL, angiotensin II type 1 receptor is a GENE-Y, AT1 is a GENE-Y, Eprosartan is a CHEMICAL, AT1 receptors is a GENE-Y, AT1 receptors is a GENE-Y, noradrenaline is a CHEMICAL, eprosartan is a CHEMICAL, angiotensin - converting enzyme is a GENE-Y, Eprosartan is a CHEMICAL, Eprosartan is a CHEMICAL

21749_task1

Sentence: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus. Instructions: please typing these entity words according to sentence: eprosartan, renin, angiotensin, Angiotensin II type 1 receptor, eprosartan, angiotensin II type 1 receptor, AT1, Eprosartan, AT1 receptors, AT1 receptors, noradrenaline, eprosartan, angiotensin - converting enzyme, Eprosartan, Eprosartan Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus.

[ "Introduction", ":", "The", "pharmacological", "profile", "of", "eprosartan", "--", "implications", "for", "cerebrovascular", "and", "cardiovascular", "risk", "reduction", ".", "\n", "Moderate", "elevations", "in", "blood", "pressure", "translate", "to", "significant", "increases", "in", "cardiovascular", "and", "cerebro", "vascular", "risk", ".", "Beneficially", ",", "this", "relationship", "allows", "small", "decreases", "in", "blood", "pressure", "to", "be", "associated", "with", "risk", "reduction", ".", "Both", "the", "renin", "-", "angiotensin", "system", "and", "the", "sympathetic", "nervous", "system", "are", "involved", "in", "hypertension", ",", "hence", "targeting", "these", "systems", "is", "likely", "to", "be", "of", "benefit", "in", "the", "treatment", "of", "hypertension", ".", "Angiotensin", "II", "type", "1", "receptor", "blockers", "(", "ARBs", ")", "are", "used", "for", "controlling", "blood", "pressure", "and", "treating", "heart", "failure", "in", "a", "broad", "range", "of", "patients", ",", "including", "those", "with", "diabetes", "and", "the", "elderly", ".", "Not", "only", "have", "ARBs", "shown", "good", "efficacy", "and", "tolerability", ",", "they", "also", "appear", "to", "have", "a", "protective", "effect", "that", "goes", "beyond", "that", "expected", "from", "the", "reduction", "of", "blood", "pressure", ".", "The", "ARB", "eprosartan", "is", "a", "nonbiphenyl", "nontetrazole", "angiotensin", "II", "type", "1", "receptor", "(", "AT1", ")", "antagonist", ",", "which", "acts", "to", "decrease", "total", "peripheral", "resistance", ".", "Eprosartan", "acts", "at", "vascular", "AT1", "receptors", "(", "postsynaptically", ")", "and", "at", "presynaptic", "AT1", "receptors", ",", "where", "it", "inhibits", "noradrenaline", "release", ".", "In", "clinical", "studies", ",", "eprosartan", "has", "been", "shown", "to", "significantly", "reduce", "cardiovascular", "and", "cerebrovascular", "events", ",", "whilst", "avoiding", "the", "persistent", "cough", "that", "commonly", "occurs", "with", "the", "use", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", ".", "Eprosartan", "can", "also", "be", "differentiated", "from", "other", "ARBs", "due", "to", "its", "noradrenergic", "effects", ",", "which", "other", "ARBs", "used", "at", "therapeutic", "doses", "do", "not", "possess", ".", "Eprosartan", ",", "therefore", ",", "represents", "a", "useful", "therapeutic", "option", "in", "the", "management", "of", "patients", "with", "hypertension", ",", "including", "those", "with", "a", "history", "of", "stroke", "or", "with", "co", "-", "morbid", "type", "2", "diabetes", "mellitus", "." ]

[ "GENE-Y", "CHEMICAL" ]

eprosartan, renin, angiotensin, Angiotensin II type 1 receptor, eprosartan, angiotensin II type 1 receptor, AT1, Eprosartan, AT1 receptors, AT1 receptors, noradrenaline, eprosartan, angiotensin - converting enzyme, Eprosartan, Eprosartan

21749_task2

Sentence: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Moderate elevations in blood pressure translate to significant increases in cardiovascular and cerebro vascular risk. Beneficially, this relationship allows small decreases in blood pressure to be associated with risk reduction. Both the renin-angiotensin system and the sympathetic nervous system are involved in hypertension, hence targeting these systems is likely to be of benefit in the treatment of hypertension. Angiotensin II type 1 receptor blockers (ARBs) are used for controlling blood pressure and treating heart failure in a broad range of patients, including those with diabetes and the elderly. Not only have ARBs shown good efficacy and tolerability, they also appear to have a protective effect that goes beyond that expected from the reduction of blood pressure. The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance. Eprosartan acts at vascular AT1 receptors (postsynaptically) and at presynaptic AT1 receptors, where it inhibits noradrenaline release. In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. Eprosartan can also be differentiated from other ARBs due to its noradrenergic effects, which other ARBs used at therapeutic doses do not possess. Eprosartan, therefore, represents a useful therapeutic option in the management of patients with hypertension, including those with a history of stroke or with co-morbid type 2 diabetes mellitus.

[ "Introduction", ":", "The", "pharmacological", "profile", "of", "eprosartan", "--", "implications", "for", "cerebrovascular", "and", "cardiovascular", "risk", "reduction", ".", "\n", "Moderate", "elevations", "in", "blood", "pressure", "translate", "to", "significant", "increases", "in", "cardiovascular", "and", "cerebro", "vascular", "risk", ".", "Beneficially", ",", "this", "relationship", "allows", "small", "decreases", "in", "blood", "pressure", "to", "be", "associated", "with", "risk", "reduction", ".", "Both", "the", "renin", "-", "angiotensin", "system", "and", "the", "sympathetic", "nervous", "system", "are", "involved", "in", "hypertension", ",", "hence", "targeting", "these", "systems", "is", "likely", "to", "be", "of", "benefit", "in", "the", "treatment", "of", "hypertension", ".", "Angiotensin", "II", "type", "1", "receptor", "blockers", "(", "ARBs", ")", "are", "used", "for", "controlling", "blood", "pressure", "and", "treating", "heart", "failure", "in", "a", "broad", "range", "of", "patients", ",", "including", "those", "with", "diabetes", "and", "the", "elderly", ".", "Not", "only", "have", "ARBs", "shown", "good", "efficacy", "and", "tolerability", ",", "they", "also", "appear", "to", "have", "a", "protective", "effect", "that", "goes", "beyond", "that", "expected", "from", "the", "reduction", "of", "blood", "pressure", ".", "The", "ARB", "eprosartan", "is", "a", "nonbiphenyl", "nontetrazole", "angiotensin", "II", "type", "1", "receptor", "(", "AT1", ")", "antagonist", ",", "which", "acts", "to", "decrease", "total", "peripheral", "resistance", ".", "Eprosartan", "acts", "at", "vascular", "AT1", "receptors", "(", "postsynaptically", ")", "and", "at", "presynaptic", "AT1", "receptors", ",", "where", "it", "inhibits", "noradrenaline", "release", ".", "In", "clinical", "studies", ",", "eprosartan", "has", "been", "shown", "to", "significantly", "reduce", "cardiovascular", "and", "cerebrovascular", "events", ",", "whilst", "avoiding", "the", "persistent", "cough", "that", "commonly", "occurs", "with", "the", "use", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", ".", "Eprosartan", "can", "also", "be", "differentiated", "from", "other", "ARBs", "due", "to", "its", "noradrenergic", "effects", ",", "which", "other", "ARBs", "used", "at", "therapeutic", "doses", "do", "not", "possess", ".", "Eprosartan", ",", "therefore", ",", "represents", "a", "useful", "therapeutic", "option", "in", "the", "management", "of", "patients", "with", "hypertension", ",", "including", "those", "with", "a", "history", "of", "stroke", "or", "with", "co", "-", "morbid", "type", "2", "diabetes", "mellitus", "." ]

[ "GENE-Y", "CHEMICAL" ]

Competitive memory training ( COMET ) is a Intervention_Other, low self - esteem is a Outcome_Mental, depressive disorders is a Participant_Condition, Low self - esteem is a Outcome_Mental, of is a Intervention_Other, Competitive Memory Training ( COMET ) is a Intervention_Other, Sixty - one is a Participant_Sample-size, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] is a Intervention_Other, ongoing regular therapy ( TAU only is a Intervention_Control, effects of COMET is a Outcome_Mental, stable is a Outcome_Mental, significant improvement is a Outcome_Other, large effect sizes on indices of self - esteem , depression , and depressive rumination . is a Outcome_Mental, therapeutic effects is a Outcome_Mental

54510_task0

Sentence: Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Control, Participant_Condition, Intervention_Other, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders .

[ "Competitive", "memory", "training", "(", "COMET", ")", "for", "treating", "low", "self", "-", "esteem", "in", "patients", "with", "depressive", "disorders", ":", "a", "randomized", "clinical", "trial", ".", "BACKGROUND", "Self", "-", "esteem", "is", "a", "major", "concern", "in", "mood", "disorders", ".", "Low", "self", "-", "esteem", "is", "a", "symptom", "of", "depressive", "disorders", "and", "is", "considered", "by", "some", "to", "be", "a", "predictor", "for", "relapse", ",", "whereas", "high", "self", "-", "esteem", "seems", "to", "buffer", "against", "depression", ".", "Recently", ",", "Competitive", "Memory", "Training", "(", "COMET", ")", "has", "shown", "to", "be", "effective", "for", "the", "enhancement", "of", "self", "-", "esteem", "in", "several", "psychopathological", "conditions", ".", "The", "current", "study", "assesses", "whether", "COMET", "is", "also", "an", "effective", "intervention", "for", "patients", "with", "depressive", "disorders", ".", "METHODS", "Sixty", "-", "one", "patients", "with", "depressive", "disorders", "who", "were", "already", "in", "therapy", "in", "an", "outpatient", "mental", "health", "institution", "were", "randomly", "assigned", "to", "either", "eight", "group", "sessions", "of", "COMET", "in", "addition", "to", "their", "regular", "therapy", "(", "COMET", "+", "therapy", "as", "usual", "[", "TAU", "]", ":", "the", "experimental", "group", ")", "or", "to", "8", "weeks", "of", "ongoing", "regular", "therapy", "(", "TAU", "only", ":", "the", "control", "group", ")", ".", "These", "latter", "(", "control", ")", "patients", "received", "COMET", "after", "their", "TAU", "only", "period", ".", "All", "patients", "in", "both", "groups", "that", "completed", "COMET", "were", "contacted", "3", "and", "6", "months", "later", "to", "assess", "whether", "the", "effects", "of", "COMET", "had", "remained", "stable", ".", "RESULTS", "Compared", "to", "the", "patients", "who", "received", "TAU", "only", ",", "patients", "in", "the", "COMET", "+", "TAU", "condition", "showed", "significant", "improvement", "with", "large", "effect", "sizes", "on", "indices", "of", "self", "-", "esteem", ",", "depression", ",", "and", "depressive", "rumination", ".", "The", "therapeutic", "effects", "of", "COMET", "+", "TAU", "remained", "stable", "after", "3", "and", "6", "months", "on", "all", "outcome", "measures", "or", "improved", "even", "further", ".", "CONCLUSION", "COMET", "for", "low", "self", "-", "esteem", "seems", "to", "be", "an", "efficacious", "trans", "-", "diagnostic", "intervention", "that", "can", "relatively", "easily", "be", "added", "to", "the", "regular", "treatment", "of", "patients", "with", "depressive", "disorders", "." ]

[ "Outcome_Mental", "Intervention_Other", "Intervention_Control", "Outcome_Other", "Participant_Condition", "Participant_Sample-size" ]

Competitive memory training ( COMET ) is a Intervention_Other, low self - esteem is a Outcome_Mental, depressive disorders is a Participant_Condition, Low self - esteem is a Outcome_Mental, of is a Intervention_Other, Competitive Memory Training ( COMET ) is a Intervention_Other, Sixty - one is a Participant_Sample-size, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] is a Intervention_Other, ongoing regular therapy ( TAU only is a Intervention_Control, effects of COMET is a Outcome_Mental, stable is a Outcome_Mental, significant improvement is a Outcome_Other, large effect sizes on indices of self - esteem , depression , and depressive rumination . is a Outcome_Mental, therapeutic effects is a Outcome_Mental

54510_task1

Sentence: Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders . Instructions: please typing these entity words according to sentence: Competitive memory training ( COMET ), low self - esteem, depressive disorders, Low self - esteem, of, Competitive Memory Training ( COMET ), Sixty - one, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ], ongoing regular therapy ( TAU only, effects of COMET, stable, significant improvement, large effect sizes on indices of self - esteem , depression , and depressive rumination ., therapeutic effects Options: Intervention_Control, Participant_Condition, Intervention_Other, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders .

[ "Competitive", "memory", "training", "(", "COMET", ")", "for", "treating", "low", "self", "-", "esteem", "in", "patients", "with", "depressive", "disorders", ":", "a", "randomized", "clinical", "trial", ".", "BACKGROUND", "Self", "-", "esteem", "is", "a", "major", "concern", "in", "mood", "disorders", ".", "Low", "self", "-", "esteem", "is", "a", "symptom", "of", "depressive", "disorders", "and", "is", "considered", "by", "some", "to", "be", "a", "predictor", "for", "relapse", ",", "whereas", "high", "self", "-", "esteem", "seems", "to", "buffer", "against", "depression", ".", "Recently", ",", "Competitive", "Memory", "Training", "(", "COMET", ")", "has", "shown", "to", "be", "effective", "for", "the", "enhancement", "of", "self", "-", "esteem", "in", "several", "psychopathological", "conditions", ".", "The", "current", "study", "assesses", "whether", "COMET", "is", "also", "an", "effective", "intervention", "for", "patients", "with", "depressive", "disorders", ".", "METHODS", "Sixty", "-", "one", "patients", "with", "depressive", "disorders", "who", "were", "already", "in", "therapy", "in", "an", "outpatient", "mental", "health", "institution", "were", "randomly", "assigned", "to", "either", "eight", "group", "sessions", "of", "COMET", "in", "addition", "to", "their", "regular", "therapy", "(", "COMET", "+", "therapy", "as", "usual", "[", "TAU", "]", ":", "the", "experimental", "group", ")", "or", "to", "8", "weeks", "of", "ongoing", "regular", "therapy", "(", "TAU", "only", ":", "the", "control", "group", ")", ".", "These", "latter", "(", "control", ")", "patients", "received", "COMET", "after", "their", "TAU", "only", "period", ".", "All", "patients", "in", "both", "groups", "that", "completed", "COMET", "were", "contacted", "3", "and", "6", "months", "later", "to", "assess", "whether", "the", "effects", "of", "COMET", "had", "remained", "stable", ".", "RESULTS", "Compared", "to", "the", "patients", "who", "received", "TAU", "only", ",", "patients", "in", "the", "COMET", "+", "TAU", "condition", "showed", "significant", "improvement", "with", "large", "effect", "sizes", "on", "indices", "of", "self", "-", "esteem", ",", "depression", ",", "and", "depressive", "rumination", ".", "The", "therapeutic", "effects", "of", "COMET", "+", "TAU", "remained", "stable", "after", "3", "and", "6", "months", "on", "all", "outcome", "measures", "or", "improved", "even", "further", ".", "CONCLUSION", "COMET", "for", "low", "self", "-", "esteem", "seems", "to", "be", "an", "efficacious", "trans", "-", "diagnostic", "intervention", "that", "can", "relatively", "easily", "be", "added", "to", "the", "regular", "treatment", "of", "patients", "with", "depressive", "disorders", "." ]

[ "Outcome_Mental", "Intervention_Other", "Intervention_Control", "Outcome_Other", "Participant_Condition", "Participant_Sample-size" ]

Competitive memory training ( COMET ), low self - esteem, depressive disorders, Low self - esteem, of, Competitive Memory Training ( COMET ), Sixty - one, COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ], ongoing regular therapy ( TAU only, effects of COMET, stable, significant improvement, large effect sizes on indices of self - esteem , depression , and depressive rumination ., therapeutic effects

54510_task2

Sentence: Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Competitive memory training ( COMET ) for treating low self-esteem in patients with depressive disorders : a randomized clinical trial . BACKGROUND Self-esteem is a major concern in mood disorders . Low self-esteem is a symptom of depressive disorders and is considered by some to be a predictor for relapse , whereas high self-esteem seems to buffer against depression . Recently , Competitive Memory Training ( COMET ) has shown to be effective for the enhancement of self-esteem in several psychopathological conditions . The current study assesses whether COMET is also an effective intervention for patients with depressive disorders . METHODS Sixty-one patients with depressive disorders who were already in therapy in an outpatient mental health institution were randomly assigned to either eight group sessions of COMET in addition to their regular therapy ( COMET + therapy as usual [ TAU ] : the experimental group ) or to 8 weeks of ongoing regular therapy ( TAU only : the control group ) . These latter ( control ) patients received COMET after their TAU only period . All patients in both groups that completed COMET were contacted 3 and 6 months later to assess whether the effects of COMET had remained stable . RESULTS Compared to the patients who received TAU only , patients in the COMET + TAU condition showed significant improvement with large effect sizes on indices of self-esteem , depression , and depressive rumination . The therapeutic effects of COMET + TAU remained stable after 3 and 6 months on all outcome measures or improved even further . CONCLUSION COMET for low self-esteem seems to be an efficacious trans-diagnostic intervention that can relatively easily be added to the regular treatment of patients with depressive disorders .

[ "Competitive", "memory", "training", "(", "COMET", ")", "for", "treating", "low", "self", "-", "esteem", "in", "patients", "with", "depressive", "disorders", ":", "a", "randomized", "clinical", "trial", ".", "BACKGROUND", "Self", "-", "esteem", "is", "a", "major", "concern", "in", "mood", "disorders", ".", "Low", "self", "-", "esteem", "is", "a", "symptom", "of", "depressive", "disorders", "and", "is", "considered", "by", "some", "to", "be", "a", "predictor", "for", "relapse", ",", "whereas", "high", "self", "-", "esteem", "seems", "to", "buffer", "against", "depression", ".", "Recently", ",", "Competitive", "Memory", "Training", "(", "COMET", ")", "has", "shown", "to", "be", "effective", "for", "the", "enhancement", "of", "self", "-", "esteem", "in", "several", "psychopathological", "conditions", ".", "The", "current", "study", "assesses", "whether", "COMET", "is", "also", "an", "effective", "intervention", "for", "patients", "with", "depressive", "disorders", ".", "METHODS", "Sixty", "-", "one", "patients", "with", "depressive", "disorders", "who", "were", "already", "in", "therapy", "in", "an", "outpatient", "mental", "health", "institution", "were", "randomly", "assigned", "to", "either", "eight", "group", "sessions", "of", "COMET", "in", "addition", "to", "their", "regular", "therapy", "(", "COMET", "+", "therapy", "as", "usual", "[", "TAU", "]", ":", "the", "experimental", "group", ")", "or", "to", "8", "weeks", "of", "ongoing", "regular", "therapy", "(", "TAU", "only", ":", "the", "control", "group", ")", ".", "These", "latter", "(", "control", ")", "patients", "received", "COMET", "after", "their", "TAU", "only", "period", ".", "All", "patients", "in", "both", "groups", "that", "completed", "COMET", "were", "contacted", "3", "and", "6", "months", "later", "to", "assess", "whether", "the", "effects", "of", "COMET", "had", "remained", "stable", ".", "RESULTS", "Compared", "to", "the", "patients", "who", "received", "TAU", "only", ",", "patients", "in", "the", "COMET", "+", "TAU", "condition", "showed", "significant", "improvement", "with", "large", "effect", "sizes", "on", "indices", "of", "self", "-", "esteem", ",", "depression", ",", "and", "depressive", "rumination", ".", "The", "therapeutic", "effects", "of", "COMET", "+", "TAU", "remained", "stable", "after", "3", "and", "6", "months", "on", "all", "outcome", "measures", "or", "improved", "even", "further", ".", "CONCLUSION", "COMET", "for", "low", "self", "-", "esteem", "seems", "to", "be", "an", "efficacious", "trans", "-", "diagnostic", "intervention", "that", "can", "relatively", "easily", "be", "added", "to", "the", "regular", "treatment", "of", "patients", "with", "depressive", "disorders", "." ]

[ "Outcome_Mental", "Intervention_Other", "Intervention_Control", "Outcome_Other", "Participant_Condition", "Participant_Sample-size" ]

lactate dehydrogenase - X is a GENE-Y

2751392_task0

Sentence: Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]

Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats.

[ "Developmental", "changes", "in", "lactate", "dehydrogenase", "-", "X", "activity", "in", "young", "jaundiced", "male", "rats", "." ]

[ "CHEMICAL", "GENE-Y" ]

lactate dehydrogenase - X is a GENE-Y

2751392_task1

Sentence: Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats. Instructions: please typing these entity words according to sentence: lactate dehydrogenase - X Options: GENE-Y

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]

Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats.

[ "Developmental", "changes", "in", "lactate", "dehydrogenase", "-", "X", "activity", "in", "young", "jaundiced", "male", "rats", "." ]

[ "CHEMICAL", "GENE-Y" ]

lactate dehydrogenase - X

2751392_task2

Sentence: Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]

Developmental changes in lactate dehydrogenase-X activity in young jaundiced male rats.

[ "Developmental", "changes", "in", "lactate", "dehydrogenase", "-", "X", "activity", "in", "young", "jaundiced", "male", "rats", "." ]

[ "CHEMICAL", "GENE-Y" ]

MnSOD is a protein, catalase is a protein, quinclorac is a compound, bensulfuron - methyl is a compound

DS.d76_task0

Sentence: MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12.

[ "MnSOD", "and", "two", "additional", "catalase", "isozymes", "were", "induced", "by", "quinclorac", "or", "bensulfuron", "-", "methyl", "in", "S.", "maltophilia", "WZ2", ",", "but", "not", "in", "E.", "coli", "K12", "." ]

[ "compound", "protein" ]

MnSOD is a protein, catalase is a protein, quinclorac is a compound, bensulfuron - methyl is a compound

DS.d76_task1

Sentence: MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12. Instructions: please typing these entity words according to sentence: MnSOD, catalase, quinclorac, bensulfuron - methyl Options: compound, protein

[ "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12.

[ "MnSOD", "and", "two", "additional", "catalase", "isozymes", "were", "induced", "by", "quinclorac", "or", "bensulfuron", "-", "methyl", "in", "S.", "maltophilia", "WZ2", ",", "but", "not", "in", "E.", "coli", "K12", "." ]

[ "compound", "protein" ]

MnSOD, catalase, quinclorac, bensulfuron - methyl

DS.d76_task2

Sentence: MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12. Instructions: please extract entity words from the input sentence

[ "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-compound", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

MnSOD and two additional catalase isozymes were induced by quinclorac or bensulfuron-methyl in S. maltophilia WZ2, but not in E. coli K12.

[ "MnSOD", "and", "two", "additional", "catalase", "isozymes", "were", "induced", "by", "quinclorac", "or", "bensulfuron", "-", "methyl", "in", "S.", "maltophilia", "WZ2", ",", "but", "not", "in", "E.", "coli", "K12", "." ]

[ "compound", "protein" ]

depression among low - income patients with cancer . is a Participant_Condition, Alleviating Depression Among Patients With is a Intervention_Educational, Cancer ( ADAPt - C ) collaborative care management is a Intervention_Other, major depression is a Outcome_Mental, intervention is a Intervention_Educational, enhanced usual care is a Intervention_Educational, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education is a Intervention_Educational, structured psychotherapy is a Intervention_Psychological, maintenance / relapse prevention support is a Intervention_Educational, antidepressant medications is a Intervention_Pharmacological, depressive symptoms is a Outcome_Mental, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale is a Outcome_Other, PHQ-9 score is a Outcome_Other, greater rates of depression treatment is a Outcome_Mental, better quality - of - life outcomes is a Outcome_Other, emotional is a Outcome_Mental, physical well - being is a Outcome_Mental, ADAPt - C collaborative care is a Intervention_Educational

37259_task0

Sentence: Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics .

[ "Randomized", "controlled", "trial", "of", "collaborative", "care", "management", "of", "depression", "among", "low", "-", "income", "patients", "with", "cancer", ".", "PURPOSE", "To", "determine", "the", "effectiveness", "of", "the", "Alleviating", "Depression", "Among", "Patients", "With", "Cancer", "(", "ADAPt", "-", "C", ")", "collaborative", "care", "management", "for", "major", "depression", "or", "dysthymia", ".", "PATIENTS", "AND", "METHODS", "Study", "patients", "included", "472", "low", "-", "income", ",", "predominantly", "female", "Hispanic", "patients", "with", "cancer", "age", ">", "or=", "18", "years", "with", "major", "depression", "(", "49", "%", ")", ",", "dysthymia", "(", "5", "%", ")", ",", "or", "both", "(", "46", "%", ")", ".", "Patients", "were", "randomly", "assigned", "to", "intervention", "(", "n", "=", "242", ")", "or", "enhanced", "usual", "care", "(", "EUC", ";", "n", "=", "230", ")", ".", "Intervention", "patients", "had", "access", "for", "up", "to", "12", "months", "to", "a", "depression", "clinical", "specialist", "(", "supervised", "by", "a", "psychiatrist", ")", "who", "offered", "education", ",", "structured", "psychotherapy", ",", "and", "maintenance", "/", "relapse", "prevention", "support", ".", "The", "psychiatrist", "prescribed", "antidepressant", "medications", "for", "patients", "preferring", "or", "assessed", "to", "require", "medication", ".", "RESULTS", "At", "12", "months", ",", "63", "%", "of", "intervention", "patients", "had", "a", "50", "%", "or", "greater", "reduction", "in", "depressive", "symptoms", "from", "baseline", "as", "assessed", "by", "the", "Patient", "Health", "Questionnaire-9", "(", "PHQ-9", ")", "depression", "scale", "compared", "with", "50", "%", "of", "EUC", "patients", "(", "odds", "ratio", "[", "OR", "]", "=", "1.98", ";", "95", "%", "CI", ",", "1.16", "to", "3.38", ";", "P", "=", ".01", ")", ".", "Improvement", "was", "also", "found", "for", "5-point", "decrease", "in", "PHQ-9", "score", "among", "72.2", "%", "of", "intervention", "patients", "compared", "with", "59.7", "%", "of", "EUC", "patients", "(", "OR", "=", "1.99", ";", "95", "%", "CI", ",", "1.14", "to", "3.50", ";", "P", "=", ".02", ")", ".", "Intervention", "patients", "also", "experienced", "greater", "rates", "of", "depression", "treatment", "(", "72.3", "%", "v", "10.4", "%", "of", "EUC", "patients", ";", "P", "<", ".0001", ")", "and", "significantly", "better", "quality", "-", "of", "-", "life", "outcomes", ",", "including", "social", "/", "family", "(", "adjusted", "mean", "difference", "between", "groups", ",", "2.7", ";", "95", "%", "CI", ",", "1.22", "to", "4.17", ";", "P", "<", ".001", ")", ",", "emotional", "(", "adjusted", "mean", "difference", ",", "1.29", ";", "95", "%", "CI", ",", "0.26", "to", "2.22", ";", "P", "=", ".01", ")", ",", "functional", "(", "adjusted", "mean", "difference", ",", "1.34", ";", "95", "%", "CI", ",", "0.08", "to", "2.59", ";", "P", "=", ".04", ")", ",", "and", "physical", "well", "-", "being", "(", "adjusted", "mean", "difference", ",", "2.79", ";", "95", "%", "CI", ",", "0.49", "to", "5.1", ";", "P", "=", ".02", ")", ".", "CONCLUSION", "ADAPt", "-", "C", "collaborative", "care", "is", "feasible", "and", "results", "in", "significant", "reduction", "in", "depressive", "symptoms", ",", "improvement", "in", "quality", "of", "life", ",", "and", "lower", "pain", "levels", "compared", "with", "EUC", "for", "patients", "with", "depressive", "disorders", "in", "a", "low", "-", "income", ",", "predominantly", "Hispanic", "population", "in", "public", "sector", "oncology", "clinics", "." ]

[ "Intervention_Educational", "Outcome_Other", "Participant_Condition", "Intervention_Other", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Psychological" ]

depression among low - income patients with cancer . is a Participant_Condition, Alleviating Depression Among Patients With is a Intervention_Educational, Cancer ( ADAPt - C ) collaborative care management is a Intervention_Other, major depression is a Outcome_Mental, intervention is a Intervention_Educational, enhanced usual care is a Intervention_Educational, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education is a Intervention_Educational, structured psychotherapy is a Intervention_Psychological, maintenance / relapse prevention support is a Intervention_Educational, antidepressant medications is a Intervention_Pharmacological, depressive symptoms is a Outcome_Mental, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale is a Outcome_Other, PHQ-9 score is a Outcome_Other, greater rates of depression treatment is a Outcome_Mental, better quality - of - life outcomes is a Outcome_Other, emotional is a Outcome_Mental, physical well - being is a Outcome_Mental, ADAPt - C collaborative care is a Intervention_Educational

37259_task1

Sentence: Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics . Instructions: please typing these entity words according to sentence: depression among low - income patients with cancer ., Alleviating Depression Among Patients With, Cancer ( ADAPt - C ) collaborative care management, major depression, intervention, enhanced usual care, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education, structured psychotherapy, maintenance / relapse prevention support, antidepressant medications, depressive symptoms, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale, PHQ-9 score, greater rates of depression treatment, better quality - of - life outcomes, emotional, physical well - being, ADAPt - C collaborative care Options: Intervention_Psychological, Intervention_Pharmacological, Participant_Condition, Intervention_Educational, Intervention_Other, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics .

[ "Randomized", "controlled", "trial", "of", "collaborative", "care", "management", "of", "depression", "among", "low", "-", "income", "patients", "with", "cancer", ".", "PURPOSE", "To", "determine", "the", "effectiveness", "of", "the", "Alleviating", "Depression", "Among", "Patients", "With", "Cancer", "(", "ADAPt", "-", "C", ")", "collaborative", "care", "management", "for", "major", "depression", "or", "dysthymia", ".", "PATIENTS", "AND", "METHODS", "Study", "patients", "included", "472", "low", "-", "income", ",", "predominantly", "female", "Hispanic", "patients", "with", "cancer", "age", ">", "or=", "18", "years", "with", "major", "depression", "(", "49", "%", ")", ",", "dysthymia", "(", "5", "%", ")", ",", "or", "both", "(", "46", "%", ")", ".", "Patients", "were", "randomly", "assigned", "to", "intervention", "(", "n", "=", "242", ")", "or", "enhanced", "usual", "care", "(", "EUC", ";", "n", "=", "230", ")", ".", "Intervention", "patients", "had", "access", "for", "up", "to", "12", "months", "to", "a", "depression", "clinical", "specialist", "(", "supervised", "by", "a", "psychiatrist", ")", "who", "offered", "education", ",", "structured", "psychotherapy", ",", "and", "maintenance", "/", "relapse", "prevention", "support", ".", "The", "psychiatrist", "prescribed", "antidepressant", "medications", "for", "patients", "preferring", "or", "assessed", "to", "require", "medication", ".", "RESULTS", "At", "12", "months", ",", "63", "%", "of", "intervention", "patients", "had", "a", "50", "%", "or", "greater", "reduction", "in", "depressive", "symptoms", "from", "baseline", "as", "assessed", "by", "the", "Patient", "Health", "Questionnaire-9", "(", "PHQ-9", ")", "depression", "scale", "compared", "with", "50", "%", "of", "EUC", "patients", "(", "odds", "ratio", "[", "OR", "]", "=", "1.98", ";", "95", "%", "CI", ",", "1.16", "to", "3.38", ";", "P", "=", ".01", ")", ".", "Improvement", "was", "also", "found", "for", "5-point", "decrease", "in", "PHQ-9", "score", "among", "72.2", "%", "of", "intervention", "patients", "compared", "with", "59.7", "%", "of", "EUC", "patients", "(", "OR", "=", "1.99", ";", "95", "%", "CI", ",", "1.14", "to", "3.50", ";", "P", "=", ".02", ")", ".", "Intervention", "patients", "also", "experienced", "greater", "rates", "of", "depression", "treatment", "(", "72.3", "%", "v", "10.4", "%", "of", "EUC", "patients", ";", "P", "<", ".0001", ")", "and", "significantly", "better", "quality", "-", "of", "-", "life", "outcomes", ",", "including", "social", "/", "family", "(", "adjusted", "mean", "difference", "between", "groups", ",", "2.7", ";", "95", "%", "CI", ",", "1.22", "to", "4.17", ";", "P", "<", ".001", ")", ",", "emotional", "(", "adjusted", "mean", "difference", ",", "1.29", ";", "95", "%", "CI", ",", "0.26", "to", "2.22", ";", "P", "=", ".01", ")", ",", "functional", "(", "adjusted", "mean", "difference", ",", "1.34", ";", "95", "%", "CI", ",", "0.08", "to", "2.59", ";", "P", "=", ".04", ")", ",", "and", "physical", "well", "-", "being", "(", "adjusted", "mean", "difference", ",", "2.79", ";", "95", "%", "CI", ",", "0.49", "to", "5.1", ";", "P", "=", ".02", ")", ".", "CONCLUSION", "ADAPt", "-", "C", "collaborative", "care", "is", "feasible", "and", "results", "in", "significant", "reduction", "in", "depressive", "symptoms", ",", "improvement", "in", "quality", "of", "life", ",", "and", "lower", "pain", "levels", "compared", "with", "EUC", "for", "patients", "with", "depressive", "disorders", "in", "a", "low", "-", "income", ",", "predominantly", "Hispanic", "population", "in", "public", "sector", "oncology", "clinics", "." ]

[ "Intervention_Educational", "Outcome_Other", "Participant_Condition", "Intervention_Other", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Psychological" ]

depression among low - income patients with cancer ., Alleviating Depression Among Patients With, Cancer ( ADAPt - C ) collaborative care management, major depression, intervention, enhanced usual care, access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education, structured psychotherapy, maintenance / relapse prevention support, antidepressant medications, depressive symptoms, Patient Health Questionnaire-9 ( PHQ-9 ) depression scale, PHQ-9 score, greater rates of depression treatment, better quality - of - life outcomes, emotional, physical well - being, ADAPt - C collaborative care

37259_task2

Sentence: Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Randomized controlled trial of collaborative care management of depression among low-income patients with cancer . PURPOSE To determine the effectiveness of the Alleviating Depression Among Patients With Cancer ( ADAPt-C ) collaborative care management for major depression or dysthymia . PATIENTS AND METHODS Study patients included 472 low-income , predominantly female Hispanic patients with cancer age > or= 18 years with major depression ( 49 % ) , dysthymia ( 5 % ) , or both ( 46 % ) . Patients were randomly assigned to intervention ( n = 242 ) or enhanced usual care ( EUC ; n = 230 ) . Intervention patients had access for up to 12 months to a depression clinical specialist ( supervised by a psychiatrist ) who offered education , structured psychotherapy , and maintenance/relapse prevention support . The psychiatrist prescribed antidepressant medications for patients preferring or assessed to require medication . RESULTS At 12 months , 63 % of intervention patients had a 50 % or greater reduction in depressive symptoms from baseline as assessed by the Patient Health Questionnaire-9 ( PHQ-9 ) depression scale compared with 50 % of EUC patients ( odds ratio [ OR ] = 1.98 ; 95 % CI , 1.16 to 3.38 ; P = .01 ) . Improvement was also found for 5-point decrease in PHQ-9 score among 72.2 % of intervention patients compared with 59.7 % of EUC patients ( OR = 1.99 ; 95 % CI , 1.14 to 3.50 ; P = .02 ) . Intervention patients also experienced greater rates of depression treatment ( 72.3 % v 10.4 % of EUC patients ; P < .0001 ) and significantly better quality-of-life outcomes , including social/family ( adjusted mean difference between groups , 2.7 ; 95 % CI , 1.22 to 4.17 ; P < .001 ) , emotional ( adjusted mean difference , 1.29 ; 95 % CI , 0.26 to 2.22 ; P = .01 ) , functional ( adjusted mean difference , 1.34 ; 95 % CI , 0.08 to 2.59 ; P = .04 ) , and physical well-being ( adjusted mean difference , 2.79 ; 95 % CI , 0.49 to 5.1 ; P = .02 ) . CONCLUSION ADAPt-C collaborative care is feasible and results in significant reduction in depressive symptoms , improvement in quality of life , and lower pain levels compared with EUC for patients with depressive disorders in a low-income , predominantly Hispanic population in public sector oncology clinics .

[ "Randomized", "controlled", "trial", "of", "collaborative", "care", "management", "of", "depression", "among", "low", "-", "income", "patients", "with", "cancer", ".", "PURPOSE", "To", "determine", "the", "effectiveness", "of", "the", "Alleviating", "Depression", "Among", "Patients", "With", "Cancer", "(", "ADAPt", "-", "C", ")", "collaborative", "care", "management", "for", "major", "depression", "or", "dysthymia", ".", "PATIENTS", "AND", "METHODS", "Study", "patients", "included", "472", "low", "-", "income", ",", "predominantly", "female", "Hispanic", "patients", "with", "cancer", "age", ">", "or=", "18", "years", "with", "major", "depression", "(", "49", "%", ")", ",", "dysthymia", "(", "5", "%", ")", ",", "or", "both", "(", "46", "%", ")", ".", "Patients", "were", "randomly", "assigned", "to", "intervention", "(", "n", "=", "242", ")", "or", "enhanced", "usual", "care", "(", "EUC", ";", "n", "=", "230", ")", ".", "Intervention", "patients", "had", "access", "for", "up", "to", "12", "months", "to", "a", "depression", "clinical", "specialist", "(", "supervised", "by", "a", "psychiatrist", ")", "who", "offered", "education", ",", "structured", "psychotherapy", ",", "and", "maintenance", "/", "relapse", "prevention", "support", ".", "The", "psychiatrist", "prescribed", "antidepressant", "medications", "for", "patients", "preferring", "or", "assessed", "to", "require", "medication", ".", "RESULTS", "At", "12", "months", ",", "63", "%", "of", "intervention", "patients", "had", "a", "50", "%", "or", "greater", "reduction", "in", "depressive", "symptoms", "from", "baseline", "as", "assessed", "by", "the", "Patient", "Health", "Questionnaire-9", "(", "PHQ-9", ")", "depression", "scale", "compared", "with", "50", "%", "of", "EUC", "patients", "(", "odds", "ratio", "[", "OR", "]", "=", "1.98", ";", "95", "%", "CI", ",", "1.16", "to", "3.38", ";", "P", "=", ".01", ")", ".", "Improvement", "was", "also", "found", "for", "5-point", "decrease", "in", "PHQ-9", "score", "among", "72.2", "%", "of", "intervention", "patients", "compared", "with", "59.7", "%", "of", "EUC", "patients", "(", "OR", "=", "1.99", ";", "95", "%", "CI", ",", "1.14", "to", "3.50", ";", "P", "=", ".02", ")", ".", "Intervention", "patients", "also", "experienced", "greater", "rates", "of", "depression", "treatment", "(", "72.3", "%", "v", "10.4", "%", "of", "EUC", "patients", ";", "P", "<", ".0001", ")", "and", "significantly", "better", "quality", "-", "of", "-", "life", "outcomes", ",", "including", "social", "/", "family", "(", "adjusted", "mean", "difference", "between", "groups", ",", "2.7", ";", "95", "%", "CI", ",", "1.22", "to", "4.17", ";", "P", "<", ".001", ")", ",", "emotional", "(", "adjusted", "mean", "difference", ",", "1.29", ";", "95", "%", "CI", ",", "0.26", "to", "2.22", ";", "P", "=", ".01", ")", ",", "functional", "(", "adjusted", "mean", "difference", ",", "1.34", ";", "95", "%", "CI", ",", "0.08", "to", "2.59", ";", "P", "=", ".04", ")", ",", "and", "physical", "well", "-", "being", "(", "adjusted", "mean", "difference", ",", "2.79", ";", "95", "%", "CI", ",", "0.49", "to", "5.1", ";", "P", "=", ".02", ")", ".", "CONCLUSION", "ADAPt", "-", "C", "collaborative", "care", "is", "feasible", "and", "results", "in", "significant", "reduction", "in", "depressive", "symptoms", ",", "improvement", "in", "quality", "of", "life", ",", "and", "lower", "pain", "levels", "compared", "with", "EUC", "for", "patients", "with", "depressive", "disorders", "in", "a", "low", "-", "income", ",", "predominantly", "Hispanic", "population", "in", "public", "sector", "oncology", "clinics", "." ]

[ "Intervention_Educational", "Outcome_Other", "Participant_Condition", "Intervention_Other", "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Psychological" ]

Bacillus intermedius is a Microorganism, streptomycin - resistant is a Phenotype, Bacillus intermedius S3 - 19 is a Microorganism, B. intermedius is a Microorganism, Bacillus is a Microorganism

70_task0

Sentence: Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties.

[ "Isolation", "and", "properties", "of", "extracellular", "alkaline", "phosphatase", "from", "Bacillus", "intermedius", ".", "Alkaline", "phosphatase", "(", "APase", ")", "was", "isolated", "from", "the", "culture", "liquid", "of", "the", "streptomycin", "-", "resistant", "strain", "of", "Bacillus", "intermedius", "S3", "-", "19", "and", "purified", "as", "a", "homogeneous", "preparation", "by", "ion", "-", "exchange", "chromatography", "and", "FPLC", ".", "Electrophoresis", "and", "gel", "-", "filtration", "revealed", "that", "the", "active", "enzyme", "is", "a", "monomer", "with", "molecular", "weight", "of", "46", "-", "47", "kD.", "The", "enzyme", "possessed", "phosphomonoesterase", "and", "phosphodiesterase", "activities", "with", "maximal", "levels", "at", "pH", "9.5", "and", "55", "degreesC", "and", "was", "stable", "until", "60", "degreesC", "at", "pH", "8.0", "-", "10.0", ".", "The", "isolated", "APase", "exhibits", "a", "broad", "specificity", "towards", "a", "wide", "variety", "of", "substrates", ".", "The", "effect", "of", "divalent", "metal", "ions", "and", "other", "reagents", "on", "its", "catalytic", "activities", "was", "studied", ".", "It", "was", "concluded", "that", "alkaline", "phosphatase", "of", "B.", "intermedius", "is", "similar", "to", "the", "secreted", "alkaline", "phosphatases", "from", "other", "Bacillus", "species", "in", "its", "physicochemical", "and", "catalytic", "properties", ".", " " ]

[ "Microorganism", "Phenotype" ]

Bacillus intermedius is a Microorganism, streptomycin - resistant is a Phenotype, Bacillus intermedius S3 - 19 is a Microorganism, B. intermedius is a Microorganism, Bacillus is a Microorganism

70_task1

Sentence: Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties. Instructions: please typing these entity words according to sentence: Bacillus intermedius, streptomycin - resistant, Bacillus intermedius S3 - 19, B. intermedius, Bacillus Options: Microorganism, Phenotype

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties.

[ "Isolation", "and", "properties", "of", "extracellular", "alkaline", "phosphatase", "from", "Bacillus", "intermedius", ".", "Alkaline", "phosphatase", "(", "APase", ")", "was", "isolated", "from", "the", "culture", "liquid", "of", "the", "streptomycin", "-", "resistant", "strain", "of", "Bacillus", "intermedius", "S3", "-", "19", "and", "purified", "as", "a", "homogeneous", "preparation", "by", "ion", "-", "exchange", "chromatography", "and", "FPLC", ".", "Electrophoresis", "and", "gel", "-", "filtration", "revealed", "that", "the", "active", "enzyme", "is", "a", "monomer", "with", "molecular", "weight", "of", "46", "-", "47", "kD.", "The", "enzyme", "possessed", "phosphomonoesterase", "and", "phosphodiesterase", "activities", "with", "maximal", "levels", "at", "pH", "9.5", "and", "55", "degreesC", "and", "was", "stable", "until", "60", "degreesC", "at", "pH", "8.0", "-", "10.0", ".", "The", "isolated", "APase", "exhibits", "a", "broad", "specificity", "towards", "a", "wide", "variety", "of", "substrates", ".", "The", "effect", "of", "divalent", "metal", "ions", "and", "other", "reagents", "on", "its", "catalytic", "activities", "was", "studied", ".", "It", "was", "concluded", "that", "alkaline", "phosphatase", "of", "B.", "intermedius", "is", "similar", "to", "the", "secreted", "alkaline", "phosphatases", "from", "other", "Bacillus", "species", "in", "its", "physicochemical", "and", "catalytic", "properties", ".", " " ]

[ "Microorganism", "Phenotype" ]

Bacillus intermedius, streptomycin - resistant, Bacillus intermedius S3 - 19, B. intermedius, Bacillus

70_task2

Sentence: Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Isolation and properties of extracellular alkaline phosphatase from Bacillus intermedius. Alkaline phosphatase (APase) was isolated from the culture liquid of the streptomycin-resistant strain of Bacillus intermedius S3-19 and purified as a homogeneous preparation by ion-exchange chromatography and FPLC. Electrophoresis and gel-filtration revealed that the active enzyme is a monomer with molecular weight of 46-47 kD. The enzyme possessed phosphomonoesterase and phosphodiesterase activities with maximal levels at pH 9.5 and 55 degreesC and was stable until 60 degreesC at pH 8.0-10.0. The isolated APase exhibits a broad specificity towards a wide variety of substrates. The effect of divalent metal ions and other reagents on its catalytic activities was studied. It was concluded that alkaline phosphatase of B. intermedius is similar to the secreted alkaline phosphatases from other Bacillus species in its physicochemical and catalytic properties.

[ "Isolation", "and", "properties", "of", "extracellular", "alkaline", "phosphatase", "from", "Bacillus", "intermedius", ".", "Alkaline", "phosphatase", "(", "APase", ")", "was", "isolated", "from", "the", "culture", "liquid", "of", "the", "streptomycin", "-", "resistant", "strain", "of", "Bacillus", "intermedius", "S3", "-", "19", "and", "purified", "as", "a", "homogeneous", "preparation", "by", "ion", "-", "exchange", "chromatography", "and", "FPLC", ".", "Electrophoresis", "and", "gel", "-", "filtration", "revealed", "that", "the", "active", "enzyme", "is", "a", "monomer", "with", "molecular", "weight", "of", "46", "-", "47", "kD.", "The", "enzyme", "possessed", "phosphomonoesterase", "and", "phosphodiesterase", "activities", "with", "maximal", "levels", "at", "pH", "9.5", "and", "55", "degreesC", "and", "was", "stable", "until", "60", "degreesC", "at", "pH", "8.0", "-", "10.0", ".", "The", "isolated", "APase", "exhibits", "a", "broad", "specificity", "towards", "a", "wide", "variety", "of", "substrates", ".", "The", "effect", "of", "divalent", "metal", "ions", "and", "other", "reagents", "on", "its", "catalytic", "activities", "was", "studied", ".", "It", "was", "concluded", "that", "alkaline", "phosphatase", "of", "B.", "intermedius", "is", "similar", "to", "the", "secreted", "alkaline", "phosphatases", "from", "other", "Bacillus", "species", "in", "its", "physicochemical", "and", "catalytic", "properties", ".", " " ]

[ "Microorganism", "Phenotype" ]

Respiratoren is an umlsterm, Ventilation is an umlsterm, Druckanstiegszeit is an umlsterm, Atemarbeit is an umlsterm, Patienten is an umlsterm, Atemwegsobstruktion is an umlsterm, COPD is an umlsterm, Patienten is an umlsterm, Lungenerkrankung is an umlsterm, Atemarbeit is an umlsterm, Druckunterstuetzung is an umlsterm, Druckanstiegszeit is an umlsterm, Druckanstiegszeit is an umlsterm, Patientengruppen is an umlsterm, Atemarbeit is an umlsterm, Druckanstiegszeiten is an umlsterm, Druckunterstuetzung is an umlsterm, intrinsischen PEEP is an umlsterm, Patienten is an umlsterm, COPD is an umlsterm, Patientenatemarbeit is an umlsterm, Patienten is an umlsterm, Druckanstiegszeit is an umlsterm

DerAnaesthesist.60451051.ger.abstr_task0

Sentence: Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein .

[ "Bei", "einigen", "Respiratoren", "kann", "unter", "Pressure", "Support", "Ventilation", "(", "PSV", ")", "der", "Inspirationsfluss", "(", "V.", "i", ")", "durch", "Veraenderung", "der", "Druckanstiegszeit", "variiert", "werden", ".", "Ueber", "den", "Einfluss", "des", "Inspirationsflussprofils", "unter", "PSV", "auf", "die", "Atemarbeit", "ist", "besonders", "bei", "Patienten", "mit", "chronischer", "Atemwegsobstruktion", "(", "COPD", ")", "kaum", "etwas", "bekannt", ".", "Wir", "untersuchten", "an", "6", "COPD", "-", "Patienten", "und", "6", "Patienten", "ohne", "Lungenerkrankung", "(", "Kontrollgruppe", ")", "die", "Effekte", "einer", "Variation", "von", "V.", "i", "unter", "PSV", "auf", "atemmechanische", "Variablen", "und", "die", "mechanische", "Atemarbeit", ".", "Unter", "individuell", "eingestellter", "Druckunterstuetzung", "wurde", "die", "Druckanstiegszeit", "in", "5", "Stufen", "veraendert", ".", "Die", "Verlaengerung", "der", "Druckanstiegszeit", "verminderte", "den", "initialen", "V.", "i", "in", "beiden", "Patientengruppen", ".", "Gleichzeitig", "stieg", "die", "Atemarbeit", "in", "der", "COPD", "-", "Gruppe", "bei", "verringertem", "V.", "i", "signifikant", "an", ".", "Eine", "Ursache", "hierfuer", "war", ",", "dass", "bei", "den", "COPD", "-", "Patienten", "bei", "langsamen", "Druckanstiegszeiten", "die", "eingestellte", "Druckunterstuetzung", "nicht", "mehr", "erreicht", "wurde", ".", "Der", "langsamere", "V.", "i", "fuehrte", "zu", "einer", "Verlaengerung", "der", "Inspiration", "auf", "Kosten", "der", "Exspirationszeit", ".", "Dies", "verursachte", "bei", "COPD", "-", "Patienten", "eine", "unerwuenschte", "Erhoehung", "des", "intrinsischen", "PEEP", ".", "Die", "Auswirkungen", "eines", "niedrigeren", "V.", "i", "unter", "PSV", "in", "der", "Kontrollgruppe", "waren", "klinisch", "nur", "wenig", "relevant", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "besonders", "bei", "Patienten", "mit", "COPD", "unter", "PSV", "hohe", "initiale", "Inspirationsfluesse", "zu", "bevorzugen", "sind", ",", "da", "ein", "niedriger", "Fluss", "die", "Patientenatemarbeit", "erhoeht", "und", "eine", "dynamische", "Lungenueberblaehung", "verstaerkt", ".", "Allerdings", "konnte", "bei", "einem", "Patienten", "ein", "vorzeitiger", "Inspirationsabbruch", "aufgrund", "eines", "hohen", "Initialflusses", "durch", "Anpassung", "des", "Flussprofils", "korrigiert", "werden", ".", "In", "Einzelfaellen", "kann", "daher", "eine", "Verlaengerung", "der", "Druckanstiegszeit", "bis", "auf", "maximal", "1", "s", "sinnvoll", "sein", "." ]

[ "umlsterm" ]

Respiratoren is an umlsterm, Ventilation is an umlsterm, Druckanstiegszeit is an umlsterm, Atemarbeit is an umlsterm, Patienten is an umlsterm, Atemwegsobstruktion is an umlsterm, COPD is an umlsterm, Patienten is an umlsterm, Lungenerkrankung is an umlsterm, Atemarbeit is an umlsterm, Druckunterstuetzung is an umlsterm, Druckanstiegszeit is an umlsterm, Druckanstiegszeit is an umlsterm, Patientengruppen is an umlsterm, Atemarbeit is an umlsterm, Druckanstiegszeiten is an umlsterm, Druckunterstuetzung is an umlsterm, intrinsischen PEEP is an umlsterm, Patienten is an umlsterm, COPD is an umlsterm, Patientenatemarbeit is an umlsterm, Patienten is an umlsterm, Druckanstiegszeit is an umlsterm

DerAnaesthesist.60451051.ger.abstr_task1

Sentence: Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein . Instructions: please typing these entity words according to sentence: Respiratoren, Ventilation, Druckanstiegszeit, Atemarbeit, Patienten, Atemwegsobstruktion, COPD, Patienten, Lungenerkrankung, Atemarbeit, Druckunterstuetzung, Druckanstiegszeit, Druckanstiegszeit, Patientengruppen, Atemarbeit, Druckanstiegszeiten, Druckunterstuetzung, intrinsischen PEEP, Patienten, COPD, Patientenatemarbeit, Patienten, Druckanstiegszeit Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein .

[ "Bei", "einigen", "Respiratoren", "kann", "unter", "Pressure", "Support", "Ventilation", "(", "PSV", ")", "der", "Inspirationsfluss", "(", "V.", "i", ")", "durch", "Veraenderung", "der", "Druckanstiegszeit", "variiert", "werden", ".", "Ueber", "den", "Einfluss", "des", "Inspirationsflussprofils", "unter", "PSV", "auf", "die", "Atemarbeit", "ist", "besonders", "bei", "Patienten", "mit", "chronischer", "Atemwegsobstruktion", "(", "COPD", ")", "kaum", "etwas", "bekannt", ".", "Wir", "untersuchten", "an", "6", "COPD", "-", "Patienten", "und", "6", "Patienten", "ohne", "Lungenerkrankung", "(", "Kontrollgruppe", ")", "die", "Effekte", "einer", "Variation", "von", "V.", "i", "unter", "PSV", "auf", "atemmechanische", "Variablen", "und", "die", "mechanische", "Atemarbeit", ".", "Unter", "individuell", "eingestellter", "Druckunterstuetzung", "wurde", "die", "Druckanstiegszeit", "in", "5", "Stufen", "veraendert", ".", "Die", "Verlaengerung", "der", "Druckanstiegszeit", "verminderte", "den", "initialen", "V.", "i", "in", "beiden", "Patientengruppen", ".", "Gleichzeitig", "stieg", "die", "Atemarbeit", "in", "der", "COPD", "-", "Gruppe", "bei", "verringertem", "V.", "i", "signifikant", "an", ".", "Eine", "Ursache", "hierfuer", "war", ",", "dass", "bei", "den", "COPD", "-", "Patienten", "bei", "langsamen", "Druckanstiegszeiten", "die", "eingestellte", "Druckunterstuetzung", "nicht", "mehr", "erreicht", "wurde", ".", "Der", "langsamere", "V.", "i", "fuehrte", "zu", "einer", "Verlaengerung", "der", "Inspiration", "auf", "Kosten", "der", "Exspirationszeit", ".", "Dies", "verursachte", "bei", "COPD", "-", "Patienten", "eine", "unerwuenschte", "Erhoehung", "des", "intrinsischen", "PEEP", ".", "Die", "Auswirkungen", "eines", "niedrigeren", "V.", "i", "unter", "PSV", "in", "der", "Kontrollgruppe", "waren", "klinisch", "nur", "wenig", "relevant", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "besonders", "bei", "Patienten", "mit", "COPD", "unter", "PSV", "hohe", "initiale", "Inspirationsfluesse", "zu", "bevorzugen", "sind", ",", "da", "ein", "niedriger", "Fluss", "die", "Patientenatemarbeit", "erhoeht", "und", "eine", "dynamische", "Lungenueberblaehung", "verstaerkt", ".", "Allerdings", "konnte", "bei", "einem", "Patienten", "ein", "vorzeitiger", "Inspirationsabbruch", "aufgrund", "eines", "hohen", "Initialflusses", "durch", "Anpassung", "des", "Flussprofils", "korrigiert", "werden", ".", "In", "Einzelfaellen", "kann", "daher", "eine", "Verlaengerung", "der", "Druckanstiegszeit", "bis", "auf", "maximal", "1", "s", "sinnvoll", "sein", "." ]

[ "umlsterm" ]

Respiratoren, Ventilation, Druckanstiegszeit, Atemarbeit, Patienten, Atemwegsobstruktion, COPD, Patienten, Lungenerkrankung, Atemarbeit, Druckunterstuetzung, Druckanstiegszeit, Druckanstiegszeit, Patientengruppen, Atemarbeit, Druckanstiegszeiten, Druckunterstuetzung, intrinsischen PEEP, Patienten, COPD, Patientenatemarbeit, Patienten, Druckanstiegszeit

DerAnaesthesist.60451051.ger.abstr_task2

Sentence: Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bei einigen Respiratoren kann unter Pressure Support Ventilation ( PSV ) der Inspirationsfluss ( V. i ) durch Veraenderung der Druckanstiegszeit variiert werden . Ueber den Einfluss des Inspirationsflussprofils unter PSV auf die Atemarbeit ist besonders bei Patienten mit chronischer Atemwegsobstruktion ( COPD ) kaum etwas bekannt . Wir untersuchten an 6 COPD-Patienten und 6 Patienten ohne Lungenerkrankung ( Kontrollgruppe ) die Effekte einer Variation von V. i unter PSV auf atemmechanische Variablen und die mechanische Atemarbeit . Unter individuell eingestellter Druckunterstuetzung wurde die Druckanstiegszeit in 5 Stufen veraendert . Die Verlaengerung der Druckanstiegszeit verminderte den initialen V. i in beiden Patientengruppen . Gleichzeitig stieg die Atemarbeit in der COPD-Gruppe bei verringertem V. i signifikant an . Eine Ursache hierfuer war , dass bei den COPD-Patienten bei langsamen Druckanstiegszeiten die eingestellte Druckunterstuetzung nicht mehr erreicht wurde . Der langsamere V. i fuehrte zu einer Verlaengerung der Inspiration auf Kosten der Exspirationszeit . Dies verursachte bei COPD-Patienten eine unerwuenschte Erhoehung des intrinsischen PEEP . Die Auswirkungen eines niedrigeren V. i unter PSV in der Kontrollgruppe waren klinisch nur wenig relevant . Unsere Ergebnisse zeigen , dass besonders bei Patienten mit COPD unter PSV hohe initiale Inspirationsfluesse zu bevorzugen sind , da ein niedriger Fluss die Patientenatemarbeit erhoeht und eine dynamische Lungenueberblaehung verstaerkt . Allerdings konnte bei einem Patienten ein vorzeitiger Inspirationsabbruch aufgrund eines hohen Initialflusses durch Anpassung des Flussprofils korrigiert werden . In Einzelfaellen kann daher eine Verlaengerung der Druckanstiegszeit bis auf maximal 1 s sinnvoll sein .

[ "Bei", "einigen", "Respiratoren", "kann", "unter", "Pressure", "Support", "Ventilation", "(", "PSV", ")", "der", "Inspirationsfluss", "(", "V.", "i", ")", "durch", "Veraenderung", "der", "Druckanstiegszeit", "variiert", "werden", ".", "Ueber", "den", "Einfluss", "des", "Inspirationsflussprofils", "unter", "PSV", "auf", "die", "Atemarbeit", "ist", "besonders", "bei", "Patienten", "mit", "chronischer", "Atemwegsobstruktion", "(", "COPD", ")", "kaum", "etwas", "bekannt", ".", "Wir", "untersuchten", "an", "6", "COPD", "-", "Patienten", "und", "6", "Patienten", "ohne", "Lungenerkrankung", "(", "Kontrollgruppe", ")", "die", "Effekte", "einer", "Variation", "von", "V.", "i", "unter", "PSV", "auf", "atemmechanische", "Variablen", "und", "die", "mechanische", "Atemarbeit", ".", "Unter", "individuell", "eingestellter", "Druckunterstuetzung", "wurde", "die", "Druckanstiegszeit", "in", "5", "Stufen", "veraendert", ".", "Die", "Verlaengerung", "der", "Druckanstiegszeit", "verminderte", "den", "initialen", "V.", "i", "in", "beiden", "Patientengruppen", ".", "Gleichzeitig", "stieg", "die", "Atemarbeit", "in", "der", "COPD", "-", "Gruppe", "bei", "verringertem", "V.", "i", "signifikant", "an", ".", "Eine", "Ursache", "hierfuer", "war", ",", "dass", "bei", "den", "COPD", "-", "Patienten", "bei", "langsamen", "Druckanstiegszeiten", "die", "eingestellte", "Druckunterstuetzung", "nicht", "mehr", "erreicht", "wurde", ".", "Der", "langsamere", "V.", "i", "fuehrte", "zu", "einer", "Verlaengerung", "der", "Inspiration", "auf", "Kosten", "der", "Exspirationszeit", ".", "Dies", "verursachte", "bei", "COPD", "-", "Patienten", "eine", "unerwuenschte", "Erhoehung", "des", "intrinsischen", "PEEP", ".", "Die", "Auswirkungen", "eines", "niedrigeren", "V.", "i", "unter", "PSV", "in", "der", "Kontrollgruppe", "waren", "klinisch", "nur", "wenig", "relevant", ".", "Unsere", "Ergebnisse", "zeigen", ",", "dass", "besonders", "bei", "Patienten", "mit", "COPD", "unter", "PSV", "hohe", "initiale", "Inspirationsfluesse", "zu", "bevorzugen", "sind", ",", "da", "ein", "niedriger", "Fluss", "die", "Patientenatemarbeit", "erhoeht", "und", "eine", "dynamische", "Lungenueberblaehung", "verstaerkt", ".", "Allerdings", "konnte", "bei", "einem", "Patienten", "ein", "vorzeitiger", "Inspirationsabbruch", "aufgrund", "eines", "hohen", "Initialflusses", "durch", "Anpassung", "des", "Flussprofils", "korrigiert", "werden", ".", "In", "Einzelfaellen", "kann", "daher", "eine", "Verlaengerung", "der", "Druckanstiegszeit", "bis", "auf", "maximal", "1", "s", "sinnvoll", "sein", "." ]

[ "umlsterm" ]

Transcriptional and posttranscriptional regulation is a (AND other_name other_name), erythroid gene expression is an other_name, anthracycline - induced differentiation is an other_name, human erythroleukemic cells is a cell_type

24063_task0

Sentence: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name, (AND other_name other_name)

[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]

Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.

[ "Transcriptional", "and", "posttranscriptional", "regulation", "of", "erythroid", "gene", "expression", "in", "anthracycline", "-", "induced", "differentiation", "of", "human", "erythroleukemic", "cells", "." ]

[ "(AND other_name other_name)", "protein_molecule", "(BUT_NOT cell_line cell_line)", "other_name", "cell_line", "cell_type", "protein_family_or_group", "(AND RNA_molecule RNA_molecule)", "", "DNA_family_or_group", "DNA_domain_or_region", "RNA_family_or_group", "other_organic_compound", "other_artificial_source" ]

Transcriptional and posttranscriptional regulation is a (AND other_name other_name), erythroid gene expression is an other_name, anthracycline - induced differentiation is an other_name, human erythroleukemic cells is a cell_type

24063_task1

Sentence: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Instructions: please typing these entity words according to sentence: Transcriptional and posttranscriptional regulation, erythroid gene expression, anthracycline - induced differentiation, human erythroleukemic cells Options: cell_type, other_name, (AND other_name other_name)

[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]

Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.

[ "Transcriptional", "and", "posttranscriptional", "regulation", "of", "erythroid", "gene", "expression", "in", "anthracycline", "-", "induced", "differentiation", "of", "human", "erythroleukemic", "cells", "." ]

[ "(AND other_name other_name)", "protein_molecule", "(BUT_NOT cell_line cell_line)", "other_name", "cell_line", "cell_type", "protein_family_or_group", "(AND RNA_molecule RNA_molecule)", "", "DNA_family_or_group", "DNA_domain_or_region", "RNA_family_or_group", "other_organic_compound", "other_artificial_source" ]

Transcriptional and posttranscriptional regulation, erythroid gene expression, anthracycline - induced differentiation, human erythroleukemic cells

24063_task2

Sentence: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Instructions: please extract entity words from the input sentence

[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "B-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]

Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells.

[ "Transcriptional", "and", "posttranscriptional", "regulation", "of", "erythroid", "gene", "expression", "in", "anthracycline", "-", "induced", "differentiation", "of", "human", "erythroleukemic", "cells", "." ]

[ "(AND other_name other_name)", "protein_molecule", "(BUT_NOT cell_line cell_line)", "other_name", "cell_line", "cell_type", "protein_family_or_group", "(AND RNA_molecule RNA_molecule)", "", "DNA_family_or_group", "DNA_domain_or_region", "RNA_family_or_group", "other_organic_compound", "other_artificial_source" ]

tumor necrosis factor alpha is a Protein, TNF - alpha is a Protein, p24 antigen is a Protein

858_task0

Sentence: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients.

[ "Potent", "inhibition", "of", "HIV", "type", "1", "replication", "by", "an", "antiinflammatory", "alkaloid", ",", "cepharanthine", ",", "in", "chronically", "infected", "monocytic", "cells", ".", "\n", "Cepharanthine", "is", "a", "biscoclaurine", "alkaloid", "isolated", "from", "Stephania", "cepharantha", "Hayata", "and", "has", "been", "shown", "to", "have", "antiinflammatory", ",", "antiallergic", ",", "and", "immunomodulatory", "activities", "in", "vivo", ".", "As", "several", "inflammatory", "cytokines", "and", "oxidative", "stresses", "are", "involved", "in", "the", "pathogenesis", "of", "HIV-1", "infection", ",", "we", "investigated", "the", "inhibitory", "effects", "of", "cepharanthine", "on", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha)-", "and", "phorbol", "12-myristate", "13-acetate", "(", "PMA)-induced", "HIV-1", "replication", "in", "chronically", "infected", "cell", "lines", ".", "Two", "chronically", "HIV-1-infected", "cell", "lines", ",", "U1", "(", "monocytic", ")", "and", "ACH-2", "(", "T", "lymphocytic", ")", ",", "were", "stimulated", "with", "TNF", "-", "alpha", "or", "PMA", "and", "cultured", "in", "the", "presence", "of", "various", "concentrations", "of", "the", "compound", ".", "HIV-1", "replication", "was", "determined", "by", "p24", "antigen", "level", ".", "The", "inhibitory", "effects", "of", "cepharanthine", "on", "HIV-1", "long", "terminal", "repeat", "(", "LTR)-driven", "gene", "expression", "and", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", "activation", "were", "also", "examined", ".", "Cepharanthine", "dose", "dependently", "inhibited", "HIV-1", "replication", "in", "TNF", "-", "alpha-", "and", "PMA", "-", "stimulated", "U1", "cells", "but", "not", "in", "ACH-2", "cells", ".", "Its", "50", "%", "effective", "and", "cytotoxic", "concentrations", "were", "0.016", "and", "2.2", "microg", "/", "ml", "in", "PMA", "-", "stimulated", "U1", "cells", ",", "respectively", ".", "Cepharanthine", "was", "found", "to", "suppress", "HIV-1", "LTR", "-", "driven", "gene", "expression", "through", "the", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "These", "results", "indicate", "that", "cepharanthine", "is", "a", "highly", "potent", "inhibitor", "of", "HIV-1", "replication", "in", "a", "chronically", "infected", "monocytic", "cell", "line", ".", "Since", "biscoclaurine", "alkaloids", ",", "containing", "cepharanthine", "as", "a", "major", "component", ",", "are", "widely", "used", "for", "the", "treatment", "of", "patients", "with", "various", "inflammatory", "diseases", "in", "Japan", ",", "cepharanthine", "should", "be", "further", "pursued", "for", "its", "chemotherapeutic", "potential", "in", "HIV-1-infected", "patients", "." ]

[ "Protein" ]

tumor necrosis factor alpha is a Protein, TNF - alpha is a Protein, p24 antigen is a Protein

858_task1

Sentence: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients. Instructions: please typing these entity words according to sentence: tumor necrosis factor alpha, TNF - alpha, p24 antigen Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients.

[ "Potent", "inhibition", "of", "HIV", "type", "1", "replication", "by", "an", "antiinflammatory", "alkaloid", ",", "cepharanthine", ",", "in", "chronically", "infected", "monocytic", "cells", ".", "\n", "Cepharanthine", "is", "a", "biscoclaurine", "alkaloid", "isolated", "from", "Stephania", "cepharantha", "Hayata", "and", "has", "been", "shown", "to", "have", "antiinflammatory", ",", "antiallergic", ",", "and", "immunomodulatory", "activities", "in", "vivo", ".", "As", "several", "inflammatory", "cytokines", "and", "oxidative", "stresses", "are", "involved", "in", "the", "pathogenesis", "of", "HIV-1", "infection", ",", "we", "investigated", "the", "inhibitory", "effects", "of", "cepharanthine", "on", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha)-", "and", "phorbol", "12-myristate", "13-acetate", "(", "PMA)-induced", "HIV-1", "replication", "in", "chronically", "infected", "cell", "lines", ".", "Two", "chronically", "HIV-1-infected", "cell", "lines", ",", "U1", "(", "monocytic", ")", "and", "ACH-2", "(", "T", "lymphocytic", ")", ",", "were", "stimulated", "with", "TNF", "-", "alpha", "or", "PMA", "and", "cultured", "in", "the", "presence", "of", "various", "concentrations", "of", "the", "compound", ".", "HIV-1", "replication", "was", "determined", "by", "p24", "antigen", "level", ".", "The", "inhibitory", "effects", "of", "cepharanthine", "on", "HIV-1", "long", "terminal", "repeat", "(", "LTR)-driven", "gene", "expression", "and", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", "activation", "were", "also", "examined", ".", "Cepharanthine", "dose", "dependently", "inhibited", "HIV-1", "replication", "in", "TNF", "-", "alpha-", "and", "PMA", "-", "stimulated", "U1", "cells", "but", "not", "in", "ACH-2", "cells", ".", "Its", "50", "%", "effective", "and", "cytotoxic", "concentrations", "were", "0.016", "and", "2.2", "microg", "/", "ml", "in", "PMA", "-", "stimulated", "U1", "cells", ",", "respectively", ".", "Cepharanthine", "was", "found", "to", "suppress", "HIV-1", "LTR", "-", "driven", "gene", "expression", "through", "the", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "These", "results", "indicate", "that", "cepharanthine", "is", "a", "highly", "potent", "inhibitor", "of", "HIV-1", "replication", "in", "a", "chronically", "infected", "monocytic", "cell", "line", ".", "Since", "biscoclaurine", "alkaloids", ",", "containing", "cepharanthine", "as", "a", "major", "component", ",", "are", "widely", "used", "for", "the", "treatment", "of", "patients", "with", "various", "inflammatory", "diseases", "in", "Japan", ",", "cepharanthine", "should", "be", "further", "pursued", "for", "its", "chemotherapeutic", "potential", "in", "HIV-1-infected", "patients", "." ]

[ "Protein" ]

tumor necrosis factor alpha, TNF - alpha, p24 antigen

858_task2

Sentence: Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Cepharanthine is a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata and has been shown to have antiinflammatory, antiallergic, and immunomodulatory activities in vivo. As several inflammatory cytokines and oxidative stresses are involved in the pathogenesis of HIV-1 infection, we investigated the inhibitory effects of cepharanthine on tumor necrosis factor alpha (TNF-alpha)- and phorbol 12-myristate 13-acetate (PMA)-induced HIV-1 replication in chronically infected cell lines. Two chronically HIV-1-infected cell lines, U1 (monocytic) and ACH-2 (T lymphocytic), were stimulated with TNF-alpha or PMA and cultured in the presence of various concentrations of the compound. HIV-1 replication was determined by p24 antigen level. The inhibitory effects of cepharanthine on HIV-1 long terminal repeat (LTR)-driven gene expression and nuclear factor kappaB (NF-kappaB) activation were also examined. Cepharanthine dose dependently inhibited HIV-1 replication in TNF-alpha- and PMA-stimulated U1 cells but not in ACH-2 cells. Its 50% effective and cytotoxic concentrations were 0.016 and 2.2 microg/ml in PMA-stimulated U1 cells, respectively. Cepharanthine was found to suppress HIV-1 LTR-driven gene expression through the inhibition of NF-kappaB activation. These results indicate that cepharanthine is a highly potent inhibitor of HIV-1 replication in a chronically infected monocytic cell line. Since biscoclaurine alkaloids, containing cepharanthine as a major component, are widely used for the treatment of patients with various inflammatory diseases in Japan, cepharanthine should be further pursued for its chemotherapeutic potential in HIV-1-infected patients.

[ "Potent", "inhibition", "of", "HIV", "type", "1", "replication", "by", "an", "antiinflammatory", "alkaloid", ",", "cepharanthine", ",", "in", "chronically", "infected", "monocytic", "cells", ".", "\n", "Cepharanthine", "is", "a", "biscoclaurine", "alkaloid", "isolated", "from", "Stephania", "cepharantha", "Hayata", "and", "has", "been", "shown", "to", "have", "antiinflammatory", ",", "antiallergic", ",", "and", "immunomodulatory", "activities", "in", "vivo", ".", "As", "several", "inflammatory", "cytokines", "and", "oxidative", "stresses", "are", "involved", "in", "the", "pathogenesis", "of", "HIV-1", "infection", ",", "we", "investigated", "the", "inhibitory", "effects", "of", "cepharanthine", "on", "tumor", "necrosis", "factor", "alpha", "(", "TNF", "-", "alpha)-", "and", "phorbol", "12-myristate", "13-acetate", "(", "PMA)-induced", "HIV-1", "replication", "in", "chronically", "infected", "cell", "lines", ".", "Two", "chronically", "HIV-1-infected", "cell", "lines", ",", "U1", "(", "monocytic", ")", "and", "ACH-2", "(", "T", "lymphocytic", ")", ",", "were", "stimulated", "with", "TNF", "-", "alpha", "or", "PMA", "and", "cultured", "in", "the", "presence", "of", "various", "concentrations", "of", "the", "compound", ".", "HIV-1", "replication", "was", "determined", "by", "p24", "antigen", "level", ".", "The", "inhibitory", "effects", "of", "cepharanthine", "on", "HIV-1", "long", "terminal", "repeat", "(", "LTR)-driven", "gene", "expression", "and", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", "activation", "were", "also", "examined", ".", "Cepharanthine", "dose", "dependently", "inhibited", "HIV-1", "replication", "in", "TNF", "-", "alpha-", "and", "PMA", "-", "stimulated", "U1", "cells", "but", "not", "in", "ACH-2", "cells", ".", "Its", "50", "%", "effective", "and", "cytotoxic", "concentrations", "were", "0.016", "and", "2.2", "microg", "/", "ml", "in", "PMA", "-", "stimulated", "U1", "cells", ",", "respectively", ".", "Cepharanthine", "was", "found", "to", "suppress", "HIV-1", "LTR", "-", "driven", "gene", "expression", "through", "the", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "These", "results", "indicate", "that", "cepharanthine", "is", "a", "highly", "potent", "inhibitor", "of", "HIV-1", "replication", "in", "a", "chronically", "infected", "monocytic", "cell", "line", ".", "Since", "biscoclaurine", "alkaloids", ",", "containing", "cepharanthine", "as", "a", "major", "component", ",", "are", "widely", "used", "for", "the", "treatment", "of", "patients", "with", "various", "inflammatory", "diseases", "in", "Japan", ",", "cepharanthine", "should", "be", "further", "pursued", "for", "its", "chemotherapeutic", "potential", "in", "HIV-1-infected", "patients", "." ]

[ "Protein" ]

DNA methyltransferases is a GENE-N, methyl cytosine - binding proteins is a GENE-N

23246732_task0

Sentence: Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]

Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus.

[ "Influence", "of", "developmental", "lead", "exposure", "on", "expression", "of", "DNA", "methyltransferases", "and", "methyl", "cytosine", "-", "binding", "proteins", "in", "hippocampus", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

DNA methyltransferases is a GENE-N, methyl cytosine - binding proteins is a GENE-N

23246732_task1

Sentence: Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Instructions: please typing these entity words according to sentence: DNA methyltransferases, methyl cytosine - binding proteins Options: GENE-N

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]

Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus.

[ "Influence", "of", "developmental", "lead", "exposure", "on", "expression", "of", "DNA", "methyltransferases", "and", "methyl", "cytosine", "-", "binding", "proteins", "in", "hippocampus", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

DNA methyltransferases, methyl cytosine - binding proteins

23246732_task2

Sentence: Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O" ]

Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus.

[ "Influence", "of", "developmental", "lead", "exposure", "on", "expression", "of", "DNA", "methyltransferases", "and", "methyl", "cytosine", "-", "binding", "proteins", "in", "hippocampus", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

melanoma is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, lesión pulmonar is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor maligno muy indiferenciado is a MORFOLOGIA_NEOPLASIA, MELANOMA is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, metastásico is a MORFOLOGIA_NEOPLASIA, metástasis de melanoma is a MORFOLOGIA_NEOPLASIA

289_task0

Sentence: Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta.

[ "Anamnesis", "\n", "Varón", "de", "61", "años", "con", "antecedentes", "personales", "de", "tabaquismo", ",", "diabetes", "mellitus", "tipo", "2", ",", "enfermedad", "renal", "crónica", "secundaria", "a", "nefropatía", "diabética", "y", "melanoma", "cutáneo", "intervenido", "(", "estadío", "Ib", ")", "en", "1993", ",", "sin", "evidencia", "de", "recidiva", "en", "seguimiento", "posterior", ".", "Consultó", "en", "el", "servicio", "de", "Urgencias", "por", "cuadro", "catarral", "y", "astenia", "de", "1", "mes", "de", "evolución", "sin", "otra", "sintomatología", "añadida", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "presentaba", "un", "buen", "estado", "general", "y", "las", "constantes", "vitales", "se", "encontraban", "en", "rango", "de", "normalidad", ".", "En", "la", "exploración", "física", "destacaba", "una", "cicatriz", "quirúrgica", "de", "melanoma", "extirpado", "en", "región", "dorsal", ",", "así", "como", "disminución", "del", "murmullo", "vesicular", "en", "base", "izquierda", "a", "la", "auscultación", "pulmonar", ".", "No", "se", "objetivaron", "lesiones", "dérmicas", "sospechosas", "de", "malignidad", "ni", "otros", "hallazgos", "de", "interés", "en", "la", "exploración", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "radiografía", "de", "tórax", "se", "produjo", "hallazgo", "casual", "de", "una", "masa", "retrocardíaca", "de", "bordes", "bien", "definidos", ".", "El", "TAC", "torácico", "confirmó", "la", "presencia", "de", "una", "lesión", "pulmonar", "de", "7", "cm", "a", "nivel", "del", "lóbulo", "inferior", "izquierdo", "y", "un", "conglomerado", "adenopático", "subcarinal", "de", "3.5x2.5", "cm", ".", "\n", "El", "hemograma", "mostró", "una", "anemia", "leve", ",", "con", "hemoglobina", "de", "11.5", ",", "y", "una", "leucocitosis", "de", "17100", "con", "desviación", "izquierda", ".", "La", "coagulación", "no", "presentaba", "alteraciones", ",", "y", "en", "la", "bioquímica", "destacaba", "una", "creatinina", "de", "1.49", "y", "una", "PCR", "de", "50.9", ",", "sin", "otros", "hallazgos", "reseñables", ".", "Se", "solicitaron", "marcadores", "tumorales", ",", "encontrándose", "todos", "ellos", "en", "rango", "de", "normalidad", ".", "\n", "Se", "procedió", "a", "realización", "de", "broncoscopia", "con", "toma", "de", "biopsia", "de", "la", "masa", "pulmonar", ",", "sin", "poder", "alcanzar", "una", "tipificación", "histológica", "debido", "a", "la", "gran", "indiferenciación", "y", "extensa", "necrosis", "tumoral", "de", "la", "lesión", ".", "Se", "llevó", "a", "cabo", "biopsia", "guiada", "por", "TAC", ",", "que", "aportó", "un", "diagnóstico", "de", "tumor", "maligno", "muy", "indiferenciado", ",", "sin", "poder", "precisar", "el", "origen", "primario", ".", "\n\n", "Diagnóstico", "\n", "Ante", "la", "escasa", "información", "aportada", "por", "las", "sucesivas", "biopsias", "de", "la", "masa", ",", "se", "realizó", "una", "biopsia", "ganglionar", "mediante", "EBUS", "del", "conglomerado", "adenopático", "descrito", "en", "el", "TAC", ".", "En", "esta", "ocasión", ",", "la", "anatomía", "patológica", "arrojó", "un", "resultado", "compatible", "con", "INFILTRACIÓN", "POR", "MELANOMA", ",", "con", "fuerte", "expresión", "positiva", "para", "MELAN", "-", "A", "y", "HMB-45", "y", "reordenamiento", "del", "gen", "BRAF", "V600E.", "\n", "El", "estudio", "de", "extensión", "mediante", "PET", "-", "TAC", "mostró", "captación", "a", "nivel", "de", "la", "masa", "pulmonar", "y", "el", "conglomerado", "adenopático", "subcarinal", ",", "además", "de", "objetivar", "zonas", "hipercaptantes", "susceptibles", "de", "origen", "metastásico", "a", "nivel", "de", "glándula", "suprarrenal", "izquierda", "e", "íleon", ".", "\n\n", "Tratamiento", "\n", "Se", "inició", "tratamiento", "con", "inhibidores", "de", "BRAF", "y", "MEK", "(", "Dabrafenib", "y", "Trametinib", ")", ".", "\n\n", "Evolución", "\n", "Un", "mes", "después", "del", "diagnóstico", "el", "paciente", "ingresó", "por", "cuadro", "de", "dolor", "y", "distensión", "abdominal", ";", "se", "diagnosticó", "de", "obstrucción", "intestinal", "y", "fue", "intervenido", "de", "urgencia", ".", "La", "anatomía", "patológica", "de", "la", "pieza", "quirúrgica", "resultó", "compatible", "con", "metástasis", "de", "melanoma", ",", "con", "mutación", "del", "gen", "BRAF", "y", "con", "pérdida", "de", "marcadores", "melanocíticos", ".", "\n", "En", "la", "actualidad", "el", "paciente", "continúa", "con", "tratamiento", "tras", "un", "intervalo", "libre", "de", "progresión", "de", "9", "meses", ",", "habiéndose", "objetivado", "una", "respuesta", "parcial", "mayor", "morfológica", "como", "máxima", "respuesta", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

melanoma is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, malignidad is a MORFOLOGIA_NEOPLASIA, lesión pulmonar is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor maligno muy indiferenciado is a MORFOLOGIA_NEOPLASIA, MELANOMA is a MORFOLOGIA_NEOPLASIA, masa pulmonar is a MORFOLOGIA_NEOPLASIA, metastásico is a MORFOLOGIA_NEOPLASIA, metástasis de melanoma is a MORFOLOGIA_NEOPLASIA

289_task1

Sentence: Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta. Instructions: please typing these entity words according to sentence: melanoma, melanoma, malignidad, lesión pulmonar, masa pulmonar, tumoral, tumor maligno muy indiferenciado, MELANOMA, masa pulmonar, metastásico, metástasis de melanoma Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta.

[ "Anamnesis", "\n", "Varón", "de", "61", "años", "con", "antecedentes", "personales", "de", "tabaquismo", ",", "diabetes", "mellitus", "tipo", "2", ",", "enfermedad", "renal", "crónica", "secundaria", "a", "nefropatía", "diabética", "y", "melanoma", "cutáneo", "intervenido", "(", "estadío", "Ib", ")", "en", "1993", ",", "sin", "evidencia", "de", "recidiva", "en", "seguimiento", "posterior", ".", "Consultó", "en", "el", "servicio", "de", "Urgencias", "por", "cuadro", "catarral", "y", "astenia", "de", "1", "mes", "de", "evolución", "sin", "otra", "sintomatología", "añadida", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "presentaba", "un", "buen", "estado", "general", "y", "las", "constantes", "vitales", "se", "encontraban", "en", "rango", "de", "normalidad", ".", "En", "la", "exploración", "física", "destacaba", "una", "cicatriz", "quirúrgica", "de", "melanoma", "extirpado", "en", "región", "dorsal", ",", "así", "como", "disminución", "del", "murmullo", "vesicular", "en", "base", "izquierda", "a", "la", "auscultación", "pulmonar", ".", "No", "se", "objetivaron", "lesiones", "dérmicas", "sospechosas", "de", "malignidad", "ni", "otros", "hallazgos", "de", "interés", "en", "la", "exploración", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "radiografía", "de", "tórax", "se", "produjo", "hallazgo", "casual", "de", "una", "masa", "retrocardíaca", "de", "bordes", "bien", "definidos", ".", "El", "TAC", "torácico", "confirmó", "la", "presencia", "de", "una", "lesión", "pulmonar", "de", "7", "cm", "a", "nivel", "del", "lóbulo", "inferior", "izquierdo", "y", "un", "conglomerado", "adenopático", "subcarinal", "de", "3.5x2.5", "cm", ".", "\n", "El", "hemograma", "mostró", "una", "anemia", "leve", ",", "con", "hemoglobina", "de", "11.5", ",", "y", "una", "leucocitosis", "de", "17100", "con", "desviación", "izquierda", ".", "La", "coagulación", "no", "presentaba", "alteraciones", ",", "y", "en", "la", "bioquímica", "destacaba", "una", "creatinina", "de", "1.49", "y", "una", "PCR", "de", "50.9", ",", "sin", "otros", "hallazgos", "reseñables", ".", "Se", "solicitaron", "marcadores", "tumorales", ",", "encontrándose", "todos", "ellos", "en", "rango", "de", "normalidad", ".", "\n", "Se", "procedió", "a", "realización", "de", "broncoscopia", "con", "toma", "de", "biopsia", "de", "la", "masa", "pulmonar", ",", "sin", "poder", "alcanzar", "una", "tipificación", "histológica", "debido", "a", "la", "gran", "indiferenciación", "y", "extensa", "necrosis", "tumoral", "de", "la", "lesión", ".", "Se", "llevó", "a", "cabo", "biopsia", "guiada", "por", "TAC", ",", "que", "aportó", "un", "diagnóstico", "de", "tumor", "maligno", "muy", "indiferenciado", ",", "sin", "poder", "precisar", "el", "origen", "primario", ".", "\n\n", "Diagnóstico", "\n", "Ante", "la", "escasa", "información", "aportada", "por", "las", "sucesivas", "biopsias", "de", "la", "masa", ",", "se", "realizó", "una", "biopsia", "ganglionar", "mediante", "EBUS", "del", "conglomerado", "adenopático", "descrito", "en", "el", "TAC", ".", "En", "esta", "ocasión", ",", "la", "anatomía", "patológica", "arrojó", "un", "resultado", "compatible", "con", "INFILTRACIÓN", "POR", "MELANOMA", ",", "con", "fuerte", "expresión", "positiva", "para", "MELAN", "-", "A", "y", "HMB-45", "y", "reordenamiento", "del", "gen", "BRAF", "V600E.", "\n", "El", "estudio", "de", "extensión", "mediante", "PET", "-", "TAC", "mostró", "captación", "a", "nivel", "de", "la", "masa", "pulmonar", "y", "el", "conglomerado", "adenopático", "subcarinal", ",", "además", "de", "objetivar", "zonas", "hipercaptantes", "susceptibles", "de", "origen", "metastásico", "a", "nivel", "de", "glándula", "suprarrenal", "izquierda", "e", "íleon", ".", "\n\n", "Tratamiento", "\n", "Se", "inició", "tratamiento", "con", "inhibidores", "de", "BRAF", "y", "MEK", "(", "Dabrafenib", "y", "Trametinib", ")", ".", "\n\n", "Evolución", "\n", "Un", "mes", "después", "del", "diagnóstico", "el", "paciente", "ingresó", "por", "cuadro", "de", "dolor", "y", "distensión", "abdominal", ";", "se", "diagnosticó", "de", "obstrucción", "intestinal", "y", "fue", "intervenido", "de", "urgencia", ".", "La", "anatomía", "patológica", "de", "la", "pieza", "quirúrgica", "resultó", "compatible", "con", "metástasis", "de", "melanoma", ",", "con", "mutación", "del", "gen", "BRAF", "y", "con", "pérdida", "de", "marcadores", "melanocíticos", ".", "\n", "En", "la", "actualidad", "el", "paciente", "continúa", "con", "tratamiento", "tras", "un", "intervalo", "libre", "de", "progresión", "de", "9", "meses", ",", "habiéndose", "objetivado", "una", "respuesta", "parcial", "mayor", "morfológica", "como", "máxima", "respuesta", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

melanoma, melanoma, malignidad, lesión pulmonar, masa pulmonar, tumoral, tumor maligno muy indiferenciado, MELANOMA, masa pulmonar, metastásico, metástasis de melanoma

289_task2

Sentence: Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Varón de 61 años con antecedentes personales de tabaquismo, diabetes mellitus tipo 2, enfermedad renal crónica secundaria a nefropatía diabética y melanoma cutáneo intervenido (estadío Ib) en 1993, sin evidencia de recidiva en seguimiento posterior. Consultó en el servicio de Urgencias por cuadro catarral y astenia de 1 mes de evolución sin otra sintomatología añadida. Exploración física El paciente presentaba un buen estado general y las constantes vitales se encontraban en rango de normalidad. En la exploración física destacaba una cicatriz quirúrgica de melanoma extirpado en región dorsal, así como disminución del murmullo vesicular en base izquierda a la auscultación pulmonar. No se objetivaron lesiones dérmicas sospechosas de malignidad ni otros hallazgos de interés en la exploración. Pruebas complementarias En la radiografía de tórax se produjo hallazgo casual de una masa retrocardíaca de bordes bien definidos. El TAC torácico confirmó la presencia de una lesión pulmonar de 7cm a nivel del lóbulo inferior izquierdo y un conglomerado adenopático subcarinal de 3.5x2.5cm. El hemograma mostró una anemia leve, con hemoglobina de 11.5, y una leucocitosis de 17100 con desviación izquierda. La coagulación no presentaba alteraciones, y en la bioquímica destacaba una creatinina de 1.49 y una PCR de 50.9, sin otros hallazgos reseñables. Se solicitaron marcadores tumorales, encontrándose todos ellos en rango de normalidad. Se procedió a realización de broncoscopia con toma de biopsia de la masa pulmonar, sin poder alcanzar una tipificación histológica debido a la gran indiferenciación y extensa necrosis tumoral de la lesión. Se llevó a cabo biopsia guiada por TAC, que aportó un diagnóstico de tumor maligno muy indiferenciado, sin poder precisar el origen primario. Diagnóstico Ante la escasa información aportada por las sucesivas biopsias de la masa, se realizó una biopsia ganglionar mediante EBUS del conglomerado adenopático descrito en el TAC. En esta ocasión, la anatomía patológica arrojó un resultado compatible con INFILTRACIÓN POR MELANOMA, con fuerte expresión positiva para MELAN-A y HMB-45 y reordenamiento del gen BRAF V600E. El estudio de extensión mediante PET-TAC mostró captación a nivel de la masa pulmonar y el conglomerado adenopático subcarinal, además de objetivar zonas hipercaptantes susceptibles de origen metastásico a nivel de glándula suprarrenal izquierda e íleon. Tratamiento Se inició tratamiento con inhibidores de BRAF y MEK (Dabrafenib y Trametinib). Evolución Un mes después del diagnóstico el paciente ingresó por cuadro de dolor y distensión abdominal; se diagnosticó de obstrucción intestinal y fue intervenido de urgencia. La anatomía patológica de la pieza quirúrgica resultó compatible con metástasis de melanoma, con mutación del gen BRAF y con pérdida de marcadores melanocíticos. En la actualidad el paciente continúa con tratamiento tras un intervalo libre de progresión de 9 meses, habiéndose objetivado una respuesta parcial mayor morfológica como máxima respuesta.

[ "Anamnesis", "\n", "Varón", "de", "61", "años", "con", "antecedentes", "personales", "de", "tabaquismo", ",", "diabetes", "mellitus", "tipo", "2", ",", "enfermedad", "renal", "crónica", "secundaria", "a", "nefropatía", "diabética", "y", "melanoma", "cutáneo", "intervenido", "(", "estadío", "Ib", ")", "en", "1993", ",", "sin", "evidencia", "de", "recidiva", "en", "seguimiento", "posterior", ".", "Consultó", "en", "el", "servicio", "de", "Urgencias", "por", "cuadro", "catarral", "y", "astenia", "de", "1", "mes", "de", "evolución", "sin", "otra", "sintomatología", "añadida", ".", "\n\n", "Exploración", "física", "\n", "El", "paciente", "presentaba", "un", "buen", "estado", "general", "y", "las", "constantes", "vitales", "se", "encontraban", "en", "rango", "de", "normalidad", ".", "En", "la", "exploración", "física", "destacaba", "una", "cicatriz", "quirúrgica", "de", "melanoma", "extirpado", "en", "región", "dorsal", ",", "así", "como", "disminución", "del", "murmullo", "vesicular", "en", "base", "izquierda", "a", "la", "auscultación", "pulmonar", ".", "No", "se", "objetivaron", "lesiones", "dérmicas", "sospechosas", "de", "malignidad", "ni", "otros", "hallazgos", "de", "interés", "en", "la", "exploración", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "radiografía", "de", "tórax", "se", "produjo", "hallazgo", "casual", "de", "una", "masa", "retrocardíaca", "de", "bordes", "bien", "definidos", ".", "El", "TAC", "torácico", "confirmó", "la", "presencia", "de", "una", "lesión", "pulmonar", "de", "7", "cm", "a", "nivel", "del", "lóbulo", "inferior", "izquierdo", "y", "un", "conglomerado", "adenopático", "subcarinal", "de", "3.5x2.5", "cm", ".", "\n", "El", "hemograma", "mostró", "una", "anemia", "leve", ",", "con", "hemoglobina", "de", "11.5", ",", "y", "una", "leucocitosis", "de", "17100", "con", "desviación", "izquierda", ".", "La", "coagulación", "no", "presentaba", "alteraciones", ",", "y", "en", "la", "bioquímica", "destacaba", "una", "creatinina", "de", "1.49", "y", "una", "PCR", "de", "50.9", ",", "sin", "otros", "hallazgos", "reseñables", ".", "Se", "solicitaron", "marcadores", "tumorales", ",", "encontrándose", "todos", "ellos", "en", "rango", "de", "normalidad", ".", "\n", "Se", "procedió", "a", "realización", "de", "broncoscopia", "con", "toma", "de", "biopsia", "de", "la", "masa", "pulmonar", ",", "sin", "poder", "alcanzar", "una", "tipificación", "histológica", "debido", "a", "la", "gran", "indiferenciación", "y", "extensa", "necrosis", "tumoral", "de", "la", "lesión", ".", "Se", "llevó", "a", "cabo", "biopsia", "guiada", "por", "TAC", ",", "que", "aportó", "un", "diagnóstico", "de", "tumor", "maligno", "muy", "indiferenciado", ",", "sin", "poder", "precisar", "el", "origen", "primario", ".", "\n\n", "Diagnóstico", "\n", "Ante", "la", "escasa", "información", "aportada", "por", "las", "sucesivas", "biopsias", "de", "la", "masa", ",", "se", "realizó", "una", "biopsia", "ganglionar", "mediante", "EBUS", "del", "conglomerado", "adenopático", "descrito", "en", "el", "TAC", ".", "En", "esta", "ocasión", ",", "la", "anatomía", "patológica", "arrojó", "un", "resultado", "compatible", "con", "INFILTRACIÓN", "POR", "MELANOMA", ",", "con", "fuerte", "expresión", "positiva", "para", "MELAN", "-", "A", "y", "HMB-45", "y", "reordenamiento", "del", "gen", "BRAF", "V600E.", "\n", "El", "estudio", "de", "extensión", "mediante", "PET", "-", "TAC", "mostró", "captación", "a", "nivel", "de", "la", "masa", "pulmonar", "y", "el", "conglomerado", "adenopático", "subcarinal", ",", "además", "de", "objetivar", "zonas", "hipercaptantes", "susceptibles", "de", "origen", "metastásico", "a", "nivel", "de", "glándula", "suprarrenal", "izquierda", "e", "íleon", ".", "\n\n", "Tratamiento", "\n", "Se", "inició", "tratamiento", "con", "inhibidores", "de", "BRAF", "y", "MEK", "(", "Dabrafenib", "y", "Trametinib", ")", ".", "\n\n", "Evolución", "\n", "Un", "mes", "después", "del", "diagnóstico", "el", "paciente", "ingresó", "por", "cuadro", "de", "dolor", "y", "distensión", "abdominal", ";", "se", "diagnosticó", "de", "obstrucción", "intestinal", "y", "fue", "intervenido", "de", "urgencia", ".", "La", "anatomía", "patológica", "de", "la", "pieza", "quirúrgica", "resultó", "compatible", "con", "metástasis", "de", "melanoma", ",", "con", "mutación", "del", "gen", "BRAF", "y", "con", "pérdida", "de", "marcadores", "melanocíticos", ".", "\n", "En", "la", "actualidad", "el", "paciente", "continúa", "con", "tratamiento", "tras", "un", "intervalo", "libre", "de", "progresión", "de", "9", "meses", ",", "habiéndose", "objetivado", "una", "respuesta", "parcial", "mayor", "morfológica", "como", "máxima", "respuesta", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

total occlusive ionic silver - containing dressing combination is a Intervention_Physical, risk of surgical site infection : is a Outcome_Adverse-effects, total occlusive ionic silver - containing dressing ( TOISD ) combination is a Intervention_Physical, no dressing is a Intervention_Control

53467_task0

Sentence: Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Adverse-effects, Intervention_Control

[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI .

[ "Efficacy", "of", "a", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "combination", "in", "decreasing", "risk", "of", "surgical", "site", "infection", ":", "an", "RCT", ".", "OBJECTIVE", "To", "perform", "a", "comparative", "assessment", "of", "the", "efficacy", "of", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "(", "TOISD", ")", "combination", "vs", "no", "dressing", "after", "colorectal", "surgery", ".", "METHOD", "The", "surgical", "sites", "from", "both", "groups", "were", "swabbed", "and", "sent", "for", "culture", "and", "sensitivity", "upon", "wound", "closure", "(", "superficial", "incisional", "skin", "surface", ")", "in", "the", "operating", "theatre", ",", "as", "a", "baseline", "for", "bacterial", "colonisation", ".", "The", "patients", "'", "surgical", "wounds", "in", "the", "study", "group", "were", "dressed", "with", "TOISD", "combination", "and", "the", "patient", "'", "s", "surgical", "wounds", "in", "the", "control", "group", "received", "the", "conventional", "method", "of", "no", "dressing", ".", "A", "second", "swab", "was", "taken", "from", "the", "superficial", "incisional", "skin", "surface", "for", "culture", "and", "sensitivity", "investigation", "between", "the", "fifth", "to", "seventh", "postoperative", "day", "for", "comparison", "of", "the", "bacterial", "colonisation", "in", "the", "two", "groups", ".", "RESULTS", "One", "-", "hundred", "and", "sixty", "-", "six", "patients", "were", "recruited", ".", "Six", "patients", "dropped", "out", "before", "the", "fifth", "postoperative", "day", ",", "leaving", "79", "patients", "in", "the", "control", "group", "and", "81", "patients", "in", "the", "study", "group", ".", "Microbial", "swab", "cultures", "revealed", "significant", "differences", "between", "the", "two", "groups", "(", "p", "<", "0.001", ",", "mean=1.43±0.63", ")", "in", "bacterial", "colonisation", ".", "The", "odds", "ratio", "(", "OR", ")", "of", "patients", "with", "wounds", "in", "the", "control", "group", "was", "4.1", "(", "95", "%", "CI", "is", "1.884", ",", "8.964", ")", "more", "likely", "to", "be", "contaminated", "with", "bacteria", "compared", "with", "wounds", "covered", "with", "occlusive", "ionic", "silver", "-", "containing", "dressing", ".", "CONCLUSION", "TOISD", "was", "found", "to", "be", "effective", "in", "reducing", "bacterial", "colonisation", "on", "the", "surgical", "site", "compared", "with", "no", "dressing", ".", "However", ",", "it", "properties", "were", "unable", "to", "be", "put", "into", "use", "if", "there", "were", "the", "surgical", "sites", "were", "not", "infested", "with", "bacterial", ".", "Although", "TOISD", "might", "not", "be", "necessarily", "on", "surgical", "incisional", "site", "not", "infested", "with", "bacteria", "for", "the", "initial", "post", "-", "operation", "days", ",", "it", "is", "helpful", "in", "preventing", "further", "transcription", "and", "division", "for", "opportunistic", "bacteria", ",", "thus", "might", "reduce", "the", "risk", "of", "superficial", "incisional", "SSI", ".", "The", "use", "of", "TOSID", "though", "statistically", "insignificant", "compared", "to", "no", "dressing", ",", "could", "also", "be", "possible", "in", "reducing", "the", "risk", "and", "exaceration", "of", "deep", "incisional", "SSI", "." ]

[ "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]

total occlusive ionic silver - containing dressing combination is a Intervention_Physical, risk of surgical site infection : is a Outcome_Adverse-effects, total occlusive ionic silver - containing dressing ( TOISD ) combination is a Intervention_Physical, no dressing is a Intervention_Control

53467_task1

Sentence: Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI . Instructions: please typing these entity words according to sentence: total occlusive ionic silver - containing dressing combination, risk of surgical site infection :, total occlusive ionic silver - containing dressing ( TOISD ) combination, no dressing Options: Intervention_Physical, Outcome_Adverse-effects, Intervention_Control

[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI .

[ "Efficacy", "of", "a", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "combination", "in", "decreasing", "risk", "of", "surgical", "site", "infection", ":", "an", "RCT", ".", "OBJECTIVE", "To", "perform", "a", "comparative", "assessment", "of", "the", "efficacy", "of", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "(", "TOISD", ")", "combination", "vs", "no", "dressing", "after", "colorectal", "surgery", ".", "METHOD", "The", "surgical", "sites", "from", "both", "groups", "were", "swabbed", "and", "sent", "for", "culture", "and", "sensitivity", "upon", "wound", "closure", "(", "superficial", "incisional", "skin", "surface", ")", "in", "the", "operating", "theatre", ",", "as", "a", "baseline", "for", "bacterial", "colonisation", ".", "The", "patients", "'", "surgical", "wounds", "in", "the", "study", "group", "were", "dressed", "with", "TOISD", "combination", "and", "the", "patient", "'", "s", "surgical", "wounds", "in", "the", "control", "group", "received", "the", "conventional", "method", "of", "no", "dressing", ".", "A", "second", "swab", "was", "taken", "from", "the", "superficial", "incisional", "skin", "surface", "for", "culture", "and", "sensitivity", "investigation", "between", "the", "fifth", "to", "seventh", "postoperative", "day", "for", "comparison", "of", "the", "bacterial", "colonisation", "in", "the", "two", "groups", ".", "RESULTS", "One", "-", "hundred", "and", "sixty", "-", "six", "patients", "were", "recruited", ".", "Six", "patients", "dropped", "out", "before", "the", "fifth", "postoperative", "day", ",", "leaving", "79", "patients", "in", "the", "control", "group", "and", "81", "patients", "in", "the", "study", "group", ".", "Microbial", "swab", "cultures", "revealed", "significant", "differences", "between", "the", "two", "groups", "(", "p", "<", "0.001", ",", "mean=1.43±0.63", ")", "in", "bacterial", "colonisation", ".", "The", "odds", "ratio", "(", "OR", ")", "of", "patients", "with", "wounds", "in", "the", "control", "group", "was", "4.1", "(", "95", "%", "CI", "is", "1.884", ",", "8.964", ")", "more", "likely", "to", "be", "contaminated", "with", "bacteria", "compared", "with", "wounds", "covered", "with", "occlusive", "ionic", "silver", "-", "containing", "dressing", ".", "CONCLUSION", "TOISD", "was", "found", "to", "be", "effective", "in", "reducing", "bacterial", "colonisation", "on", "the", "surgical", "site", "compared", "with", "no", "dressing", ".", "However", ",", "it", "properties", "were", "unable", "to", "be", "put", "into", "use", "if", "there", "were", "the", "surgical", "sites", "were", "not", "infested", "with", "bacterial", ".", "Although", "TOISD", "might", "not", "be", "necessarily", "on", "surgical", "incisional", "site", "not", "infested", "with", "bacteria", "for", "the", "initial", "post", "-", "operation", "days", ",", "it", "is", "helpful", "in", "preventing", "further", "transcription", "and", "division", "for", "opportunistic", "bacteria", ",", "thus", "might", "reduce", "the", "risk", "of", "superficial", "incisional", "SSI", ".", "The", "use", "of", "TOSID", "though", "statistically", "insignificant", "compared", "to", "no", "dressing", ",", "could", "also", "be", "possible", "in", "reducing", "the", "risk", "and", "exaceration", "of", "deep", "incisional", "SSI", "." ]

[ "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]

total occlusive ionic silver - containing dressing combination, risk of surgical site infection :, total occlusive ionic silver - containing dressing ( TOISD ) combination, no dressing

53467_task2

Sentence: Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Efficacy of a total occlusive ionic silver-containing dressing combination in decreasing risk of surgical site infection : an RCT . OBJECTIVE To perform a comparative assessment of the efficacy of total occlusive ionic silver-containing dressing ( TOISD ) combination vs no dressing after colorectal surgery . METHOD The surgical sites from both groups were swabbed and sent for culture and sensitivity upon wound closure ( superficial incisional skin surface ) in the operating theatre , as a baseline for bacterial colonisation . The patients ' surgical wounds in the study group were dressed with TOISD combination and the patient 's surgical wounds in the control group received the conventional method of no dressing . A second swab was taken from the superficial incisional skin surface for culture and sensitivity investigation between the fifth to seventh postoperative day for comparison of the bacterial colonisation in the two groups . RESULTS One-hundred and sixty-six patients were recruited . Six patients dropped out before the fifth postoperative day , leaving 79 patients in the control group and 81 patients in the study group . Microbial swab cultures revealed significant differences between the two groups ( p < 0.001 , mean=1.43±0.63 ) in bacterial colonisation . The odds ratio ( OR ) of patients with wounds in the control group was 4.1 ( 95 % CI is 1.884 , 8.964 ) more likely to be contaminated with bacteria compared with wounds covered with occlusive ionic silver-containing dressing . CONCLUSION TOISD was found to be effective in reducing bacterial colonisation on the surgical site compared with no dressing . However , it properties were unable to be put into use if there were the surgical sites were not infested with bacterial . Although TOISD might not be necessarily on surgical incisional site not infested with bacteria for the initial post-operation days , it is helpful in preventing further transcription and division for opportunistic bacteria , thus might reduce the risk of superficial incisional SSI . The use of TOSID though statistically insignificant compared to no dressing , could also be possible in reducing the risk and exaceration of deep incisional SSI .

[ "Efficacy", "of", "a", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "combination", "in", "decreasing", "risk", "of", "surgical", "site", "infection", ":", "an", "RCT", ".", "OBJECTIVE", "To", "perform", "a", "comparative", "assessment", "of", "the", "efficacy", "of", "total", "occlusive", "ionic", "silver", "-", "containing", "dressing", "(", "TOISD", ")", "combination", "vs", "no", "dressing", "after", "colorectal", "surgery", ".", "METHOD", "The", "surgical", "sites", "from", "both", "groups", "were", "swabbed", "and", "sent", "for", "culture", "and", "sensitivity", "upon", "wound", "closure", "(", "superficial", "incisional", "skin", "surface", ")", "in", "the", "operating", "theatre", ",", "as", "a", "baseline", "for", "bacterial", "colonisation", ".", "The", "patients", "'", "surgical", "wounds", "in", "the", "study", "group", "were", "dressed", "with", "TOISD", "combination", "and", "the", "patient", "'", "s", "surgical", "wounds", "in", "the", "control", "group", "received", "the", "conventional", "method", "of", "no", "dressing", ".", "A", "second", "swab", "was", "taken", "from", "the", "superficial", "incisional", "skin", "surface", "for", "culture", "and", "sensitivity", "investigation", "between", "the", "fifth", "to", "seventh", "postoperative", "day", "for", "comparison", "of", "the", "bacterial", "colonisation", "in", "the", "two", "groups", ".", "RESULTS", "One", "-", "hundred", "and", "sixty", "-", "six", "patients", "were", "recruited", ".", "Six", "patients", "dropped", "out", "before", "the", "fifth", "postoperative", "day", ",", "leaving", "79", "patients", "in", "the", "control", "group", "and", "81", "patients", "in", "the", "study", "group", ".", "Microbial", "swab", "cultures", "revealed", "significant", "differences", "between", "the", "two", "groups", "(", "p", "<", "0.001", ",", "mean=1.43±0.63", ")", "in", "bacterial", "colonisation", ".", "The", "odds", "ratio", "(", "OR", ")", "of", "patients", "with", "wounds", "in", "the", "control", "group", "was", "4.1", "(", "95", "%", "CI", "is", "1.884", ",", "8.964", ")", "more", "likely", "to", "be", "contaminated", "with", "bacteria", "compared", "with", "wounds", "covered", "with", "occlusive", "ionic", "silver", "-", "containing", "dressing", ".", "CONCLUSION", "TOISD", "was", "found", "to", "be", "effective", "in", "reducing", "bacterial", "colonisation", "on", "the", "surgical", "site", "compared", "with", "no", "dressing", ".", "However", ",", "it", "properties", "were", "unable", "to", "be", "put", "into", "use", "if", "there", "were", "the", "surgical", "sites", "were", "not", "infested", "with", "bacterial", ".", "Although", "TOISD", "might", "not", "be", "necessarily", "on", "surgical", "incisional", "site", "not", "infested", "with", "bacteria", "for", "the", "initial", "post", "-", "operation", "days", ",", "it", "is", "helpful", "in", "preventing", "further", "transcription", "and", "division", "for", "opportunistic", "bacteria", ",", "thus", "might", "reduce", "the", "risk", "of", "superficial", "incisional", "SSI", ".", "The", "use", "of", "TOSID", "though", "statistically", "insignificant", "compared", "to", "no", "dressing", ",", "could", "also", "be", "possible", "in", "reducing", "the", "risk", "and", "exaceration", "of", "deep", "incisional", "SSI", "." ]

[ "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]

GI toxicity is a ADVERSE, GI toxicity is a ADVERSE, hypertension is a ADVERSE, renal impairment is a ADVERSE

example-261_task0

Sentence: Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality.

[ "Utility", "of", "published", "guidelines", "on", "the", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "in", "the", "elderly", ".", " ", "Canadian", "Consensus", "guidelines", "regarding", "appropriate", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAID", ")", "were", "recently", "published", ".", "This", "study", "was", "done", "to", "evaluate", "the", "application", "of", "these", "guidelines", "on", "NSAID", "practice", "patterns", "in", "frail", "elderly", "patients", "referred", "to", "a", "specialist", "Geriatric", "Assessment", "Clinic", ".", "A", "retrospective", "chart", "review", "was", "undertaken", "of", "referrals", "who", "were", "currently", "prescribed", "NSAIDs", ".", "Data", "were", "captured", "on", "age", ",", "sex", ",", "weight", ",", "diagnoses", ",", "medications", "and", "dosages", ",", "indication", "for", "NSAID", "treatment", ",", "lying", "BP", "(", "as", "assessed", "in", "the", "clinic", ")", "and", "recent", "serum", "creatinine", "result", ".", "Creatinine", "clearance", "was", "subsequently", "calculated", "use", "the", "Cockcroft", "-", "Gault", "equation", ".", "Complete", "data", "were", "available", "on", "107", "patients", "(", "68", "%", "women", ",", "average", "age", "80.6", "years", ")", ".", "Thirty", "percent", "were", "on", "a", "traditional", "NSAID", ",", "the", "remainder", "were", "on", "a", "Coxib", ".", "Concomitant", "aspirin", "was", "prescribed", "in", "37", "%", ".", "Cytoprotection", "was", "being", "used", "in", "38", "%", "and", "did", "not", "increase", "appreciably", "in", "patients", "with", "additional", "risk", "factors", "for", "GI", "toxicity", ",", "i.e", ".", ",", "concomitant", "aspirin", "usage", "(", "35", "%", ")", ",", "and", "history", "of", "GI", "toxicity", "(", "48", "%", ")", ".", "Sixty", "-", "seven", "were", "taking", "anti", "-", "hypertensive", "medications", ",", "although", "more", "than", "two", "thirds", "of", "these", "patients", "were", "uncontrolled", ".", "Newly", "diagnosed", "hypertension", "was", "present", "in", "19.6", "%", ".", "Calculated", "creatinine", "clearance", "revealed", "moderate", "to", "severe", "renal", "impairment", "in", "79", "%", "of", "subjects", ",", "although", "serum", "creatinine", "was", "only", "elevated", "in", "18", "%", ".", "In", "total", ",", "70", "%", "of", "subjects", "were", "found", "to", "have", "relative", "or", "absolute", "risk", "factors", "for", "NSAID", "therapy", ".", "Given", "the", "high", "prevalence", "of", "potential", "contraindications", "to", "anti", "-", "inflammatory", "drug", "usage", "in", "this", "study", ",", "we", "advocate", "the", "dissemination", "and", "application", "of", "these", "guidelines", "in", "geriatric", "patients", "in", "an", "attempt", "to", "reduce", "potential", "morbidity", "and", "mortality", "." ]

[ "ADVERSE" ]

GI toxicity is a ADVERSE, GI toxicity is a ADVERSE, hypertension is a ADVERSE, renal impairment is a ADVERSE

example-261_task1

Sentence: Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality. Instructions: please typing these entity words according to sentence: GI toxicity, GI toxicity, hypertension, renal impairment Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality.

[ "Utility", "of", "published", "guidelines", "on", "the", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "in", "the", "elderly", ".", " ", "Canadian", "Consensus", "guidelines", "regarding", "appropriate", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAID", ")", "were", "recently", "published", ".", "This", "study", "was", "done", "to", "evaluate", "the", "application", "of", "these", "guidelines", "on", "NSAID", "practice", "patterns", "in", "frail", "elderly", "patients", "referred", "to", "a", "specialist", "Geriatric", "Assessment", "Clinic", ".", "A", "retrospective", "chart", "review", "was", "undertaken", "of", "referrals", "who", "were", "currently", "prescribed", "NSAIDs", ".", "Data", "were", "captured", "on", "age", ",", "sex", ",", "weight", ",", "diagnoses", ",", "medications", "and", "dosages", ",", "indication", "for", "NSAID", "treatment", ",", "lying", "BP", "(", "as", "assessed", "in", "the", "clinic", ")", "and", "recent", "serum", "creatinine", "result", ".", "Creatinine", "clearance", "was", "subsequently", "calculated", "use", "the", "Cockcroft", "-", "Gault", "equation", ".", "Complete", "data", "were", "available", "on", "107", "patients", "(", "68", "%", "women", ",", "average", "age", "80.6", "years", ")", ".", "Thirty", "percent", "were", "on", "a", "traditional", "NSAID", ",", "the", "remainder", "were", "on", "a", "Coxib", ".", "Concomitant", "aspirin", "was", "prescribed", "in", "37", "%", ".", "Cytoprotection", "was", "being", "used", "in", "38", "%", "and", "did", "not", "increase", "appreciably", "in", "patients", "with", "additional", "risk", "factors", "for", "GI", "toxicity", ",", "i.e", ".", ",", "concomitant", "aspirin", "usage", "(", "35", "%", ")", ",", "and", "history", "of", "GI", "toxicity", "(", "48", "%", ")", ".", "Sixty", "-", "seven", "were", "taking", "anti", "-", "hypertensive", "medications", ",", "although", "more", "than", "two", "thirds", "of", "these", "patients", "were", "uncontrolled", ".", "Newly", "diagnosed", "hypertension", "was", "present", "in", "19.6", "%", ".", "Calculated", "creatinine", "clearance", "revealed", "moderate", "to", "severe", "renal", "impairment", "in", "79", "%", "of", "subjects", ",", "although", "serum", "creatinine", "was", "only", "elevated", "in", "18", "%", ".", "In", "total", ",", "70", "%", "of", "subjects", "were", "found", "to", "have", "relative", "or", "absolute", "risk", "factors", "for", "NSAID", "therapy", ".", "Given", "the", "high", "prevalence", "of", "potential", "contraindications", "to", "anti", "-", "inflammatory", "drug", "usage", "in", "this", "study", ",", "we", "advocate", "the", "dissemination", "and", "application", "of", "these", "guidelines", "in", "geriatric", "patients", "in", "an", "attempt", "to", "reduce", "potential", "morbidity", "and", "mortality", "." ]

[ "ADVERSE" ]

GI toxicity, GI toxicity, hypertension, renal impairment

example-261_task2

Sentence: Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Canadian Consensus guidelines regarding appropriate use of nonsteroidal anti-inflammatory drugs (NSAID) were recently published. This study was done to evaluate the application of these guidelines on NSAID practice patterns in frail elderly patients referred to a specialist Geriatric Assessment Clinic. A retrospective chart review was undertaken of referrals who were currently prescribed NSAIDs. Data were captured on age, sex, weight, diagnoses, medications and dosages, indication for NSAID treatment, lying BP (as assessed in the clinic) and recent serum creatinine result. Creatinine clearance was subsequently calculated use the Cockcroft-Gault equation. Complete data were available on 107 patients (68% women, average age 80.6 years). Thirty percent were on a traditional NSAID, the remainder were on a Coxib. Concomitant aspirin was prescribed in 37%. Cytoprotection was being used in 38% and did not increase appreciably in patients with additional risk factors for GI toxicity, i.e., concomitant aspirin usage (35%), and history of GI toxicity (48%). Sixty-seven were taking anti-hypertensive medications, although more than two thirds of these patients were uncontrolled. Newly diagnosed hypertension was present in 19.6%. Calculated creatinine clearance revealed moderate to severe renal impairment in 79% of subjects, although serum creatinine was only elevated in 18%. In total, 70% of subjects were found to have relative or absolute risk factors for NSAID therapy. Given the high prevalence of potential contraindications to anti-inflammatory drug usage in this study, we advocate the dissemination and application of these guidelines in geriatric patients in an attempt to reduce potential morbidity and mortality.

[ "Utility", "of", "published", "guidelines", "on", "the", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "in", "the", "elderly", ".", " ", "Canadian", "Consensus", "guidelines", "regarding", "appropriate", "use", "of", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAID", ")", "were", "recently", "published", ".", "This", "study", "was", "done", "to", "evaluate", "the", "application", "of", "these", "guidelines", "on", "NSAID", "practice", "patterns", "in", "frail", "elderly", "patients", "referred", "to", "a", "specialist", "Geriatric", "Assessment", "Clinic", ".", "A", "retrospective", "chart", "review", "was", "undertaken", "of", "referrals", "who", "were", "currently", "prescribed", "NSAIDs", ".", "Data", "were", "captured", "on", "age", ",", "sex", ",", "weight", ",", "diagnoses", ",", "medications", "and", "dosages", ",", "indication", "for", "NSAID", "treatment", ",", "lying", "BP", "(", "as", "assessed", "in", "the", "clinic", ")", "and", "recent", "serum", "creatinine", "result", ".", "Creatinine", "clearance", "was", "subsequently", "calculated", "use", "the", "Cockcroft", "-", "Gault", "equation", ".", "Complete", "data", "were", "available", "on", "107", "patients", "(", "68", "%", "women", ",", "average", "age", "80.6", "years", ")", ".", "Thirty", "percent", "were", "on", "a", "traditional", "NSAID", ",", "the", "remainder", "were", "on", "a", "Coxib", ".", "Concomitant", "aspirin", "was", "prescribed", "in", "37", "%", ".", "Cytoprotection", "was", "being", "used", "in", "38", "%", "and", "did", "not", "increase", "appreciably", "in", "patients", "with", "additional", "risk", "factors", "for", "GI", "toxicity", ",", "i.e", ".", ",", "concomitant", "aspirin", "usage", "(", "35", "%", ")", ",", "and", "history", "of", "GI", "toxicity", "(", "48", "%", ")", ".", "Sixty", "-", "seven", "were", "taking", "anti", "-", "hypertensive", "medications", ",", "although", "more", "than", "two", "thirds", "of", "these", "patients", "were", "uncontrolled", ".", "Newly", "diagnosed", "hypertension", "was", "present", "in", "19.6", "%", ".", "Calculated", "creatinine", "clearance", "revealed", "moderate", "to", "severe", "renal", "impairment", "in", "79", "%", "of", "subjects", ",", "although", "serum", "creatinine", "was", "only", "elevated", "in", "18", "%", ".", "In", "total", ",", "70", "%", "of", "subjects", "were", "found", "to", "have", "relative", "or", "absolute", "risk", "factors", "for", "NSAID", "therapy", ".", "Given", "the", "high", "prevalence", "of", "potential", "contraindications", "to", "anti", "-", "inflammatory", "drug", "usage", "in", "this", "study", ",", "we", "advocate", "the", "dissemination", "and", "application", "of", "these", "guidelines", "in", "geriatric", "patients", "in", "an", "attempt", "to", "reduce", "potential", "morbidity", "and", "mortality", "." ]

[ "ADVERSE" ]

methotrexate is an intervention, progression of muscle weakness is an outcome, serum creatine kinase activity is an outcome

1434_task0

Sentence: We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome

[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]

We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity .

[ "We", "conclude", "that", "oral", "methotrexate", "did", "not", "slow", "down", "progression", "of", "muscle", "weakness", "but", "decreased", "serum", "creatine", "kinase", "activity", "." ]

[ "outcome", "intervention" ]

methotrexate is an intervention, progression of muscle weakness is an outcome, serum creatine kinase activity is an outcome

1434_task1

Sentence: We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity . Instructions: please typing these entity words according to sentence: methotrexate, progression of muscle weakness, serum creatine kinase activity Options: intervention, outcome

[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]

We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity .

[ "We", "conclude", "that", "oral", "methotrexate", "did", "not", "slow", "down", "progression", "of", "muscle", "weakness", "but", "decreased", "serum", "creatine", "kinase", "activity", "." ]

[ "outcome", "intervention" ]

methotrexate, progression of muscle weakness, serum creatine kinase activity

1434_task2

Sentence: We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]

We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity .

[ "We", "conclude", "that", "oral", "methotrexate", "did", "not", "slow", "down", "progression", "of", "muscle", "weakness", "but", "decreased", "serum", "creatine", "kinase", "activity", "." ]

[ "outcome", "intervention" ]

microsomal triglyceride transfer protein is a gene, manganese superoxide dismutase is a gene

73_task0

Sentence: Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: gene

[ "O", "O", "O", "B-gene", "I-gene", "I-gene", "I-gene", "O", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O" ]

Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.

[ "Polymorphisms", "of", " ", "microsomal", "triglyceride", "transfer", "protein", " ", "gene", "and", " ", "manganese", "superoxide", "dismutase", " ", "gene", "in", "non", "-", "alcoholic", "steatohepatitis", "." ]

[ "gene", "variant" ]

microsomal triglyceride transfer protein is a gene, manganese superoxide dismutase is a gene

73_task1

Sentence: Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. Instructions: please typing these entity words according to sentence: microsomal triglyceride transfer protein, manganese superoxide dismutase Options: gene

[ "O", "O", "O", "B-gene", "I-gene", "I-gene", "I-gene", "O", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O" ]

Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.

[ "Polymorphisms", "of", " ", "microsomal", "triglyceride", "transfer", "protein", " ", "gene", "and", " ", "manganese", "superoxide", "dismutase", " ", "gene", "in", "non", "-", "alcoholic", "steatohepatitis", "." ]

[ "gene", "variant" ]

microsomal triglyceride transfer protein, manganese superoxide dismutase

73_task2

Sentence: Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-gene", "I-gene", "I-gene", "I-gene", "O", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O" ]

Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.

[ "Polymorphisms", "of", " ", "microsomal", "triglyceride", "transfer", "protein", " ", "gene", "and", " ", "manganese", "superoxide", "dismutase", " ", "gene", "in", "non", "-", "alcoholic", "steatohepatitis", "." ]

[ "gene", "variant" ]

BRLF1 is a Protein, BZLF1 is a Protein, BZLF1 is a Protein, BRLF1 is a Protein

8799177_task0

Sentence: Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific.

[ "Epstein", "-", "Barr", "viral", "latency", "is", "disrupted", "by", "the", "immediate", "-", "early", "BRLF1", "protein", "through", "a", "cell", "-", "specific", "mechanism", ".", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ",", "the", "causative", "agent", "of", "infectious", "mononucleosis", ",", "is", "a", "human", "herpesvirus", "associated", "with", "epithelial", "cell", "malignancies", "(", "nasopharyngeal", "carcinoma", ")", "as", "well", "as", "B", "-", "cell", "malignancies", ".", "Understanding", "how", "viral", "latency", "is", "disrupted", "is", "a", "central", "issue", "in", "herpesvirus", "biology", ".", "Epithelial", "cells", "are", "the", "major", "site", "of", "lytic", "EBV", "replication", "within", "the", "human", "host", ",", "and", "viral", "reactivation", "occurs", "in", "EBV", "-", "associated", "nasopharyngeal", "carcinomas", ".", "It", "is", "known", "that", "expression", "of", "a", "single", "viral", "immediate", "-", "early", "protein", ",", "BZLF1", ",", "is", "sufficient", "to", "initiate", "the", "switch", "from", "latent", "to", "lytic", "infection", "in", "B", "cells", ".", "Cellular", "regulation", "of", "BZLF1", "transcription", "is", "therefore", "thought", "to", "play", "a", "key", "role", "in", "regulating", "the", "stringency", "of", "viral", "latency", ".", "Here", "we", "show", "that", ",", "unexpectedly", ",", "expression", "of", "another", "viral", "immediate", "-", "early", "protein", ",", "BRLF1", ",", "can", "disrupt", "viral", "latency", "in", "an", "epithelial", "cell", "-", "specific", "fashion", ".", "Therefore", ",", "the", "mechanisms", "leading", "to", "disruption", "of", "EBV", "latency", "appear", "to", "be", "cell", "-", "type", "specific", "." ]

[ "Protein" ]

BRLF1 is a Protein, BZLF1 is a Protein, BZLF1 is a Protein, BRLF1 is a Protein

8799177_task1

Sentence: Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific. Instructions: please typing these entity words according to sentence: BRLF1, BZLF1, BZLF1, BRLF1 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific.

[ "Epstein", "-", "Barr", "viral", "latency", "is", "disrupted", "by", "the", "immediate", "-", "early", "BRLF1", "protein", "through", "a", "cell", "-", "specific", "mechanism", ".", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ",", "the", "causative", "agent", "of", "infectious", "mononucleosis", ",", "is", "a", "human", "herpesvirus", "associated", "with", "epithelial", "cell", "malignancies", "(", "nasopharyngeal", "carcinoma", ")", "as", "well", "as", "B", "-", "cell", "malignancies", ".", "Understanding", "how", "viral", "latency", "is", "disrupted", "is", "a", "central", "issue", "in", "herpesvirus", "biology", ".", "Epithelial", "cells", "are", "the", "major", "site", "of", "lytic", "EBV", "replication", "within", "the", "human", "host", ",", "and", "viral", "reactivation", "occurs", "in", "EBV", "-", "associated", "nasopharyngeal", "carcinomas", ".", "It", "is", "known", "that", "expression", "of", "a", "single", "viral", "immediate", "-", "early", "protein", ",", "BZLF1", ",", "is", "sufficient", "to", "initiate", "the", "switch", "from", "latent", "to", "lytic", "infection", "in", "B", "cells", ".", "Cellular", "regulation", "of", "BZLF1", "transcription", "is", "therefore", "thought", "to", "play", "a", "key", "role", "in", "regulating", "the", "stringency", "of", "viral", "latency", ".", "Here", "we", "show", "that", ",", "unexpectedly", ",", "expression", "of", "another", "viral", "immediate", "-", "early", "protein", ",", "BRLF1", ",", "can", "disrupt", "viral", "latency", "in", "an", "epithelial", "cell", "-", "specific", "fashion", ".", "Therefore", ",", "the", "mechanisms", "leading", "to", "disruption", "of", "EBV", "latency", "appear", "to", "be", "cell", "-", "type", "specific", "." ]

[ "Protein" ]

BRLF1, BZLF1, BZLF1, BRLF1

8799177_task2

Sentence: Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, is a human herpesvirus associated with epithelial cell malignancies (nasopharyngeal carcinoma) as well as B-cell malignancies. Understanding how viral latency is disrupted is a central issue in herpesvirus biology. Epithelial cells are the major site of lytic EBV replication within the human host, and viral reactivation occurs in EBV-associated nasopharyngeal carcinomas. It is known that expression of a single viral immediate-early protein, BZLF1, is sufficient to initiate the switch from latent to lytic infection in B cells. Cellular regulation of BZLF1 transcription is therefore thought to play a key role in regulating the stringency of viral latency. Here we show that, unexpectedly, expression of another viral immediate-early protein, BRLF1, can disrupt viral latency in an epithelial cell-specific fashion. Therefore, the mechanisms leading to disruption of EBV latency appear to be cell-type specific.

[ "Epstein", "-", "Barr", "viral", "latency", "is", "disrupted", "by", "the", "immediate", "-", "early", "BRLF1", "protein", "through", "a", "cell", "-", "specific", "mechanism", ".", "\n", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", ",", "the", "causative", "agent", "of", "infectious", "mononucleosis", ",", "is", "a", "human", "herpesvirus", "associated", "with", "epithelial", "cell", "malignancies", "(", "nasopharyngeal", "carcinoma", ")", "as", "well", "as", "B", "-", "cell", "malignancies", ".", "Understanding", "how", "viral", "latency", "is", "disrupted", "is", "a", "central", "issue", "in", "herpesvirus", "biology", ".", "Epithelial", "cells", "are", "the", "major", "site", "of", "lytic", "EBV", "replication", "within", "the", "human", "host", ",", "and", "viral", "reactivation", "occurs", "in", "EBV", "-", "associated", "nasopharyngeal", "carcinomas", ".", "It", "is", "known", "that", "expression", "of", "a", "single", "viral", "immediate", "-", "early", "protein", ",", "BZLF1", ",", "is", "sufficient", "to", "initiate", "the", "switch", "from", "latent", "to", "lytic", "infection", "in", "B", "cells", ".", "Cellular", "regulation", "of", "BZLF1", "transcription", "is", "therefore", "thought", "to", "play", "a", "key", "role", "in", "regulating", "the", "stringency", "of", "viral", "latency", ".", "Here", "we", "show", "that", ",", "unexpectedly", ",", "expression", "of", "another", "viral", "immediate", "-", "early", "protein", ",", "BRLF1", ",", "can", "disrupt", "viral", "latency", "in", "an", "epithelial", "cell", "-", "specific", "fashion", ".", "Therefore", ",", "the", "mechanisms", "leading", "to", "disruption", "of", "EBV", "latency", "appear", "to", "be", "cell", "-", "type", "specific", "." ]

[ "Protein" ]

Abstract is an umlsterm, birth is an umlsterm, anomalies is an umlsterm, family is an umlsterm, history is an umlsterm, disorder is an umlsterm, Physical examination is an umlsterm, toe is an umlsterm, toe is an umlsterm, toe is an umlsterm, syndactylia is an umlsterm, fingers is an umlsterm, congenital is an umlsterm

DerHautarzt.50460053.eng.abstr_task0

Sentence: Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported .

[ "Abstract", ".", "A", "1-year", "-", "old", "girl", "shows", "changes", "of", "the", "toenails", "since", "birth", ".", "There", "are", "no", "associated", "anomalies", "typical", "for", "genodermatoses", ",", "nor", "is", "there", "a", "family", "history", "of", "this", "disorder", ".", "Physical", "examination", "shows", "missing", "or", "incomplete", "toenails", ".", "In", "addition", "a", "shortening", "of", "the", "second", "toe", "on", "both", "sides", "and", "the", "third", "toe", "on", "the", "left", "side", "is", "found", ".", "The", "second", "and", "third", "toe", "on", "the", "left", "side", "shows", "incomplete", "syndactylia", ".", "The", "fingers", "and", "fingernails", "are", "all", "normal", ".", "Isolated", "congenital", "onychodysplasia", "of", "the", "toenails", "has", "not", "been", "previously", "reported", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, birth is an umlsterm, anomalies is an umlsterm, family is an umlsterm, history is an umlsterm, disorder is an umlsterm, Physical examination is an umlsterm, toe is an umlsterm, toe is an umlsterm, toe is an umlsterm, syndactylia is an umlsterm, fingers is an umlsterm, congenital is an umlsterm

DerHautarzt.50460053.eng.abstr_task1

Sentence: Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported . Instructions: please typing these entity words according to sentence: Abstract, birth, anomalies, family, history, disorder, Physical examination, toe, toe, toe, syndactylia, fingers, congenital Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported .

[ "Abstract", ".", "A", "1-year", "-", "old", "girl", "shows", "changes", "of", "the", "toenails", "since", "birth", ".", "There", "are", "no", "associated", "anomalies", "typical", "for", "genodermatoses", ",", "nor", "is", "there", "a", "family", "history", "of", "this", "disorder", ".", "Physical", "examination", "shows", "missing", "or", "incomplete", "toenails", ".", "In", "addition", "a", "shortening", "of", "the", "second", "toe", "on", "both", "sides", "and", "the", "third", "toe", "on", "the", "left", "side", "is", "found", ".", "The", "second", "and", "third", "toe", "on", "the", "left", "side", "shows", "incomplete", "syndactylia", ".", "The", "fingers", "and", "fingernails", "are", "all", "normal", ".", "Isolated", "congenital", "onychodysplasia", "of", "the", "toenails", "has", "not", "been", "previously", "reported", "." ]

[ "umlsterm" ]

Abstract, birth, anomalies, family, history, disorder, Physical examination, toe, toe, toe, syndactylia, fingers, congenital

DerHautarzt.50460053.eng.abstr_task2

Sentence: Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Abstract . A 1-year-old girl shows changes of the toenails since birth . There are no associated anomalies typical for genodermatoses , nor is there a family history of this disorder . Physical examination shows missing or incomplete toenails . In addition a shortening of the second toe on both sides and the third toe on the left side is found . The second and third toe on the left side shows incomplete syndactylia . The fingers and fingernails are all normal . Isolated congenital onychodysplasia of the toenails has not been previously reported .

[ "Abstract", ".", "A", "1-year", "-", "old", "girl", "shows", "changes", "of", "the", "toenails", "since", "birth", ".", "There", "are", "no", "associated", "anomalies", "typical", "for", "genodermatoses", ",", "nor", "is", "there", "a", "family", "history", "of", "this", "disorder", ".", "Physical", "examination", "shows", "missing", "or", "incomplete", "toenails", ".", "In", "addition", "a", "shortening", "of", "the", "second", "toe", "on", "both", "sides", "and", "the", "third", "toe", "on", "the", "left", "side", "is", "found", ".", "The", "second", "and", "third", "toe", "on", "the", "left", "side", "shows", "incomplete", "syndactylia", ".", "The", "fingers", "and", "fingernails", "are", "all", "normal", ".", "Isolated", "congenital", "onychodysplasia", "of", "the", "toenails", "has", "not", "been", "previously", "reported", "." ]

[ "umlsterm" ]

Children is an umlsterm, risk is an umlsterm, adults is an umlsterm, infection is an umlsterm, prophylaxis is an umlsterm, bacterial infections is an umlsterm, paper is an umlsterm, preventive measures is an umlsterm, children is an umlsterm, education is an umlsterm, patient is an umlsterm, parents is an umlsterm, Vaccinations is an umlsterm, Streptococcus pneumoniae is an umlsterm, Hemophilus influenzae is an umlsterm, Neisseria meningitidis is an umlsterm, antibiotic prophylaxis is an umlsterm, children is an umlsterm, vaccine is an umlsterm, development is an umlsterm, antibiotic resistance is an umlsterm

DerChirurg.70680591.eng.abstr_task0

Sentence: Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed .

[ "Children", "are", "exposed", "to", "a", "greater", "risk", "than", "adults", "for", "severe", "late", "postsplenectomy", "infection", ".", "Therefore", ",", "prophylaxis", "against", "bacterial", "infections", "need", "to", "be", "more", "extensive", ".", "This", "paper", "presents", "a", "protocol", "for", "preventive", "measures", "in", "children", ".", "Repeated", "education", "of", "the", "patient", "and", "his", "/", "her", "parents", "about", "the", "consequences", "of", "splenic", "loss", "is", "mandatory", ".", "Vaccinations", "against", "Streptococcus", "pneumoniae", "and", "Hemophilus", "influenzae", "are", "highly", "recommended", "and", "also", "against", "Neisseria", "meningitidis", "in", "certain", "situations", ".", "The", "importance", "of", "long", "-", "term", "antibiotic", "prophylaxis", "in", "children", "is", "emphasized", ".", "Recent", "advances", "in", "vaccine", "development", "and", "the", "increasing", "problems", "with", "antibiotic", "resistance", "are", "discussed", "." ]

[ "umlsterm" ]

Children is an umlsterm, risk is an umlsterm, adults is an umlsterm, infection is an umlsterm, prophylaxis is an umlsterm, bacterial infections is an umlsterm, paper is an umlsterm, preventive measures is an umlsterm, children is an umlsterm, education is an umlsterm, patient is an umlsterm, parents is an umlsterm, Vaccinations is an umlsterm, Streptococcus pneumoniae is an umlsterm, Hemophilus influenzae is an umlsterm, Neisseria meningitidis is an umlsterm, antibiotic prophylaxis is an umlsterm, children is an umlsterm, vaccine is an umlsterm, development is an umlsterm, antibiotic resistance is an umlsterm

DerChirurg.70680591.eng.abstr_task1

Sentence: Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed . Instructions: please typing these entity words according to sentence: Children, risk, adults, infection, prophylaxis, bacterial infections, paper, preventive measures, children, education, patient, parents, Vaccinations, Streptococcus pneumoniae, Hemophilus influenzae, Neisseria meningitidis, antibiotic prophylaxis, children, vaccine, development, antibiotic resistance Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed .

[ "Children", "are", "exposed", "to", "a", "greater", "risk", "than", "adults", "for", "severe", "late", "postsplenectomy", "infection", ".", "Therefore", ",", "prophylaxis", "against", "bacterial", "infections", "need", "to", "be", "more", "extensive", ".", "This", "paper", "presents", "a", "protocol", "for", "preventive", "measures", "in", "children", ".", "Repeated", "education", "of", "the", "patient", "and", "his", "/", "her", "parents", "about", "the", "consequences", "of", "splenic", "loss", "is", "mandatory", ".", "Vaccinations", "against", "Streptococcus", "pneumoniae", "and", "Hemophilus", "influenzae", "are", "highly", "recommended", "and", "also", "against", "Neisseria", "meningitidis", "in", "certain", "situations", ".", "The", "importance", "of", "long", "-", "term", "antibiotic", "prophylaxis", "in", "children", "is", "emphasized", ".", "Recent", "advances", "in", "vaccine", "development", "and", "the", "increasing", "problems", "with", "antibiotic", "resistance", "are", "discussed", "." ]

[ "umlsterm" ]

Children, risk, adults, infection, prophylaxis, bacterial infections, paper, preventive measures, children, education, patient, parents, Vaccinations, Streptococcus pneumoniae, Hemophilus influenzae, Neisseria meningitidis, antibiotic prophylaxis, children, vaccine, development, antibiotic resistance

DerChirurg.70680591.eng.abstr_task2

Sentence: Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

Children are exposed to a greater risk than adults for severe late postsplenectomy infection . Therefore , prophylaxis against bacterial infections need to be more extensive . This paper presents a protocol for preventive measures in children . Repeated education of the patient and his/her parents about the consequences of splenic loss is mandatory . Vaccinations against Streptococcus pneumoniae and Hemophilus influenzae are highly recommended and also against Neisseria meningitidis in certain situations . The importance of long-term antibiotic prophylaxis in children is emphasized . Recent advances in vaccine development and the increasing problems with antibiotic resistance are discussed .

[ "Children", "are", "exposed", "to", "a", "greater", "risk", "than", "adults", "for", "severe", "late", "postsplenectomy", "infection", ".", "Therefore", ",", "prophylaxis", "against", "bacterial", "infections", "need", "to", "be", "more", "extensive", ".", "This", "paper", "presents", "a", "protocol", "for", "preventive", "measures", "in", "children", ".", "Repeated", "education", "of", "the", "patient", "and", "his", "/", "her", "parents", "about", "the", "consequences", "of", "splenic", "loss", "is", "mandatory", ".", "Vaccinations", "against", "Streptococcus", "pneumoniae", "and", "Hemophilus", "influenzae", "are", "highly", "recommended", "and", "also", "against", "Neisseria", "meningitidis", "in", "certain", "situations", ".", "The", "importance", "of", "long", "-", "term", "antibiotic", "prophylaxis", "in", "children", "is", "emphasized", ".", "Recent", "advances", "in", "vaccine", "development", "and", "the", "increasing", "problems", "with", "antibiotic", "resistance", "are", "discussed", "." ]

[ "umlsterm" ]

SP-1 is a Protein, site is a Entity, interleukin-1 beta is a Protein, promoter is a Entity, interleukin-1beta is a Protein, IL-1beta is a Protein, IL-1beta is a Protein, promoter is a Entity, promoter segment is a Entity, 43-mer oligonucleotide is a Entity, cis - acting element is a Entity, transcription factor consensus sequence oligonucleotides is a Entity, SP-1 is a Protein, regulatory element is a Entity, SP-1 is a Protein, consensus sequence is a Entity, TCCCCTCCCCT motif is a Entity, low - mobility complexes is a Entity, IL-1beta is a Protein, tumor necrosis factor - alpha is a Protein, SP-1 is a Protein, site is a Entity, SP-1 is a Protein, site is a Entity, IL-1beta is a Protein, promoter is a Entity

188_task0

Sentence: A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes.

[ "A", "novel", "SP-1", "site", "in", "the", "human", "interleukin-1", "beta", "promoter", "confers", "preferential", "transcriptional", "activity", "in", "keratinocytes", ".", "\n", "To", "investigate", "the", "mechanisms", "of", "transcriptional", "activation", "of", "interleukin-1beta", "(", "IL-1beta", ")", "in", "non", "-", "monocytic", "cells", ",", "we", "constructed", "a", "series", "of", "reporter", "plasmids", "with", "the", "bacterial", "chloramphenicol", "acetyltransferase", "gene", "linked", "to", "various", "parts", "of", "the", "human", "IL-1beta", "promoter", "and", "performed", "transient", "transfection", "experiments", ".", "We", "identified", "a", "promoter", "segment", "that", "activates", "transcription", "most", "efficiently", "in", "keratinocytes", ".", "Electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "with", "a", "43-mer", "oligonucleotide", "derived", "from", "the", "functionally", "identified", "cis", "-", "acting", "element", "revealed", "specific", "complexes", ".", "By", "competition", "analysis", "with", "transcription", "factor", "consensus", "sequence", "oligonucleotides", "and", "by", "immunosupershift", ",", "transcription", "factor", "SP-1", "or", "a", "closely", "related", "protein", "was", "shown", "to", "bind", "to", "this", "regulatory", "element", ".", "The", "closest", "match", "to", "the", "known", "SP-1", "consensus", "sequence", "within", "the", "respective", "region", "is", "a", "TCCCCTCCCCT", "motif", ".", "Mutation", "of", "this", "motif", "almost", "completely", ",", "and", "specifically", ",", "abolished", "the", "binding", "of", "two", "low", "-", "mobility", "complexes", "and", "led", "to", "a", "95", "%", "decrease", "of", "constitutive", "transcriptional", "activation", "of", "a", "reporter", "construct", "IL-1beta", "(", "-170/+108", ")", ".", "Likewise", ",", "activation", "of", "this", "reporter", "construct", "by", "tumor", "necrosis", "factor", "-", "alpha", "depended", "on", "the", "SP-1", "site", ".", "These", "observations", "suggest", "that", "a", "so", "-", "far", "-", "unrecognized", "SP-1", "site", "in", "the", "human", "IL-1beta", "promoter", "may", "participate", "in", "the", "transcriptional", "regulation", "of", "this", "gene", "in", "keratinocytes", ".", "\n" ]

[ "Entity", "Protein" ]

SP-1 is a Protein, site is a Entity, interleukin-1 beta is a Protein, promoter is a Entity, interleukin-1beta is a Protein, IL-1beta is a Protein, IL-1beta is a Protein, promoter is a Entity, promoter segment is a Entity, 43-mer oligonucleotide is a Entity, cis - acting element is a Entity, transcription factor consensus sequence oligonucleotides is a Entity, SP-1 is a Protein, regulatory element is a Entity, SP-1 is a Protein, consensus sequence is a Entity, TCCCCTCCCCT motif is a Entity, low - mobility complexes is a Entity, IL-1beta is a Protein, tumor necrosis factor - alpha is a Protein, SP-1 is a Protein, site is a Entity, SP-1 is a Protein, site is a Entity, IL-1beta is a Protein, promoter is a Entity

188_task1

Sentence: A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes. Instructions: please typing these entity words according to sentence: SP-1, site, interleukin-1 beta, promoter, interleukin-1beta, IL-1beta, IL-1beta, promoter, promoter segment, 43-mer oligonucleotide, cis - acting element, transcription factor consensus sequence oligonucleotides, SP-1, regulatory element, SP-1, consensus sequence, TCCCCTCCCCT motif, low - mobility complexes, IL-1beta, tumor necrosis factor - alpha, SP-1, site, SP-1, site, IL-1beta, promoter Options: Entity, Protein

[ "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes.

[ "A", "novel", "SP-1", "site", "in", "the", "human", "interleukin-1", "beta", "promoter", "confers", "preferential", "transcriptional", "activity", "in", "keratinocytes", ".", "\n", "To", "investigate", "the", "mechanisms", "of", "transcriptional", "activation", "of", "interleukin-1beta", "(", "IL-1beta", ")", "in", "non", "-", "monocytic", "cells", ",", "we", "constructed", "a", "series", "of", "reporter", "plasmids", "with", "the", "bacterial", "chloramphenicol", "acetyltransferase", "gene", "linked", "to", "various", "parts", "of", "the", "human", "IL-1beta", "promoter", "and", "performed", "transient", "transfection", "experiments", ".", "We", "identified", "a", "promoter", "segment", "that", "activates", "transcription", "most", "efficiently", "in", "keratinocytes", ".", "Electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "with", "a", "43-mer", "oligonucleotide", "derived", "from", "the", "functionally", "identified", "cis", "-", "acting", "element", "revealed", "specific", "complexes", ".", "By", "competition", "analysis", "with", "transcription", "factor", "consensus", "sequence", "oligonucleotides", "and", "by", "immunosupershift", ",", "transcription", "factor", "SP-1", "or", "a", "closely", "related", "protein", "was", "shown", "to", "bind", "to", "this", "regulatory", "element", ".", "The", "closest", "match", "to", "the", "known", "SP-1", "consensus", "sequence", "within", "the", "respective", "region", "is", "a", "TCCCCTCCCCT", "motif", ".", "Mutation", "of", "this", "motif", "almost", "completely", ",", "and", "specifically", ",", "abolished", "the", "binding", "of", "two", "low", "-", "mobility", "complexes", "and", "led", "to", "a", "95", "%", "decrease", "of", "constitutive", "transcriptional", "activation", "of", "a", "reporter", "construct", "IL-1beta", "(", "-170/+108", ")", ".", "Likewise", ",", "activation", "of", "this", "reporter", "construct", "by", "tumor", "necrosis", "factor", "-", "alpha", "depended", "on", "the", "SP-1", "site", ".", "These", "observations", "suggest", "that", "a", "so", "-", "far", "-", "unrecognized", "SP-1", "site", "in", "the", "human", "IL-1beta", "promoter", "may", "participate", "in", "the", "transcriptional", "regulation", "of", "this", "gene", "in", "keratinocytes", ".", "\n" ]

[ "Entity", "Protein" ]

SP-1, site, interleukin-1 beta, promoter, interleukin-1beta, IL-1beta, IL-1beta, promoter, promoter segment, 43-mer oligonucleotide, cis - acting element, transcription factor consensus sequence oligonucleotides, SP-1, regulatory element, SP-1, consensus sequence, TCCCCTCCCCT motif, low - mobility complexes, IL-1beta, tumor necrosis factor - alpha, SP-1, site, SP-1, site, IL-1beta, promoter

188_task2

Sentence: A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel SP-1 site in the human interleukin-1 beta promoter confers preferential transcriptional activity in keratinocytes. To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments. We identified a promoter segment that activates transcription most efficiently in keratinocytes. Electrophoretic mobility shift assays (EMSA) with a 43-mer oligonucleotide derived from the functionally identified cis-acting element revealed specific complexes. By competition analysis with transcription factor consensus sequence oligonucleotides and by immunosupershift, transcription factor SP-1 or a closely related protein was shown to bind to this regulatory element. The closest match to the known SP-1 consensus sequence within the respective region is a TCCCCTCCCCT motif. Mutation of this motif almost completely, and specifically, abolished the binding of two low-mobility complexes and led to a 95% decrease of constitutive transcriptional activation of a reporter construct IL-1beta (-170/+108). Likewise, activation of this reporter construct by tumor necrosis factor-alpha depended on the SP-1 site. These observations suggest that a so-far-unrecognized SP-1 site in the human IL-1beta promoter may participate in the transcriptional regulation of this gene in keratinocytes.

[ "A", "novel", "SP-1", "site", "in", "the", "human", "interleukin-1", "beta", "promoter", "confers", "preferential", "transcriptional", "activity", "in", "keratinocytes", ".", "\n", "To", "investigate", "the", "mechanisms", "of", "transcriptional", "activation", "of", "interleukin-1beta", "(", "IL-1beta", ")", "in", "non", "-", "monocytic", "cells", ",", "we", "constructed", "a", "series", "of", "reporter", "plasmids", "with", "the", "bacterial", "chloramphenicol", "acetyltransferase", "gene", "linked", "to", "various", "parts", "of", "the", "human", "IL-1beta", "promoter", "and", "performed", "transient", "transfection", "experiments", ".", "We", "identified", "a", "promoter", "segment", "that", "activates", "transcription", "most", "efficiently", "in", "keratinocytes", ".", "Electrophoretic", "mobility", "shift", "assays", "(", "EMSA", ")", "with", "a", "43-mer", "oligonucleotide", "derived", "from", "the", "functionally", "identified", "cis", "-", "acting", "element", "revealed", "specific", "complexes", ".", "By", "competition", "analysis", "with", "transcription", "factor", "consensus", "sequence", "oligonucleotides", "and", "by", "immunosupershift", ",", "transcription", "factor", "SP-1", "or", "a", "closely", "related", "protein", "was", "shown", "to", "bind", "to", "this", "regulatory", "element", ".", "The", "closest", "match", "to", "the", "known", "SP-1", "consensus", "sequence", "within", "the", "respective", "region", "is", "a", "TCCCCTCCCCT", "motif", ".", "Mutation", "of", "this", "motif", "almost", "completely", ",", "and", "specifically", ",", "abolished", "the", "binding", "of", "two", "low", "-", "mobility", "complexes", "and", "led", "to", "a", "95", "%", "decrease", "of", "constitutive", "transcriptional", "activation", "of", "a", "reporter", "construct", "IL-1beta", "(", "-170/+108", ")", ".", "Likewise", ",", "activation", "of", "this", "reporter", "construct", "by", "tumor", "necrosis", "factor", "-", "alpha", "depended", "on", "the", "SP-1", "site", ".", "These", "observations", "suggest", "that", "a", "so", "-", "far", "-", "unrecognized", "SP-1", "site", "in", "the", "human", "IL-1beta", "promoter", "may", "participate", "in", "the", "transcriptional", "regulation", "of", "this", "gene", "in", "keratinocytes", ".", "\n" ]

[ "Entity", "Protein" ]

profilin is a Individual_protein, actin is a Individual_protein

648_task0

Sentence: Structural studies on the ribbon-to-helix transition in profilin: actin crystals. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O" ]

Structural studies on the ribbon-to-helix transition in profilin: actin crystals.

[ "Structural", "studies", "on", "the", "ribbon", "-", "to", "-", "helix", "transition", "in", "profilin", ":", "actin", "crystals", "." ]

[ "Individual_protein" ]

profilin is a Individual_protein, actin is a Individual_protein

648_task1

Sentence: Structural studies on the ribbon-to-helix transition in profilin: actin crystals. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O" ]

Structural studies on the ribbon-to-helix transition in profilin: actin crystals.

[ "Structural", "studies", "on", "the", "ribbon", "-", "to", "-", "helix", "transition", "in", "profilin", ":", "actin", "crystals", "." ]

[ "Individual_protein" ]

profilin, actin

648_task2

Sentence: Structural studies on the ribbon-to-helix transition in profilin: actin crystals. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O" ]

Structural studies on the ribbon-to-helix transition in profilin: actin crystals.

[ "Structural", "studies", "on", "the", "ribbon", "-", "to", "-", "helix", "transition", "in", "profilin", ":", "actin", "crystals", "." ]

[ "Individual_protein" ]

LAD - stent is an umlsterm, cardiopulmonary resuscitation is an umlsterm, CPR is an umlsterm, stent is an umlsterm, implantation is an umlsterm, knowledge is an umlsterm

ZfuerKardiologie.90880296.eng.abstr_task0

Sentence: We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case .

[ "We", "report", "a", "case", "of", "LAD", "-", "stent", "deformation", "by", "extracorporeal", "cardiopulmonary", "resuscitation", "(", "CPR", ")", "shortly", "after", "stent", "implantation", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "." ]

[ "umlsterm" ]

LAD - stent is an umlsterm, cardiopulmonary resuscitation is an umlsterm, CPR is an umlsterm, stent is an umlsterm, implantation is an umlsterm, knowledge is an umlsterm

ZfuerKardiologie.90880296.eng.abstr_task1

Sentence: We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case . Instructions: please typing these entity words according to sentence: LAD - stent, cardiopulmonary resuscitation, CPR, stent, implantation, knowledge Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case .

[ "We", "report", "a", "case", "of", "LAD", "-", "stent", "deformation", "by", "extracorporeal", "cardiopulmonary", "resuscitation", "(", "CPR", ")", "shortly", "after", "stent", "implantation", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "." ]

[ "umlsterm" ]

LAD - stent, cardiopulmonary resuscitation, CPR, stent, implantation, knowledge

ZfuerKardiologie.90880296.eng.abstr_task2

Sentence: We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

We report a case of LAD-stent deformation by extracorporeal cardiopulmonary resuscitation ( CPR ) shortly after stent implantation . To our knowledge , this is the first reported case .

[ "We", "report", "a", "case", "of", "LAD", "-", "stent", "deformation", "by", "extracorporeal", "cardiopulmonary", "resuscitation", "(", "CPR", ")", "shortly", "after", "stent", "implantation", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "." ]

[ "umlsterm" ]

Behandlung is an umlsterm, Verwendung is an umlsterm, Techniken is an umlsterm, Leichenstudie is an umlsterm, Methodik is an umlsterm, Rohrprothese is an umlsterm, Stent is an umlsterm, Leichenextremitaeten is an umlsterm, Extremitaeten is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Patienten is an umlsterm, Leichenstudie is an umlsterm, Methode is an umlsterm, Patienten is an umlsterm

Gefaesschirurgie.90040194.ger.abstr_task0

Sentence: Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen .

[ "Fragestellung", ":", "Die", "Implantation", "eines", "femoropoplitealen", "Bypasses", "stellt", "heute", "den", "Goldstandard", "zur", "Behandlung", "der", "AVK", "bei", "Verschlussprozessen", "im", "femoropoplitealen", "Bereich", "dar", ".", "Durch", "Verwendung", "interventioneller", "Techniken", "konnte", "ein", "endovasculaer", "implantierbares", "Bypassystem", "entwickelt", "werden", ".", "Im", "Rahmen", "einer", "Leichenstudie", "wurde", "die", "technische", "Funktionsfaehigkeit", "des", "neuen", "Systems", "erprobt", "und", "danach", "die", "Evaluation", "in", "der", "humanen", "Anwendung", "begonnen", ".", "Methodik", ":", "Der", "Endopass", "besteht", "aus", "einer", "53", "cm", "langen", ",", "duennwandigen", "Rohrprothese", "aus", "Polycarbourethan", ".", "Das", "distale", "Ende", "ist", "auf", "eine", "Laenge", "von", "4", "cm", "mit", "einem", "selbstexpandierenden", "Stent", "armiert", ".", "Die", "Implantation", "erfolgt", "ueber", "eine", "Leisteninzision", ".", "Nach", "antegrader", "Ringsonden", "-", "TEA", "wird", "der", "Endopass", "ueber", "einem", "Fuehrungsdraht", "in", "der", "A.", "femoralis", "superficialis", "plaziert", ".", "Die", "proximale", "Anastomose", "erfolgt", "chirurgisch", ".", "Ergebnisse", ":", "Die", "technische", "Durchfuehrbarkeit", "und", "Funktionsfaehigkeit", "wurde", "an", "12", "Leichenextremitaeten", "erprobt", ".", "Bei", "8", "Extremitaeten", "mit", "Verschluessen", "der", "A.", "femoralis", "superficialis", "konnte", "das", "Verfahren", "in", "7", "Faellen", "technisch", "durchgefuehrt", "werden", ".", "Entscheidende", "Probleme", "sind", "die", "komplette", "Ringsonden", "-", "TEA", ",", "die", "Plazierung", "des", "Fuehrungsdrahts", "nach", "TEA", "und", "die", "Entfaltung", "des", "Endopasses", "aus", "dem", "Introducer", ".", "Nach", "Aenderung", "des", "Equipments", "und", "Freigabe", "der", "Anwendung", "durch", "die", "Ethikkommission", "wurde", "der", "Endopass", "von", "6/97", "bis", "3/98", "bisher", "bei", "5", "Patienten", "angewandt", ".", "Bei", "3", "Patienten", "ist", "der", "Endopass", "offen", "und", "zeigt", "eine", "gute", "Funktion", ".", "Ein", "Patient", "erlitt", "einen", "nicht", "korrigierbaren", "Fruehverschluss", "bei", "schlechter", "Ausstrombahn", "und", "bei", "einem", "Patienten", "musste", "das", "Verfahren", "bei", "Ringsondenperforation", "gewechselt", "werden", ".", "Schlussfolgerungen", ":", "Die", "Erfahrungen", "der", "Leichenstudie", "und", "der", "ersten", "humanen", "Anwendungen", "bestaetigen", "die", "praktische", "Durchfuehrbarkeit", "der", "Methode", ".", "Es", "sind", "jedoch", "weitere", "Entwicklungsarbeit", "und", "methodische", "Verbesserungen", "notwendig", ",", "die", "nur", "durch", "weitere", "Erfahrungen", "am", "Patienten", "gewonnen", "werden", "koennen", "." ]

[ "umlsterm" ]

Behandlung is an umlsterm, Verwendung is an umlsterm, Techniken is an umlsterm, Leichenstudie is an umlsterm, Methodik is an umlsterm, Rohrprothese is an umlsterm, Stent is an umlsterm, Leichenextremitaeten is an umlsterm, Extremitaeten is an umlsterm, Ethikkommission is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Patienten is an umlsterm, Leichenstudie is an umlsterm, Methode is an umlsterm, Patienten is an umlsterm

Gefaesschirurgie.90040194.ger.abstr_task1

Sentence: Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen . Instructions: please typing these entity words according to sentence: Behandlung, Verwendung, Techniken, Leichenstudie, Methodik, Rohrprothese, Stent, Leichenextremitaeten, Extremitaeten, Ethikkommission, Patienten, Patienten, Patient, Patienten, Leichenstudie, Methode, Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen .

[ "Fragestellung", ":", "Die", "Implantation", "eines", "femoropoplitealen", "Bypasses", "stellt", "heute", "den", "Goldstandard", "zur", "Behandlung", "der", "AVK", "bei", "Verschlussprozessen", "im", "femoropoplitealen", "Bereich", "dar", ".", "Durch", "Verwendung", "interventioneller", "Techniken", "konnte", "ein", "endovasculaer", "implantierbares", "Bypassystem", "entwickelt", "werden", ".", "Im", "Rahmen", "einer", "Leichenstudie", "wurde", "die", "technische", "Funktionsfaehigkeit", "des", "neuen", "Systems", "erprobt", "und", "danach", "die", "Evaluation", "in", "der", "humanen", "Anwendung", "begonnen", ".", "Methodik", ":", "Der", "Endopass", "besteht", "aus", "einer", "53", "cm", "langen", ",", "duennwandigen", "Rohrprothese", "aus", "Polycarbourethan", ".", "Das", "distale", "Ende", "ist", "auf", "eine", "Laenge", "von", "4", "cm", "mit", "einem", "selbstexpandierenden", "Stent", "armiert", ".", "Die", "Implantation", "erfolgt", "ueber", "eine", "Leisteninzision", ".", "Nach", "antegrader", "Ringsonden", "-", "TEA", "wird", "der", "Endopass", "ueber", "einem", "Fuehrungsdraht", "in", "der", "A.", "femoralis", "superficialis", "plaziert", ".", "Die", "proximale", "Anastomose", "erfolgt", "chirurgisch", ".", "Ergebnisse", ":", "Die", "technische", "Durchfuehrbarkeit", "und", "Funktionsfaehigkeit", "wurde", "an", "12", "Leichenextremitaeten", "erprobt", ".", "Bei", "8", "Extremitaeten", "mit", "Verschluessen", "der", "A.", "femoralis", "superficialis", "konnte", "das", "Verfahren", "in", "7", "Faellen", "technisch", "durchgefuehrt", "werden", ".", "Entscheidende", "Probleme", "sind", "die", "komplette", "Ringsonden", "-", "TEA", ",", "die", "Plazierung", "des", "Fuehrungsdrahts", "nach", "TEA", "und", "die", "Entfaltung", "des", "Endopasses", "aus", "dem", "Introducer", ".", "Nach", "Aenderung", "des", "Equipments", "und", "Freigabe", "der", "Anwendung", "durch", "die", "Ethikkommission", "wurde", "der", "Endopass", "von", "6/97", "bis", "3/98", "bisher", "bei", "5", "Patienten", "angewandt", ".", "Bei", "3", "Patienten", "ist", "der", "Endopass", "offen", "und", "zeigt", "eine", "gute", "Funktion", ".", "Ein", "Patient", "erlitt", "einen", "nicht", "korrigierbaren", "Fruehverschluss", "bei", "schlechter", "Ausstrombahn", "und", "bei", "einem", "Patienten", "musste", "das", "Verfahren", "bei", "Ringsondenperforation", "gewechselt", "werden", ".", "Schlussfolgerungen", ":", "Die", "Erfahrungen", "der", "Leichenstudie", "und", "der", "ersten", "humanen", "Anwendungen", "bestaetigen", "die", "praktische", "Durchfuehrbarkeit", "der", "Methode", ".", "Es", "sind", "jedoch", "weitere", "Entwicklungsarbeit", "und", "methodische", "Verbesserungen", "notwendig", ",", "die", "nur", "durch", "weitere", "Erfahrungen", "am", "Patienten", "gewonnen", "werden", "koennen", "." ]

[ "umlsterm" ]

Behandlung, Verwendung, Techniken, Leichenstudie, Methodik, Rohrprothese, Stent, Leichenextremitaeten, Extremitaeten, Ethikkommission, Patienten, Patienten, Patient, Patienten, Leichenstudie, Methode, Patienten

Gefaesschirurgie.90040194.ger.abstr_task2

Sentence: Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Fragestellung : Die Implantation eines femoropoplitealen Bypasses stellt heute den Goldstandard zur Behandlung der AVK bei Verschlussprozessen im femoropoplitealen Bereich dar . Durch Verwendung interventioneller Techniken konnte ein endovasculaer implantierbares Bypassystem entwickelt werden . Im Rahmen einer Leichenstudie wurde die technische Funktionsfaehigkeit des neuen Systems erprobt und danach die Evaluation in der humanen Anwendung begonnen . Methodik : Der Endopass besteht aus einer 53 cm langen , duennwandigen Rohrprothese aus Polycarbourethan . Das distale Ende ist auf eine Laenge von 4 cm mit einem selbstexpandierenden Stent armiert . Die Implantation erfolgt ueber eine Leisteninzision . Nach antegrader Ringsonden-TEA wird der Endopass ueber einem Fuehrungsdraht in der A. femoralis superficialis plaziert . Die proximale Anastomose erfolgt chirurgisch . Ergebnisse : Die technische Durchfuehrbarkeit und Funktionsfaehigkeit wurde an 12 Leichenextremitaeten erprobt . Bei 8 Extremitaeten mit Verschluessen der A. femoralis superficialis konnte das Verfahren in 7 Faellen technisch durchgefuehrt werden . Entscheidende Probleme sind die komplette Ringsonden-TEA , die Plazierung des Fuehrungsdrahts nach TEA und die Entfaltung des Endopasses aus dem Introducer . Nach Aenderung des Equipments und Freigabe der Anwendung durch die Ethikkommission wurde der Endopass von 6/97 bis 3/98 bisher bei 5 Patienten angewandt . Bei 3 Patienten ist der Endopass offen und zeigt eine gute Funktion . Ein Patient erlitt einen nicht korrigierbaren Fruehverschluss bei schlechter Ausstrombahn und bei einem Patienten musste das Verfahren bei Ringsondenperforation gewechselt werden . Schlussfolgerungen : Die Erfahrungen der Leichenstudie und der ersten humanen Anwendungen bestaetigen die praktische Durchfuehrbarkeit der Methode . Es sind jedoch weitere Entwicklungsarbeit und methodische Verbesserungen notwendig , die nur durch weitere Erfahrungen am Patienten gewonnen werden koennen .

[ "Fragestellung", ":", "Die", "Implantation", "eines", "femoropoplitealen", "Bypasses", "stellt", "heute", "den", "Goldstandard", "zur", "Behandlung", "der", "AVK", "bei", "Verschlussprozessen", "im", "femoropoplitealen", "Bereich", "dar", ".", "Durch", "Verwendung", "interventioneller", "Techniken", "konnte", "ein", "endovasculaer", "implantierbares", "Bypassystem", "entwickelt", "werden", ".", "Im", "Rahmen", "einer", "Leichenstudie", "wurde", "die", "technische", "Funktionsfaehigkeit", "des", "neuen", "Systems", "erprobt", "und", "danach", "die", "Evaluation", "in", "der", "humanen", "Anwendung", "begonnen", ".", "Methodik", ":", "Der", "Endopass", "besteht", "aus", "einer", "53", "cm", "langen", ",", "duennwandigen", "Rohrprothese", "aus", "Polycarbourethan", ".", "Das", "distale", "Ende", "ist", "auf", "eine", "Laenge", "von", "4", "cm", "mit", "einem", "selbstexpandierenden", "Stent", "armiert", ".", "Die", "Implantation", "erfolgt", "ueber", "eine", "Leisteninzision", ".", "Nach", "antegrader", "Ringsonden", "-", "TEA", "wird", "der", "Endopass", "ueber", "einem", "Fuehrungsdraht", "in", "der", "A.", "femoralis", "superficialis", "plaziert", ".", "Die", "proximale", "Anastomose", "erfolgt", "chirurgisch", ".", "Ergebnisse", ":", "Die", "technische", "Durchfuehrbarkeit", "und", "Funktionsfaehigkeit", "wurde", "an", "12", "Leichenextremitaeten", "erprobt", ".", "Bei", "8", "Extremitaeten", "mit", "Verschluessen", "der", "A.", "femoralis", "superficialis", "konnte", "das", "Verfahren", "in", "7", "Faellen", "technisch", "durchgefuehrt", "werden", ".", "Entscheidende", "Probleme", "sind", "die", "komplette", "Ringsonden", "-", "TEA", ",", "die", "Plazierung", "des", "Fuehrungsdrahts", "nach", "TEA", "und", "die", "Entfaltung", "des", "Endopasses", "aus", "dem", "Introducer", ".", "Nach", "Aenderung", "des", "Equipments", "und", "Freigabe", "der", "Anwendung", "durch", "die", "Ethikkommission", "wurde", "der", "Endopass", "von", "6/97", "bis", "3/98", "bisher", "bei", "5", "Patienten", "angewandt", ".", "Bei", "3", "Patienten", "ist", "der", "Endopass", "offen", "und", "zeigt", "eine", "gute", "Funktion", ".", "Ein", "Patient", "erlitt", "einen", "nicht", "korrigierbaren", "Fruehverschluss", "bei", "schlechter", "Ausstrombahn", "und", "bei", "einem", "Patienten", "musste", "das", "Verfahren", "bei", "Ringsondenperforation", "gewechselt", "werden", ".", "Schlussfolgerungen", ":", "Die", "Erfahrungen", "der", "Leichenstudie", "und", "der", "ersten", "humanen", "Anwendungen", "bestaetigen", "die", "praktische", "Durchfuehrbarkeit", "der", "Methode", ".", "Es", "sind", "jedoch", "weitere", "Entwicklungsarbeit", "und", "methodische", "Verbesserungen", "notwendig", ",", "die", "nur", "durch", "weitere", "Erfahrungen", "am", "Patienten", "gewonnen", "werden", "koennen", "." ]

[ "umlsterm" ]

surgery is an umlsterm, LASIK is an umlsterm, intraocular pressure is an umlsterm, intraocular pressure is an umlsterm, pressure is an umlsterm

DerOpthalmologe.80950137.eng.abstr_task0

Sentence: Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure .

[ "Microkeratome", "systems", "are", "being", "increasingly", "applied", "in", "lamellar", "corneal", "surgery", "(", "e", ".", "g", ".", ",", "LASIK", ")", ".", "The", "results", "of", "the", "few", "studies", "on", "intraocular", "pressure", "changes", "during", "the", "microkeratome", "cut", "vary", "widely", ".", "In", "this", "study", ",", "we", "examined", "the", "intraocular", "pressure", "pattern", "(", "IOP", ")", "in", "relation", "to", "the", "initial", "pressure", "." ]

[ "umlsterm" ]

surgery is an umlsterm, LASIK is an umlsterm, intraocular pressure is an umlsterm, intraocular pressure is an umlsterm, pressure is an umlsterm

DerOpthalmologe.80950137.eng.abstr_task1

Sentence: Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure . Instructions: please typing these entity words according to sentence: surgery, LASIK, intraocular pressure, intraocular pressure, pressure Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure .

[ "Microkeratome", "systems", "are", "being", "increasingly", "applied", "in", "lamellar", "corneal", "surgery", "(", "e", ".", "g", ".", ",", "LASIK", ")", ".", "The", "results", "of", "the", "few", "studies", "on", "intraocular", "pressure", "changes", "during", "the", "microkeratome", "cut", "vary", "widely", ".", "In", "this", "study", ",", "we", "examined", "the", "intraocular", "pressure", "pattern", "(", "IOP", ")", "in", "relation", "to", "the", "initial", "pressure", "." ]

[ "umlsterm" ]

surgery, LASIK, intraocular pressure, intraocular pressure, pressure

DerOpthalmologe.80950137.eng.abstr_task2

Sentence: Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Microkeratome systems are being increasingly applied in lamellar corneal surgery ( e . g . , LASIK ) . The results of the few studies on intraocular pressure changes during the microkeratome cut vary widely . In this study , we examined the intraocular pressure pattern ( IOP ) in relation to the initial pressure .

[ "Microkeratome", "systems", "are", "being", "increasingly", "applied", "in", "lamellar", "corneal", "surgery", "(", "e", ".", "g", ".", ",", "LASIK", ")", ".", "The", "results", "of", "the", "few", "studies", "on", "intraocular", "pressure", "changes", "during", "the", "microkeratome", "cut", "vary", "widely", ".", "In", "this", "study", ",", "we", "examined", "the", "intraocular", "pressure", "pattern", "(", "IOP", ")", "in", "relation", "to", "the", "initial", "pressure", "." ]

[ "umlsterm" ]

Aloe and Placebo is a Intervention_Control, Powder is a Intervention_Pharmacological, Breast Cancer is a Participant_Condition, aloe extract is a Intervention_Pharmacological, moist cream is a Intervention_Pharmacological, dry powder skin care regimen . is a Intervention_Pharmacological, 248 is a Participant_Sample-size, breast cancer is a Participant_Condition, powder , aloe cream is a Intervention_Pharmacological, placebo cream . is a Intervention_Control

69884_task0

Sentence: Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Pharmacological, Intervention_Control, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy .

[ "Three", "-", "Arm", "Randomized", "Phase", "III", "Trial", ":", "Quality", "Aloe", "and", "Placebo", "Cream", "Versus", "Powder", "as", "Skin", "Treatment", "During", "Breast", "Cancer", "Radiation", "Therapy", ".", "BACKGROUND", "The", "efficacy", "of", "aloe", "extract", "in", "reducing", "radiation", "-", "induced", "skin", "injury", "is", "controversial", ".", "The", "purpose", "of", "the", "present", "3-arm", "randomized", "trial", "was", "to", "test", "the", "efficacy", "of", "quality", "-", "tested", "aloe", "extract", "in", "reducing", "the", "severity", "of", "radiation", "-", "induced", "skin", "injury", "and", ",", "secondarily", ",", "to", "examine", "the", "effect", "of", "a", "moist", "cream", "versus", "a", "dry", "powder", "skin", "care", "regimen", ".", "MATERIALS", "AND", "METHODS", "A", "total", "of", "248", "patients", "with", "breast", "cancer", "were", "randomized", "to", "powder", ",", "aloe", "cream", ",", "or", "placebo", "cream", ".", "Acute", "skin", "toxicity", "was", "scored", "weekly", "and", "after", "treatment", "at", "weeks", "1", ",", "2", ",", "and", "4", "using", "a", "modified", "10-point", "Catterall", "scale", ".", "The", "patients", "scored", "their", "symptom", "severity", "using", "a", "6-point", "Likert", "scale", "and", "kept", "an", "acute", "phase", "diary", ".", "RESULTS", "The", "aloe", "formulation", "did", "not", "reduce", "acute", "skin", "toxicity", "or", "symptom", "severity", ".", "Patients", "with", "a", "greater", "body", "mass", "index", "were", "more", "likely", "to", "develop", "acute", "skin", "toxicity", ".", "A", "similar", "pattern", "of", "increased", "skin", "reaction", "toxicity", "occurred", "with", "both", "study", "creams", "compared", "with", "the", "dry", "powder", "regimen", ".", "CONCLUSION", "No", "evidence", "was", "found", "to", "support", "prophylactic", "application", "of", "quality", "aloe", "extract", "or", "cream", "to", "improve", "the", "symptoms", "or", "reduce", "the", "skin", "reaction", "severity", ".", "Our", "results", "support", "a", "dry", "skin", "care", "regimen", "of", "powder", "during", "radiation", "therapy", "." ]

[ "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition", "Participant_Sample-size" ]

Aloe and Placebo is a Intervention_Control, Powder is a Intervention_Pharmacological, Breast Cancer is a Participant_Condition, aloe extract is a Intervention_Pharmacological, moist cream is a Intervention_Pharmacological, dry powder skin care regimen . is a Intervention_Pharmacological, 248 is a Participant_Sample-size, breast cancer is a Participant_Condition, powder , aloe cream is a Intervention_Pharmacological, placebo cream . is a Intervention_Control

69884_task1

Sentence: Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy . Instructions: please typing these entity words according to sentence: Aloe and Placebo, Powder, Breast Cancer, aloe extract, moist cream, dry powder skin care regimen ., 248, breast cancer, powder , aloe cream, placebo cream . Options: Participant_Condition, Intervention_Pharmacological, Intervention_Control, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy .

[ "Three", "-", "Arm", "Randomized", "Phase", "III", "Trial", ":", "Quality", "Aloe", "and", "Placebo", "Cream", "Versus", "Powder", "as", "Skin", "Treatment", "During", "Breast", "Cancer", "Radiation", "Therapy", ".", "BACKGROUND", "The", "efficacy", "of", "aloe", "extract", "in", "reducing", "radiation", "-", "induced", "skin", "injury", "is", "controversial", ".", "The", "purpose", "of", "the", "present", "3-arm", "randomized", "trial", "was", "to", "test", "the", "efficacy", "of", "quality", "-", "tested", "aloe", "extract", "in", "reducing", "the", "severity", "of", "radiation", "-", "induced", "skin", "injury", "and", ",", "secondarily", ",", "to", "examine", "the", "effect", "of", "a", "moist", "cream", "versus", "a", "dry", "powder", "skin", "care", "regimen", ".", "MATERIALS", "AND", "METHODS", "A", "total", "of", "248", "patients", "with", "breast", "cancer", "were", "randomized", "to", "powder", ",", "aloe", "cream", ",", "or", "placebo", "cream", ".", "Acute", "skin", "toxicity", "was", "scored", "weekly", "and", "after", "treatment", "at", "weeks", "1", ",", "2", ",", "and", "4", "using", "a", "modified", "10-point", "Catterall", "scale", ".", "The", "patients", "scored", "their", "symptom", "severity", "using", "a", "6-point", "Likert", "scale", "and", "kept", "an", "acute", "phase", "diary", ".", "RESULTS", "The", "aloe", "formulation", "did", "not", "reduce", "acute", "skin", "toxicity", "or", "symptom", "severity", ".", "Patients", "with", "a", "greater", "body", "mass", "index", "were", "more", "likely", "to", "develop", "acute", "skin", "toxicity", ".", "A", "similar", "pattern", "of", "increased", "skin", "reaction", "toxicity", "occurred", "with", "both", "study", "creams", "compared", "with", "the", "dry", "powder", "regimen", ".", "CONCLUSION", "No", "evidence", "was", "found", "to", "support", "prophylactic", "application", "of", "quality", "aloe", "extract", "or", "cream", "to", "improve", "the", "symptoms", "or", "reduce", "the", "skin", "reaction", "severity", ".", "Our", "results", "support", "a", "dry", "skin", "care", "regimen", "of", "powder", "during", "radiation", "therapy", "." ]

[ "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition", "Participant_Sample-size" ]

Aloe and Placebo, Powder, Breast Cancer, aloe extract, moist cream, dry powder skin care regimen ., 248, breast cancer, powder , aloe cream, placebo cream .

69884_task2

Sentence: Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Three-Arm Randomized Phase III Trial : Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy . BACKGROUND The efficacy of aloe extract in reducing radiation-induced skin injury is controversial . The purpose of the present 3-arm randomized trial was to test the efficacy of quality-tested aloe extract in reducing the severity of radiation-induced skin injury and , secondarily , to examine the effect of a moist cream versus a dry powder skin care regimen . MATERIALS AND METHODS A total of 248 patients with breast cancer were randomized to powder , aloe cream , or placebo cream . Acute skin toxicity was scored weekly and after treatment at weeks 1 , 2 , and 4 using a modified 10-point Catterall scale . The patients scored their symptom severity using a 6-point Likert scale and kept an acute phase diary . RESULTS The aloe formulation did not reduce acute skin toxicity or symptom severity . Patients with a greater body mass index were more likely to develop acute skin toxicity . A similar pattern of increased skin reaction toxicity occurred with both study creams compared with the dry powder regimen . CONCLUSION No evidence was found to support prophylactic application of quality aloe extract or cream to improve the symptoms or reduce the skin reaction severity . Our results support a dry skin care regimen of powder during radiation therapy .

[ "Three", "-", "Arm", "Randomized", "Phase", "III", "Trial", ":", "Quality", "Aloe", "and", "Placebo", "Cream", "Versus", "Powder", "as", "Skin", "Treatment", "During", "Breast", "Cancer", "Radiation", "Therapy", ".", "BACKGROUND", "The", "efficacy", "of", "aloe", "extract", "in", "reducing", "radiation", "-", "induced", "skin", "injury", "is", "controversial", ".", "The", "purpose", "of", "the", "present", "3-arm", "randomized", "trial", "was", "to", "test", "the", "efficacy", "of", "quality", "-", "tested", "aloe", "extract", "in", "reducing", "the", "severity", "of", "radiation", "-", "induced", "skin", "injury", "and", ",", "secondarily", ",", "to", "examine", "the", "effect", "of", "a", "moist", "cream", "versus", "a", "dry", "powder", "skin", "care", "regimen", ".", "MATERIALS", "AND", "METHODS", "A", "total", "of", "248", "patients", "with", "breast", "cancer", "were", "randomized", "to", "powder", ",", "aloe", "cream", ",", "or", "placebo", "cream", ".", "Acute", "skin", "toxicity", "was", "scored", "weekly", "and", "after", "treatment", "at", "weeks", "1", ",", "2", ",", "and", "4", "using", "a", "modified", "10-point", "Catterall", "scale", ".", "The", "patients", "scored", "their", "symptom", "severity", "using", "a", "6-point", "Likert", "scale", "and", "kept", "an", "acute", "phase", "diary", ".", "RESULTS", "The", "aloe", "formulation", "did", "not", "reduce", "acute", "skin", "toxicity", "or", "symptom", "severity", ".", "Patients", "with", "a", "greater", "body", "mass", "index", "were", "more", "likely", "to", "develop", "acute", "skin", "toxicity", ".", "A", "similar", "pattern", "of", "increased", "skin", "reaction", "toxicity", "occurred", "with", "both", "study", "creams", "compared", "with", "the", "dry", "powder", "regimen", ".", "CONCLUSION", "No", "evidence", "was", "found", "to", "support", "prophylactic", "application", "of", "quality", "aloe", "extract", "or", "cream", "to", "improve", "the", "symptoms", "or", "reduce", "the", "skin", "reaction", "severity", ".", "Our", "results", "support", "a", "dry", "skin", "care", "regimen", "of", "powder", "during", "radiation", "therapy", "." ]

[ "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition", "Participant_Sample-size" ]

angiography is an umlsterm, vascular resistance is an umlsterm, surgery is an umlsterm, Peripheral resistance is an umlsterm, method is an umlsterm, pressure is an umlsterm, measurement is an umlsterm, patients is an umlsterm, blood is an umlsterm, blood is an umlsterm, angiographies is an umlsterm, recommendations is an umlsterm, Standards is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, Society is an umlsterm, Cardiovascular Surgery is an umlsterm, association is an umlsterm, angiography is an umlsterm, cor - relation is an umlsterm, regression analyses is an umlsterm, overall is an umlsterm, regression analysis is an umlsterm, popliteal artery is an umlsterm, angiography is an umlsterm, peripheral resistance is an umlsterm

Gefaesschirurgie.70020208.eng.abstr_task0

Sentence: The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance .

[ "The", "correlation", "between", "angiography", "and", "vascular", "resistance", "measured", "during", "surgery", "is", "still", "controversial", ".", "Peripheral", "resistance", "in", "40", "infra", "-", "inguinal", "reconstructions", "was", "measured", "using", "a", "new", "method", "which", "integrates", "pressure", "and", "flow", "measurement", "into", "a", "temporary", "bypass", "system", ".", "Data", "are", "therefore", "collected", "under", "maximal", "physiological", "conditions", "using", "the", "patients", "'", "own", "blood", "and", "pulsatile", "blood", "flow", ".", "The", "angiographies", "were", "scored", "according", "to", "the", "recommendations", "of", "the", "Ad", "Hoc", "Committee", "on", "Reporting", "Standards", ",", "Society", "for", "Vascular", "Surgery", ",", "International", "Society", "for", "Cardiovascular", "Surgery", "(", "SVS", "/", "ISCVS", ")", ".", "To", "estimate", "the", "association", "between", "angiography", "and", "resistance", "both", "simple", "cor", "-", "relation", "and", "multiple", "regression", "analyses", "were", "computed", ".", "The", "overall", "correlation", "coefficient", "was", "rs", "=", "0.34", "(", "P", "0.05", ")", ".", "Multiple", "regression", "analysis", "only", "revealed", "a", "prospective", "model", "for", "the", "popliteal", "artery", ".", "The", "results", "indicated", "that", "there", "is", "a", "poor", "correlation", "between", "angiography", "and", "peripheral", "resistance", "." ]

[ "umlsterm" ]

angiography is an umlsterm, vascular resistance is an umlsterm, surgery is an umlsterm, Peripheral resistance is an umlsterm, method is an umlsterm, pressure is an umlsterm, measurement is an umlsterm, patients is an umlsterm, blood is an umlsterm, blood is an umlsterm, angiographies is an umlsterm, recommendations is an umlsterm, Standards is an umlsterm, Society is an umlsterm, Vascular Surgery is an umlsterm, Society is an umlsterm, Cardiovascular Surgery is an umlsterm, association is an umlsterm, angiography is an umlsterm, cor - relation is an umlsterm, regression analyses is an umlsterm, overall is an umlsterm, regression analysis is an umlsterm, popliteal artery is an umlsterm, angiography is an umlsterm, peripheral resistance is an umlsterm

Gefaesschirurgie.70020208.eng.abstr_task1

Sentence: The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance . Instructions: please typing these entity words according to sentence: angiography, vascular resistance, surgery, Peripheral resistance, method, pressure, measurement, patients, blood, blood, angiographies, recommendations, Standards, Society, Vascular Surgery, Society, Cardiovascular Surgery, association, angiography, cor - relation, regression analyses, overall, regression analysis, popliteal artery, angiography, peripheral resistance Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance .

[ "The", "correlation", "between", "angiography", "and", "vascular", "resistance", "measured", "during", "surgery", "is", "still", "controversial", ".", "Peripheral", "resistance", "in", "40", "infra", "-", "inguinal", "reconstructions", "was", "measured", "using", "a", "new", "method", "which", "integrates", "pressure", "and", "flow", "measurement", "into", "a", "temporary", "bypass", "system", ".", "Data", "are", "therefore", "collected", "under", "maximal", "physiological", "conditions", "using", "the", "patients", "'", "own", "blood", "and", "pulsatile", "blood", "flow", ".", "The", "angiographies", "were", "scored", "according", "to", "the", "recommendations", "of", "the", "Ad", "Hoc", "Committee", "on", "Reporting", "Standards", ",", "Society", "for", "Vascular", "Surgery", ",", "International", "Society", "for", "Cardiovascular", "Surgery", "(", "SVS", "/", "ISCVS", ")", ".", "To", "estimate", "the", "association", "between", "angiography", "and", "resistance", "both", "simple", "cor", "-", "relation", "and", "multiple", "regression", "analyses", "were", "computed", ".", "The", "overall", "correlation", "coefficient", "was", "rs", "=", "0.34", "(", "P", "0.05", ")", ".", "Multiple", "regression", "analysis", "only", "revealed", "a", "prospective", "model", "for", "the", "popliteal", "artery", ".", "The", "results", "indicated", "that", "there", "is", "a", "poor", "correlation", "between", "angiography", "and", "peripheral", "resistance", "." ]

[ "umlsterm" ]

angiography, vascular resistance, surgery, Peripheral resistance, method, pressure, measurement, patients, blood, blood, angiographies, recommendations, Standards, Society, Vascular Surgery, Society, Cardiovascular Surgery, association, angiography, cor - relation, regression analyses, overall, regression analysis, popliteal artery, angiography, peripheral resistance

Gefaesschirurgie.70020208.eng.abstr_task2

Sentence: The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O" ]

The correlation between angiography and vascular resistance measured during surgery is still controversial . Peripheral resistance in 40 infra-inguinal reconstructions was measured using a new method which integrates pressure and flow measurement into a temporary bypass system . Data are therefore collected under maximal physiological conditions using the patients ' own blood and pulsatile blood flow . The angiographies were scored according to the recommendations of the Ad Hoc Committee on Reporting Standards , Society for Vascular Surgery , International Society for Cardiovascular Surgery ( SVS/ISCVS ) . To estimate the association between angiography and resistance both simple cor-relation and multiple regression analyses were computed . The overall correlation coefficient was rs = 0.34 ( P 0.05 ) . Multiple regression analysis only revealed a prospective model for the popliteal artery . The results indicated that there is a poor correlation between angiography and peripheral resistance .

[ "The", "correlation", "between", "angiography", "and", "vascular", "resistance", "measured", "during", "surgery", "is", "still", "controversial", ".", "Peripheral", "resistance", "in", "40", "infra", "-", "inguinal", "reconstructions", "was", "measured", "using", "a", "new", "method", "which", "integrates", "pressure", "and", "flow", "measurement", "into", "a", "temporary", "bypass", "system", ".", "Data", "are", "therefore", "collected", "under", "maximal", "physiological", "conditions", "using", "the", "patients", "'", "own", "blood", "and", "pulsatile", "blood", "flow", ".", "The", "angiographies", "were", "scored", "according", "to", "the", "recommendations", "of", "the", "Ad", "Hoc", "Committee", "on", "Reporting", "Standards", ",", "Society", "for", "Vascular", "Surgery", ",", "International", "Society", "for", "Cardiovascular", "Surgery", "(", "SVS", "/", "ISCVS", ")", ".", "To", "estimate", "the", "association", "between", "angiography", "and", "resistance", "both", "simple", "cor", "-", "relation", "and", "multiple", "regression", "analyses", "were", "computed", ".", "The", "overall", "correlation", "coefficient", "was", "rs", "=", "0.34", "(", "P", "0.05", ")", ".", "Multiple", "regression", "analysis", "only", "revealed", "a", "prospective", "model", "for", "the", "popliteal", "artery", ".", "The", "results", "indicated", "that", "there", "is", "a", "poor", "correlation", "between", "angiography", "and", "peripheral", "resistance", "." ]

[ "umlsterm" ]

argininosuccinate synthetase is a Gene, argininosuccinate synthetase is a Gene, A118 T is a SNP, A192V is a SNP, R272C is a SNP, G280R is a SNP, R304W is a SNP, R363L is a SNP, R304W is a SNP

220_task0

Sentence: Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene, SNP

[ "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations.

[ "Mutations", "in", "argininosuccinate", "synthetase", "mRNA", "of", "Japanese", "patients", ",", "causing", "classical", "citrullinemia", ".", "Citrullinemia", "is", "an", "autosomal", "recessive", "disease", "caused", "by", "a", "genetic", "deficiency", "of", "argininosuccinate", "synthetase", ".", "In", "order", "to", "characterize", "mutations", "in", "Japanese", "patients", "with", "classical", "citrullinemia", ",", "RNA", "isolated", "from", "10", "unrelated", "patients", "was", "reverse", "-", "transcribed", ",", "and", "cDNA", "amplified", "by", "PCR", "was", "cloned", "and", "sequenced", ".", "The", "10", "mutations", "identified", "included", "6", "missense", "mutations", "(", "A118", "T", ",", "A192V", ",", "R272C", ",", "G280R", ",", "R304W", ",", "and", "R363L", ")", ",", "2", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "7", "or", "exon", "13", ",", "1", "mutation", "with", "a", "deletion", "of", "the", "first", "7", "bp", "in", "exon", "16", "(", "which", "might", "be", "caused", "by", "abnormal", "splicing", ")", ",", "and", "1", "mutation", "with", "an", "insertion", "of", "37", "bp", "within", "exons", "15", "and", "16", "in", "cDNA", ".", "The", "insertion", "mutation", "and", "the", "five", "missense", "mutations", "(", "R304W", "being", "excluded", ")", "are", "new", "mutations", "described", "in", "the", "present", "paper", ".", "These", "are", "in", "addition", "to", "14", "mutations", "(", "9", "missense", "mutations", ",", "4", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "in", "mRNA", ",", "and", "1", "splicing", "mutation", ")", "that", "we", "identified", "previously", "in", "mainly", "American", "patients", "with", "neonatal", "citrullinemia", ".", "Two", "of", "these", "20", "mutations", ",", "a", "deletion", "of", "exon", "13", "sequence", "and", "a", "7-bp", "deletion", "in", "exon", "16", ",", "were", "common", "to", "Japanese", "and", "American", "populations", "from", "different", "ethnic", "backgrounds", ";", "however", ",", "other", "mutations", "were", "unique", "to", "each", "population", ".", "Furthermore", ",", "the", "presence", "of", "a", "frequent", "mutation", "--", "the", "exon", "7", "deletion", "mutation", "in", "mRNA", ",", "which", "accounts", "for", "10", "of", "23", "affected", "alleles", "--", "was", "demonstrated", "in", "Japanese", "citrullinemia", ".", "This", "differs", "from", "the", "situation", "in", "the", "United", "States", ",", "where", "there", "was", "far", "greater", "heterogeneity", "of", "mutations", ".", "\n" ]

[ "Gene", "SNP" ]

argininosuccinate synthetase is a Gene, argininosuccinate synthetase is a Gene, A118 T is a SNP, A192V is a SNP, R272C is a SNP, G280R is a SNP, R304W is a SNP, R363L is a SNP, R304W is a SNP

220_task1

Sentence: Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations. Instructions: please typing these entity words according to sentence: argininosuccinate synthetase, argininosuccinate synthetase, A118 T, A192V, R272C, G280R, R304W, R363L, R304W Options: Gene, SNP

[ "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations.

[ "Mutations", "in", "argininosuccinate", "synthetase", "mRNA", "of", "Japanese", "patients", ",", "causing", "classical", "citrullinemia", ".", "Citrullinemia", "is", "an", "autosomal", "recessive", "disease", "caused", "by", "a", "genetic", "deficiency", "of", "argininosuccinate", "synthetase", ".", "In", "order", "to", "characterize", "mutations", "in", "Japanese", "patients", "with", "classical", "citrullinemia", ",", "RNA", "isolated", "from", "10", "unrelated", "patients", "was", "reverse", "-", "transcribed", ",", "and", "cDNA", "amplified", "by", "PCR", "was", "cloned", "and", "sequenced", ".", "The", "10", "mutations", "identified", "included", "6", "missense", "mutations", "(", "A118", "T", ",", "A192V", ",", "R272C", ",", "G280R", ",", "R304W", ",", "and", "R363L", ")", ",", "2", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "7", "or", "exon", "13", ",", "1", "mutation", "with", "a", "deletion", "of", "the", "first", "7", "bp", "in", "exon", "16", "(", "which", "might", "be", "caused", "by", "abnormal", "splicing", ")", ",", "and", "1", "mutation", "with", "an", "insertion", "of", "37", "bp", "within", "exons", "15", "and", "16", "in", "cDNA", ".", "The", "insertion", "mutation", "and", "the", "five", "missense", "mutations", "(", "R304W", "being", "excluded", ")", "are", "new", "mutations", "described", "in", "the", "present", "paper", ".", "These", "are", "in", "addition", "to", "14", "mutations", "(", "9", "missense", "mutations", ",", "4", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "in", "mRNA", ",", "and", "1", "splicing", "mutation", ")", "that", "we", "identified", "previously", "in", "mainly", "American", "patients", "with", "neonatal", "citrullinemia", ".", "Two", "of", "these", "20", "mutations", ",", "a", "deletion", "of", "exon", "13", "sequence", "and", "a", "7-bp", "deletion", "in", "exon", "16", ",", "were", "common", "to", "Japanese", "and", "American", "populations", "from", "different", "ethnic", "backgrounds", ";", "however", ",", "other", "mutations", "were", "unique", "to", "each", "population", ".", "Furthermore", ",", "the", "presence", "of", "a", "frequent", "mutation", "--", "the", "exon", "7", "deletion", "mutation", "in", "mRNA", ",", "which", "accounts", "for", "10", "of", "23", "affected", "alleles", "--", "was", "demonstrated", "in", "Japanese", "citrullinemia", ".", "This", "differs", "from", "the", "situation", "in", "the", "United", "States", ",", "where", "there", "was", "far", "greater", "heterogeneity", "of", "mutations", ".", "\n" ]

[ "Gene", "SNP" ]

argininosuccinate synthetase, argininosuccinate synthetase, A118 T, A192V, R272C, G280R, R304W, R363L, R304W

220_task2

Sentence: Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "I-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "B-SNP", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SNP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Citrullinemia is an autosomal recessive disease caused by a genetic deficiency of argininosuccinate synthetase. In order to characterize mutations in Japanese patients with classical citrullinemia, RNA isolated from 10 unrelated patients was reverse-transcribed, and cDNA amplified by PCR was cloned and sequenced. The 10 mutations identified included 6 missense mutations (A118T, A192V, R272C, G280R, R304W, and R363L), 2 mutations associated with an absence of an exon 7 or exon 13, 1 mutation with a deletion of the first 7 bp in exon 16 (which might be caused by abnormal splicing), and 1 mutation with an insertion of 37 bp within exons 15 and 16 in cDNA. The insertion mutation and the five missense mutations (R304W being excluded) are new mutations described in the present paper. These are in addition to 14 mutations (9 missense mutations, 4 mutations associated with an absence of an exon in mRNA, and 1 splicing mutation) that we identified previously in mainly American patients with neonatal citrullinemia. Two of these 20 mutations, a deletion of exon 13 sequence and a 7-bp deletion in exon 16, were common to Japanese and American populations from different ethnic backgrounds; however, other mutations were unique to each population. Furthermore, the presence of a frequent mutation--the exon 7 deletion mutation in mRNA, which accounts for 10 of 23 affected alleles--was demonstrated in Japanese citrullinemia. This differs from the situation in the United States, where there was far greater heterogeneity of mutations.

[ "Mutations", "in", "argininosuccinate", "synthetase", "mRNA", "of", "Japanese", "patients", ",", "causing", "classical", "citrullinemia", ".", "Citrullinemia", "is", "an", "autosomal", "recessive", "disease", "caused", "by", "a", "genetic", "deficiency", "of", "argininosuccinate", "synthetase", ".", "In", "order", "to", "characterize", "mutations", "in", "Japanese", "patients", "with", "classical", "citrullinemia", ",", "RNA", "isolated", "from", "10", "unrelated", "patients", "was", "reverse", "-", "transcribed", ",", "and", "cDNA", "amplified", "by", "PCR", "was", "cloned", "and", "sequenced", ".", "The", "10", "mutations", "identified", "included", "6", "missense", "mutations", "(", "A118", "T", ",", "A192V", ",", "R272C", ",", "G280R", ",", "R304W", ",", "and", "R363L", ")", ",", "2", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "7", "or", "exon", "13", ",", "1", "mutation", "with", "a", "deletion", "of", "the", "first", "7", "bp", "in", "exon", "16", "(", "which", "might", "be", "caused", "by", "abnormal", "splicing", ")", ",", "and", "1", "mutation", "with", "an", "insertion", "of", "37", "bp", "within", "exons", "15", "and", "16", "in", "cDNA", ".", "The", "insertion", "mutation", "and", "the", "five", "missense", "mutations", "(", "R304W", "being", "excluded", ")", "are", "new", "mutations", "described", "in", "the", "present", "paper", ".", "These", "are", "in", "addition", "to", "14", "mutations", "(", "9", "missense", "mutations", ",", "4", "mutations", "associated", "with", "an", "absence", "of", "an", "exon", "in", "mRNA", ",", "and", "1", "splicing", "mutation", ")", "that", "we", "identified", "previously", "in", "mainly", "American", "patients", "with", "neonatal", "citrullinemia", ".", "Two", "of", "these", "20", "mutations", ",", "a", "deletion", "of", "exon", "13", "sequence", "and", "a", "7-bp", "deletion", "in", "exon", "16", ",", "were", "common", "to", "Japanese", "and", "American", "populations", "from", "different", "ethnic", "backgrounds", ";", "however", ",", "other", "mutations", "were", "unique", "to", "each", "population", ".", "Furthermore", ",", "the", "presence", "of", "a", "frequent", "mutation", "--", "the", "exon", "7", "deletion", "mutation", "in", "mRNA", ",", "which", "accounts", "for", "10", "of", "23", "affected", "alleles", "--", "was", "demonstrated", "in", "Japanese", "citrullinemia", ".", "This", "differs", "from", "the", "situation", "in", "the", "United", "States", ",", "where", "there", "was", "far", "greater", "heterogeneity", "of", "mutations", ".", "\n" ]

[ "Gene", "SNP" ]

SMC6 is a GENE-Y, ATPase domain is a GENE-N

23518413_task0

Sentence: SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N

[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities.

[ "SMC6", "is", "an", "essential", "gene", "in", "mice", ",", "but", "a", "hypomorphic", "mutant", "in", "the", "ATPase", "domain", "has", "a", "mild", "phenotype", "with", "a", "range", "of", "subtle", "abnormalities", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

SMC6 is a GENE-Y, ATPase domain is a GENE-N

23518413_task1

Sentence: SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities. Instructions: please typing these entity words according to sentence: SMC6, ATPase domain Options: GENE-Y, GENE-N

[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities.

[ "SMC6", "is", "an", "essential", "gene", "in", "mice", ",", "but", "a", "hypomorphic", "mutant", "in", "the", "ATPase", "domain", "has", "a", "mild", "phenotype", "with", "a", "range", "of", "subtle", "abnormalities", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

SMC6, ATPase domain

23518413_task2

Sentence: SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

SMC6 is an essential gene in mice, but a hypomorphic mutant in the ATPase domain has a mild phenotype with a range of subtle abnormalities.

[ "SMC6", "is", "an", "essential", "gene", "in", "mice", ",", "but", "a", "hypomorphic", "mutant", "in", "the", "ATPase", "domain", "has", "a", "mild", "phenotype", "with", "a", "range", "of", "subtle", "abnormalities", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

History is a Observation, significant is a Qualifier, skin disease is a Condition, skin manifestations is a Condition, allergic illness or other dermatologic condition is a Scope, except is a Negation, chronic moderate or severe is a Scope, atopic dermatitis is a Condition, skin diseases is a Condition, except is a Negation, chronic atopic dermatitis is a Condition, could disturb the study assessment and evaluation of the skin is a Qualifier, active is a Temporal, systemic medication is a Drug, chronic atopic dermatitis is a Condition, within one month is a Temporal, active is a Temporal, topical medication is a Drug, chronic atopic dermatitis is a Condition, within two weeks is a Temporal, sunny holiday , UV - light therapy or solarium use is a Scope, within one month before beginning of study treatments is a Temporal, planning is a Observation, during the study or within 7 days after the study is a Scope, Allergy is a Condition, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment is a Scope, History is a Observation, skin - related cancer is a Condition, acquired immunodeficiency is a Condition, ongoing is a Temporal, therapy that cause immunosuppression is a Procedure, clinically significant is a Qualifier, laboratory test is a Procedure, Suspected is a Observation, current is a Temporal, drug or alcohol abuse is a Scope, Clinically significant is a Qualifier, illness is a Condition, during the 4 weeks prior to the first dose administration is a Temporal

NCT01320579_exc_task0

Sentence: History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Observation, Procedure, Negation, Scope, Drug

[ "B-Observation", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Procedure", "I-Procedure", "O", "O", "B-Observation", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study

[ "History", "of", "other", "significant", "skin", "disease", ",", "or", "skin", "manifestations", "of", "allergic", "illness", "or", "other", "dermatologic", "condition", ",", "except", "chronic", "moderate", "or", "severe", "atopic", "dermatitis", ",", "that", "would", "interfere", "with", "the", "trial", "assessments", "or", "compromise", "the", "patient", "'s", "safety", "according", "to", "the", "opinion", "of", "the", "Investigator", "\n", "Present", "symptoms", "of", "other", "skin", "diseases", ",", "except", "chronic", "atopic", "dermatitis", ",", "that", "could", "disturb", "the", "study", "assessment", "and", "evaluation", "of", "the", "skin", "\n", "Current", "use", "of", "any", "active", "systemic", "medication", "for", "chronic", "atopic", "dermatitis", "within", "one", "month", "\n", "Current", "use", "of", "active", "topical", "medication", "in", "the", "planned", "investigational", "area", "for", "chronic", "atopic", "dermatitis", "within", "two", "weeks", "\n", "History", "of", "a", "sunny", "holiday", ",", "UV", "-", "light", "therapy", "or", "solarium", "use", "within", "one", "month", "before", "beginning", "of", "study", "treatments", ",", "or", "planning", "such", "during", "the", "study", "or", "within", "7", "days", "after", "the", "study", "\n", "Allergy", "to", "cis", "-", "UCA", ",", "or", "any", "constituents", "of", "the", "placebo", "emulsion", "cream", "or", "any", "constituents", "of", "Protopic", "®", "ointment", "\n", "History", "of", "any", "skin", "-", "related", "cancer", "\n", "Congenital", "or", "acquired", "immunodeficiency", "or", "ongoing", "therapy", "that", "cause", "immunosuppression", "\n", "Earlier", "participation", "in", "a", "clinical", "study", "performed", "with", "cis", "-", "UCA", "\n", "Any", "clinically", "significant", "laboratory", "test", "result", "\n", "Suspected", "current", "drug", "or", "alcohol", "abuse", "\n", "Clinically", "significant", "illness", "during", "the", "4", "weeks", "prior", "to", "the", "first", "dose", "administration", "\n", "Any", "other", "condition", "that", "in", "the", "opinion", "of", "the", "Investigator", "would", "interfere", "with", "the", "evaluation", "of", "the", "study", "results", "or", "constitute", "a", "health", "hazard", "for", "the", "patient", "\n", "Unwillingness", "or", "doubtful", "capacity", "to", "comply", "with", "the", "protocol", "\n", "Doubtful", "availability", "to", "complete", "the", "study", " \n \n" ]

[ "Scope", "Qualifier", "Temporal", "Procedure", "Reference_point", "Condition", "Drug", "Observation", "Negation" ]

History is a Observation, significant is a Qualifier, skin disease is a Condition, skin manifestations is a Condition, allergic illness or other dermatologic condition is a Scope, except is a Negation, chronic moderate or severe is a Scope, atopic dermatitis is a Condition, skin diseases is a Condition, except is a Negation, chronic atopic dermatitis is a Condition, could disturb the study assessment and evaluation of the skin is a Qualifier, active is a Temporal, systemic medication is a Drug, chronic atopic dermatitis is a Condition, within one month is a Temporal, active is a Temporal, topical medication is a Drug, chronic atopic dermatitis is a Condition, within two weeks is a Temporal, sunny holiday , UV - light therapy or solarium use is a Scope, within one month before beginning of study treatments is a Temporal, planning is a Observation, during the study or within 7 days after the study is a Scope, Allergy is a Condition, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment is a Scope, History is a Observation, skin - related cancer is a Condition, acquired immunodeficiency is a Condition, ongoing is a Temporal, therapy that cause immunosuppression is a Procedure, clinically significant is a Qualifier, laboratory test is a Procedure, Suspected is a Observation, current is a Temporal, drug or alcohol abuse is a Scope, Clinically significant is a Qualifier, illness is a Condition, during the 4 weeks prior to the first dose administration is a Temporal

NCT01320579_exc_task1

Sentence: History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study Instructions: please typing these entity words according to sentence: History, significant, skin disease, skin manifestations, allergic illness or other dermatologic condition, except, chronic moderate or severe, atopic dermatitis, skin diseases, except, chronic atopic dermatitis, could disturb the study assessment and evaluation of the skin, active, systemic medication, chronic atopic dermatitis, within one month, active, topical medication, chronic atopic dermatitis, within two weeks, sunny holiday , UV - light therapy or solarium use, within one month before beginning of study treatments, planning, during the study or within 7 days after the study, Allergy, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment, History, skin - related cancer, acquired immunodeficiency, ongoing, therapy that cause immunosuppression, clinically significant, laboratory test, Suspected, current, drug or alcohol abuse, Clinically significant, illness, during the 4 weeks prior to the first dose administration Options: Temporal, Condition, Qualifier, Observation, Procedure, Negation, Scope, Drug

[ "B-Observation", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Procedure", "I-Procedure", "O", "O", "B-Observation", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study

[ "History", "of", "other", "significant", "skin", "disease", ",", "or", "skin", "manifestations", "of", "allergic", "illness", "or", "other", "dermatologic", "condition", ",", "except", "chronic", "moderate", "or", "severe", "atopic", "dermatitis", ",", "that", "would", "interfere", "with", "the", "trial", "assessments", "or", "compromise", "the", "patient", "'s", "safety", "according", "to", "the", "opinion", "of", "the", "Investigator", "\n", "Present", "symptoms", "of", "other", "skin", "diseases", ",", "except", "chronic", "atopic", "dermatitis", ",", "that", "could", "disturb", "the", "study", "assessment", "and", "evaluation", "of", "the", "skin", "\n", "Current", "use", "of", "any", "active", "systemic", "medication", "for", "chronic", "atopic", "dermatitis", "within", "one", "month", "\n", "Current", "use", "of", "active", "topical", "medication", "in", "the", "planned", "investigational", "area", "for", "chronic", "atopic", "dermatitis", "within", "two", "weeks", "\n", "History", "of", "a", "sunny", "holiday", ",", "UV", "-", "light", "therapy", "or", "solarium", "use", "within", "one", "month", "before", "beginning", "of", "study", "treatments", ",", "or", "planning", "such", "during", "the", "study", "or", "within", "7", "days", "after", "the", "study", "\n", "Allergy", "to", "cis", "-", "UCA", ",", "or", "any", "constituents", "of", "the", "placebo", "emulsion", "cream", "or", "any", "constituents", "of", "Protopic", "®", "ointment", "\n", "History", "of", "any", "skin", "-", "related", "cancer", "\n", "Congenital", "or", "acquired", "immunodeficiency", "or", "ongoing", "therapy", "that", "cause", "immunosuppression", "\n", "Earlier", "participation", "in", "a", "clinical", "study", "performed", "with", "cis", "-", "UCA", "\n", "Any", "clinically", "significant", "laboratory", "test", "result", "\n", "Suspected", "current", "drug", "or", "alcohol", "abuse", "\n", "Clinically", "significant", "illness", "during", "the", "4", "weeks", "prior", "to", "the", "first", "dose", "administration", "\n", "Any", "other", "condition", "that", "in", "the", "opinion", "of", "the", "Investigator", "would", "interfere", "with", "the", "evaluation", "of", "the", "study", "results", "or", "constitute", "a", "health", "hazard", "for", "the", "patient", "\n", "Unwillingness", "or", "doubtful", "capacity", "to", "comply", "with", "the", "protocol", "\n", "Doubtful", "availability", "to", "complete", "the", "study", " \n \n" ]

[ "Scope", "Qualifier", "Temporal", "Procedure", "Reference_point", "Condition", "Drug", "Observation", "Negation" ]

History, significant, skin disease, skin manifestations, allergic illness or other dermatologic condition, except, chronic moderate or severe, atopic dermatitis, skin diseases, except, chronic atopic dermatitis, could disturb the study assessment and evaluation of the skin, active, systemic medication, chronic atopic dermatitis, within one month, active, topical medication, chronic atopic dermatitis, within two weeks, sunny holiday , UV - light therapy or solarium use, within one month before beginning of study treatments, planning, during the study or within 7 days after the study, Allergy, cis - UCA , or any constituents of the placebo emulsion cream or any constituents of Protopic ® ointment, History, skin - related cancer, acquired immunodeficiency, ongoing, therapy that cause immunosuppression, clinically significant, laboratory test, Suspected, current, drug or alcohol abuse, Clinically significant, illness, during the 4 weeks prior to the first dose administration

NCT01320579_exc_task2

Sentence: History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study Instructions: please extract entity words from the input sentence

[ "B-Observation", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Negation", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Condition", "I-Condition", "I-Condition", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Temporal", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Observation", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Temporal", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Procedure", "I-Procedure", "O", "O", "B-Observation", "B-Temporal", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

History of other significant skin disease, or skin manifestations of allergic illness or other dermatologic condition, except chronic moderate or severe atopic dermatitis, that would interfere with the trial assessments or compromise the patient's safety according to the opinion of the Investigator Present symptoms of other skin diseases, except chronic atopic dermatitis, that could disturb the study assessment and evaluation of the skin Current use of any active systemic medication for chronic atopic dermatitis within one month Current use of active topical medication in the planned investigational area for chronic atopic dermatitis within two weeks History of a sunny holiday, UV-light therapy or solarium use within one month before beginning of study treatments, or planning such during the study or within 7 days after the study Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any constituents of Protopic® ointment History of any skin-related cancer Congenital or acquired immunodeficiency or ongoing therapy that cause immunosuppression Earlier participation in a clinical study performed with cis-UCA Any clinically significant laboratory test result Suspected current drug or alcohol abuse Clinically significant illness during the 4 weeks prior to the first dose administration Any other condition that in the opinion of the Investigator would interfere with the evaluation of the study results or constitute a health hazard for the patient Unwillingness or doubtful capacity to comply with the protocol Doubtful availability to complete the study

[ "History", "of", "other", "significant", "skin", "disease", ",", "or", "skin", "manifestations", "of", "allergic", "illness", "or", "other", "dermatologic", "condition", ",", "except", "chronic", "moderate", "or", "severe", "atopic", "dermatitis", ",", "that", "would", "interfere", "with", "the", "trial", "assessments", "or", "compromise", "the", "patient", "'s", "safety", "according", "to", "the", "opinion", "of", "the", "Investigator", "\n", "Present", "symptoms", "of", "other", "skin", "diseases", ",", "except", "chronic", "atopic", "dermatitis", ",", "that", "could", "disturb", "the", "study", "assessment", "and", "evaluation", "of", "the", "skin", "\n", "Current", "use", "of", "any", "active", "systemic", "medication", "for", "chronic", "atopic", "dermatitis", "within", "one", "month", "\n", "Current", "use", "of", "active", "topical", "medication", "in", "the", "planned", "investigational", "area", "for", "chronic", "atopic", "dermatitis", "within", "two", "weeks", "\n", "History", "of", "a", "sunny", "holiday", ",", "UV", "-", "light", "therapy", "or", "solarium", "use", "within", "one", "month", "before", "beginning", "of", "study", "treatments", ",", "or", "planning", "such", "during", "the", "study", "or", "within", "7", "days", "after", "the", "study", "\n", "Allergy", "to", "cis", "-", "UCA", ",", "or", "any", "constituents", "of", "the", "placebo", "emulsion", "cream", "or", "any", "constituents", "of", "Protopic", "®", "ointment", "\n", "History", "of", "any", "skin", "-", "related", "cancer", "\n", "Congenital", "or", "acquired", "immunodeficiency", "or", "ongoing", "therapy", "that", "cause", "immunosuppression", "\n", "Earlier", "participation", "in", "a", "clinical", "study", "performed", "with", "cis", "-", "UCA", "\n", "Any", "clinically", "significant", "laboratory", "test", "result", "\n", "Suspected", "current", "drug", "or", "alcohol", "abuse", "\n", "Clinically", "significant", "illness", "during", "the", "4", "weeks", "prior", "to", "the", "first", "dose", "administration", "\n", "Any", "other", "condition", "that", "in", "the", "opinion", "of", "the", "Investigator", "would", "interfere", "with", "the", "evaluation", "of", "the", "study", "results", "or", "constitute", "a", "health", "hazard", "for", "the", "patient", "\n", "Unwillingness", "or", "doubtful", "capacity", "to", "comply", "with", "the", "protocol", "\n", "Doubtful", "availability", "to", "complete", "the", "study", " \n \n" ]

[ "Scope", "Qualifier", "Temporal", "Procedure", "Reference_point", "Condition", "Drug", "Observation", "Negation" ]

Doppelblindstudie is an umlsterm, Patienten is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Analgetika is an umlsterm, Adrenalin is an umlsterm, Patienten is an umlsterm, Intoxikation is an umlsterm, Injektionsende is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Zyanose is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Prilocain is an umlsterm

DerAnaesthesist.60450052.ger.abstr_task0

Sentence: In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist .

[ "In", "einer", "prospektiven", ",", "randomisierten", "Doppelblindstudie", "wurde", "bei", "3", "mal", "20", "Patienten", "eine", "kombinierte", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", "durchgefuehrt", ".", "Wir", "verglichen", "den", "Blockadeerfolg", ",", "die", "arteriellen", "Serumspiegel", "und", "die", "Nebenwirkungen", "beim", "Einsatz", "von", "700", "mg", "Mepivacain", "1", "%", "ohne", "Gruppe", "I", ")", "(", "und", "mit", "Adrenalin", "1:350000", "(", "Gruppe", "II", ")", "sowie", "700", "mg", "Prilocain", "1", "%", "(", "Gruppe", "III", ")", ".", "Der", "primaere", "Blockadeerfolg", "ohne", "supplementierende", "Analgetika", "war", "in", "allen", "drei", "Gruppen", "vergleichbar", "und", "lag", "zwischen", "90", "und", "95", "%", ".", "Die", "maximalen", "Serumspiegel", "betrugen", "in", "Gruppe", "I", "3,91", "+", "/-", "0,95", "µg", "/", "ml", "nach", "60", "min", "und", "in", "Gruppe", "II", "2,94", "+", "/-", "0,58", "µg", "/", "ml", "nach", "120", "min", ".", "Zu", "allen", "Zeitpunkten", "fuehrte", "Adrenalin", "zu", "einer", "signifikanten", "Reduktion", "der", "Mepivacain", "-", "Serumspiegel", "(", "p", "0,01", ")", ".", "In", "der", "Prilocaingruppe", "waren", "die", "maximalen", "Serumspiegel", "mit", "2,07", "+", "/-", "0,56", "µg", "/", "ml", "signifikant", "niedriger", "als", "in", "beiden", "Mepivacaingruppen", "(", "p", "0,001", ")", "und", "traten", "nach", "15", "min", "auch", "signifikant", "frueher", "auf", ".", "Bei", "keinem", "Patienten", "fanden", "sich", "Symptome", "oder", "klinische", "Zeichen", "einer", "Intoxikation", "durch", "zu", "hohe", "intravasale", "Lokalanaesthetikumspiegel", ".", "Als", "einzige", "Nebenwirkung", "kam", "es", "in", "der", "Prilocaingruppe", "zu", "einer", "Methaemoglobinbildung", "von", "im", "Median", "10,1", "%", "3", "bis", "4", "h", "nach", "Injektionsende", ",", "wobei", "drei", "Patienten", "Werte", "zwischen", "16", "und", "17", "%", "aufwiesen", ".", "Bei", "fuenf", "Patienten", "dieser", "Gruppe", "war", "auch", "nach", "6", "h", "noch", "eine", "ausgepraegte", "periphere", "Zyanose", "nachweisbar", ".", "Sowohl", "Mepivacain", "1", "%", "ohne", "und", "mit", "Adrenalin", "als", "auch", "Prilocain", "1", "%", "eignen", "sich", "in", "einer", "Dosierung", "von", "700", "mg", "fuer", "die", "Durchfuehrung", "der", "kombinierten", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", ",", "wobei", "Prilocain", "allerdings", "den", "Nachteil", "einer", "im", "Einzelfall", "klinisch", "relevanten", "Methaemoglobinbildung", "aufweist", "." ]

[ "umlsterm" ]

Doppelblindstudie is an umlsterm, Patienten is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Analgetika is an umlsterm, Adrenalin is an umlsterm, Patienten is an umlsterm, Intoxikation is an umlsterm, Injektionsende is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Zyanose is an umlsterm, Mepivacain is an umlsterm, Adrenalin is an umlsterm, Prilocain is an umlsterm, Prilocain is an umlsterm

DerAnaesthesist.60450052.ger.abstr_task1

Sentence: In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist . Instructions: please typing these entity words according to sentence: Doppelblindstudie, Patienten, Mepivacain, Adrenalin, Prilocain, Analgetika, Adrenalin, Patienten, Intoxikation, Injektionsende, Patienten, Patienten, Zyanose, Mepivacain, Adrenalin, Prilocain, Prilocain Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist .

[ "In", "einer", "prospektiven", ",", "randomisierten", "Doppelblindstudie", "wurde", "bei", "3", "mal", "20", "Patienten", "eine", "kombinierte", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", "durchgefuehrt", ".", "Wir", "verglichen", "den", "Blockadeerfolg", ",", "die", "arteriellen", "Serumspiegel", "und", "die", "Nebenwirkungen", "beim", "Einsatz", "von", "700", "mg", "Mepivacain", "1", "%", "ohne", "Gruppe", "I", ")", "(", "und", "mit", "Adrenalin", "1:350000", "(", "Gruppe", "II", ")", "sowie", "700", "mg", "Prilocain", "1", "%", "(", "Gruppe", "III", ")", ".", "Der", "primaere", "Blockadeerfolg", "ohne", "supplementierende", "Analgetika", "war", "in", "allen", "drei", "Gruppen", "vergleichbar", "und", "lag", "zwischen", "90", "und", "95", "%", ".", "Die", "maximalen", "Serumspiegel", "betrugen", "in", "Gruppe", "I", "3,91", "+", "/-", "0,95", "µg", "/", "ml", "nach", "60", "min", "und", "in", "Gruppe", "II", "2,94", "+", "/-", "0,58", "µg", "/", "ml", "nach", "120", "min", ".", "Zu", "allen", "Zeitpunkten", "fuehrte", "Adrenalin", "zu", "einer", "signifikanten", "Reduktion", "der", "Mepivacain", "-", "Serumspiegel", "(", "p", "0,01", ")", ".", "In", "der", "Prilocaingruppe", "waren", "die", "maximalen", "Serumspiegel", "mit", "2,07", "+", "/-", "0,56", "µg", "/", "ml", "signifikant", "niedriger", "als", "in", "beiden", "Mepivacaingruppen", "(", "p", "0,001", ")", "und", "traten", "nach", "15", "min", "auch", "signifikant", "frueher", "auf", ".", "Bei", "keinem", "Patienten", "fanden", "sich", "Symptome", "oder", "klinische", "Zeichen", "einer", "Intoxikation", "durch", "zu", "hohe", "intravasale", "Lokalanaesthetikumspiegel", ".", "Als", "einzige", "Nebenwirkung", "kam", "es", "in", "der", "Prilocaingruppe", "zu", "einer", "Methaemoglobinbildung", "von", "im", "Median", "10,1", "%", "3", "bis", "4", "h", "nach", "Injektionsende", ",", "wobei", "drei", "Patienten", "Werte", "zwischen", "16", "und", "17", "%", "aufwiesen", ".", "Bei", "fuenf", "Patienten", "dieser", "Gruppe", "war", "auch", "nach", "6", "h", "noch", "eine", "ausgepraegte", "periphere", "Zyanose", "nachweisbar", ".", "Sowohl", "Mepivacain", "1", "%", "ohne", "und", "mit", "Adrenalin", "als", "auch", "Prilocain", "1", "%", "eignen", "sich", "in", "einer", "Dosierung", "von", "700", "mg", "fuer", "die", "Durchfuehrung", "der", "kombinierten", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", ",", "wobei", "Prilocain", "allerdings", "den", "Nachteil", "einer", "im", "Einzelfall", "klinisch", "relevanten", "Methaemoglobinbildung", "aufweist", "." ]

[ "umlsterm" ]

Doppelblindstudie, Patienten, Mepivacain, Adrenalin, Prilocain, Analgetika, Adrenalin, Patienten, Intoxikation, Injektionsende, Patienten, Patienten, Zyanose, Mepivacain, Adrenalin, Prilocain, Prilocain

DerAnaesthesist.60450052.ger.abstr_task2

Sentence: In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In einer prospektiven , randomisierten Doppelblindstudie wurde bei 3 mal 20 Patienten eine kombinierte " 3-in-1"/Ischiadicus-Blockade durchgefuehrt . Wir verglichen den Blockadeerfolg , die arteriellen Serumspiegel und die Nebenwirkungen beim Einsatz von 700 mg Mepivacain 1% ohne Gruppe I ) ( und mit Adrenalin 1:350000 ( Gruppe II ) sowie 700 mg Prilocain 1% ( Gruppe III ) . Der primaere Blockadeerfolg ohne supplementierende Analgetika war in allen drei Gruppen vergleichbar und lag zwischen 90 und 95% . Die maximalen Serumspiegel betrugen in Gruppe I 3,91 +/- 0,95 µg/ml nach 60 min und in Gruppe II 2,94 +/- 0,58 µg/ml nach 120 min . Zu allen Zeitpunkten fuehrte Adrenalin zu einer signifikanten Reduktion der Mepivacain-Serumspiegel ( p 0,01 ) . In der Prilocaingruppe waren die maximalen Serumspiegel mit 2,07 +/- 0,56 µg/ml signifikant niedriger als in beiden Mepivacaingruppen ( p 0,001 ) und traten nach 15 min auch signifikant frueher auf . Bei keinem Patienten fanden sich Symptome oder klinische Zeichen einer Intoxikation durch zu hohe intravasale Lokalanaesthetikumspiegel . Als einzige Nebenwirkung kam es in der Prilocaingruppe zu einer Methaemoglobinbildung von im Median 10,1% 3 bis 4 h nach Injektionsende , wobei drei Patienten Werte zwischen 16 und 17% aufwiesen . Bei fuenf Patienten dieser Gruppe war auch nach 6 h noch eine ausgepraegte periphere Zyanose nachweisbar . Sowohl Mepivacain 1% ohne und mit Adrenalin als auch Prilocain 1% eignen sich in einer Dosierung von 700 mg fuer die Durchfuehrung der kombinierten " 3-in-1"/Ischiadicus-Blockade, wobei Prilocain allerdings den Nachteil einer im Einzelfall klinisch relevanten Methaemoglobinbildung aufweist .

[ "In", "einer", "prospektiven", ",", "randomisierten", "Doppelblindstudie", "wurde", "bei", "3", "mal", "20", "Patienten", "eine", "kombinierte", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", "durchgefuehrt", ".", "Wir", "verglichen", "den", "Blockadeerfolg", ",", "die", "arteriellen", "Serumspiegel", "und", "die", "Nebenwirkungen", "beim", "Einsatz", "von", "700", "mg", "Mepivacain", "1", "%", "ohne", "Gruppe", "I", ")", "(", "und", "mit", "Adrenalin", "1:350000", "(", "Gruppe", "II", ")", "sowie", "700", "mg", "Prilocain", "1", "%", "(", "Gruppe", "III", ")", ".", "Der", "primaere", "Blockadeerfolg", "ohne", "supplementierende", "Analgetika", "war", "in", "allen", "drei", "Gruppen", "vergleichbar", "und", "lag", "zwischen", "90", "und", "95", "%", ".", "Die", "maximalen", "Serumspiegel", "betrugen", "in", "Gruppe", "I", "3,91", "+", "/-", "0,95", "µg", "/", "ml", "nach", "60", "min", "und", "in", "Gruppe", "II", "2,94", "+", "/-", "0,58", "µg", "/", "ml", "nach", "120", "min", ".", "Zu", "allen", "Zeitpunkten", "fuehrte", "Adrenalin", "zu", "einer", "signifikanten", "Reduktion", "der", "Mepivacain", "-", "Serumspiegel", "(", "p", "0,01", ")", ".", "In", "der", "Prilocaingruppe", "waren", "die", "maximalen", "Serumspiegel", "mit", "2,07", "+", "/-", "0,56", "µg", "/", "ml", "signifikant", "niedriger", "als", "in", "beiden", "Mepivacaingruppen", "(", "p", "0,001", ")", "und", "traten", "nach", "15", "min", "auch", "signifikant", "frueher", "auf", ".", "Bei", "keinem", "Patienten", "fanden", "sich", "Symptome", "oder", "klinische", "Zeichen", "einer", "Intoxikation", "durch", "zu", "hohe", "intravasale", "Lokalanaesthetikumspiegel", ".", "Als", "einzige", "Nebenwirkung", "kam", "es", "in", "der", "Prilocaingruppe", "zu", "einer", "Methaemoglobinbildung", "von", "im", "Median", "10,1", "%", "3", "bis", "4", "h", "nach", "Injektionsende", ",", "wobei", "drei", "Patienten", "Werte", "zwischen", "16", "und", "17", "%", "aufwiesen", ".", "Bei", "fuenf", "Patienten", "dieser", "Gruppe", "war", "auch", "nach", "6", "h", "noch", "eine", "ausgepraegte", "periphere", "Zyanose", "nachweisbar", ".", "Sowohl", "Mepivacain", "1", "%", "ohne", "und", "mit", "Adrenalin", "als", "auch", "Prilocain", "1", "%", "eignen", "sich", "in", "einer", "Dosierung", "von", "700", "mg", "fuer", "die", "Durchfuehrung", "der", "kombinierten", "\"", "3-in-1\"/Ischiadicus", "-", "Blockade", ",", "wobei", "Prilocain", "allerdings", "den", "Nachteil", "einer", "im", "Einzelfall", "klinisch", "relevanten", "Methaemoglobinbildung", "aufweist", "." ]

[ "umlsterm" ]

ADP is a CHEMICAL, guanosine is a CHEMICAL, SCO5461 is a GENE-Y

23212047_task0

Sentence: ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]

ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor.

[ "ADP", "-", "ribosylation", "of", "guanosine", "by", "SCO5461", "protein", "secreted", "from", "Streptomyces", "coelicolor", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

ADP is a CHEMICAL, guanosine is a CHEMICAL, SCO5461 is a GENE-Y

23212047_task1

Sentence: ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor. Instructions: please typing these entity words according to sentence: ADP, guanosine, SCO5461 Options: GENE-Y, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]

ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor.

[ "ADP", "-", "ribosylation", "of", "guanosine", "by", "SCO5461", "protein", "secreted", "from", "Streptomyces", "coelicolor", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

ADP, guanosine, SCO5461

23212047_task2

Sentence: ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O" ]

ADP-ribosylation of guanosine by SCO5461 protein secreted from Streptomyces coelicolor.

[ "ADP", "-", "ribosylation", "of", "guanosine", "by", "SCO5461", "protein", "secreted", "from", "Streptomyces", "coelicolor", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein

10_task0

Sentence: Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC).

[ "Increase", "of", "IRF-4", "expression", "in", "hematopoietic", "cells", "after", "demethylating", "treatment", "\n", "We", "next", "analyzed", "whether", "promoter", "methylation", "could", "be", "responsible", "for", "down", "-", "regulation", "of", "IRF-4", "expression", ".", "A", "region", "including", "exon1", "in", "the", "IRF-4", "promoter", "exhibited", "a", "large", "number", "of", "CpG", "-", "rich", "sequences", "(", "Figure", "3A", ")", ".", "Several", "chemical", "substances", "such", "as", "5-aza-2-deoxycytidine", "(", "AzadC", ")", "or", "5-azacytidine", "(", "AzaC", ")", "inhibit", "de", "novo", "and", "maintenance", "methylation", ",", "and", "thus", "can", "be", "used", "to", "discern", "promoter", "methylation", "(", "32,33", ")", ".", "We", "used", "AzadC", "to", "generate", "unmethylated", "DNA", ".", "A", "72", "h", "AzadC", "-", "treatment", "resulted", "in", "a", "concentration", "-", "dependent", "activation", "of", "IRF-4", "transcription", "in", "Jurkat", "and", "CML", "-", "T1", "T", "-", "cells", "as", "well", "as", "in", "U-937", ",", "K-562", "and", "EM-2", "cell", "lines", "(", "Figure", "2A", ")", ".", "IRF-4", "transcription", "was", "induced", "in", "a", "time", "-", "dependent", "manner", "and", "was", "observed", "as", "early", "as", "24", "h", "after", "treatment", "with", "AzadC", "and", "increased", "over", "time", "until", "72", "h", "(", "Figure", "2B", ")", ".", "Time", "and", "strength", "of", "the", "appearance", "of", "IRF-4", "transcripts", "varied", "among", "cell", "lines", ",", "i.e", ".", "CML", "-", "T1", "responded", "strongest", "to", "AzadC", "-", "treatment", "(", "data", "not", "shown", ")", ".", "In", "line", "with", "this", ",", "AzadC", "-", "treatment", "of", "CML", "-", "T1", "and", "LAMA-84", "cells", "also", "translated", "in", "an", "induction", "of", "IRF-4", "protein", "expression", "(", "Figure", "2C", ")", ".", "Accordingly", ",", "treatment", "of", "the", "IRF-4-positive", "cell", "line", "BV-173", ",", "SD-1", "and", "RPMI-8226", "with", "AzadC", "had", "no", "effect", "on", "IRF-4", "expression", "(", "Figure", "2D", ")", ".", "There", "was", "no", "difference", "in", "the", "effects", "of", "AzaC", "versus", "AzadC", ",", "as", "both", "increased", "the", "IRF-4", "mRNA", "level", "in", "CML", "-", "T1", "cells", "as", "well", "(", "data", "not", "shown", ")", ".", "This", "implied", "that", "promoter", "methylation", "may", "control", "IRF-4", "expression", ",", "but", "an", "alternative", "explanation", "may", "be", "activation", "of", "positive", "transcriptional", "regulators", "of", "IRF-4", "by", "AzadC", "(", "or", "AzaC", ")", ".", "\n" ]

[ "Protein" ]

IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein

10_task1

Sentence: Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC). Instructions: please typing these entity words according to sentence: IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4 Options: Protein

[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC).

[ "Increase", "of", "IRF-4", "expression", "in", "hematopoietic", "cells", "after", "demethylating", "treatment", "\n", "We", "next", "analyzed", "whether", "promoter", "methylation", "could", "be", "responsible", "for", "down", "-", "regulation", "of", "IRF-4", "expression", ".", "A", "region", "including", "exon1", "in", "the", "IRF-4", "promoter", "exhibited", "a", "large", "number", "of", "CpG", "-", "rich", "sequences", "(", "Figure", "3A", ")", ".", "Several", "chemical", "substances", "such", "as", "5-aza-2-deoxycytidine", "(", "AzadC", ")", "or", "5-azacytidine", "(", "AzaC", ")", "inhibit", "de", "novo", "and", "maintenance", "methylation", ",", "and", "thus", "can", "be", "used", "to", "discern", "promoter", "methylation", "(", "32,33", ")", ".", "We", "used", "AzadC", "to", "generate", "unmethylated", "DNA", ".", "A", "72", "h", "AzadC", "-", "treatment", "resulted", "in", "a", "concentration", "-", "dependent", "activation", "of", "IRF-4", "transcription", "in", "Jurkat", "and", "CML", "-", "T1", "T", "-", "cells", "as", "well", "as", "in", "U-937", ",", "K-562", "and", "EM-2", "cell", "lines", "(", "Figure", "2A", ")", ".", "IRF-4", "transcription", "was", "induced", "in", "a", "time", "-", "dependent", "manner", "and", "was", "observed", "as", "early", "as", "24", "h", "after", "treatment", "with", "AzadC", "and", "increased", "over", "time", "until", "72", "h", "(", "Figure", "2B", ")", ".", "Time", "and", "strength", "of", "the", "appearance", "of", "IRF-4", "transcripts", "varied", "among", "cell", "lines", ",", "i.e", ".", "CML", "-", "T1", "responded", "strongest", "to", "AzadC", "-", "treatment", "(", "data", "not", "shown", ")", ".", "In", "line", "with", "this", ",", "AzadC", "-", "treatment", "of", "CML", "-", "T1", "and", "LAMA-84", "cells", "also", "translated", "in", "an", "induction", "of", "IRF-4", "protein", "expression", "(", "Figure", "2C", ")", ".", "Accordingly", ",", "treatment", "of", "the", "IRF-4-positive", "cell", "line", "BV-173", ",", "SD-1", "and", "RPMI-8226", "with", "AzadC", "had", "no", "effect", "on", "IRF-4", "expression", "(", "Figure", "2D", ")", ".", "There", "was", "no", "difference", "in", "the", "effects", "of", "AzaC", "versus", "AzadC", ",", "as", "both", "increased", "the", "IRF-4", "mRNA", "level", "in", "CML", "-", "T1", "cells", "as", "well", "(", "data", "not", "shown", ")", ".", "This", "implied", "that", "promoter", "methylation", "may", "control", "IRF-4", "expression", ",", "but", "an", "alternative", "explanation", "may", "be", "activation", "of", "positive", "transcriptional", "regulators", "of", "IRF-4", "by", "AzadC", "(", "or", "AzaC", ")", ".", "\n" ]

[ "Protein" ]

IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4, IRF-4

10_task2

Sentence: Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC). Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Increase of IRF-4 expression in hematopoietic cells after demethylating treatment We next analyzed whether promoter methylation could be responsible for down-regulation of IRF-4 expression. A region including exon1 in the IRF-4 promoter exhibited a large number of CpG-rich sequences (Figure 3A). Several chemical substances such as 5-aza-2-deoxycytidine (AzadC) or 5-azacytidine (AzaC) inhibit de novo and maintenance methylation, and thus can be used to discern promoter methylation (32,33). We used AzadC to generate unmethylated DNA. A 72 h AzadC-treatment resulted in a concentration-dependent activation of IRF-4 transcription in Jurkat and CML-T1 T-cells as well as in U-937, K-562 and EM-2 cell lines (Figure 2A). IRF-4 transcription was induced in a time-dependent manner and was observed as early as 24 h after treatment with AzadC and increased over time until 72 h (Figure 2B). Time and strength of the appearance of IRF-4 transcripts varied among cell lines, i.e. CML-T1 responded strongest to AzadC-treatment (data not shown). In line with this, AzadC-treatment of CML-T1 and LAMA-84 cells also translated in an induction of IRF-4 protein expression (Figure 2C). Accordingly, treatment of the IRF-4-positive cell line BV-173, SD-1 and RPMI-8226 with AzadC had no effect on IRF-4 expression (Figure 2D). There was no difference in the effects of AzaC versus AzadC, as both increased the IRF-4 mRNA level in CML-T1 cells as well (data not shown). This implied that promoter methylation may control IRF-4 expression, but an alternative explanation may be activation of positive transcriptional regulators of IRF-4 by AzadC (or AzaC).

[ "Increase", "of", "IRF-4", "expression", "in", "hematopoietic", "cells", "after", "demethylating", "treatment", "\n", "We", "next", "analyzed", "whether", "promoter", "methylation", "could", "be", "responsible", "for", "down", "-", "regulation", "of", "IRF-4", "expression", ".", "A", "region", "including", "exon1", "in", "the", "IRF-4", "promoter", "exhibited", "a", "large", "number", "of", "CpG", "-", "rich", "sequences", "(", "Figure", "3A", ")", ".", "Several", "chemical", "substances", "such", "as", "5-aza-2-deoxycytidine", "(", "AzadC", ")", "or", "5-azacytidine", "(", "AzaC", ")", "inhibit", "de", "novo", "and", "maintenance", "methylation", ",", "and", "thus", "can", "be", "used", "to", "discern", "promoter", "methylation", "(", "32,33", ")", ".", "We", "used", "AzadC", "to", "generate", "unmethylated", "DNA", ".", "A", "72", "h", "AzadC", "-", "treatment", "resulted", "in", "a", "concentration", "-", "dependent", "activation", "of", "IRF-4", "transcription", "in", "Jurkat", "and", "CML", "-", "T1", "T", "-", "cells", "as", "well", "as", "in", "U-937", ",", "K-562", "and", "EM-2", "cell", "lines", "(", "Figure", "2A", ")", ".", "IRF-4", "transcription", "was", "induced", "in", "a", "time", "-", "dependent", "manner", "and", "was", "observed", "as", "early", "as", "24", "h", "after", "treatment", "with", "AzadC", "and", "increased", "over", "time", "until", "72", "h", "(", "Figure", "2B", ")", ".", "Time", "and", "strength", "of", "the", "appearance", "of", "IRF-4", "transcripts", "varied", "among", "cell", "lines", ",", "i.e", ".", "CML", "-", "T1", "responded", "strongest", "to", "AzadC", "-", "treatment", "(", "data", "not", "shown", ")", ".", "In", "line", "with", "this", ",", "AzadC", "-", "treatment", "of", "CML", "-", "T1", "and", "LAMA-84", "cells", "also", "translated", "in", "an", "induction", "of", "IRF-4", "protein", "expression", "(", "Figure", "2C", ")", ".", "Accordingly", ",", "treatment", "of", "the", "IRF-4-positive", "cell", "line", "BV-173", ",", "SD-1", "and", "RPMI-8226", "with", "AzadC", "had", "no", "effect", "on", "IRF-4", "expression", "(", "Figure", "2D", ")", ".", "There", "was", "no", "difference", "in", "the", "effects", "of", "AzaC", "versus", "AzadC", ",", "as", "both", "increased", "the", "IRF-4", "mRNA", "level", "in", "CML", "-", "T1", "cells", "as", "well", "(", "data", "not", "shown", ")", ".", "This", "implied", "that", "promoter", "methylation", "may", "control", "IRF-4", "expression", ",", "but", "an", "alternative", "explanation", "may", "be", "activation", "of", "positive", "transcriptional", "regulators", "of", "IRF-4", "by", "AzadC", "(", "or", "AzaC", ")", ".", "\n" ]

[ "Protein" ]

Arp11 is a protein, Arp1 is a protein, actin is a protein-family

1.0alpha7.train.244_task0

Sentence: At present, we do not know whether Arp11 binds directly to Arp1 or actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "B-protein-family", "O" ]

At present, we do not know whether Arp11 binds directly to Arp1 or actin.

[ "At", "present", ",", "we", "do", "not", "know", "whether", "Arp11", "binds", "directly", "to", "Arp1", "or", "actin", "." ]

[ "protein", "protein-family" ]

Arp11 is a protein, Arp1 is a protein, actin is a protein-family

1.0alpha7.train.244_task1

Sentence: At present, we do not know whether Arp11 binds directly to Arp1 or actin. Instructions: please typing these entity words according to sentence: Arp11, Arp1, actin Options: protein-family, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "B-protein-family", "O" ]

At present, we do not know whether Arp11 binds directly to Arp1 or actin.

[ "At", "present", ",", "we", "do", "not", "know", "whether", "Arp11", "binds", "directly", "to", "Arp1", "or", "actin", "." ]

[ "protein", "protein-family" ]

Arp11, Arp1, actin

1.0alpha7.train.244_task2

Sentence: At present, we do not know whether Arp11 binds directly to Arp1 or actin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "B-protein-family", "O" ]

At present, we do not know whether Arp11 binds directly to Arp1 or actin.

[ "At", "present", ",", "we", "do", "not", "know", "whether", "Arp11", "binds", "directly", "to", "Arp1", "or", "actin", "." ]

[ "protein", "protein-family" ]

Arrhythmiemechanismus is an umlsterm, Arrhythmien is an umlsterm, Sinustachykardie is an umlsterm, ektope atriale Tachykardie is an umlsterm, Vorhofflimmern is an umlsterm, Vorhofflattern is an umlsterm, Tachykardien is an umlsterm, Arrhythmien is an umlsterm, Elektrophysiologie is an umlsterm

ZfuerKardiologie.0089x043.ger.abstr_task0

Sentence: Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns .

[ "Hinter", "dem", "Begriff", "\"", "supraventrikulaere", "Tachyarrhythmien", "\"", "verbergen", "sich", "elektrophysiologisch", "unterschiedliche", "Rhythmusstoerungen", ".", "Nach", "Identifizierung", "des", "Arrhythmiemechanismus", "'", "ist", "eine", "Lokalisation", "des", "Schwachpunktes", "der", "Rhythmusstoerung", "durch", "verschiedene", "Mappingtechniken", "erforderlich", ".", "Danach", "erfolgt", "in", "der", "Regel", "die", "Ablation", "als", "fokale", "Ablation", "bei", "automatischen", "Arrhythmien", "(", "Sinustachykardie", ",", "ektope", "atriale", "Tachykardie", ",", "fokales", "Vorhofflimmern", ")", "oder", "zur", "Unterbrechung", "von", "Leitbahnen", "(", "Praeexzitationssyndrom", ",", "AV", "-", "Knoten", "-", "Tachykardie", ")", ".", "Eine", "singulaere", "Ablationslinie", "ist", "fuer", "das", "isthmusabhaengige", "Vorhofflattern", "und", "fuer", "einige", "inzisionale", "Tachykardien", "erforderlich", ";", "dieses", "Vorgehen", "ist", "bereits", "weniger", "verbreitet", ".", "Multiple", "Ablationslinien", "sind", "fuer", "die", "Ablation", "eines", "Vorhofflimmerns", "erforderlich", ",", "was", "gegenwaertig", "nur", "in", "wenigen", "Zentren", "erfolgen", "kann", ".", "Verschiedene", "Arrhythmien", "sind", "bislang", "zu", "wenig", "verstanden", ",", "nicht", "induzierbar", ",", "nicht", "genau", "lokalisierbar", "und", "damit", "bislang", "nicht", "abladierbar", ".", "Neue", "dreidimensionale", "Mappingmethoden", ",", "koennten", "hier", "weiterhelfen", ".", "Die", "gegenwaertig", "groesste", "Herausforderung", "der", "interventionellen", "Elektrophysiologie", "ist", "die", "Ablation", "des", "Vorhofflimmerns", "." ]

[ "umlsterm" ]

Arrhythmiemechanismus is an umlsterm, Arrhythmien is an umlsterm, Sinustachykardie is an umlsterm, ektope atriale Tachykardie is an umlsterm, Vorhofflimmern is an umlsterm, Vorhofflattern is an umlsterm, Tachykardien is an umlsterm, Arrhythmien is an umlsterm, Elektrophysiologie is an umlsterm

ZfuerKardiologie.0089x043.ger.abstr_task1

Sentence: Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns . Instructions: please typing these entity words according to sentence: Arrhythmiemechanismus, Arrhythmien, Sinustachykardie, ektope atriale Tachykardie, Vorhofflimmern, Vorhofflattern, Tachykardien, Arrhythmien, Elektrophysiologie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns .

[ "Hinter", "dem", "Begriff", "\"", "supraventrikulaere", "Tachyarrhythmien", "\"", "verbergen", "sich", "elektrophysiologisch", "unterschiedliche", "Rhythmusstoerungen", ".", "Nach", "Identifizierung", "des", "Arrhythmiemechanismus", "'", "ist", "eine", "Lokalisation", "des", "Schwachpunktes", "der", "Rhythmusstoerung", "durch", "verschiedene", "Mappingtechniken", "erforderlich", ".", "Danach", "erfolgt", "in", "der", "Regel", "die", "Ablation", "als", "fokale", "Ablation", "bei", "automatischen", "Arrhythmien", "(", "Sinustachykardie", ",", "ektope", "atriale", "Tachykardie", ",", "fokales", "Vorhofflimmern", ")", "oder", "zur", "Unterbrechung", "von", "Leitbahnen", "(", "Praeexzitationssyndrom", ",", "AV", "-", "Knoten", "-", "Tachykardie", ")", ".", "Eine", "singulaere", "Ablationslinie", "ist", "fuer", "das", "isthmusabhaengige", "Vorhofflattern", "und", "fuer", "einige", "inzisionale", "Tachykardien", "erforderlich", ";", "dieses", "Vorgehen", "ist", "bereits", "weniger", "verbreitet", ".", "Multiple", "Ablationslinien", "sind", "fuer", "die", "Ablation", "eines", "Vorhofflimmerns", "erforderlich", ",", "was", "gegenwaertig", "nur", "in", "wenigen", "Zentren", "erfolgen", "kann", ".", "Verschiedene", "Arrhythmien", "sind", "bislang", "zu", "wenig", "verstanden", ",", "nicht", "induzierbar", ",", "nicht", "genau", "lokalisierbar", "und", "damit", "bislang", "nicht", "abladierbar", ".", "Neue", "dreidimensionale", "Mappingmethoden", ",", "koennten", "hier", "weiterhelfen", ".", "Die", "gegenwaertig", "groesste", "Herausforderung", "der", "interventionellen", "Elektrophysiologie", "ist", "die", "Ablation", "des", "Vorhofflimmerns", "." ]

[ "umlsterm" ]

Arrhythmiemechanismus, Arrhythmien, Sinustachykardie, ektope atriale Tachykardie, Vorhofflimmern, Vorhofflattern, Tachykardien, Arrhythmien, Elektrophysiologie

ZfuerKardiologie.0089x043.ger.abstr_task2

Sentence: Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Hinter dem Begriff " supraventrikulaere Tachyarrhythmien " verbergen sich elektrophysiologisch unterschiedliche Rhythmusstoerungen . Nach Identifizierung des Arrhythmiemechanismus ' ist eine Lokalisation des Schwachpunktes der Rhythmusstoerung durch verschiedene Mappingtechniken erforderlich . Danach erfolgt in der Regel die Ablation als fokale Ablation bei automatischen Arrhythmien ( Sinustachykardie , ektope atriale Tachykardie , fokales Vorhofflimmern ) oder zur Unterbrechung von Leitbahnen ( Praeexzitationssyndrom , AV-Knoten-Tachykardie ) . Eine singulaere Ablationslinie ist fuer das isthmusabhaengige Vorhofflattern und fuer einige inzisionale Tachykardien erforderlich ; dieses Vorgehen ist bereits weniger verbreitet . Multiple Ablationslinien sind fuer die Ablation eines Vorhofflimmerns erforderlich , was gegenwaertig nur in wenigen Zentren erfolgen kann . Verschiedene Arrhythmien sind bislang zu wenig verstanden , nicht induzierbar , nicht genau lokalisierbar und damit bislang nicht abladierbar . Neue dreidimensionale Mappingmethoden , koennten hier weiterhelfen . Die gegenwaertig groesste Herausforderung der interventionellen Elektrophysiologie ist die Ablation des Vorhofflimmerns .

[ "Hinter", "dem", "Begriff", "\"", "supraventrikulaere", "Tachyarrhythmien", "\"", "verbergen", "sich", "elektrophysiologisch", "unterschiedliche", "Rhythmusstoerungen", ".", "Nach", "Identifizierung", "des", "Arrhythmiemechanismus", "'", "ist", "eine", "Lokalisation", "des", "Schwachpunktes", "der", "Rhythmusstoerung", "durch", "verschiedene", "Mappingtechniken", "erforderlich", ".", "Danach", "erfolgt", "in", "der", "Regel", "die", "Ablation", "als", "fokale", "Ablation", "bei", "automatischen", "Arrhythmien", "(", "Sinustachykardie", ",", "ektope", "atriale", "Tachykardie", ",", "fokales", "Vorhofflimmern", ")", "oder", "zur", "Unterbrechung", "von", "Leitbahnen", "(", "Praeexzitationssyndrom", ",", "AV", "-", "Knoten", "-", "Tachykardie", ")", ".", "Eine", "singulaere", "Ablationslinie", "ist", "fuer", "das", "isthmusabhaengige", "Vorhofflattern", "und", "fuer", "einige", "inzisionale", "Tachykardien", "erforderlich", ";", "dieses", "Vorgehen", "ist", "bereits", "weniger", "verbreitet", ".", "Multiple", "Ablationslinien", "sind", "fuer", "die", "Ablation", "eines", "Vorhofflimmerns", "erforderlich", ",", "was", "gegenwaertig", "nur", "in", "wenigen", "Zentren", "erfolgen", "kann", ".", "Verschiedene", "Arrhythmien", "sind", "bislang", "zu", "wenig", "verstanden", ",", "nicht", "induzierbar", ",", "nicht", "genau", "lokalisierbar", "und", "damit", "bislang", "nicht", "abladierbar", ".", "Neue", "dreidimensionale", "Mappingmethoden", ",", "koennten", "hier", "weiterhelfen", ".", "Die", "gegenwaertig", "groesste", "Herausforderung", "der", "interventionellen", "Elektrophysiologie", "ist", "die", "Ablation", "des", "Vorhofflimmerns", "." ]

[ "umlsterm" ]

Retinoblastoma is a Protein, Oct-1 is a Protein, interleukin-8 is a Protein, retinoblastoma is a Protein, IFN - gamma is a Protein, Rb is a Protein, IFN - gamma is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Rb is a Protein, Rb is a Protein, Oct-1 is a Protein, Oct-1 is a Protein, interleukin 8 is a Protein, promoter is a Entity, Oct-1 is a Protein, Rb is a Protein, interleukin 8 is a Protein

215_task0

Sentence: Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Tumor cell lines with a defective retinoblastoma gene are unable to transcribe the HLA class II genes in response to IFN-gamma treatment, and reconstitution of functional Rb rescues IFN-gamma-induced class II gene expression. However, the molecular mechanism of Rb rescue of the class II genes is unknown. We have examined the effect of Rb expression on the activation of the promoter for HLA-DRA, the prototype class II gene. Oct-1, a POU domain transcription factor, was identified as a repressor of HLA-DRA promoter activity in the Rb-defective cells. Rb expression led to phosphorylation of Oct-1, thus relieving its repressive effect. Oct-1 has also been shown to repress interleukin 8 promoter activity. Consistent with reduced levels of Oct-1 DNA binding activity in the Rb-transformed cell lines, interleukin 8 expression is higher in these cell lines.

[ "Retinoblastoma", "protein", "expression", "leads", "to", "reduced", "Oct-1", "DNA", "binding", "activity", "and", "enhances", "interleukin-8", "expression", ".", "\n", "Tumor", "cell", "lines", "with", "a", "defective", "retinoblastoma", "gene", "are", "unable", "to", "transcribe", "the", "HLA", "class", "II", "genes", "in", "response", "to", "IFN", "-", "gamma", "treatment", ",", "and", "reconstitution", "of", "functional", "Rb", "rescues", "IFN", "-", "gamma", "-", "induced", "class", "II", "gene", "expression", ".", "However", ",", "the", "molecular", "mechanism", "of", "Rb", "rescue", "of", "the", "class", "II", "genes", "is", "unknown", ".", "We", "have", "examined", "the", "effect", "of", "Rb", "expression", "on", "the", "activation", "of", "the", "promoter", "for", "HLA", "-", "DRA", ",", "the", "prototype", "class", "II", "gene", ".", "Oct-1", ",", "a", "POU", "domain", "transcription", "factor", ",", "was", "identified", "as", "a", "repressor", "of", "HLA", "-", "DRA", "promoter", "activity", "in", "the", "Rb", "-", "defective", "cells", ".", "Rb", "expression", "led", "to", "phosphorylation", "of", "Oct-1", ",", "thus", "relieving", "its", "repressive", "effect", ".", "Oct-1", "has", "also", "been", "shown", "to", "repress", "interleukin", "8", "promoter", "activity", ".", "Consistent", "with", "reduced", "levels", "of", "Oct-1", "DNA", "binding", "activity", "in", "the", "Rb", "-", "transformed", "cell", "lines", ",", "interleukin", "8", "expression", "is", "higher", "in", "these", "cell", "lines", "." ]

[ "Protein", "Entity" ]